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Abstract 
The medium-chain triglyceride (MCT) ketogenic diet is a high fat diet used to prevent 
seizures in patients with drug resistant epilepsy. In addition, there is emerging 
evidence that the MCT diet could be useful in other areas of health and medicine, 
however, the molecular mechanisms behind these effects are poorly understood. In 
this study, the tractable model organism, Dictyostelium discoideum, was employed 
to investigate novel mechanisms of action of the two medium-chain fatty acids, 
decanoic acid and octanoic acid, provided by the diet. A non-biased genetic screen 
was utilised to identify a mechanism of decanoic acid dependent upon the activity of 
a ubiquitin regulatory X (UBX) domain containing protein (UBXD18). Investigating this 
mechanism identified that UBXD18-GFP interacts with the ubiquitous protein p97(-
RFP), where decanoic acid inhibited p97(-RFP) activity in a UBXD18 dependent 
manner. Due to the role of p97 in regulating homeostasis through autophagy, the 
effects of both decanoic acid and octanoic acid on this pathway were investigated, 
with both fatty acids demonstrated to activate autophagy independently of UBXD18. 
To investigate this further, decanoic acid was found to inhibit the major regulator of 
autophagy, mTORC1, a process linked to a range of positive medical and health-
related effects. This effect on mTORC1 was shown to be specific for decanoic acid, 
and thus supports a model where decanoic acid acts through UBXD18 dependent 
inhibition of p97 to reduce mTORC1 signalling. Finally, the inhibitory effect of 
decanoic acid on mTORC1 was shown to be conserved in a rat hippocampal slice 
model and in tuberous sclerosis complex (TSC) patient-derived astrocytes. Thus, this 
study provides a novel therapeutic approach to down-regulate mTORC1 signalling 
and activate autophagy through dietary decanoic acid intake, with potential 
relevance for a wide range of medical treatments. 
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1.1 The ketogenic diet 
Fasting has long been known to reduce seizures in patients with epilepsy, with 
records of this effect appearing in multiple ancient texts, including the Hippocratic 
collection (Bailey, Pfeifer and Thiele, 2005; Hippocrates and Adams, 1985), and the 
bible (Matthew 17:21, Mark 9:29). The anti-seizure effects of fasting are thought to 
result from a build-up of ketone bodies, produced from fatty acids when 
carbohydrate levels are low, providing an alternative energy supply to the brain 
(Simeone, Simeone and Rho, 2017). Developed to mimic the effects of fasting, the 
ketogenic diet was introduced in the 1920s as a treatment for refractory epilepsy 
(Wilder, 1921; Wheless, 2008). This diet involves restricting carbohydrates and 
supplementing long-chain triglycerides (making up 60 % to 80 % of dietary energy), 
which are converted to ketone bodies by the liver (Krebs, 1966). This process involves 
the breakdown of triglycerides into free fatty acids, which are activated though the 
addition of Coenzyme A to form fatty acyl-CoA esters, allowing transportation to the 
mitochondria. In the mitochondria, β-oxidation takes place forming acetyl-CoA, 
which is subsequently converted into the ketone bodies, 3-β-hydroxybutyrate, 
acetoacetate, and acetone, in a process called ketogenesis. Levels of these ketone 
bodies are naturally present in the blood at concentrations less than 0.5 mM, and are 
raised to around 5 mM to 8 mM in patients on the ketogenic diet (Laffel, 1999; Veech, 
2004). While this diet has been demonstrated to lead to a reduction of seizures (Neal 
et al., 2008), the severe dietary restrictions and adverse gastrointestinal effects 
associated with this diet (Cai et al., 2017) lead to limited patient compliance. In order 
to overcome these limitations, modified forms of the ketogenic diet have been 
developed.  
1.2 The medium-chain triglyceride (MCT) diet  
Developed to provide increased flexibility over the classical ketogenic diet, a 
modified ketogenic diet called the medium-chain triglyceride (MCT) diet has been 
used as a treatment for drug resistant epilepsy since 1971 (Huttenlocher, Wilbourn 
and Signore, 1971). In contrast to the long-chain triglycerides provided by the 
classical ketogenic diet, this form of the diet involves the supplementary intake of 
medium-chain triglycerides. As in the classical ketogenic diet these triglycerides are 
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metabolised to form ketone bodies, however, due to the improved efficiency of 
absorption and transport of medium-chain triglycerides only 45 % of dietary energy 
is required as fatty acids to maintain raised levels of ketone bodies in the blood 
(compared with 60 %  to 80 % on the classical ketogenic diet) (Neal, 2016). Although 
most fatty acids are metabolised in this process, some medium-chain fatty acids are 
distributed by the blood to the brain, with raised plasma levels of decanoic acid 
(raised to an average levels of 157 µM (87-552 µM)) and octanoic acid (raised to an 
average of 310 µM (194-859 µM) detected in patients on the diet (Fig. 1.1) (Sills, 
Forsythe and Haidukewych, 1986; Haidukewych, Forsythe and Sills, 1982; Dean, 
Bonser and Gent, 1989). This reduction in the proportion of total fat required allows 
a greater quantity of carbohydrate and protein to be included in the diet and thus, 
improves palatability and patient health, whilst maintaining equivalent seizure 
control (Neal et al., 2008; Neal and Cross, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Epilepsy  
Epilepsy is a chronic neurological disorder, which results in seizures caused by 
excessive, and hypersynchronous electrical discharge of neurons in the brain (Bazil, 
2005). Occurring in 0.5 %  to 1 % of the population, epilepsy is one of the most common 
serious neurological diseases (Bell and Sander, 2002). Epilepsy is a broad term 
representing a group of heterogenous disorders, often caused by interactions 
between genes and environmental factors (Steinlein, 2008). A range of epilepsy 
A B 
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                                                                                                         The MCT ketogenic diet 
involves the oral intake of A) medium-chain triglycerides (such as Glycerol-1-
decanoate-2,3-dioctanoate displayed here), which are converted into the fatty acids 
B) decanoic acid (capric acid) and C) octanoic acid (caprylic acid) in the intestine. 
Figure 1. 1 Medium-chain triglycerides provided by the MCT diet are broken down 
into the free fatty acids decanoic acid and octanoic acid. 
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disorders are linked to genetic factors such as mutations in ion channels (for example 
SCN1A), however, factors such as a head trauma, fever, brain tumours or stroke can 
also initiate epilepsy (Lukasiuk and Pitkanen, 2012; Maschio, 2012). Dysfunctions in 
mitochondria have also been suggested to play a critical role in seizure generation, 
with epilepsy commonly manifesting from mitochondrial disease (Kunz et al., 2000). 
Genetic epilepsies arising from a single gene mutation, such as mutations leading to 
the epilepsy condition, Tuberous Sclerosis Complex (TSC), are rare, however, the 
identification of these genes has led to important discoveries into epilepsy 
aetiologies. Mutations in TSC patients have been identified as leading to 
dysregulation in mechanistic target of rapamycin complex 1 (mTORC1) signalling 
(Nabbout et al., 2018) and autophagy (Parkhitko et al., 2011), processes increasingly 
associated with epilepsy (Griffith and Wong, 2018; Wong, 2013). However, despite 
the prevalence of epilepsy research, in the majority of cases the cause of epilepsy 
remains unknown (Lukasiuk and Pitkanen, 2012).  
1.4 Anti-epileptic drugs 
 The underlying physiology of epilepsy is an imbalance of excitatory and 
inhibitory neuronal activity (Scharfman, 2007), and altering this balance is the target 
of many antiepileptic drugs (AEDs). These AEDs provide the most commonly used 
approach for managing epilepsy, and they work by achieving a balance in neuronal 
activity, either through reducing excitatory activity by blocking ion channels (e.g. 
carbamazepine, and perampanel) (Lang, Wang and Cooper, 1993; Hibi et al., 2012) or 
by increasing the inhibitory effect of GABA (e.g. Benzodiazepines, tiagabine and 
vigabatrin) (Isojarvi and Tokola, 1998; Hanada, 2014). Although AEDs provide 
complete seizure control for more than half of epilepsy patients, side effects 
including mental slowing, sedation, migraine, gastrointestinal disturbances, and 
behavioural changes limit the success of these drugs (Nevitt et al., 2017). 
Furthermore, teratogenicity associated with AEDs (which is thought to be caused by 
an inhibitory effect on the activity of histone deacetylases) (Güveli et al., 2017), can 
prevent these drugs being used in pregnant women, and with over 220,000 women 
of childbearing age with epilepsy in the UK alone (Epilepsy action), this highlights the 
need for improved AEDs lacking teratogenicity. Aside from problems associated with 
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side effects, roughly   30% of epilepsy sufferers are unresponsive to AEDs (Bialer and 
White, 2010), emphasising the need for the development of novel epilepsy 
treatments.  
1.5 Classical ketogenic diet in seizure control 
Unmanaged epilepsy is severely damaging, with repeated seizures enhancing 
excitatory brain circuits, perpetuating further seizures and leading to neuronal 
damage (Dingledine, Varvel and Dudek, 2014).  Thus, despite there being over 20 
available AEDs, in addition to surgical and other therapies to manage epilepsy, many 
patients remain without seizure control, substantially increasing their chances of 
neuronal damage and limiting their quality of life. Ketogenic diets provide an 
excellent alternative treatment for these patients. 
The effects of the classical ketogenic diet on seizure control have been widely 
studied with multiple publications supporting a role of ketone bodies in this activity. 
Ketone bodies have been suggested to influence a range of cellular factors to provide 
seizure control, with no single mechanism able to explain the full effect of the diet. 
The antiseizure effect of ketone bodies has been suggested to be mediated through 
mitochondrial regulation, where ketone bodies are thought to enhance 
mitochondrial respiration and ATP production, and limit the production of reactive 
oxygen species (Kim et al., 2015b; Kim, Vallejo and Rho, 2010; Maalouf and Rho, 
2008). Further studies suggest that the ketogenic diet functions to provide seizure 
control through a mechanism involving increased activation of adenosine A1 
receptors and regulation of adenosine metabolism (Masino et al., 2011; Kovács et al., 
2017). Ketone bodies have also been suggested to function through epigenetic 
changes, such as restoring aberrant DNA methylation (Kobow et al., 2013; Lusardi et 
al., 2015). Finally, ketone bodies have also been shown to induce synaptic protection 
through regulating ATP-sensitive potassium (KATP) channels (Kim et al., 2015a), thus 
providing further evidence in support of the efficacy of ketone bodies in seizure 
control. 
Despite considerable evidence supporting the importance of ketone bodies in 
seizure control, this role remains controversial due to studies reporting poor 
correlation between levels of ketone bodies in the blood and anticonvulsant efficacy 
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(Likhodii et al., 2000; Thavendiranathan et al., 2000). Furthermore, mechanisms 
behind the anti-seizure effects of ketone bodies are unclear with one study 
demonstrating that the anticonvulsant properties of the ketogenic diet are not 
consistent with a direct effect of ketone bodies on the ion channels mediating 
hippocampal neurotransmission, since neither acetoacetate or β-hydroxybutyrate 
affect  synaptic transmission in cultured neurones or brain slice models (Thio, Wong 
and Yamada, 2000). In addition,  β-hydroxybutyrate and acetone have been shown 
not to block seizure activity in a rat hippocampal slice model (Chang et al., 2016), 
where the established epilepsy drug valproic acid (VPA) shows efficacy (Chang, 
Walker and Williams, 2014; Chang et al., 2012). As a diet-based therapy the ketogenic 
diet is expected to cause a wide range of cellular and biochemical changes thus, 
ketone bodies may only partly explain the anticonvulsant efficacy of the diet, with 
other mechanisms yet to be determined.  
1.6 The medium-chain triglyceride ketogenic diet in seizure control 
 The MCT ketogenic diet has been developed as a less stringent version of the 
classical ketogenic diet, designed to maintain ketosis while delivering a reduced 
quantity of fat. Despite being developed to induce ketosis, the identification of raised 
levels of decanoic acid and octanoic acid in the plasma of patients on the MCT diet 
has led to research implicating these fatty acids in the seizure control effects of the 
diet independently of ketone bodies.   
Decanoic acid has been demonstrated to provide seizure control in multiple 
in vitro and in vivo models.  A rat hippocampal slice model, induced to display seizure 
like activity, using the gamma aminobutyric acid (GABA) receptor antagonist 
pentylenetetrazol (PTZ), has been used to demonstrate that decanoic acid but not 
octanoic acid reduces epileptiform activity (Chang et al., 2013). Additionally, in 
mouse seizure models, chronic feeding with the triglyceride of decanoic acid 
(tridecanoin) has been shown to be anticonvulsant, while the triglyceride of octanoic 
acid (trioctanoin) has no effect (Tan et al., 2017). Despite both fatty acids being 
capable of crossing the blood brain barrier (Wlaz et al., 2015; Ebert, Haller and 
Walton, 2003), the majority of studies are consistent in suggesting that decanoic acid 
but not octanoic is the therapeutically effective component of the diet. Findings from 
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a neuronal cell line support this, suggesting that decanoic acid but not octanoic acid 
causes an increase in mitochondrial biogenesis, a mechanism credited with mediating 
the long-term anti-seizure effects of the diet (Hughes et al., 2014). Additionally, a 
study suggesting a mechanism for the antiseizure effects of the MCT diet shows that 
decanoic acid, but not octanoic acid, acts as an antagonist of AMPA receptors thus 
inhibiting excitatory neurotransmission (Chang et al., 2016). These findings support a 
role for decanoic acid in providing the anti-seizure effects of the MCT diet. 
While octanoic acid has been widely reported to lack anticonvulsant activities 
it has been suggested that octanoic acid and decanoic acid have an additive 
interaction, with delivery of the two fatty acids together increasing the seizure 
threshold in the 6Hz seizure test on mice (Wlaz et al., 2015). Furthermore, it has been 
demonstrated that the presence of octanoic acid in the MCT diet leads to the 
preferential metabolism of this fatty acid in neurones, allowing decanoic acid to 
escape breakdown, and thus accumulate to mediate therapeutic effects (Khabbush 
et al., 2017).  
Evidence supporting a direct role for decanoic acid in the anti-seizure effects 
of the MCT ketogenic diet and a supporting role for octanoic acid have informed the 
development of a dietary supplement called “Betashot”, made up of a high ratio of 
decanoic acid to octanoic acid supplied as triglycerides. This product developed by 
Vitaflo (International) Ltd, has recently progressed through a feasibility study to 
evaluate palatability, gastrointestinal tolerance and compliance in children and 
adults with epilepsy (ClinicalTrials.gov Identifier: NCT02825745). 
1.7 Cellular targets of decanoic acid and octanoic acid provided by the MCT diet 
Following the identification of a role for decanoic acid in seizure control in 
both in vitro (Chang et al., 2013) and in vivo models (Tan et al., 2017), mechanisms 
to explain this anti-seizure effect have been investigated. Several mechanisms of 
action of decanoic acid have been well established, such as the inhibition of 
excitatory neurotransmission through the direct inhibition of AMPA receptors, and 
the increase in mitochondrial biogenesis, while other potential mechanisms such as 
the regulation of mTORC1 signalling and cellular autophagy are not yet fully 
understood.  
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1.7.1 AMPA receptors 
AMPA receptors are responsible for most of the fast-synaptic excitatory 
neurotransmission within the brain, and thus play an important role in initiating and 
propagating epileptiform discharges. Decanoic acid has been shown to possess 
strong inhibitory effects on excitatory neurotransmission in two ex vivo rat 
hippocampal slice models of epileptiform activity (Chang et al., 2016). To establish a 
mechanism for this effect, electrophysiological characterisation has been carried out 
on AMPA receptor subunits expressed in a Xenopus oocyte model, finding that 
decanoic acid but not octanoic acid acts to reduce glutamate generated currents 
(Chang et al., 2016). It has been further demonstrated that AMPA receptor inhibition 
using a pharmacological non-competitive inhibitor is sufficient to completely block 
epileptiform activity in vitro, indicating that this mechanism could explain the 
pharmacological effect of decanoic acid (Chang et al., 2016).  Furthermore, AMPA 
receptors have also been identified as targets for the AED perampanel (Rogawski and 
Hanada, 2013) and it has been revealed that decanoic acid and perampanel work 
synergistically in reducing AMPA receptor currents. These findings suggest that the 
MCT diet could be used in combination with perampanel to provide an improved 
strategy for the treatment for epilepsy (Augustin et al., 2018b). 
1.7.2 Mitochondrial biogenesis 
Aside from evidence demonstrating that decanoic acid acutely controls 
seizure activity through the inhibition of AMPA receptors, it has been suggested that 
the anti-seizure effects of decanoic acid may also arise from beneficial effects of this 
fatty acid on brain energy metabolism. The classical ketogenic diet has been reported 
to increase mitochondrial biogenesis in the brains of rats, and since loss of respiratory 
chain enzyme activity is associated with seizure activity (Kunz et al., 2000), this has 
led to the suggestion that an increase in mitochondrial proliferation could explain the 
antiseizure effects of this diet (Bough et al., 2006). Investigations into the effects of 
decanoic acid on mitochondria have demonstrated that this fatty acid leads to an 
increase in mitochondrial biogenesis (citrate synthase levels) in the neuronal cell line 
SH-SY5Y and in cultured fibroblasts (Hughes et al., 2014). This mitochondrial 
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enrichment was observed without a corresponding increase in oxidative stress, which 
was suggested to be minimised by elevated catalase activity (Hughes et al., 2014). 
Decanoic acid has also been found to result in a significant increase in the activity of 
complex I, supporting evidence suggesting that this fatty acid leads to an increase in 
ATP production (Davey, Peuchen and Clark, 1998; Tan et al., 2017; Hughes et al., 
2014). Furthermore, this study also demonstrated an increase in mitochondrial 
number in neuronal cells following treatment with decanoic acid (Hughes et al., 
2014). These findings suggest that the MCT diet as well as the classical ketogenic diet 
may lead to an increase in mitochondrial biogenesis. 
To explain the effect of decanoic acid on mitochondrial biogenesis, this fatty 
acid has been characterised as an agonist for the transcription factor peroxisome 
proliferator activator receptor γ (PPARγ) (Malapaka et al., 2012), with PPARγ 
stimulation sufficient to promote mitochondrial biogenesis. This mechanism appears 
to be specific for decanoic acid, with studies demonstrating that octanoic acid has no 
effect on PPARγ or mitochondrial function (Malapaka et al., 2012; Hughes et al., 2014; 
Tan et al., 2017). The increase in mitochondrial biogenesis resulting from decanoic 
acid treatment is thought to lead to an increase in ATP availability and improved brain 
energy metabolism leading to reduced seizure activity, thus suggesting that a 
targeted more tolerable version of the MCT diet, with a higher decanoic acid content, 
could be developed for use in patients with epilepsy syndromes and mitochondrial 
disorders.  
1.7.3 Autophagy regulation 
Autophagy is a degradative process, by which cellular components are 
delivered to the lysosomes for recycling. This catabolic process plays an important 
role in maintaining cellular energy as well as removing misfolded proteins, and 
damaged organelles to maintain cellular homeostasis. Dysfunction of this process has 
been associated with a range of diseases including epilepsy and neurodegenerative 
disorders (Wong, 2013), and while the classical ketogenic diet has been linked to 
therapeutically activating this process (Wang et al., 2018), the effects of medium-
chain fatty acids on autophagy have not yet been well studied. 
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 Macroautophagy, the most prevalent form of autophagy is well conserved 
throughout eukaryotes, enabling research into this pathway to be carried out in 
model organisms such as Dictyostelium as well as in higher eukaryotes. This pathway 
begins with the capture of intracellular cargo using a specialised membrane, called a 
phagophore, which engulfs material targeted for degradation to form a double 
membraned vesicle called an autophagosome (Fig. 1.2A). Fusion of this 
autophagosome with a lysosome, forming an autolysosome, allows the degradation 
of the sequestered material by lysosomal acid hydrolases (Fig. 1.2A). Following 
degradation, the resulting material is released back to the cytosol where it can be 
metabolised or re-used for building macromolecules (Glick, Barth and Macleod, 
2010). Impairments in this pathway have been linked to epileptogenesis (Fig. 1.2B), 
and thus, strategies to activate autophagy are under investigation as novel 
therapeutics for epilepsy.  
 Fasting, a process known to reduce seizures in epileptic patients, is well 
established to activate autophagy, with this pathway widely linked to the associated 
therapeutic benefits (Yuen and Sander, 2014). In addition to providing nutrients 
during starvation, autophagy plays a role in degrading damaged organelles and 
misfolded proteins and this function has emerged as central in promoting health and 
longevity (Bareja, Lee and White, 2019). Impairments in autophagy have been 
suggested to play an important role in the development of epilepsy, with artificial 
inhibition of this pathway shown to result in spontaneous seizures in mice (McMahon 
et al., 2012). Further links between autophagy and epilepsy have been established, 
with blockages in autophagy identified in patients with the genetic epilepsy 
conditions tuberous sclerosis complex (TSC) (Wong, 2013; McMahon et al., 2012) and 
Lafora disease (Knecht et al., 2010). Furthermore, an accumulation of autophagy 
structures has been reported in the hippocampi of mice following repeated seizures 
(Shacka et al., 2007), signifying a blockage in autophagic flux. Additional findings 
suggest that neuronal damage induced by seizures can be prevented by autophagy 
inducers (Fornai et al., 2008; Caldero et al., 2010), and thus, therapies known to 
activate autophagy are being investigated as potential epilepsy treatments (Kim et 
al., 2019; Giorgi et al., 2015).  
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Lysosome 
Phagophore Autophagosome Autolysosome 
B 
                                                                                    A) Autophagy is initiated by the 
formation of the phagophore membrane that engulfs cytoplasmic material. This 
membrane matures into a double membraned vesicle called an autophagosome, 
which then fuses with a lysosome, causing degradation of the sequestered material. 
B) Schematic summarising links between autophagy and epilepsy. Artificial inhibition 
of autophagy leads to spontaneous seizures, with factors such as the ketogenic diet, 
fasting and rapamycin that are known to activate autophagy, via mTORC1 inhibition, 
demonstrating seizure suppression. Genetic epilepsies such as TSC and Lefora disease 
are known show dysfunctional autophagy, via overactivation of mTORC1. 
Furthermore, artificially triggered seizures have been demonstrated to lead to a 
blockage in autophagic flux, with autophagy activation under investigation as a 
potential therapy. 
Figure 1. 2 The role of autophagy in epilepsy.
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The classical ketogenic diet has been demonstrated to activate autophagy, 
with this mechanism suggested to provide a neuroprotective effect (Wang et al., 
2018; Camberos-Luna et al., 2016). As with many autophagy inducing processes the 
classical ketogenic diet is thought to modulate autophagy through the major 
regulator of this pathway, mTORC1 (McDaniel et al., 2011) (Fig. 1.2B), a complex with 
multiple links to epilepsy (Griffith and Wong, 2018). Further research into autophagy 
inducing therapies could lead to the development of improved epilepsy treatments. 
Additionally, investigations into the effects of medium-chain fatty acids on this 
process could shed light on the mechanisms of action of the MCT diet and may lead 
to the development of more effective therapies.  
1.7.4 mTORC1 signalling 
The mTORC1 pathway is a highly conserved pathway that functions as a 
central regulator of cellular nutrient and energy state. This pathway regulates 
downstream catabolic processes such as autophagy, as well as anabolic processes 
such as protein synthesis (Tatebe et al., 2017). While mTOR is essential (Gangloff et 
al., 2004), uncontrolled activation of mTORC1 signalling and the corresponding 
reduction in autophagy has been linked to an increasing number of human diseases 
including certain epilepsies (Griffith and Wong, 2018). 
mTORC1 is a protein complex that acts as a growth regulator sensing and 
integrating nutritional and environmental cues. Following exposure to nutrient rich 
conditions mTORC1 is activated by signals from growth factors via the 
phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signalling pathway (Fig. 1.3) 
(Bond, 2016). High energy levels (high ATP:ADP ratio) and glucose activate mTORC1 
via inhibition of 5' AMP-activated protein kinase (AMPK), and amino acids activate 
mTORC1 by recruiting the protein complex to the lysosome allowing activation by Ras 
homolog enriched in brain bound to guanosine triphosphate (Rheb-GTP) (Fig. 1.3) 
(Bond, 2016). Activation of mTORC1 leads to the phosphorylation of the downstream 
effectors  p70 ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation 
factor 4E-binding protein (4E-BP1), which promotes the synthesis of proteins 
resulting in increased cell growth and proliferation (Fig. 1.3) (Tatebe et al., 2017). 
Conversely, following nutrient starvation and the inhibition of mTORC1, the initiation 
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of autophagy is activated via dephosphorylation of a pro-autophagic complex 
(Atg1/ULK1) triggering degradation of cytoplasmic constituents allowing cells to 
reutilize their own constituents for energy and maintain homeostasis (Fig. 1.3)  
(Ganley et al., 2009). In addition to regulating autophagy initiation, mTORC1 has also 
been demonstrated to directly regulate the subsequent steps of autophagy such as 
autophagosome elongation and maturation through modulating the phosphorylation 
state, and thus activation of the autophagy machinery, as well as altering gene 
expression through the phosphorylation of transcription factors (Dossou and Basu, 
2019).  
   
.                                                                                                                                           
 
                     The mechanistic target of rapamycin 
complex 1 (mTORC1) is a protein complex that 
senses cellular nutrient and energy state and 
regulates protein synthesis and degradation. 
Growth factors activate the PI3K/AKT pathway 
to inhibit the tuberous sclerosis complex (TSC), 
allowing GTP-bound RHEB to activate mTORC1. 
Glucose and high cellular energy (high ATP:ADP 
ratio) inhibit AMPK thus preventing the 
activation of the TSC complex and maintaining 
mTORC1 activation. Presence of amino acids 
leads to recruitment of mTORC1 to the lysosome 
allowing activation by RHEB. Activation of 
mTORC1 leads to the phosphorylation of 4E-BP1 
inducing its dissociation from the eukaryotic 
translation initiation factor 4E (eIF4E) enabling 
translation. Activation of mTORC1 also leads to 
the phosphorylation of p70 ribosomal protein 
S6 kinase (S6K), which phosphorylates the S6 
ribosomal protein, inducing protein synthesis at 
the ribosome. mTORC1 activation also leads to 
phosphorylation of the pro-autophagic complex 
Atg1/ULK1 inhibiting the degradation of 
cytoplasmic constituents by autophagy. 
Figure 1. 3 Nutrient regulation of mTORC1 
signalling
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Hyperactivation of mTORC1 has been associated with a range of human 
diseases including epilepsy (McMahon et al., 2012), as well as neurodegenerative 
disorders such as Alzheimer’s disease (Tang et al., 2013; Morita and Sobue, 2009) and 
certain cancers (Xie, Wang and Proud, 2016). Inhibition of this pathway has been 
suggested to provide clinical benefits in many of these conditions (Hillmann and 
Fabbro, 2019). Inhibition of mTORC1, caused by a reduction in glucose and insulin 
signalling, has been attributed to the therapeutic effects of ketogenic diets (McDaniel 
et al, 2011; Newman et al, 2017; Ostendorf & Wong, 2015; Roberts et al, 2017; 
Sweeney et al, 2017; Thio et al, 2006). While dietary intervention using the classical 
ketogenic diet is well established to reduce mTORC1 activity, this diet is highly 
restrictive for patients resulting in low compliance (Ye et al., 2015a). The ability of the 
more palatable MCT diet to regulate this pathway has not yet been investigated. 
Investigating the effects of medium-chain fatty acids on mTORC1 signalling could help 
to establish whether this diet could prove useful for restoring balanced mTORC1 
signalling in a range of human diseases.  
1.7.5 Phosphoinositide signalling 
 Phosphoinositides, the phosphorylated derivatives of phosphatidylinositol 
are key regulators of plasma membrane signalling and membrane transport, and are 
thought to play an important role in neural function (Raghu et al., 2019). A link 
between phosphoinositides and epilepsy has been suggested since increased 
phosphoinositide production has been shown during seizures (Van Rooijen et al., 
1986) and the loss of enzymes responsible for dephosphorylation of PIP3 have been 
associated with seizures in mouse models (Backman et al., 2001) and linked to seizure 
disorders (Hardies et al., 2016; Raghu et al., 2019). 
The anti-epileptic drug VPA has been shown to reduce phosphoinositide 
production in Dictyostelium in relation to seizure control (Chang et al., 2012) and the 
ability of fatty acids to reduce phosphoinositide turnover has been investigated in 
order to find compounds with enhanced potency (Chang et al., 2012). Both decanoic 
acid and octanoic acid have been shown to attenuate phosphoinositide production 
more potently than VPA, leading to the direct demonstration that these fatty acids 
block PTZ-induced epileptiform activity in an in vitro rat hippocampal slice model 
 
30 
 
(Chang et al., 2013). Not only do these findings provide an important insight into 
decanoic acid induced seizure control, they also emphasise the value of using 
Dictyostelium as a model in epilepsy research. 
Phosphoinositides are well established to regulate both autophagy, and 
mTORC1 signalling, with these processes representing potential therapeutic roles for 
reduced phosphoinositide production in epilepsy treatment. Phosphatidylinositol 3-
phosphate (PI3P), phosphatidylinositol 3,5-bisphosphate (PI-3,5-P2) and 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) have all been demonstrated to 
activate mTORC1 either directly (Jin et al., 2014) or through the recruitment of AKT 
and phosphoinositide-dependent kinase-1 (PDK1) to the plasma membrane enabling 
the phosphorylation of AKT, the activation of mTORC1 and the corresponding 
inhibition of autophagy (Fig. 1.3) (Palamiuc, Ravi and Emerling, 2020; Jang and Lee, 
2016). Despite the well-established link between mTORC1 activation and autophagy 
inhibition, phosphoinositides have been suggested to play contrasting roles in this 
process, with PI3P and phosphatidylinositol 4,5-bisphosphate (PI-4,5-P2) required for 
autophagy activation (Nascimbeni, Codogno and Morel, 2017; Burman and Ktistakis, 
2010; Tan et al., 2016; Rong et al., 2012). 
While both decanoic acid and octanoic acid have been demonstrated to 
reduce phosphoinositide production, with synthesis of phosphatidylinositol 
monophosphates (PIP) and phosphatidylinositol bisphosphates (PIP2) shown to be 
reduced in Dictyostelium (Chang et al., 2012), neither production of, nor total levels 
of PIP3 have been assessed in the presence of medium-chain fatty acids, with changes 
in levels of this signalling molecule predicted to modulate mTORC1 and autophagy 
activity. Thus, alterations in PIP3 levels caused by medium-chain fatty acids represent 
a potential, unexplored therapeutic mechanism for the MCT diet.  
Multiple mechanisms of action for decanoic acid in the therapeutic effects of 
the MCT diet have been suggested. The effects of decanoic acid on AMPA receptors 
and mitochondrial biogenesis are well explained, while potential effects on signalling 
pathways such as mTORC1 and autophagy are yet to be fully explored. Understanding 
these mechanisms of action could help to develop a better understanding of the 
potential health benefits and could lead to the development of this diet for use in 
treating other medical conditions.   
 
31 
 
1.8 Ketogenic diets in disease treatment and health 
In addition to treating epilepsy, the MCT diet has gained interest as a potential 
treatment for a range of conditions, such as cognitive impairment, mitochondrial 
disorders, diabetes, cancer and neurodegenerative disorders. It was initially assumed 
that the therapeutic mechanisms of the MCT diet in these areas would be through 
the provision of ketone bodies as an alternative energy source, however, recent 
findings suggest a potential role for medium-chain fatty acids in treating these 
conditions. 
1.8.1 Cognitive impairment 
 Subjective assessment of patient experience has suggested that the ketogenic 
diet may improve cognitive function in children and adults on the MCT diet (IJff et al., 
2016; van Berkel, DM and Verkuyl, 2018). These reports have led to investigations 
into the use of medium-chain triglycerides to improve cognition in patients with 
diverse conditions associated with cognitive decline. Medium-chain triglycerides 
have been shown to prevent the decline in cognitive function associated with 
hypoglycaemia in patients with diabetes (Page et al., 2009). Further studies have 
reported improved cognition in elderly patients and patients with Alzheimer's disease 
fed a MCT diet (Ota et al., 2016; Ota et al., 2019), however, whether these effects are 
derived from medium-chain triglycerides or ketone bodies is unclear. Recent data 
suggests that decanoic acid and octanoic acid may provide cognition enhancing 
properties independently of ketone bodies (Wang and Mitchell, 2016). Interestingly, 
a medium-chain triglyceride containing product is provided commercially to people 
over the age of fifty in China (Nestlé YIYANG Fuel for brainTM senior milk powder) and 
is promoted to delay brain aging and to improve brain response and memory, based 
on findings from aged beagle dogs (Pan et al., 2010). Further investigation into the 
cognitive benefits of medium-chain fatty acids could lead to more widespread use of 
MCT supplements to prevent cognitive decline associated with epilepsy, age, 
traumatic brain injury, hypoglycaemia and Alzheimer’s disease. 
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1.8.2 Mitochondrial diseases 
Mitochondrial diseases are a group of disorders caused by defects in the 
respiratory chain, thus affecting tissues and organs with high energy demands such 
as the central nervous system, as well as skeletal and cardiac muscles. Decanoic acid 
has been implicated in regulating mitochondrial function following the finding that it 
activates the nuclear receptor, peroxisome proliferator-activated receptor gamma 
(PPAR-γ), involved in mitochondrial biogenesis (Malapaka et al., 2012). Data from a 
neuronal cell line demonstrates that decanoic acid leads to an increase in 
mitochondrial number, along with an increase in the activities of citrate synthase (a 
biomarker for mitochondrial enrichment) and complex I  (Hughes et al., 2014). These 
findings have raised the possibility that the MCT ketogenic diet could provide 
potential therapeutic benefits for patients with mitochondrial disorders. Leigh 
syndrome is a severe mitochondrial disease resulting in progressive neurological 
abnormalities, such as loss of motor skills (Fassone and Rahman, 2012).  Decanoic 
acid has been shown to increase mitochondrial content in fibroblasts from patients 
with nuclear-encoded complex I deficient Leigh syndrome, as well as increasing 
cellular resistance to oxidative stress (Kanabus et al., 2016). These findings suggest 
that the MCT ketogenic could be used to provide therapeutic benefits in some 
patients with Leigh syndrome, and that further investigations into the use of decanoic 
acid to treat mitochondrial disorders should be carried out in in vivo mammalian 
models. 
1.8.3 Diabetes mellitus 
 Diabetes mellitus represents a group of metabolic disorders characterised by 
raised blood sugar levels, caused by suppressed insulin production (type 1 diabetes) 
or insulin resistance caused by lifestyle factors, such as obesity and lack of exercise 
(type 2 diabetes). Dietary interventions, including the MCT diet, have been 
investigated as novel therapeutic approaches for treating type 2 diabetes. In multiple 
studies MCT diets have been shown to reduce serum lipid concentrations and 
improve lipid profiles, decrease body fat, and reduce total bodyweight in animals and 
humans (Geng et al., 2016; Mumme and Stonehouse, 2015; Malapaka et al., 2012). 
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Medium-chain triglycerides have also been shown to reduce insulin resistance and 
improve glucose tolerance (Geng et al., 2016; Takeuchi et al., 2006). Furthermore, 
findings linking mitochondrial dysfunction with insulin resistance and type 2 diabetes 
(Petersen et al., 2004; Koves et al., 2008), suggest that the beneficial effects 
associated with decanoic acid on mitochondrial function and biogenesis could prove 
therapeutic in patients with this disorder. Drugs in the thiazolidinedione (TZD) family 
are used to activate PPAR-γ in the treatment of type 2 diabetes, however, this family 
of drugs is associated with several adverse effects, such as weight gain and 
cardiovascular disease (Graham et al., 2010; Larsen, Toubro and Astrup, 2003). 
Decanoic acid activates PPAR-γ without the associated side effects of TZDs (Malapaka 
et al., 2012), suggesting that designing therapies based around decanoic acid 
activation of PPAR-γ could lead to safer treatments for type 2 diabetes.  
1.8.4 Cancer 
Since the discovery by Otto Warburg in the 1920s that cancer cells rely on 
glycolysis regardless of oxygen availability, dietary therapies that reduce glucose 
availability have gained substantial interest as cancer treatments (Warburg, Wind 
and Negelein, 1927). Reducing the glucose availability for cancer cells by 
administering the ketogenic diet while providing normal cells with ketone bodies as 
an alternative fuel, is thought to result in reduced tumour growth (Brooks, Woolf and 
Scheck, 2016; Branco et al., 2016). This has been demonstrated in studies using 
mouse astrocytoma allograft models (Seyfried et al., 2012), and in mouse models of 
glioma (Stafford et al., 2010; Klement et al., 2016). Observational studies in patients 
suggest that the ketogenic diet is effective alone and as an adjunctive therapy in 
patients with multiple cancer types (Scheck et al., 2012; Poff et al., 2013; Tan-Shalaby, 
2017; Zuccoli et al., 2010; Allen et al., 2014), however, more evidence for clinical 
efficacy in randomised controlled trials is required. While reduced glucose availability 
remains the most accepted explanation for the efficacy of ketogenic diets in treating 
cancers, medium-chain fatty acids have been suggested to have direct anticancer 
effects (Narayanan et al., 2015; Fauser et al., 2013; Jóźwiak et al., 2020). Further 
investigation into the effects of medium-chain fatty acids on cancer progression could 
lead to improved therapies.  
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1.8.5 Neurodegenerative diseases 
 Neurodegenerative diseases are incurable conditions resulting in the 
progressive degeneration of nerve cells. Ketogenic diets have been suggested to 
provide therapeutic benefits in a range of neurological disorders, such as 
amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, with 
evidence suggesting potential benefits of medium-chain triglycerides in these 
conditions.  
ALS is a neurodegenerative condition characterised by the degradation of 
motor neurons, leading to progressive motor weakness and death (Rowland and 
Shneider, 2001). Ketogenic diets have been suggested to improve degeneration in 
these patients (Siva, 2006; Zhao et al., 2006; Paganoni and Wills, 2013), due to their 
beneficial effects on mitochondrial function (Carrì, D’Ambrosi and Cozzolino, 2017; 
Hughes et al., 2014; Kim, Vallejo and Rho, 2010). Improved motor neuron survival has 
been reported in mice following administration of octanoic acid triglyceride, thought 
to be caused by an increase in mitochondrial energy production resulting from the 
use of an alternative energy source for neuronal metabolism (Zhao et al., 2012). 
These findings suggest that using octanoic acid to restore energy metabolism could 
provide a therapeutic approach to treat patients with ALS. In addition, dysregulation 
of autophagy (Nguyen, Thombre and Wang, 2019; Hartman, 2012) and mTORC1 
signalling has been reported in patients with ALS (Saxena et al., 2013; Perera and 
Turner, 2016), suggesting that regulation of these pathways by the ketogenic diet 
(McDaniel et al., 2011) could lead to therapeutic benefits in these patients.  
Medium-chain triglycerides have also been suggested to have positive effects 
in patients with Alzheimer’s disease. Alzheimer’s is a neurodegenerative disease, 
characterised by deposits of β-amyloid peptide, resulting in neurotoxicity and loss of 
mental function (Murphy and LeVine, 2010). β-amyloid peptide is known to cause 
neurotoxicity via the formation of neurofibrillary tangles, inflammation and oxidative 
stress (Hardy and Allsop, 1991), with studies in cultured neurones and mouse models 
suggesting that ketogenic diets provide protection against the toxicity of this peptide 
(Kashiwaya et al., 2000; Van der Auwera et al., 2005). Furthermore, studies with 
Alzheimer’s patients have demonstrated that treatment with medium-chain 
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triglycerides improves memory (Reger et al., 2004; Henderson et al., 2009; Ota et al., 
2019; Taylor et al., 2018). Glucose hypometabolism is thought to be an underlying 
feature of the Alzheimer’s brain, with the ketogenic diet widely believed to improve 
Alzheimer’s symptoms by providing the brain with an alternative energy supply (Heiss 
et al., 1991). The medical food, Axona®, which is primarily octanoic acid triglyceride, 
was developed to bypass glucose metabolism in the brain, and has been 
demonstrated to enhance memory and cognition in some patients in clinical trials 
(Henderson et al., 2009; Roman, 2010; Ohnuma et al., 2016). In addition to bypassing 
glucose metabolism, ketogenic diets are thought to provide benefits to patients 
through correcting mitochondrial disfunction (Johri and Beal, 2012) and restoring 
disrupted autophagy (Takahashi, Nagao and Gouras, 2017; Uddin et al., 2018) 
processes which could be directly modulated by medium-chain fatty acids (Hughes et 
al., 2014; Sauvat et al., 2018). Interestingly, evidence from post-mortem brains has 
indicated that mTORC1 signalling is hyperactivated in patients with Alzheimer’s 
disease (An et al., 2003; Chang et al., 2002), suggesting that regulation of this 
pathway by the ketogenic diet (McDaniel et al., 2011), could provide corresponding 
therapeutic benefits. Further investigation into the mechanisms of medium-chain 
fatty acids is required to better understand their capacity to benefit patients with 
Alzheimer’s disease. 
Parkinson’s disease is another disorder of the central nervous system that has 
potential to be treated by the ketogenic diet. This disease is characterised by the 
accumulation of a neuronal protein called α-Synuclein, which leads to the 
degeneration of dopaminergic neurons, and presents with defects in movement and 
cognition (Sveinbjornsdottir, 2016). The ketogenic diet and β-hydroxybutyrate have 
been suggested to provide neuronal protection in rodent models of Parkinson’s 
disease (Tieu et al., 2003; Yang and Cheng, 2010; Cheng et al., 2009; Shaafi et al., 
2016). Additionally, clinical trials suggest that the ketogenic diet could lead to an 
improvement of symptoms in Parkinson’s patients (Vanitallie et al., 2005; Phillips et 
al., 2018). Dysfunctional autophagy has been linked to the accumulation of α-
synuclein in the brains of Parkinson’s patients contributing to the pathogenesis of this 
disease (Lynch-Day et al., 2012). Further evidence is required to establish whether 
medium-chain fatty acids provided by the MCT ketogenic diet could promote 
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autophagic activation to reduce neuronal loss and slow disease progression in these 
patients. Furthermore, as in other neurodegenerative diseases, mitochondrial 
dysfunction has been suggested be involved in the pathogenesis of this disease 
(Winklhofer and Haass, 2010), suggesting that the beneficial effects of decanoic acid 
on mitochondrial function (Hughes et al., 2014) could provide therapeutic benefits in 
this condition.   
A broad range of evidence supports the potential benefits of medium-chain 
triglycerides for use in neurodegenerative diseases. These conditions share common 
dysfunctionality in mitochondrial function, as well as in mTORC1 signalling and 
autophagic degradation, suggesting that modulation of these cellular processes could 
provide therapeutic benefits in multiple conditions. Further research into the 
mechanisms of actions behind the MCT diet could help to develop better targeted 
and more effective treatments. 
1.9 Limitations of the MCT diet 
Despite being effective for the treatment of drug resistant epilepsy, with 
multiple potential benefits in treating other conditions, the MCT diet is associated 
with adverse gastro-intestinal related side effects such as diarrhoea, vomiting, 
bloating and cramps (Raper, 1935; Liu, 2008). These side effects have limited the 
implementation of this diet in epilepsy treatment, especially in adults, due to 
difficultly with compliance (Ye et al., 2015a). Developing a better understanding of 
the mechanisms of action of the fatty acids provided by the diet could lead to refined 
formulations that lack these adverse effects. Moreover, understanding the 
mechanisms of action behind the therapeutic effects of the diet will help to develop 
a better appreciation of the potential health benefits and could lead to the 
development of this diet for use in treating other medical conditions. 
 In this project we employ Dictyostelium discoideum as a model system to 
elucidate and verify mechanisms of action of medium-chain fatty acids. In addition to 
investigating decanoic acid and octanoic acid we also consider the cyclic derivative of 
octanoic acid, 4-butylcyclohexane carboxylic acid (4-BCCA), which has been identified 
as a potential anti-seizure agent (Fig. 1.4).  Identified as displaying potent antiseizure 
activity (Chang et al., 2015), while lacking the teratogenically associated inhibitory 
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effects on histone deacetylase (HDAC) activity that is  often observed with AEDs, this 
compound represents an exciting potential therapeutic with an enhanced safety 
profile over traditional AEDs (Chang et al., 2015; Koren et al., 2006; Jentink et al., 
2010).   
 
  
1.10 Dictyostelium discoideum as a model organism  
The eukaryotic social amoeba, Dictyostelium discoideum (referred to as 
Dictyostelium) was first found by Raper in 1935, living in forest detritus in North 
America (Raper, 1935), and has since been established as a popular model organism. 
Dictyostelium belongs to the Phylum Amoebozoa (Schilde and Schaap, 2013) and 
possesses a unique developmental lifestyle that make it a valuable model for studying 
processes such as cell motility, chemotaxis, signal transduction, and cell 
differentiation. Under ideal growth conditions Dictyostelium amoeba grow as 
individual independent cells, using phagocytosis to feed on bacteria and dividing by 
binary fission (Raper, 1935). When faced with adverse conditions such as starvation 
the amoebae enter the developmental stage of their life cycle (Fig. 1.5). Development 
is initiated by the release of the extracellular chemoattractant cAMP, which signals 
the mass movement of cells towards a central region (Meima and Schaap, 1999). 
Upon aggregation the interacting cells form multicellular motile slugs allowing 
movement towards attractants such as heat and light (Bonner et al., 1950). These 
slugs consist of prespore and prestalk cells which, during culmination, differentiate 
forming fruiting bodies consisting of viable spores held above the substratum by dead 
                                                                                                                                                          
.                                                                                                                           The compound 
4-butylcyclohexane carboxylic acid (4-BCCA) has been identified as showing enhanced 
epileptiform activity over VPA, and decanoic acid in rat hippocampal slice models. 
  
Figure 1. 4 Skeletal structure of 4-butylcyclohexane carboxylic acid.
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vacuolated stalk cells (Thomason et al., 1998). The whole process of fruiting body 
formation takes around 24 hours at which point mature spores can be released to 
germinate and re-enable unicellular growth when conditions are favourable. These 
spores can survive for months in the absence of food, thus, allowing Dictyostelium to 
endure starvation and desiccating conditions (Dubravcic, van Baalen and Nizak, 
2014). This unique social behaviour has made Dictyostelium a popular system for 
studying altruism and cooperation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In addition to possessing a remarkable developmental cycle, the genetics 
of Dictyostelium make it an ideal model system. Despite having diverged from the 
animal lineage before the divergence of yeasts (Eichinger et al., 2005), the 
evolutionary distance between Dictyostelium and humans is less than the distance 
between human and yeasts, due to the higher rate of evolutionary change in the 
yeast lineage (Insall, 2005). Dictyostelium is valuable as a simple system with many of 
                                                                                                                         During favourable 
conditions cells grow as individual free-living amoebae, dividing by binary fission. 
Following nutrient deprivation cells aggregate to form multicellular structures termed, 
mounds, fingers and motile slugs which are capable of movement towards 
chemoattractants. Culmination results in the formation of differentiated fruiting 
bodies, where spore cells are held aloft by dead vacuolated stalk cells. These viable 
spores can survive long periods of time, thus allowing dispersal and germination when 
conditions become favourable. 
  
Figure 1. 5 The developmental cycle of Dictyostelium discoideum.   
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the genes in its 34 Mb genome homologous to those of higher eukaryotes (Eichinger 
et al., 2005). The complete genome sequence of Dictyostelium is available (Eichinger 
et al., 2005) and the molecular genetics of this haploid organism facilitate gene 
disruption experiments through insertional mutagenesis (Faix et al., 2013). The 
generation of libraries of Dictyostelium mutants has enabled pharmacogenetic 
studies leading to the identification of targets for compounds such as naringenin, 
curcumin and cannabidiol (Cocorocchio et al., 2018; Waheed et al., 2014; Perry et al., 
2020). This approach allows rapid identification of genes encoding proteins that 
control the sensitivity to a compound, thus implicating the identified protein or the 
wider pathway in the action of the compound.  
Dictyostelium is a well-established model for use in epilepsy research, with 
findings being translated into mammalian systems and directing clinical progress. 
Studies using Dictyostelium have shown that the anti-epileptic drug VPA acts to 
inhibit phosphoinositide signalling, implicating phosphoinositides as a target for 
epilepsy treatments (Xu et al., 2007; Chang et al., 2012). A structure-activity 
relationship (SAR) study in Dictyostelium has led to the discovery that decanoic acid 
is more potent than VPA in reducing phosphoinositide production (Chang et al., 
2012). Subsequently, these findings have been translated into mammalian models, 
identifying that decanoic acid has improved efficacy in seizure models over VPA 
(Chang et al., 2013; Chang, Walker and Williams, 2014; Augustin et al., 2018a). These 
findings have contributed to the development of a MCT diet with a high decanoic acid 
content (Betashot, ClinicalTrials.gov: NCT02825745) and have validated the use of 
Dictyostelium in ketogenic diet research. 
Autophagy, a cellular process central to health, longevity and epilepsy has 
been widely studied in Dictyostelium. As in other eukaryotes, autophagy is required 
for Dictyostelium to survive starvation, and to degrade dysfunctional proteins and 
organelles. Autophagy has been recognised in this organism since 1969 (Cotter, 
Miura-Santo and Hohl, 1969), and since then many of the proteins and complexes 
involved in autophagy have been identified as being conserved in Dictyostelium 
(Mesquita et al., 2016). This organism has been widely employed in studying this 
process, with findings in this organism providing important advances in the study of 
autophagy-related pathologies, such as in neurodegenerative diseases (Munoz-
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Braceras, Calvo and Escalante, 2015), cancer (Calvo-Garrido and Escalante, 2010), and 
neuronal malfunction (Kim et al., 2009; Schmauch et al., 2009). The major regulator 
of autophagy, mTORC1 signalling, has also been well characterised in Dictyostelium. 
Components of the mTORC1 complex, including, TOR, Raptor and Lst8 are conserved 
throughout eukaryotes, as is the eukaryotic initiation factor 4E-binding protein (4E-
BP1) (Morio et al., 2001; Liao et al., 2008). Dictyostelium has been used in a range of 
mTORC1-related studies, from studies on autophagy (Mesquita et al., 2016) to 
studies on cell migration (Liu et al., 2010) and phagocytosis (Rosel et al., 2012). The 
prevalence of Dictyostelium research in the areas of autophagy and mTORC1 
highlights the suitability of this model for studying these conserved processes.  
1.10.1 Mutant library principles 
Insertional mutant libraries of Dictyostelium have proved valuable in multiple 
pharmacogenetic studies identifying targets for a diverse range of compounds. These 
libraries are prepared though the use of restriction enzyme mediated integration 
(REMI) mutagenesis (Kuspa, 2006), a technique that has been available in 
Dictyostelium since 1992 (Kuspa and Loomis, 1992). This method involves the random 
insertion of linearized DNA (BamH1) from a plasmid carrying a selectable resistance 
gene (blasticidin resistance (BSR)) via electroporation with a restriction enzyme (Fig. 
1.6A and B). Digestion of the genomic DNA with the supplied restriction enzyme 
(DpnII or NlaIII) generates complementary sticky ends to those of the linearized 
plasmid (GATC), thus allowing the plasmid to become integrated into the genome at 
the site of digestion. DpnII and NlaIII are the restriction enzymes used to digest the 
gDNA, chosen since more than 95 % of the protein coding genes in Dictyostelium 
contain one of these sites (Guerin and Larochelle, 2002) (Fig. 1.6B). This technique 
generates random insertions within the genome of Dictyostelium thereby disrupting 
gene expression at the sites of integration. This REMI process has been optimised to 
produce a maximum of one gene disruption per Dictyostelium cell. Mutants are then 
selected for in the presence of blasticidin, generating a pool of mutants termed a 
“library” with a wide coverage of mutated genes (Guerin and Larochelle, 2002) (Fig. 
1.6C).  
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Mutant libraries generated using REMI mutagenesis can be used to identify 
Dictyostelium mutants with reduced sensitivity to compounds, either in growth (Fig. 
1.6D), development or cell behaviour, thus suggesting that the encoded proteins are 
potential targets for these compounds. The genes disrupted by the REMI insert can 
be determined by isolating the flanking DNA sequence on either side of the 
integrated plasmid. In this process a restriction enzyme (Rsa1) that cuts within the 
integrated plasmid and within the flanking DNA is used to digest the genomic DNA 
(Fig. 1.6E) before self-ligation to generate a circular piece of DNA (Fig. 1.6F). Primers 
from within the REMI integration plasmid can then be used to amplify the flanking 
DNA using PCR (Fig. 1.6F). The DNA sequence of this PCR product can then be 
determined through sequencing (Fig. 1.6G), either directly or following amplification 
in bacteria, and the resulting DNA sequence can be used to identify where in the 
genome the integration took place. In order to confirm that an identified gene 
disruption is responsible for the resistant phenotype, this gene must be 
independently disrupted to recreate the genotype and confirm the phenotype. This 
recapitulation can be carried out using either homologous integration of knockout 
cassettes (Faix et al., 2004) or by using the more recently established CRISPR/Cas9 
techniques (Sekine, Kawata and Muramoto, 2018). Through identifying and analysing 
Dictyostelium mutants lacking potential target proteins, the cellular mechanisms of 
target compounds can be rapidly explored. 
Dictyostelium provides a powerful model system, which has been well 
established in the fields of epilepsy, ketogenic diet, autophagy and mTORC1 research. 
Furthermore, Dictyostelium mutant libraries provide a valuable resource allowing the 
rapid identification of molecular targets for compounds. The position of 
Dictyostelium at the forefront of epilepsy research, and the availability of verified 
molecular genetic approaches, make this organism an appropriate model for 
investigating mechanisms of action of medium-chain fatty acids.  
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                                                               The REMI library is generated though A) the 
BamH1 digestion of a plasmid containing a blasticidin resistance (BSR) sequence. B) 
The resulting linearized plasmid DNA is electroporated into cells along with DpnII or 
NlaIII facilitating the integration of the plasmid sequence into the Dictyostelium 
genome. C) This technique allows the generation of libraries of Dictyostelium cells 
with thousands of different genes disrupted. D) These libraries can be screened for 
mutants resistant to the growth inhibitory effects of compounds. The disrupted 
genes leading to resistance can then be identified. E) To identify the disrupted genes 
first, genomic DNA is extracted from the mutants and digested using RsaI. F) This 
digested region is then subjected to self-ligation, and from this circularised DNA, 
primers from inside the known disruption cassette are used to PCR amplify the 
disrupted gene surrounding the insert. G) Sequencing of this amplified section 
allows the identification of the site of genomic integration. 
  
Figure 1. 6 Restriction enzyme-mediated integration (REMI) library generation, 
screening and gene identification.
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1.11 Aims and objectives 
The aim of this project was to investigate novel molecular targets for the 
medium-chain fatty acid, decanoic acid, provided by the MCT ketogenic diet. In order 
to achieve this, a molecular genetics approach was employed to screen a 
Dictyostelium mutant library for mutants resistant to the effects of decanoic acid. A 
role for the identified genes in the cellular response to decanoic acid were confirmed 
using independent gene knockouts, and the wider molecular pathways implicated by 
these genes were investigated for potential therapeutic benefits. Finally, novel 
findings from Dictyostelium were confirmed in a rat hippocampal slice model and in 
patient derived astrocytes.  
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Chapter 2 
 
Materials and methods 
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2.1 Cell culture 
Dictyostelium cell lines were stored at -80°C in freezing medium (Horse serum, 
7 % DMSO (VWR, VWRV0231)). Every month cells were taken from storage and grown 
on SM agar plates (ForMedium, SMA0102) in association with Raoultella planticola 
or axenically in HL5 media (ForMedium, HLB0103) with 10 % glucose (Sigma, G8270). 
HL5 media was supplemented with 100 units/ml penicillin and 100 µg/ml 
streptomycin (Thermo Fisher Scientific, 15140122), and cells were maintained at 22°C 
in shaking suspension at 220 rpm in flasks, or without shaking in tissue culture dishes.  
2.2 Growth assays 
Cells were washed from a confluent 9 cm dish and diluted to 2 x 104 cells/ml 
in HL5. Stocks of decanoic acid (Alfa Aesar, A14788), octanoic acid (Alfa Aesar, 
A11149) and 4-BCCA (Tokyo Chemical Industry, B1136) were made in DMSO to a final 
concentration of 1 M. Compound stocks (1 M) or DMSO as a solvent control, were 
added to 500 µl of cells (in triplicate) in a 24 well plate, to achieve final concentrations 
of 0 - 125 µM (0.2 % final DMSO concentration). Cells were incubated at 22°C and 
counted at 24-hour intervals after the first 74 hours.  
2.3 Development assay on nitrocellulose filters 
Exponentially growing Dictyostelium cells were harvested by centrifugation at 
500 g for 3 min, washed twice in KK2 and resuspended in KK2 at a density of 1 x 107 
cells/ml. Cells (1 ml) were pipetted evenly onto a whole nitrocellulose filter 
(Millipore, HABP04700) on top of Whatman® cellulose chromatography paper 
(Sigma, WHA3030917) allowing the absorption of excess KK2. Millipore absorbent 
pads (Merck, AP1004700), were cut into quarters and placed in to 2 ml culture dishes 
and soaked with 500 µl of compound or control. The nitrocellulose membranes 
supporting cells were cut into quarters and transferred onto the compound soaked 
absorbent pads. Cells were then left in a humid environment at 22°C for 22 hours, 
before developmental morphology was observed using a dissection microscope 
(Leica) and a QICAM FAST 1394 camera (QImaging). 
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2.4 Electroporation procedure 
Exponentially growing Dictyostelium cells were harvested, washed three 
times with ice-cold electroporation buffer (H50) and resuspended to a density of 5 x 
107 cells/ml. Cells (100 µl) were mixed with 4 µg to 8 µg of plasmid and left to rest on 
ice for 5 minutes, followed by exposure to two consecutive pulses of 650 V 
(capacitance- 25 μF) with a 5 second recovery between pulses in a chilled 1 mm gap 
electroporation cuvette (Sigma, Z706078-50EA). Cells were left on ice for 5 min 
before plating in HL5. Transfected knockout cells were selected for with 10 µg/ml 
blasticidin (BS) (Apollo Scientific, BIB4432) in 96 well plates, and overexpressor cells 
were selected for with 10 µg/ml G418 (Geneticin) (Sigma, A1720) or 10 μg/ml 
hygromycin (InvivoGen, ant-hg-5) in 10 cm dishes. 
2.5 Molecular biology methods 
2.5.1 Restriction digests 
Restriction digests were carried out according to manufacturer’s protocol (all 
restriction enzymes were obtained from Thermo Fisher Scientific). In cases where 
multiple enzymes were required, appropriate buffer conditions were found using the 
DoubleDigest Calculator—Thermo Fisher Scientific. 
2.5.2 Polymerase chain reaction 
Amplification of DNA was carried out using GoTaq® G2 Flexi DNA Polymerase 
(Promega, M7801), or Q5 high fidelity DNA polymerase (New England Biolabs, 
M0491). For routine PCR with GoTaq® G2 Flexi DNA Polymerase, a standard 20 µl 
reaction was carried out containing 0.5 μg DNA template, 4 μl 5x GoTaq® Flexi Buffer, 
2 mM MgCl2, 0.5 mM dNTP mix, 0.5 μM primers, 0.1 μl GoTaq® G2 Flexi DNA 
Polymerase (5 U/μl), made up to 20 μl with nuclease-free water (Sigma, W4502). For 
PCR reactions requiring proofreading activity Q5® high fidelity DNA polymerase was 
used in a 20 μl reaction containing 0.5 μg DNA template, 0.5 μM primers, 4 μl 5x Q5 
buffer, 0.5 mM dNTP mix, 0.2 μl Q5® DNA polymerase (2 U/μl), made up to 20 μl 
nuclease-free water. DNA amplifications were carried out using PCR with an initial 
denaturing step for step for 1 minute at 95°C, followed by 32 cycles of 95°C for 30 
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seconds (denaturation), 50-65°C (depending on primers) for 30 seconds (annealing) 
and 68°C for 1 minute per 1000 bps (extension) before a final extension step at 68°C 
for 10 minutes.  
2.5.3 Agarose gel electrophoresis 
 Gel electrophoresis was used to separate and visualise DNA. Gels were made 
containing 1 % agarose (Bioline, B10-41026) with TAE buffer (Severn Biotech Limited, 
20-6001-50) and ethidium bromide (Bio-Rad, 1610433). 5x loading buffer (Bioline, 
BIO-37045) was added to DNA samples before running, and 1 kb plus hyperladder 
(Bioline, BIO-33026) was used as a marker for DNA size. Gels were run at 100 V for 30 
minutes in TAE buffer. DNA was visualised using UV. 
2.6 Mutant library screen 
A Dictyostelium REMI mutant library containing 28000 insertional mutants 
was provided by Professor Harwood (Cardiff University) and Professor Thompson 
(Manchester University). This library was created using Ax4 cells transfected with the 
restriction enzymes DpnII and NlaIII and linearized DNA (REMI plasmid digested with 
BamH1) containing the blasticidin resistance (BSR) sequence. This process facilitated 
the incorporation of the BSR DNA into the genome at compatible sites, thus 
disrupting the genes at the sites of integration (Fig. 1.6A and B). Mutants were 
selected for in the presence of blasticidin.  
To select for resistant mutants, the library was screened alongside Ax4 as a 
control. Mutant library cells or control Ax4 cells at 1.25 x 104 cells/ml were prepared 
in either compound or 0.5 % DMSO control. Cells (2 ml) were added to each well of a 
6 well plate resulting in 2.5 x 104 cells/well. Plates were left to grow until resistant 
colonies appeared, with the media being replaced every 3 days (Fig. 1.6D). 
Once colonies appeared in the mutant library wells, these colonies were 
isolated and grown up on Raoultella planticola SM agar plates to allow selection of 
isogenic colonies. Isogenic colonies were selected from the bacterial plates and the 
rate of growth of these colonies in compound was compared to that of the REMI 
library and wild type (Ax4) to confirm resistance.  
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2.6.1 Identifying disrupted genes 
 Genomic DNA (gDNA) extraction of the resistant Dictyostelium mutants was 
carried out using Qiagen DNeasy kit (Qiagen, 69504) according to manufacturer’s 
protocol. gDNA (10 µl) was digested with 5 units of Rsa1 (Thermo Fisher Scientific, 
ER1122) at 37 ᵒC for 2 hours in Tango buffer (Thermo Fisher Scientific, BY5). The 
digest was purified by ethanol precipitation using 0.1 x 3 M sodium acetate (Sigma, 
S2889) and 2x 100 % Ethanol (VWR, 20821.330DP) to precipitate the DNA at -20° 
which was then collected by centrifugation at 16,000g for 15 minutes. The DNA was 
then resuspended in nuclease-free water and circularised by ligation with T4 DNA 
ligase (Fermentas, 15224041) at room temperature for 1 hour (0.5 µl ligase per 10 µl 
reaction). The genomic sequence flanking the BsR insertion site was amplified by PCR 
with primers p09 and p10 (or p11 and p13) (Fig. 2.2) with an annealing temperature 
of 50°C.  
PCR products were either spin column purified (Qiagen, 28104), according to 
manufacturer’s protocol, and sent directly for sequencing or were ligated into the 
TOPO pCR® 2.1 vector and cloned into competent E. coli (TOP10) using TOPO TA 
Cloning® kit (Invitrogen, K450002) according to manufacturer’s protocol. Plasmid 
DNA was isolated from the bacteria using the Qiagen miniprep kit (Qiagen, 27104) 
according to manufacturer’s protocol. This DNA was then sequenced using the 
sequencing primers T7 and M13 (Fig. 2.2). 
2.7 Bioinformatics 
2.7.1 Protein sequence analysis 
Sequences of proteins were taken from dictybase (http://dictybase.org) or 
uniprot (http://www.uniprot.org). Regions of similarity between proteins were found 
using the Basic Local Alignment Search Tool (BLAST) (https://blast.ncbi.nlm.nih.gov). 
Sequences were aligned using Clustal (http://www.ebi.ac.uk/Tools/msa/clustalo/) 
which annotates sequence homology results across the whole protein. The program 
MEGA 7 was used to generate neighbour joining phylogenetic trees from these 
alignments (http://www.megasoftware.net). Domains were identified based on 
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annotations from InterPro (https://www.ebi.ac.uk/interp ro/) and Oma Browser 
(http://omabrowser.org/oma/home/). 
2.7.2 Predicted protein-ligand docking analysis 
The tertiary structure of the Dictyostelium UBXD18 protein was predicted 
using Phyre2 (protein Homology and Analogy Recognition Engine V2.0) in the 
intensive modelling mode (Kelley et al., 2015). SwissDock was used to provide protein 
docking predictions for decanoic acid and octanoic acid (Grosdidier, Zoete and 
Michielin, 2011a; Grosdidier, Zoete and Michielin, 2011b). Predicted docking files 
were visualised using UCSF chimera. 
2.8 Knockout generation 
2.8.1 Generation of knockout construct 
Two techniques were employed for knockout generation. To knockout the 
gene ubxd18 (official gene name DDB_G0276057) a knockout cassette was generated 
by PCR amplification over the REMI insert site of the REMI mutant DNA. This 
generated a construct with approximately 500 bp of gene homology on either side of 
the REMI insert sequence conveying blasticidin resistance. The PCR product was 
purified by spin column according to the manufacturer’s protocol (Qiagen, 28104), 
then 6 μg was electroporated into Dictyostelium cells. This resulted in disruption of 
the ubxd18 gene through homologous recombination. 
 To knockout the transketolase gene (tkt) a knockout construct was generated 
by PCR amplifying two sequences (arms) of approximately 500 bp from the 5’ and 3’ 
regions of the tkt gene sequence. A BamH1 site was inserted at the 5’ end of the 5’ 
arm and a pstI site at the 3’ end of this arm. A Nco1 site was inserted at the 5’ end of 
the 3’ arm and a HindIII site at the 3’ end of this arm. These arms were cloned 
sequentially into the pLPBLP vector at sites flanking the gene for blasticidin resistance 
(BSR).  This process generated a disruption fragment with arms homologous to tkt 
flanking the BSR gene. Transfection of 6 μg of this knockout construct into wild type 
Dictyostelium resulted in disruption of the tkt gene via homologous recombination. 
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2.8.2 Screening for knockout cell lines 
Cells transfected with the knockout constructs were grown in HL5 
supplemented with 10 μg/ml of blasticidin in several 96 well plates. Cells resistant to 
blasticidin were collected and centrifuged in PCR tubes before lysis in 24 μl lyse B 
buffer and 1 μl proteinase K (Fermentas, EO0491). Cells were incubated at room 
temperature for 5 minutes before heat inactivation at 95°C for 5 minutes. The 
resulting cell lysate was used in PCR analysis to identify successful homologous 
recombinants. To screen for a ubxd18 knockout, primers were designed that would 
generate 7 diagnostic fragments unique to the knockout (Fig. 2.2). To screen for a tkt 
gene knockout, primers were designed that would generate 6 diagnostic fragments 
(Fig. 2.2) 
2.8.3 RT-PCR to confirm knockout 
RNA was extracted from the wild type and the knockout cell lines using 
RNeasy mini kit (Qiagen, 74104) according to the manufacturer’s protocol. DNA was 
removed from the RNA using the DNA-free kit (Invitrogen, AM1906) according to the 
manufacturer’s protocol. cDNA was synthesised using the RevertAid First Strand 
cDNA Synthesis Kit using oligo(dT)18 primers (Thermo Fisher Scientific, K1621) 
according to the manufacturer’s protocol. PCR amplification of the knockout gene 
and Ig7 (positive control, DDB_G0294034) was carried out (Fig. 2.2). 
2.8.4 qPCR to confirm knockdown 
RNA was extracted from the wild type and the knockout cell lines using 
RNeasy mini kit (Qiagen, 74104) according to the manufacturer’s protocol. DNA was 
removed from the RNA using the DNA-free kit (Invitrogen, AM1906) according to the 
manufacturer’s protocol. cDNA was synthesised using the RevertAid First Strand 
cDNA Synthesis Kit using oligo(dT)18 primers (Thermo Fisher Scientific, K1621) 
according to the manufacturer’s protocol. qPCR was carried out using primers within 
the region of tkt disrupted in the tkt null cell line (TKT-) and the Ig7 gene was used as 
an internal control (Fig. 2.2). qPCR was carried out using SYBR® Green JumpStart™ 
Taq ReadyMix™ (Sigma, S4438), and relative quantification was carried out using the 
2−ΔΔCt method. 
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2.9 Generation of overexpressor cell lines 
2.9.1 Creation of GFP-UBXD18, GFP-FcsA and p97-RFP constructs  
RNA was extracted from wild type cells using the RNeasy mini kit (Qiagen, 
74104) according to the manufacturer’s protocol. DNA was removed from the RNA 
using the DNA-free kit (Invitrogen, AM1906) according to the manufacturer’s 
protocol. cDNA was synthesised using the RevertAid First Strand cDNA Synthesis Kit 
using oligo(dT)18 primers (Thermo Fisher Scientific, K1621) according to the 
manufacturer’s protocol. ubxd18, fcsA or p97 cDNA was amplified using primers 
designed to amplify the whole length of the coding sequence (Fig. 2.2). ubxd18, fcsA 
or p97 cDNA was cloned into extrachromosomal vectors (ptx-GFP, ptx-GFP and 
pdm451-RFP respectively) and the resulting plasmids were sequenced by sanger 
sequencing to confirm that no mutations were introduced, before electroporation 
into Dictyostelium cells. Transfected overexpressor cells were selected for with 10 
µg/ml G418 (ptx-GFP) or 10 µg/ml hygromycin (InvivoGen, ant-hg-1) (pdm451-RFP). 
2.9.2 Western blotting for GFP-tagged and RFP-tagged proteins 
Western blotting for GFP-tagged and RFP-tagged proteins was used to 
confirm functionality of expression constructs. Whole cell lysates were prepared 
harvesting cells by centrifugation at 500 g for 3 min followed by lysis in RIPA buffer 
(10 x 107 cells/ml) containing protease inhibitor (Roche, 04693159001), before mixing 
1:1 in 2x laemmli buffer resulting in 5 x 107 cells/ml. Lysates were boiled in laemmli 
at 95°C for 5 minutes before vortexing, and centrifuging at max speed for 5 minutes. 
Samples (8 µl) were fractioned using a 12.5 % gel, and transferred to a PVDF 
membrane (Millipore, IPFL00010) by wet transfer using transfer apparatus according 
to the manufacturer’s protocols (Bio-Rad, UK). After incubation with 5 % BSA (Thermo 
Fisher Scientific, AM2616) in PBS (Thermo Fisher Scientific, 10010023) for 60 min, the 
membrane was incubated in 5 % BSA in PBS with antibodies against GFP (Chromotek, 
3H9, 1:1000) or RFP (Chromotek, 5F8, 1:1000) at 4°C overnight. Membranes were 
washed in PBST and incubated with a 1:10000 dilution of odyssey goat anti-rat IR DYE 
800 (Li-Cor Biosciences, UK), and 1 in 10000 streptavidin (Thermo Fisher Scientific, 
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UK) in 5 % BSA in PBS for 1h. Blots were washed in PBST and visualised using the 
Odyssey CLx imager (LI-COR). 
2.10 Fluorescent microscopy 
Cells expressing the fluorescently tagged proteins GFP-UBXD18, GFP-FcsA and 
p97-RFP were assessed using fluorescent microscopy. Cells were washed and 
resuspended in KK2 before being photographed under 1 % KK2 agar (Sigma, A5306) 
using an Olympus IX71 wide-field fluorescence microscope at 96 x magnification. 
Images were captured using a QICAM FAST 1394 camera. 
2.11 Methanol fixation and immunofluorescence 
Glass coverslips were prepared by submersion in 50 % nitric acid (VWR, 
20425.242) for two hours, before the nitric acid was decanted and the coverslips 
were washed 10 times in 100 % ethanol. Coverslips were placed into the base of a 12 
well plate and cells in liquid media added and allowed to adhere overnight. The next 
day coverslips supporting adhered cells were briefly dabbed on tissue to remove 
excess media then plunged into -80°C methanol (Sigma, 179337). Fixed coverslips 
were then placed into a rack at the base of the ultra-cold methanol beaker for 30 
minutes. Coverslips were removed and plunged 4 times into a beaker of room 
temperature PBS (Thermo Fisher Scientific, 10010023). Cells were then blocked for 
30 minutes by inverting each coverslip onto a 50 μl drop of 5 % BSA (Thermo Fisher 
Scientific, AM2616) in PBS on a piece of para-film (Sigma, P7793). Excess blocking 
agent was removed, and the coverslip was inverted onto a second 50 μl drop of PBS 
containing 5 % BSA and primary antibodies (GFP tag monoclonal mouse (Proteintech, 
66002-1), and RFP antibody rat (chromotek, 5F8)). After incubation with primary 
antibodies for 1 hour, the coverslips were washed twice by placing coverslips in the 
well of a 12 well plate containing 3 ml of PBS and soaked for 5 minutes each time. 
Coverslips were then inverted onto a 50 μl drop of PBS containing 5 % BSA and 
secondary antibodies (goat anti mouse alexafluor 568 IgG (Thermo Fisher Scientific, 
A-11004), rabbit anti rat alexafluor 488 IgG (Thermo Fisher Scientific, A-21210). After 
incubation for 1 hour, the coverslips were washed twice in PBS as before, plus a final 
wash in ddH2O to remove excess salt. All coverslips were mounted onto glass slides 
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using Fluoromount-GTM, with DAPI (Thermo Fisher Scientific, 00-4959-52). 
Fluorescent images were obtained using an Olympus IX71 wide-field fluorescence 
microscope. Images were captured using a QICAM FAST 1394 camera. 
2.12 Immunoprecipitation  
GFP-Trap®A beads were used for Immunoprecipitation of GFP-fusion proteins 
according to the manufacturer’s protocol (Chromotek, gta). Briefly, Dictyostelium 
cells (1 × 107) co-expressing the indicated GFP-tagged and the RFP-tagged proteins 
were pelleted and washed in nutrient free phosphate buffer (KK2) before being 
suspended in GFP-trap Lysis buffer. The extract was centrifuged, and the pellet was 
discarded. The lysate was diluted with dilution buffer and incubated for 1 hour at 4°C 
with GFP-trap beads (Chromotek, gta). The beads were washed with dilution buffer, 
suspended in laemmli and boiled at 100°C for 5 min before running on an SDS-PAGE 
gel for analysis (as described 2.9.2).  
2.13 ATPase assay  
Dictyostelium cells (wild type or UBXD18- expressing p97-RFP) in the 
exponential phase of growth were treated for 24 hours with compound (60 μM 
decanoic acid, 120 μM octanoic acid or 7.5 μM p97 inhibitor DBeQ (Tocris Bioscience, 
4417). RFP-Trap®A beads were used for the immunoprecipitation of RFP-tagged 
proteins (p97-RFP) (Chromotek, rta). Following immunoprecipitation the RFP-Trap®A 
beads were washed with dilution buffer, and suspended in 10 μl HNG buffer, and 
used for ATPase activity analysis using the malachite green phosphate assay kit 
(Sigma, MAK307) according to published methodology (Rule et al., 2016) and 
manufacturer’s procedure. Briefly, ATP hydrolysis reactions were set up using 5 μl of 
RFP-Trap®A beads, 6 μl of 5x HNG buffer, 1.5 μl of MgCl2 (100 μM) (Sigma, M8266) 
and 1.5 μl of ATP (100 μM) (Sigma, A2383), and 16 μl H2O. The reaction was incubated 
at 37°C for one hour with 5 μl aliquots removed at 15-minute intervals and diluted 
1:50 in HNG buffer before freezing on dry ice. Free phosphate concentrations were 
assessed using the malachite green phosphate assay kit according to manufacturer’s 
instructions (Sigma, MAK307). Phosphate concentrations were standardised to 
protein concentration measured directly on the beads using a Bradford assay.  
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2.14 Autophagy quantification 
Cells transfected with a vector designed to express atg8a with an N-terminal 
GFP tag, GFP-Atg8, were set up at a density of 1.33 x 106 cells/ml in 6 well plates. Cells 
were pre-treated with decanoic acid (60 μM), octanoic acid (120 μM) or DMSO 
control for 22 hours or 2 hours to provide final treatment durations of 24 and 4 hours. 
Autophagy inducer AR-12 (Selleckchem, OSU-03012), or DMSO control, was added 
and shaking was continued for 1 hour before addition of protease inhibitors (Roche, 
11873580001) at a final concentration of 2.5-fold, or HL5 control. Shaking was 
continued for 1 hour before cells were removed (without additional pipetting) to 
tubes on ice. Cells were put aside for microscopy or were centrifuged for 3 min at 500 
g at 4°C and prepared for western blot analysis of GFP levels (as described 2.9.2). 
Western blots were normalised to loading control (MCCC1) and free gfp/MCCC1 and 
GFP-Atg8/MCCC1 values were adjusted to the average readout for each blot. 
2.14.1 Microscopy analysis of autophagosomes 
For live-cell imaging, cells were washed and resuspended in KK2 and were 
imaged under a layer of 1 % KK2 agar. Time in KK2 and time under agar was kept 
constant between each condition (20 minutes in KK2, and 5 minutes under agar). 
Cells were imaged on an Olympus IX71 wide-field fluorescence microscope. Images 
were captured using a QICAM FAST 1394 camera. For size and number measurement 
of GFP-Atg8-positive structures (autophagosomes), images were analysed using 
ImageJ and GFP-Atg8-positive structures were measured across the largest diameter. 
Thirty cells or autophagsomes were analysed per experiment. 
2.14.2 qPCR analysis of autophagy genes 
Exponentially growing cells were treated for 1, 4 or 24 hours with either 
decanoic acid (60 μM), octanoic acid (120 µM) or solvent (DMSO) control). RNA was 
extracted from these samples using the RNeasy mini kit (Qiagen, 74104) according to 
the manufacturer’s protocol. DNA was removed from the RNA using the DNA-free kit 
(Invitrogen, AM1906) according to the manufacturer’s protocol. cDNA was 
synthesised using the RevertAid First Strand cDNA Synthesis Kit using oligo(dT)18 
primers (Thermo Fisher Scientific, K1621) according to the manufacturer’s protocol. 
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qPCR was carried out using primers within the genes for atg8a and atg1, and the 
gapdh gene was used as an internal control (Fig. 2.2). qPCR was carried out using 
SYBR® Green JumpStart™ Taq ReadyMix™ (Sigma, S4438), and relative quantification 
was carried out using the 2−ΔΔCtmethod. 
2.15 Detection of PIP3 production 
Cells expressing green fluorescent protein (GFP) fused to the pleckstrin 
homology domain of cytosolic regulator of adenylyl cyclase (PHCRAC-GFP) (Nichols et 
al., 2019) were made chemotactically competent as described (Kamimura, Tang and 
Devreotes, 2009). Briefly, cells were washed twice in development buffer (DB) before 
being resuspended in DB to 2 x 107
 
cells/ml and rotated for 1 hour at 110 rpm. Cells 
were pulsed with 60 nM of cAMP (Sigma, A6885) every 6 mins for 4 hours, in the 
presence or absence of compound (60 µM decanoic acid or octanoic acid). Cells were 
basalated by the addition of caffeine (Sigma, C0750) to a final concentration of 5 mM, 
with rotation at 200 rpm for 30 mins, before being washed twice in cold DB buffer 
and resuspended to 2 x 107 cells/ml. For time-lapse imaging of PIP3 production, 360 
µl chemotactically competent cells expressing PHCRAC-GFP at 5 x 105
 
cells/ml were 
placed into a well of a 8-well chambered cover glass (Thermo Fisher Scientific, 
10384221) (PI3K inhibitor, LY294002 (Selleckchem, S1105) was added to one sample 
at a final concentration of 100 µM), and left to adhere for 10 minutes. Cells were 
stimulated by adding cAMP, to a final concentration of 1 µM, and images were 
captured every 2 seconds for 1 minute, using an Olympus IX71 wide-field 
fluorescence microscope and QICAM FAST 1394 camera. Images were analyzed using 
ImageJ where mean gray value of the cell membrane was quantified over time and 
adjusted relative to mean gray value of the whole cell. 
2.16 Analysis of mTORC1 signalling 
2.16.1 Preparation of Dictyostelium samples for western blot  
 Dictyostelium cells were treated as specified before centrifugation at 500 g 
for 3 min followed by direct cell lysis in 2x laemmli (7.5 x 107 cells/ml). Samples were 
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boiled at 98°C for 6.5 minutes, centrifuged at max speed and 6 µl (equivalent to 30 
µg) was loaded onto an SDS-PAGE gel. 
2.16.2 Preparation of rat hippocampal slices for western blot  
 Rat hippocampal slices were prepared by Dr Eleonora Lugarà in the lab of 
Professor Mathew C Walker at the Department of Clinical and Experimental Epilepsy, 
Institute of Neurology, University College London, as described. Sprague Dawley rats 
(approximately 270 g, males and females) were deeply anesthetised with 2 % to 3 % 
isoflurane in oxygen (2 L/min) and once unresponsive to toe and tail pinch, the animal 
was decapitated. The brain was quickly removed and placed in a glass Petri dish filled 
with bubbled ice cold artificial cerebral spinal fluid (125 mM NaCl, 26 mM NHCO3, 15 
mM Glucose, 1.25 mM NaH2PO4, 2.5 mM KCl, 1.3 mM MgSO4 7 H2O, 2 mM CaCl2, pH 
7.4 and osmolality 305-310 mOsm). Coronal slices (350 μm) were sliced with a Leica 
VT1200 vibrating blade microtome. Hippocampal slices were quickly transferred to 
submerged chambers (95 % O2, 5 % CO2) containing either artificial cerebral spinal 
fluid only or artificial cerebral spinal fluid with solvent control (DMSO), 100 μM or 
300 μM Decanoic acid (Sigma Aldrich #C1875) in DMSO. The chambers were placed 
into a warm bath (34°C) for 20 minutes and then moved at room temperature for 40 
min in carbonated standard recording cerebral spinal fluid. Samples were snap frozen 
in liquid nitrogen and lysed in a mixture of RIPA buffer (150 mM sodium chloride, 1.0 
% Triton X-100, 0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sulfate, 50 mM Tris, 
pH 8.0. Sigma Aldrich, R0278) and protease inhibitors (Thermo Fisher Scientific, 
#A32963). The tissue was mechanically disrupted by a mechanical rotor type 
homogenizer (FastPrep-24, MP Biomedicals LLC) with the use of homogenizer beads 
(SLS Scientific Laboratory Supplies, D1031-01). The samples were then centrifuged at 
max speed for 10 minutes, the pellet discarded and stored at -80°C. All further 
analysis was carried out by Eleanor Warren. Protein concentrations were determined 
by Bradford assay. Samples were mixed 1:1 with 2x laemmli and centrifuged at max 
speed for 10 minutes at 4ᵒC before 15 µg of protein was analysed by western blot 
(without boiling). 
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2.16.3 Patient derived astrocyte differentiation and preparation for western blot  
Patient derived astrocytes were prepared by Dr Stephanie Dooves, in the lab 
of Professor Vivi M Heine, at Vrije Universiteit Amsterdam, as described. iPSCs from 
3 individual control patients (hVS-228, hVS-420, and hVS-421), 2 patients with TSC1 
mutations (TSC1-) (hVS233, and hVS-401), and 2 patients with TSC2 mutations (TSC2-
) (hVS-417, hVS-424), were differentiated into astrocytes as described in Nadadhur et 
al. (2018) (Nadadhur et al., 2018). At day 45 of the differentiation protocol cells were 
switched to Sanbio medium to form a pure astrocyte culture and maintained until 
day 76. At day 76 astrocytes were plated on geltrex coated 12 well plates in Sanbio 
astrocyte medium and allowed to recover from plating. At day 80, half of the medium 
was refreshed with Sanbio astrocyte medium containing either decanoic acid (final 
concentration in well: 300 μM) or DMSO. After 24 hours, cells were harvested by 
removing medium, adding 50 μl lysis buffer (50 mM HEPES, 150mM NaCl, 1mM EDTA, 
2.5 mM EGTA, 0.1 % Triton X-100, 10 % glycerol, 1mM DTT, 1x protease inhibitor, 1x 
phosphatase inhibitor) per well on ice and scraping cells off the plate. Cells from each 
well were collected in a tube and frozen at -80°C (n = 12 per patient). All further 
analysis was carried out by Eleanor Warren. Protein concentrations were determined 
by Bradford assay. Samples were mixed 1:1 with 2x laemmli and centrifuged at max 
speed for 10 minutes at 4ᵒC before 7.5 µg of protein was analysed by western blot 
(without boiling). 
2.16.4 Western blotting for p-4E-BP1, total-4E-BP1, p-ATK-substrate, p-AMPK, p-
S6K and total-S6K 
Samples were fractioned using a 15 % gel for p-4E-BP1, total-4E-BP1 and p-
AKT-substrate and a 10 % gel for p-AMPK, total-AKT, p-AKT(Ser473), p-AKT (Thr308), 
p-S6K and total-S6K. Proteins were transferred to a 0.2 µm polyvinylidene difluoride 
membrane (Thermo Fisher Scientific, 88520) (p-4E-BP1 and total-4E-BP1), a 0.45 µm 
polyvinylidene difluoride (Millipore, IPFL00010) (p-AKT-substrate), or a 0.2 µm 
nitrocellulose membrane (Thermo Fisher Scientific, 15249794) (p-AMPK, total-AKT, 
p-AKT(Ser473), p-AKT (Thr308), p-S6K and total-S6K) by wet transfer at 15 Volts 
overnight (p-4E-BP1 and total-4E-BP1) or 90 Volts for 90 minutes (p-AKT substrate, p-
AMPK, total-AKT, p-AKT (Ser473), p-AKT (Thr308), p-S6K and total-S6K) using transfer 
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apparatus according to the manufacturer’s protocols (Bio-Rad, UK). After incubation 
with 5 % milk in TBS for 1 to 4 hours, the membranes were incubated in 5 % milk in 
TBST with antibodies against p-4E-BP1 (1:1000 p-4E-BP1(Thr37/46) rabbit antibody, 
cell signalling technology, 9459S), total-4E-BP1 (1:1000 non-phospho-4E-BP1 (Thr46) 
rabbit antibody, cell signalling technology, 4923), p-AKT substrate (1:1000 Phospho-
Akt Substrate rabbit antibody, cell signalling technology 10001), p-AMPK (1:2000 
Phospho-AMPKα (Thr172) (40H9) rabbit antibody, cell signalling technology 2535), or 
p-S6K (1:1000, Phospho-p70 ribosomal protein S6 kinase (Thr421/Ser424) rabbit 
antibody, 9204) or total-S6K (1:1000, p70 ribosomal protein S6 Kinase rabbit 
antibody, 9202), and streptavidin (1:5000 Streptavidin, Alexa Fluor™ 680 conjugate, 
Thermo Fisher Scientific, S21378) as a loading control for Dictyostelium samples, or 
β-Actin (Sigma, A1978)  as a loading control for rat hippocampal samples and 
astrocytes at 4°C overnight. Alternatively, membranes were incubated with 5 % BSA 
in TBS for 1 hour before incubation with antibodies against p-AKT (Ser473) (1:2000 
Phospho-AKT (Ser473) rabbit antibody, cell signalling technology, 4060), p-AKT 
(Thr308) (1:1000 Phospho-AKT (Thr308) rabbit antibody, cell signalling technology, 
9275), or total-AKT (1:5000 AKT rabbit antibody, cell signalling technology 9272) at 
4°C overnight. The next day membranes were washed in TBST and incubated with a 
1:2000 dilution of polyclonal goat anti-rabbit immunoglobulins/HRP (Agilent 
Technologies, DAKO P0448) (for p-4E-BP1, total 4E-BP1, and p-S6K) or a 1:10000 
dilution of IRDye® 800CW goat anti-rabbit IgG secondary antibody (LI-COR, 925-3221) 
(for p-AKT-substrate, total-AKT, p-AKT (Ser473), p-AKT (Thr308), p-AMPK and total-
S6K), and a 1:10000 goat anti-mouse antibody (Cell signalling technology, 5470) (for 
β-Actin) in 5 % milk or BSA (as described) in TBST for 1 hour (Fig. 2.1). Blots were 
washed in TBST and visualised using the Odyssey CLx imager (LI-COR). For p-4E-BP1, 
total-4E-BP1 and p-S6K Odyssey chemifluorescent substrate kit (Li-Cor Biosciences, 
Odyssey®Chemifluorescent Substrate Kit 928-30005) was used according to the 
manufacturer’s protocols. 
2.17 Statistical analysis  
The distribution of all experimental data was tested using the D'Agostino and 
Pearson omnibus normality test. Independent data showing a Gaussian distribution 
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were analysed using parametric tests. Normally distributed data from two groups 
were statistically analysed using two-tailed unpaired t-tests. The one-way ANOVA 
statistical test was used to test for significance between the means of three or more 
independent groups of normally distributed data, in conjunction with Dunnett’s post 
hoc test. Two-tailed non-parametric Mann-Whitney tests were used to assess 
significance between independent samples from two groups not showing a Gaussian 
distribution. The Kruskal-Wallis test with Dunn’s post hoc test was used to test 
significance between three or more independent groups of data not showing a 
Gaussian distribution. Western blot data from patient derived astrocytes showed a 
Gaussian distribution and were analysed using nested t-tests to account for a lack of 
independence between astrocytes from individual patients cultured in separate 
wells. Throughout this thesis where no significance is indicated, p > 0.05. Statistical 
analysis was carried out using GraphPad Prism Software.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S 
P 
p-4E-BP1 
1° p-4E-BP1 rabbit  
2° goat α-rabbit  
HRP conjugate 
Substrate  
Product 
Fluorescence (700 nm) 
p-AKT-S 
1° p-AKT rabbit 
mouse  
2° goat α-rabbit IgG 800CW  
B 
A 
                                                                                              A) For western blotting (e.g. p-
AKT-S) we used secondary antibodies conjugated to fluorescent dyes (e.g. goat α-
rabbit IgG 800CW) for direct detection at 700 nm or 800 nm. B) When monitoring 
difficult to detect small phospho-proteins (e.g. p-4E-BP1) we employed a secondary 
antibody conjugated to horseradish peroxidase (HRP) (e.g. goat α-rabbit-HRP), in 
combination with a chemifluorescent substrate (S). HRP catalyses the conversion of 
the substrate (S) into a stable fluorescent compound (P) that can be detected at 700 
nm allowing improved sensitivity over near infrared antibody detection.  
Figure 2. 1 Western blotting antibody types used.
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2.18 Buffers, gels and reagents 
Bradford reagent 
50 mg Coomassie Brilliant Blue G-250 (Sigma, 1154440025), 50 ml Methanol (Sigma, 
179337), 100 ml 85 % (w/v) phosphoric acid (Sigma, W290017), 850 ml H2O. 
 
Development buffer (DB) 
100  ml 10 ×  phosphate  buffer, 1 ml 2 M MgSO4 (Sigma, M7506), 0.2 ml 1 M CaCl2 
(Sigma, 449709), 989.8 ml H2O. 
 
GFP trap dilution buffer 
10 mM Tris/HCl pH 7.5 (Trizma-Sigma, T1503) (HCl-VWR, 20252), 150 mM NaCl, 0.5 
mM EDTA (Sigma, E9884). 
 
GFP trap lysis buffer 
10 mM Tris/HCl pH 7.5 (Trizma-Sigma, T1503) (HCl-VWR, 20252), 150 mM NaCl 
(Sigma, S9888), 0.5 mM EDTA (Sigma, E9884), 0.5 % NP-40 substitute (Sigma, 74385). 
 
H50 buffer 
20 mM HEPES (Sigma, H3375), 50 mM KCl (Sigma, P9333), 10 mM NaCl (Sigma, 
S9888), 1 mM MgSO4 (Sigma, M7506), 5 mM NaHCO3 (Sigma, S5761), 1 mM NaH2PO4 
(Sigma, S8282), pH 7.0. 
 
HNG Buffer 
 
20 mM HEPES pH 8.5 (Sigma, H3375), 13 mM NaCl (Sigma, S9888), 1 % glycerol 
(Sigma, G2025). 
 
Laemmli (2x) 
0.001 g Bromophenol blue (Sigma, B0126), 3 ml 2-mercaptoethanol (Sigma, M6250), 
6 ml 100 % glycerol (Sigma, G2025), 12 ml 10 % SDS (Sigma, L5750), 7.5 ml Tris-HCl 
(0.5 M pH 6.8) (Trizma-Sigma, T1503)(HCl-VWR, 20252), 1.5 ml H2O. 
 
Lyse B 
10 mM TRIS-HCl pH 8.3 (Trizma-Sigma, T1503) (HCl-VWR, 20252), 50 mM KCl (Sigma, 
P9333), 2.5 mM MgCl2 (Sigma, M8266), 0.45 % TWEEN (Sigma, P1379), 0.45 % NP40 
substitute (Sigma, 74385). 
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Nutrient free phosphate buffer (KK2) 
6.2 mM KH2PO4 (Sigma, NIST200B), 4 mM K2HPO4 (Sigma, 1551128). 
 
PBST 
0.1 % Tween20 (Sigma, P1379) in 1 Litre phosphate-buffered saline (PBS) (Thermo 
Fisher Scientific, 10010023). 
 
Phosphate buffer (10X) 
6.8 g KH2PO4 (Sigma, NIST200B), 13.4 g Na2HPO4·7H2O (Sigma, 431478), H2O to 1 litre. 
 
 
Radioimmunoprecipitation assay buffer (RIPA) 
10 mM Tris/Cl pH 7.5, (Trizma-Sigma, T1503) (HCl-VWR, 20252), 150 mM NaCl (Sigma, 
S9888),  0.5 mM EDTA (Sigma, E9884), 0.1 % SDS, (Sigma, L5750),  1 % Triton X-100 
(Sigma, X100), 1 % Deoxycholate (Sigma, D6750). 
 
Resolving gel (10 %) 
3.3 ml acrylamide (Sigma, 1006391000), 2.5 ml Tris-HCl (1.5 M pH 8.8) (Trizma-Sigma, 
T1503) (HCl-VWR, 20252), 4 ml dH20, 100 μl 10 % SDS (Sigma, L5750), 100 μl 
Ammonium persulphate (Sigma, A3678), 4 μl TEMED (Sigma, T9281). 
 
Resolving gel (12.5 %) 
4.15 ml acrylamide, 2.5 ml Tris-HCl (1.5 M pH 8.8), 3.15 ml H20, 100 μl 10 % SDS, 100 
μl Ammonium persulphate, 4 μl TEMED. 
 
Resolving gel (15 %) 
5 ml acrylamide, 2.5 ml Tris-HCl (1.5 M pH 8.8), 2.3 ml H20, 100 μl 10 % SDS, 100 μl 
Ammonium persulphate, 4 μl TEMED. 
 
Stacking gel 
212.5 μl acrylamide, 78.75 μl Tris-HCl (0.5 M pH 6.8), 0.938 μl dH20, 12.5 μl 10 % SDS, 
12.5 μl 10 % APS, 3.75 μl TEMED. 
 
TBST 
0.1 % Tween20 in 1 Litre Tris-buffered saline (TBS) (Thermo Fisher Scientific, 
10776834). 
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2.19 Primers 
All primers were obtained from Sigma. 
Figure 2. 2 Table of primers.  
 
No. Primer 
name 
Use Sequence (Restriction sites, underlined) Cut site 
1 p9 Inverse PCR of 
mutant library 
and screening 
knockouts 
5’-TGTATGCTATACGAAGTTATCC-3’  
2 p10 Inverse PCR of 
mutant library 
5’-GTAGAAGTAGCGACAGAGAAG-3’  
3 p11 Inverse PCR of 
mutant library 
5’-CCATTCGAAACTGCACTACC-3’  
4 p13 Inverse PCR of 
mutant library 
and screening 
knockouts 
5’-TGAATGGTGAAGATAAATATATGC-3’  
5 M13  Sequencing 
TOPO cloned 
PCR products 
5’-CAGGAAACAGCTATGACC-3’  
6 T7 Sequencing 
TOPO cloned 
PCR products 
5’-TAATACGACTCACTATAGGG-3’  
7 UbxF ubxd18 KO 
generation 
screening and 
RT-PCR 
5’-ATAGTCAAGGTGTTAGAGCAATGCC-3’  
8 UbxR ubxd18 KO 
generation 
screening and 
RT-PCR 
5’-ATGCCATTTGGTGAGAGCTTG-3’  
9 5’ubxSF  Screening 
ubxd18 KO (5’ 
genomic control, 
5’ knockout with 
p9) 
5’-ATAATGTCAAGAGTAAAAGGTGAGT-3’  
10 5’ubxSR Screening 
ubxd18 KO (5’ 
genomic control) 
5’-ATAATGCAAATGAAAGTTGTGGTTG-3’  
11 3’ubxSF Screening 
ubxd18 KO (3’ 
genomic control) 
5’-ATAGATATAAATGTAAGGTTTGCCC-3’  
12 3’ubxSR Screening 
ubxd18 KO (3’ 
genomic control, 
3’ knockout with 
p13) 
5’-ATAGACCAGCATCTTGAACTGAA-3’  
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13 Ig7F RT-PCR for Ig7 
control 
5’-GTACTGTGAAGGAAAGATGAAAAG-3’  
14 Ig7R RT-PCR for Ig7 
control 
5’-CTATGGACCTTAGCGCTC-3’  
15 5’ARM 
TKTF 
tkt knockout 
generation (5’ 
arm) and 
knockout 
screening (5’ 
vector control) 
5’-ATAGGATCCGACAAGATGGTTAAATAGAG-3’ BamH1 
16 5’ARM 
TKTR 
tkt knockout 
generation (5’ 
arm) and 
knockout 
screening (5’ 
genomic control) 
5’-ATACTGCAGCTAATACTAATTGTACTTCG-3’     PstI 
17 3’ ARM 
TKT F 
tkt knockout 
generation (3’ 
arm) and 
knockout 
screening (3’ 
genomic control) 
5’-ATACCATGGCACTCATGACTCTGTTGGTGTTG-3’    
  
NcoI 
18 3’ ARM 
TKTR 
tkt knockout 
generation (3’ 
arm) knockout 
screening (3’ 
vector control) 
5’-ATAAAGCTTCGGCATTACCTGGTGCAGAC-3’     HindIII 
19 PLPBLP 
F 
Screening tkt 
knockout (3’ 
vector control, 
3’ knockout) 
5’-ATGCTATACGAAGTTATCCGTGG-3’  
20 PLPBLP 
R 
Screening tkt 
knockout (5’ 
vector control, 
5’ knockout) 
5’-GGTTAATTCCTGCAGCCC-3’  
21 3’KO 
(GC)S    
Screening tkt 
knockout (3’ 
genomic control) 
5’-CAGAAGTCATACCTAATTGTTTC-3’  
22 5’KO 
(GC)S 
Screening tkt 
knockout (5’ 
knockout) 
5’-ATAGGCAAAGTTGCAGAATACGCT-3’  
23 tktqF tkt qPCR 5’-GGCTCATTAATCAACGCCTATC-3’  
24 tktqR tkt qPCR 5’-GCTTCACCATGACCTTTATTGG-3’  
25 cdcD 
OEF 
p97 
overexpressor 
5’-ATAGGATCCATGGCAACAATTGAAG-3’ BamH1 
26 cdcD 
OER 
p97 
overexpressor 
5’-ATAACTAGTAT26TACTGAAAAGATCATC-3’ SpeI 
27 cdcD 
seqF1 
Sequencing p97 
overexpressor 
5’-GCAGAGATCCTCGAATC-3’  
28 cdcD 
seqF2 
Sequencing p97 
overexpressor 
5’-GGATGGTATGAACGCC-3’  
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29 cdcD 
seqR1 
Sequencing p97 
overexpressor 
5’-GGTTGTTGGAACTTCGACG-3’  
30 cdcD 
seqR2 
Sequencing p97 
overexpressor 
5’-GCTTTCTTACACCACC-3’  
31 UBXOE
N-F 
BamH1                    
ubxd18 
overexpressor 
and rtPCR 
5’-ATA GGATCC ATGTCAAGAGTAAAAG-3’   BamH1 
32 UBXOE
N-R 
Xba1                       
ubxd18 
overexpressor 
and rtPCR 
5’-ATATCTAGATTATAATTTTTGAACTTGAAGGG-3’ XbaI 
33 UBX 
seqF 
Sequencing 
ubxd18 
overexpressor 
5’-ATAGTTCTCAATCTGCAATGGATTGG-3’    
34 UBX 
seqR 
Sequencing 
ubxd18 
overexpressor 
5’-ATAGGGCAAACCTTACATTTATATC-3’  
35 FcsAOE
N-F 
fcsA 
overexpressor 
5’-ATAGAGCTCATGTCAAGCCTTTCAACA-3’ Sac1 
36 FcsAOE
N-R  
fcsA 
overexpressor 
5’-ATATCTAGATTATACGTCTGGATGATCACG-3’ Xba1 
37 FseqF      Sequencing fcsA 
overexpressor 
5’-ATAGTGGTGCCCCAAGAGTATGG-3’ 
 
 
38 FseqR Sequencing fcsA 
overexpressor 
5’-ATAAATGGAGCGGAACCGGAAAG-3’  
39 Start 
screen 
R FcsA 
Sequencing fcsA 
overexpressor 
5’-ATAGTAATCACCTCTTTTGCCATCTGC-3’ 
 
 
40 End 
screen F 
FcsA 
Sequencing fcsA 
overexpressor 
5’-ATAGAACATGAACCATTCACTGAGG-3’ 
 
 
41 Atg8aF Autophagy qPCR 
(atg8a) 
5’-CTCCAAGATCAGATGCACCA-3’  
42 Atg8aR Autophagy qPCR 
(atg8a) 
5’-GCAGCAGTTGGTGGGATAGT-3’  
43 Atg1F Autophagy qPCR 
(atg1) 
5’-TCACGCCTCTTCACTTCCTT-3’  
44 Atg1R Autophagy qPCR 
(atg1) 
5’-CGGTTGTTGGATTGTAGTTGAT-3’  
45 gapdhF Autophagy qPCR 
(housekeeping) 
5’-GGTTGTCCCAATTGGTATTAATGG-3’  
46 gapdhR Autophagy qPCR 
(housekeeping) 
5’-CCGTGGGTTGAATCATATTTGAAC-3’  
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Chapter 3  
 
Identifying potential molecular targets for medium-
chain fatty acids using Dictyostelium discoideum 
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3.1 Introduction 
Many widely prescribed pharmaceutical drugs have unknown or poorly 
defined mechanisms of action. While a detailed knowledge of a drug’s molecular 
pharmacology is not required for its use, understanding the therapeutic targets of 
pharmaceutical drugs and novel compounds is beneficial for the development of new 
and improved treatments (Chang et al., 2012). To identify a mechanism of action for 
a compound, the ability to knock out potential targets is invaluable in order to 
demonstrate a resulting resistance to the compound (Schenone et al., 2013). The 
identification of such targets can be difficult, especially using mammalian models 
where ablation of potential target genes can be challenging. The simple tractable 
model Dictyostelium discoideum provides an excellent system for elucidating the 
therapeutic mechanisms of compounds since ablation of genes in Dictyostelium is 
rapid and straightforward due to the haploid nature of the organism (Faix et al., 2004; 
Schaf, Damstra-Oddy and Williams, 2019). To enable the identification of molecular 
targets of compounds, large libraries of Dictyostelium restriction enzyme mediated 
integration (REMI) mutants have been generated (Kuspa, 2006). These mutant 
libraries provide a valuable resource allowing the screening of compounds to identify 
resistant mutants. Using this approach therapeutic mechanisms of compounds can 
be elucidated, facilitating the development of new and improved treatments.     
Dictyostelium mutant libraries have been used to determine the mechanisms 
of action of a range of compounds, from natural products curcumin (Cocorocchio et 
al., 2018), and naringenin (Waheed et al., 2014), to the cancer treatment cisplatin (Li 
et al., 2000). This approach has allowed the rapid identification of proteins that 
control the sensitivity to a compound, thus implicating the identified protein or the 
wider pathway in the action of the compound. In addition to identifying genes 
conferring resistance to specific compounds, REMI libraries in Dictyostelium have also 
been used to identify regulators of cellular processes such as cell adhesion and 
migration (Lampert et al., 2017; Nagasaki and Uyeda, 2008).  Discoveries made using 
Dictyostelium genetic screens are often validated by translation into mammalian 
models (Waheed et al., 2014; Chang et al., 2012). The availability and ease of genetic 
screens in Dictyostelium provides a powerful tool for the elucidation of molecular 
targets for compounds with poorly understood mechanisms of action. 
 
67 
 
In this chapter we demonstrate that the key component of the MCT ketogenic 
diet, decanoic acid, along with the accompanying fatty acid, octanoic acid, and 
related compound, 4-BCCA, inhibit Dictyostelium proliferation in a dose dependent 
manner while having no inhibitory effect on development. We utilise these inhibitory 
effects on cell proliferation to identify potential molecular targets for decanoic acid 
and 4-BCCA by isolating resistant mutants using an unbiased genetic screen. Further 
analysis of these mutants provide insight into the molecular mechanisms of medium-
chain fatty acids.  
3.2 Results 
3.2.1 The effects of decanoic acid, octanoic acid and 4-BCCA on Dictyostelium 
proliferation 
To identify potential molecular mechanisms for the medium-chain 
triglyceride (MCT) diet we initially investigated the effects of the key dietary 
component, decanoic acid, on Dictyostelium unicellular proliferation. Dictyostelium 
cell proliferation was quantified in the presence of a range of concentrations of 
decanoic acid, with cell counts being recorded once every 24 hours, from 72 hours to 
168 hours (Fig. 3.1A). Treatment with decanoic acid caused a dose dependent 
inhibition of growth. The rate of the exponential growth phase was then used to plot 
a non-linear regression curve, and a half maximal inhibitory concentration (IC50) was 
calculated (Fig. 3.1D). Decanoic acid provided an IC50 of 18 µM (95 % CI: 17 µM to 20 
µM). The effect of octanoic acid, an accompanying medium-chain fatty acid in the 
MCT diet, on Dictyostelium unicellular proliferation, was also investigated (Fig. 3.1B). 
Octanoic acid was less potent than decanoic acid with an IC50 of 86 µM (95 % CI: 73 
µM to 100 µM) (Fig. 3.1D). Finally, we investigated the effect of 4-BCCA, a related 
compound with improved epileptiform activity control, on Dictyostelium 
proliferation (Chang et al., 2015) (Fig. 3.1C). The purified product 4-BCCA provided an 
IC50 of 1.5 μM (95 % Cl: 1.1 µM to 1.8 μM) (Fig. 3.1D). We have therefore shown that 
decanoic acid, octanoic acid and 4-BCCA each inhibited Dictyostelium proliferation, 
thus demonstrating suitability for use in genetic screens where mutants resistant to 
these growth inhibitory effects can be isolated and characterised.  
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3.2.2 The effects of decanoic acid, octanoic acid and 4-BCCA on Dictyostelium 
development 
Dictyostelium alternates between growing as single cells and developing as a 
multicellular organism, with different genes associated with these two stages 
(Loomis, 2015; Iranfar, Fuller and Loomis, 2003; Kuspa and Loomis, 1992). Where 
treatment with compound causes a visible alteration in Dictyostelium developmental 
morphology, mutant libraries can be screened for mutants resistant to these effects, 
thus identifying proteins controlling the sensitivity to the compound (Williams et al., 
 
 A B 
C D 
                 Dictyostelium (Ax2) cells were treated with A) decanoic acid (n = 6), B) 
octanoic acid (n = 6) or C) 4-BCCA (n = 6) for 168 hours (7 days) at a range of 
concentrations (µM). Percentage growth was plotted normalised to the solvent 
control (0 µM, 0.2 % DMSO) at 168 hours. C) Dose response curves of normalised 
growth rate plotted against Log concentration of compound were used to calculate 
IC50 values (n = 6). Data represent the mean ± SEM.  
Figure 3. 1 Effects of decanoic acid octanoic acid and 4-BCCA on Dictyostelium 
growth.  
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2006). Furthermore, the effects of compounds on Dictyostelium multicellular 
development can be used as a readout for developmental toxicity, with teratogens 
such as valproic acid, tretinoin and thalidomide disrupting Dictyostelium 
development (Dannat et al., 2003). We investigated the effects of decanoic acid on 
Dictyostelium development by starving cells for 22 hours on nitrocellulose filters in 
the absence or presence of 200 µM decanoic acid (Fig. 3.2). Under control conditions, 
cells formed fruiting bodies comprising dead vacuolated stalks holding viable spore 
heads aloft. This process of development was unaffected by decanoic acid at a far 
greater concentration than that which inhibited cell growth (200 µM). The effects of 
octanoic acid, and 4-BCCA on Dictyostelium development were also investigated (Fig. 
3.2). The process of multicellular development was not affected by octanoic acid or 
by 4-BCCA at concentrations higher than completely inhibited cell growth (200 µM 
and 50 µM respectively). We have shown that Dictyostelium development was 
unaffected by decanoic acid, octanoic acid, and 4-BCCA, suggesting that these 
compounds regulate molecular targets involved in cell proliferation and not in 
development. These data also suggest that the medium-chain fatty acids have 
specific molecular effects on Dictyostelium rather than a general toxic effect.  
3.2.3 Identifying potential molecular targets for decanoic acid  
In order to identify potential molecular targets for decanoic acid we utilised 
the growth inhibitory effect of decanoic acid to isolate resistant mutants using an 
unbiased genetic screen of a library of Dictyostelium mutants. A REMI mutant library 
was screened in a concentration of decanoic acid that inhibits wild type growth (120 
µM) (Fig. 3.3). Following a week-long incubation, mutants resistant to decanoic acid 
were isolated, made isogenic and decanoic acid resistance was confirmed by visual 
comparison of mutant and wild type growth in decanoic acid. Following confirmation 
of resistance, the location of the insertion site within the genome of these resistant 
mutants was determined to identify the genes controlling decanoic acid sensitivity. 
Through this approach, individual mutants with reduced sensitivity to the growth 
inhibitory effects of decanoic acid were identified.  
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Top down view Side view 
Control 
Decanoic acid  
(200 µM) 
Octanoic acid  
(200 µM) 
4-BCCA 
(50µM) 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            Qualitative evaluation of developmental effects of decanoic acid, 
octanoic acid and 4-BCCA on Dictyostelium. Phenotypes were monitored following 
starvation of Dictyostelium cells for 22 hours on nitrocellulose filters in the 
presence of compound or solvent control (DMSO). Top down view (scale bar 1 mm) 
and side on (scale bar 0.2 mm) images are displayed as representative results from 
triplicate experiments. 
 
Figure 3. 2 Effects of decanoic acid, octanoic acid and 4-BCCA on Dictyostelium 
development.
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 In order to determine the location of the insertion within the decanoic acid 
resistant mutants an inverse PCR approach was used (Keim, Williams and Harwood, 
2004). This technique involved extraction of genomic DNA from the mutants followed 
by restriction enzyme digestion, and self-ligation (Fig. 1.5). Genomic DNA flanking the 
insertion site was amplified using primers designed to bind within the insertion 
fragment and the precise sequence of this flanking DNA was determined by 
sequencing. The location of the insertion within the Dictyostelium genome was 
identified by using the blast local alignment search tool (BLAST) to locate the flanking 
DNA sequence (Fig. 3.4) (Altschul et al., 1990).  
From screening the Dictyostelium mutant library in decanoic acid, three 
distinct mutants partially resistant to the growth inhibitory effects of this fatty acids 
were identified.  These mutants had gene disruptions within the genes encoding the 
proteins DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs) (Fig. 3.4A), 
Transketolase (TKT) (Fig. 3.4B), or UBX domain-containing protein 18 (UBXD18) (Fig. 
3.4C). The blast local alignment search tool was used to identify potential human 
 
Wild 
type 
Mutant 
library 
Control 
Decanoic 
acid 
7 days 
Control 
Decanoic 
acid 
A B 
Wild type          Mutant library 
Control 
  
Decanoic 
acid 
Figure 3. 3 Dictyostelium mutant library screen for mutants resistant to decanoic 
acid.           A genetic screen of an insertional mutant library was carried out to identify 
mutants partially resistant to the growth inhibitory effects of decanoic acid. A) 
Schematic of mutant library screen. B) A representative image of the mutant library 
screen after 7 days incubation with 120 µM decanoic acid (Scale bar represents 0.5 
mm).  
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homologues and protein domain organisation was compared (Fig. 3.4). A human 
homologue of DNA-PKcs (uniprot P78527) was found to share 28.3 % sequence 
identity, and a human homologue of transketolase (uniprot P29401) was identified 
sharing 28.5 % identity. Human UBXN1 (uniprot Q04323), and UBXD2 (uniprot 
Q92575) proteins were identified as potential homologues of UBXD18. These 
proteins all contain UBX domains, the Dictyostelium UBX domain shares 28 % 
identical, and 51 % similar amino acids with the UBXN1 UBX domain, and 27 % identity 
and 51 % similarity with the UBXD2 UBX domain. Thus, this mutant library screen 
identified three genes in Dictyostelium with human homologues, that represent 
potential targets for decanoic acid.  
3.2.4 Identifying potential molecular targets for 4-BCCA 
 A second mutant library screen was carried out using 4-BCCA, a cyclic fatty 
acid derivative with superior epileptiform activity control over decanoic acid (Chang 
et al., 2015). The REMI mutant library was screened in a concentration of 4-BCCA 
capable of inhibiting wild type cell growth (80 µM) (Fig. 3.5). Following a week-long 
incubation, mutants resistant to 4-BCCA were isolated, made isogenic and the 
resistance to 4-BCCA was visually confirmed. The location of the insertion site within 
the genome of these resistant mutants was determined. One mutant partially 
resistant to 4-BCCA was identified with an insertion within the gene encoding the 
protein fatty acyl coenzyme A-synthetase (FcsA). The blast local alignment search 
tool was used to identify the existence of a human homologue of FcsA and protein 
domain organisation was compared (Fig. 3.6). The human homologue of FcsA is the 
long-chain fatty acid coA ligase (uniprot Q9ULC5) which shares 42 % identical amino 
acids with the Dictyostelium protein. The identification of a 4-BCCA resistant mutant 
with a disruption in the gene encoding FcsA implicates this protein in the cellular 
response to 4-BCCA, and the presence of a human FcsA homologue raises the 
possibility that this mechanism could be conserved between Dictyostelium and 
humans. 
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               A genetic screen carried out to identify mutants resistant to decanoic acid 
identified genes encoding A) DNA protein kinase catalytic subunit (DNA-PKcs) 
(Dictybase ID. DDB_G0281167), B) Transketolase (TKT) (Dictybase ID. 
DDB_G0274019) and C) UBX domain containing protein 18 (UBXD18) (Dictybase ID. 
DDB_G0276057) which when disrupted confer partial resistance to 120 µM  
decanoic acid. Dictyostelium protein domain organisation is displayed, compared 
to that of the closest human homologue(s). The exact location at which the REMI 
insertion was located is labelled on the corresponding protein domain with a black 
triangle, and amino acid sequence number. 
Figure 3. 4  Dictyostelium decanoic resistant mutants identified from a genetic 
screen.
A 
B 
C 
Transketolase (TKT) 
UBX domain-containing protein 18 (UBXD18)  
DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs) 
 
74 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                              An independent mutant library screen using 80 
µM 4-BCCA identified a mutant with a disruption in the gene encoding Fatty acyl 
Coenzyme A-Synthetase (FcsA) (Dictybase ID DDB_G0269242). Dictyostelium 
protein domain organisation is displayed, compared to that of the closest human 
homologue. The exact location at which the REMI insertion was located is labelled 
on the corresponding protein domain with a black triangle, and amino acid 
sequence number. 
 
Figure 3. 6 A Dictyostelium 4-BCCA resistant mutant, with a disruption in fcsA, 
identified from a genetic screen. 
Fatty acyl Coenzyme A-Synthetase (FcsA) 
A genetic screen of an insertional mutant library was carried out to identify 
mutants partially resistant to the growth inhibitory effects of 4-BCCA. A 
representative image of the mutant library screen after 7 days incubation with 80 
µM 4-BCCA is shown (Scale bar represents 0.5 mm).  
 
Figure 3. 5 Dictyostelium mutant library screen for mutants resistant to 4-BCCA. 
Wild type          Mutant library 
Control 
  
4-BCCA 
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3.2.5 Analysis of potential molecular targets for decanoic acid and 4-BCCA 
Following the identification of potential molecular targets for decanoic acid 
and 4-BCCA from mutant library screens it was necessary to confirm the fatty acid 
resistant phenotypes of these mutants. Since, mutants generated via restriction 
enzyme mediated integration (REMI) potentially have multiple sites of mutation, this 
could result in multiple gene disruptions within the REMI mutants. To confirm that 
the fatty acid resistant phenotypes were conferred by disruptions in the genes we 
have identified, we required independent knockouts for further investigation. 
Independent dna-pkcs and fcsA knockouts were available (Hudson et al., 2005; von 
Lohneysen et al., 2003). Thus, mutants lacking DNA-PKcs and FcsA proteins could be 
directly assessed for fatty acid resistance, whereas, generation of independent gene 
knockouts for ubxd18 (official gene name DDB_G0276057) and tkt was required. 
3.2.5.1 DNA-PKcs 
To confirm that the decanoic acid resistant phenotype observed in the dna-
pkcs disrupted REMI mutant was conferred by the insertion in this gene, we used an 
independent knockout to verify the effect of decanoic acid on DNA-PKcs- growth. 
DNA-PKcs- was partially resistant to the effect of decanoic acid, with an IC50 value 2-
fold higher than that of the wild type cell line (DNA-PKcs-  IC50 36 µM, 95 % CI: 32 µM 
to 40 µM, compared to wild type (Ax2) IC50 18 µM, 95 % CI: 17 µM to 20 µM, p = 
0.0357, n ≥ 3) (Fig. 3.7). These findings suggest a potential involvement for DNA-PKcs 
in the cellular response to decanoic acid. 
3.2.5.2 FcsA 
A mutant with a disruption in the gene fcsA was identified from a mutant 
library screen in 4-BCCA. In order to establish whether the resistance to 4-BCCA was 
a direct result of the disruption of fcsA, we investigated the sensitivity of an 
independent FcsA- knockout to 4-BCCA (Fig. 3.8A). FcsA- was partially resistant to 
effects of 4-BCCA (Fig. 3.8B). In FcsA-, 4-BCCA had an IC50 value 28-fold higher than 
that of the wild type cell line (FcsA- IC50 42 µM, 95 % CI: 29 µM to 61 µM, compared 
to wild type (Ax2) IC50 1.5 µM, 95 % CI: 1.1 µM to 2 µM, p = 0.0043, n ≥ 5) (Fig. 3.8C). 
In order to investigate if knocking out fcsA also conferred resistance to decanoic acid 
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we investigated the effects of decanoic acid on the growth of this knockout cell line 
(Fig. 3.8D). FcsA- was found to also be partially resistant to effects of decanoic acid, 
where FcsA-  had an IC50 value roughly 2-fold higher than that of the wild type cell line 
(FcsA-  IC50 42 µM, 95 % CI: 37 µM to 49 µM, compared to wild type (Ax2) IC50 18 µM, 
95 % CI: 17 µM to 20 µM, p = 0.0159, n ≥ 4) (Fig. 3.8E and F). 
 
  
 
 
 
 
  
  
    
    
  
 
 
  
 
 
 
 
 
 
 
 
 
 
                                                                                                            A) An independent 
knockout of dna-pkcs (DNA-PKcs-) was treated with a range of concentrations of 
decanoic acid (µM), for 168 hours (n = 3). Percentage growth was plotted normalised 
to the solvent control (0 µM, 0.2 % DMSO) at 168 hours. B) Dose response curves of 
normalised growth rate plotted against Log concentration of decanoic acid were 
used to compare the decanoic acid sensitivity of wild type (Ax2) (n = 5) and DNA-
PKcs- (n = 3). C) IC50 values for Ax2 (n = 5) and DNA-PKcs- (n = 3) in decanoic acid were 
compared. Data represent the mean ± SEM. Significance is indicated by * p ≤ 0.05 
(Mann Whitney test). 
Figure 3. 7 Effects of decanoic acid on DNA-PKcs- growth.
A B 
C 
0 24 48 72 96 120 144 168
0
20
40
60
80
100
0
10
20
40
50
60
80
100
G
ro
w
th
 (
%
)
Time (hours)
DNA-PKcs- growth in decanoic acid
M
0
20
40
60
80
100
0 1 2Control
Decanoic acid
(Log concentration M)
G
ro
w
th
 r
at
e 
(%
)
Ax2 IC50 18 M
DNA-PKcs- IC50 36 M
0
20
40
60
IC
5
0
(
M
)
*
18
36
Ax2 DNA-PKcs-
 
77 
 
0 24 48 72 96 120144168
0
20
40
60
80
100
0
10
20
40
50
60
80
100
G
ro
w
th
 (
%
)
Time (hours)
FcsA- growth in decanoic acid
M
0
20
40
60
80
100
-1 0 1 2
Decanoic acid
(log concentration M)
Ax2 IC50 18 M
FcsA- IC50 42 M
Control
G
ro
w
th
 r
at
e
 (
%
)
Ax2 FcsA-
0
20
40
60
80
100
IC
5
0
(
M
)
*
18
42
Ax2 FcsA-
0 24 48 72 96 120 144 168
0
20
40
60
80
100
0
0.1
1
5
10
25
35
50
G
ro
w
th
 (
%
)
Time (hours)
FcsA- growth in 4-BCCA
M
0
20
40
60
80
100
-1 0 1 2
Ax2 IC50 1.5 M
FcsA- IC50 42 MG
ro
w
th
 r
at
e
 (
%
)
4-BCCA
(log concentration M)
Control
Ax2 FcsA-
0
20
40
60
80
100
**
1.5
IC
5
0
(
M
)
42
Ax2 FcsA-
 
 
 
  
 
  
 
 
  
  
 
  
  
 
 
  
 
  
  
   
  
  
 
 
 
  
  
 
  
 
 
 
A D 
B 
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E 
F 
                                                                                                                     A) An independent 
knockout of fcsA (FcsA-) was treated with a range of concentrations (µM) of 4-BCCA 
for 168 hours (n = 5). Percentage growth was plotted normalised to the solvent control 
(0 µM, 0.2 % DMSO) at 168 hours. B) Dose response curves of normalised growth rate 
plotted against Log concentration of 4-BCCA were used to compare the 4-BCCA 
sensitivity of wild type (Ax2) (n = 6) and FcsA- (n = 5). C) IC50 values for Ax2 (n = 6) and 
FcsA- (n = 5) in 4-BCCA were compared. D) FcsA- was treated with a range of 
concentrations (µM) of decanoic acid for 168 hours (n = 4). E) Dose response curves 
were used to compare the decanoic acid sensitivity of (Ax2) (n = 5) and FcsA- (n = 4). F) 
IC50 values for Ax2 (n = 5) and FcsA- (n = 4) in decanoic acid were compared. Data 
represent the mean ± SEM. Significance is indicated by * p ≤ 0.05, ** p ≤ 0.01 (Mann-
Whitney test). 
 
 
Figure 3. 8 Effects of 4-BCCA and decanoic acid on FcsA- growth.   
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In order to confirm that loss of a specific gene is responsible for the observed 
phenotype, reintroduction of gene expression can be analysed for restoration of the 
wild type phenotype (Levi, Polyakov and Egelhoff, 2000). Since FcsA- demonstrated a 
significant increase in resistance to both 4-BCCA and decanoic acid compared to wild 
type (28-fold and 2.3-fold respectively), we reintroduced fcsA gene expression to 
confirm the involvement of this target in the fatty acid resistant phenotype. In order 
to reintroduce fcsA gene expression, we generated an extrachromosomal vector 
designed to express fcsA with an amino-terminal GFP domain attached (Fig. 3.9A). 
The open reading frame of fcsA was amplified from wild type (Ax2) cDNA with the 
incorporation of restriction enzyme sites enabling cloning into the pTX-GFP vector. 
The expression vector was verified by sequencing before being transfected into FcsA-
. Reintroduction of gene expression was confirmed using rt-PCR (Fig. 3.9B), and 
western blotting using an antibody against GFP confirmed the presence of the correct 
size (approximately 100 kDa) GFP-tagged protein (Fig. 3.9C). Reintroducing fcsA gene 
expression restored a 4-BCCA sensitive phenotype (FcsA-/+ IC50 1 µM, 95 % Cl: 0.94 
µM to 1.1 µM, p = 0.0357, n ≥ 3) (Fig. 3.10A, B and C). Reintroducing fcsA gene 
expression also restored a decanoic acid sensitive phenotype (FcsA-/+ IC50 6.4 µM, 95 
% Cl: 5.4 µM to 7.5 µM, p = 0.0286, n ≥ 3) (Fig. 3.10D, E and F). We have shown that 
loss of fcsA leads to partial resistance to the effects of 4-BCCA and decanoic acid on 
cell proliferation, and that reintroduction of fcsA gene expression restores wild type 
levels of sensitivity. These findings suggest that fcsA is responsible for the observed 
fatty acid resistance, thus implicating the protein FcsA as a potential molecular target 
for 4-BCCA and decanoic acid. 
3.2.5.3 TKT 
Transketolase (TKT) was identified as a potential molecular target for 
decanoic acid in a Dictyostelium mutant library screen. To confirm that the decanoic 
acid resistance displayed by the tkt disrupted REMI mutant is conferred by the 
insertion in this gene rather than an off-target mutation, we generated an 
independent knockdown of this gene (Fig. 3.11). We employed a traditional knockout 
approach using the gene disruption vector pLPBLP (Faix et al., 2004). This approach 
was   chosen   due   to  the   presence  of   a   genome   duplication  in  the  region  of  
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                                                                                              A) The open reading frame of 
fcsA was amplified from cDNA with the incorporation of restriction sites for cloning 
into the vector pTX-GFP. B) The fcsA expression vector (GFP-FcsA) was transfected 
into FcsA- and expression was confirmed using rt-PCR (with Ig7 as a positive 
control). C) Western blotting was used to confirm presence of the correct size 
protein using an antibody against GFP. MCCC1 was used as a loading control.  
 
 
Figure 3. 9 Reintroduction of fcsA gene expression.   
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F 
A) FcsA-/+ was treated with a range of concentrations (µM) of 4-BCCA for 168 hours 
(n = 3). Percentage growth was plotted normalised to the solvent control (0 µM, 0.2 
% DMSO) at 168 hours. B) Dose response curves of normalised growth rate plotted 
against Log concentration of 4-BCCA were used to compare the sensitivity of wild 
type (Ax2) (n = 6), FcsA- (n = 5) and FcsA-/+ (n = 3). C) 4-BCCA IC50 values for Ax2 (n = 
6), FcsA-/+ (n = 5) and FcsA-/+ (n = 3) were compared. D) FcsA-/+ was treated with a 
range of concentrations (µM) of decanoic acid for 168 hours (n = 3). E) Dose 
response curves were used to compare the decanoic acid sensitivity of Ax2 (n=5), 
FcsA- (n = 4) and FcsA-/+ (n = 3). F) IC50 values for Ax2 (n = 5), FcsA-/+ (n = 4) and FcsA-/+ 
(n = 3) in decanoic acid were compared. Data represent the mean ± SEM. 
Significance is indicated by * p ≤ 0.05, ** p ≤ 0.01 (Mann-Whitney test). 
 
 
Figure 3. 10 Analysis of the effects of 4-BCCA and decanoic acid on FcsA-/+ growth. 
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chromosome 2 from bases 2249563 to 3002134 in Ax4 resulting in two copies of the 
tkt gene (Bloomfield et al., 2008). A knockout construct was generated by PCR 
amplifying two sequences (arms) of approximately 500 bp from the 5’ and 3’ regions 
of the tkt gene sequence (Fig. 3.11A) and cloning these fragments into the pLPBLP 
vector at sites flanking the gene for blasticidin resistance (BSR) (Fig. 3.11B). This 
process generated a disruption fragment with sequences homologous to tkt flanking 
the BSR gene, designed to enable homologous recombination. Wild type, Ax4, 
Dictyostelium cells were transfected once with the disruption fragment for gene 
disruption by homologous recombination and were selected for resistance to 
blasticidin. Ax2 Dictyostelium cells were transfected three independent times. 
Blasticidin resistant cells (56 wells of Ax4 and 293 wells of Ax2) were screened using 
primers designed to produce six diagnostic fragments (Fig. 3.11D and E). This 
procedure generated three independent Ax4 mutants with a disruption in one copy 
of the tkt gene, recapitulating the genotype of the tkt REMI mutant identified from 
the mutant library. No successful homologous recombinants were identified in Ax2. 
Since the homologous recombination events into Ax4 are likely to disrupt just one 
copy of the gene, we used qPCR to monitor tkt gene expression normalised to the 
wild type (Ax4). Expression of tkt was reduced by 60 % in the tkt knockdown (TKT-) 
(95% Cl: 39 % to 98 %, p = 0.0286, n = 4) (Fig. 3.11F).  
The creation of a Dictyostelium tkt knockdown (TKT-) provided us with an 
independent mutant cell line recapitulating the genotype of the tkt REMI mutant 
identified from the genetic screen in decanoic acid. In order to establish whether 
disruption of one copy of the tkt gene is responsible for the observed decanoic acid 
resistance, we compared the decanoic acid sensitivity of the wild type cell line (Ax4) 
(Fig. 3.12A) to this tkt knockdown (TKT-) (Fig. 3.12B).  TKT- was partially resistant to 
the effect of decanoic acid, with an IC50 value 3-fold higher than that of the wild type 
cell line (TKT-  IC50 56 µM, 95 % CI: 51 µM to 61 µM, compared to wild type (Ax4) IC50 
17 µM, 95 % CI: 16 µM to 19 µM, p = 0.0286, n ≥ 3) (Fig. 3.12C and D). These findings 
demonstrate that knocking out one copy of tkt and reducing tkt gene expression is 
sufficient to recapitulate the decanoic acid resistant phenotype observed in the REMI 
mutant, suggesting that the protein TKT could play a role in regulating the cellular 
response to decanoic acid. 
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                                                                                         A) Two fragments (arms) of DNA 
of approximately 500 bp from the 5’ and 3’ regions of tkt were amplified by PCR 
introducing restriction sites (RS). B) These arms were cloned into the pLPBLP vector 
at multiple cloning sites flanking the gene for blasticidin resistance (BSR). The 
disruption fragment (homologous arms flanking the BSR gene) was isolated via 
restriction digest. C) Transfections of this disruption fragment into wild type (Ax4) 
Dictyostelium resulted in disruption of the tkt gene via homologous recombination. 
D) Blasticidin resistant cells were screened for the presence of homologous 
recombinants using primers designed to produce six diagnostic fragments. E) 
Representative screening confirming disruption of the tkt gene. F) qPCR was used to 
monitor tkt gene expression in the knockdown compared to Ax4 (n = 4). Data 
represent the mean ± SEM. Significance is indicated by * p ≤ 0.05 (Mann-Whitney 
test). 
Figure 3. 11 Generation of tkt gene knockdowns
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3.2.5.4 UBXD18 
A mutant with a gene disruption in ubxd18 was identified from a mutant 
library screen in decanoic acid. To confirm that the decanoic acid resistance seen in 
the ubxd18 REMI mutant is conferred by the disruption in the ubxd18 gene, we 
generated an independent gene knockout of ubxd18 (UBXD18-) (Fig. 3.13). In contrast 
to the traditional approach used to knockdown tkt, we employed a direct PCR 
method to generate a knockout construct for ubxd18 due to the presence of only one 
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                                                                                                A) Wild type (Ax4) cells (n = 4) 
or B) an independent knockdown of tkt (TKT-) (n = 3) were treated with a range of 
concentrations of decanoic acid (µM), for 168 hours. Percentage growth was plotted 
normalised to the solvent control (0 µM, 0.2 % DMSO) at 168 hours. C) Dose response 
curves of normalised growth rate plotted against Log concentration of decanoic acid 
were used to compare the decanoic sensitivity of Ax4 (n = 4) and TKT- (n = 3). D) IC50 
values for Ax4 (n = 4) and TKT- (n = 3) were compared. Data represent the mean ± SEM. 
Significance is indicated by * p ≤ 0.05 (Mann-Whitney test). 
 
Figure 3. 12 Effects of decanoic acid on TKT- growth.  
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copy of the ubxd18 gene in Dictyostelium. This knockout construct was generated by 
PCR amplification over the insertion site within the ubxd18 REMI mutant (Fig. 3.13A). 
This amplified a construct comprising two sequences (arms) with homology to the 
ubxd18 gene flanking the BSR insert, facilitating the insertion of the BSR sequence 
into the ubxd18 gene through homologous recombination, effectively recapitulating 
the REMI mutant genotype (Fig. 3.13C). Wild type (Ax2) cells were transfected once 
with this purified knockout construct and transfectants were selected for in the 
presence of blasticidin. Resistant colonies (35 colonies) were screened for the 
presence of homologous recombinants using primers designed to produce seven 
diagnostic fragments unique to the homologous transfectants (Fig. 3.13C). This 
procedure generated four homologous recombinants, verified for correct insertion 
of the knockout construct disrupting ubxd18 (Fig. 3.13D). Isogenic colonies were then 
selected and confirmed by PCR, before reverse transcriptase-PCR (RT-PCR) was used 
to verify the loss of ubxd18 expression with Ig7 as a positive control (Fig. 3.13E). The 
creation of a Dictyostelium ubxd18 knockout (UBXD18-) has provided us with an 
independent mutant cell line for the recapitulation of the decanoic acid resistant 
phenotype identified from our genetic screens in decanoic acid. 
To confirm that the decanoic acid resistance observed in the ubxd18 REMI 
mutant is conferred by a disruption in the ubxd18 gene, we used an independent 
knockout to verify the decanoic acid resistant phenotype. UBXD18-  was partially 
resistant to the effect of decanoic acid, with an IC50 value 2-fold higher than that of 
the wild type cell line (UBXD18-  IC50 37 µM, 95 % CI: 31 µM to 43 µM, compared to 
wild type (Ax2) IC50 18 µM, 95 % CI: 17 µM to 20 µM, p ≤ 0.0001) (Fig. 3.14).  
In order to confirm that loss of ubxd18 gene expression is responsible for the 
observed decanoic acid resistant phenotype, we reintroduced ubxd18 gene 
expression to investigate restoration of the wild type phenotype. We generated an 
extrachromosomal vector designed to express ubxd18 with an amino-terminal GFP 
domain attached (Fig. 3.15A). The open reading frame of ubxd18 was amplified from 
wild type (Ax2) cDNA with the addition of restriction enzyme sites allowing the coding 
region to be cloned into the pTX-GFP vector. The expression vector was verified by 
sequencing before being transfected into UBXD18-. Reintroduction of gene 
expression  was  confirmed  using  rt-PCR  (Fig.  3.15B)  and  western blotting using an     
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                                                                                             A) PCR amplification over the 
REMI insertion site was used to generate a knockout construct of 2554bp. B) 
Transfection of this knockout construct into wild type Dictyostelium results in 
disruption of the ubxd18 gene via homologous recombination. C) Blasticidin 
resistant cells were screened for the presence of homologous recombinants using 
primers designed to produce seven diagnostic fragments. D) Representative 
screening of one out of four ubxd18 knockouts. E) RT-PCR was used to confirm the 
loss of ubxd18 expression in the knockout, with Ig7 as a positive control. 
Figure 3. 13 Generation of ubxd18 gene knockouts.
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antibody against GFP confirmed the presence of the correct size (86.9 kDa) GFP-
tagged protein (Fig. 3.15C). Reintroducing ubxd18 gene expression restored a 
decanoic acid sensitive phenotype (UBXD18-/+ IC50 13 µM, 95 % CI: 8.3 µM to 18 µM, 
p ≤ 0.0001) (Fig. 3.16A, B and C). We have demonstrated that loss of ubxd18 leads to 
partial resistance to the effects of decanoic acid on growth, and that reintroduction 
of the ubxd18 gene restores wild type sensitivity to decanoic acid. These findings 
suggest that ubxd18 is responsible for the observed decanoic acid resistance, thus 
implicating UBXD18 as a potential molecular target for decanoic acid. 
 
A B 
C 
                                                                                                            A) An independent 
knockdown of ubxd18 (UBXD18-) (n = 12) was treated with a range of 
concentrations of decanoic acid (µM) for 168 hours. Percentage growth was 
plotted normalised to the solvent control (0 µM, 0.2 % DMSO) at 168 hours. B) 
Dose response curves of growth rate plotted against Log concentration of 
decanoic acid were used to compare the decanoic sensitivity of wild type (Ax2) 
(n = 13) and UBXD18- (n = 12). C) IC50 values for Ax2 (n = 13) and UBXD18- (n = 12) 
in decanoic acid were compared. Data represent the mean ± SEM. Significance 
is indicated by **** p ≤ 0.0001 (Mann-Whitney test). 
Figure 3. 14 Effects of decanoic acid on UBXD18- growth.
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                                                                                                       A) The open reading 
frame of ubxd18 was amplified from cDNA with the incorporation of restriction 
sites for cloning into the pTX-GFP over-expression plasmid. B) The ubxd18 
expression vector (GFP-UBXD18) was transfected into UBXD18- and expression was 
confirmed using rt-PCR (with Ig7 as a positive control). C) Western blotting was 
used to confirm presence of the correct size protein using an antibody against GFP. 
MCCC1 was used as a loading control.  
Figure 3. 15 Reintroduction of ubxd18 gene expression.
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3.3 Discussion 
Ketogenic diets are well established treatments for epilepsy with exciting 
potential for use in other areas of health, however, the therapeutic mechanisms and 
secondary targets are not fully understood (Augustin et al., 2018a). In this chapter, 
we have used Dictyostelium as a tractable model to establish that decanoic acid the 
key component of the MCT ketogenic diet, along with octanoic acid an accompanying 
dietary fatty acid, and 4-BCCA a related compound, all act on Dictyostelium to reduce 
cellular proliferation without disrupting Dictyostelium multicellular development. In 
A B 
C 
                                                                                                                                                     
A) UBXD18-/+ (n = 9) was treated with a range of concentrations (µM) of decanoic acid, 
for 168 hours. Percentage growth was plotted normalised to the solvent control (0 
µM, 0.2 % DMSO) at 168 hours. B) A dose response curve of growth rate plotted 
against Log concentration of decanoic acid was used to compare the decanoic 
sensitivity of wild type (Ax2) (n = 13), UBXD18-+ (n = 12) and UBXD18-/+ (n = 9). C) IC50 
values for Ax2) (n = 13), UBXD18-+ (n = 12) and UBXD18-/+ (n = 9) in decanoic acid were 
compared. Data represent the mean ± SEM. Significance is indicated by **** p ≤ 
0.0001 (Mann-Whitney test). 
Figure 3. 16 Analysis of the effects of decanoic acid on UBXD18-/+ growth. 
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order to identify the cellular mechanisms behind the antiseizure effects of decanoic 
acid and 4-BCCA we utilised the growth inhibitory effects of these compounds to 
screen a mutant library. Mutants with disruptions in the genes dna-pkcs, tkt and 
ubxd18 were found to confer resistance to decanoic acid, and a mutant with a gene 
disruption in fcsA was identified as conferring resistance to 4-BCCA, suggesting a 
potential role for the corresponding proteins in regulating the effects of these 
compounds. 
 Patients on the medium-chain triglyceride (MCT) ketogenic diet acquire 
around 45 % of their dietary energy from medium-chain triglycerides, which are 
metabolised in the intestine to generate free fatty acids (Neal et al., 2008). 
Concentrations of medium-chain fatty acids in the plasma of patients on the MCT diet 
are raised to an average level of 157 μM for decanoic acid and 310 μM for octanoic 
acid (Sills, Forsythe and Haidukewych, 1986; Haidukewych, Forsythe and Sills, 1982; 
Dean, Bonser and Gent, 1989) compared to undetectable levels in individuals not on 
the diet. We have found that in Dictyostelium, decanoic acid and octanoic acid both 
inhibited cell proliferation at concentrations physiologically relevant to those seen in 
patients. In Dictyostelium, octanoic acid had a less potent effect on growth than 
decanoic acid (IC50 86 μM compared to 18 μM), this is consistent with findings 
suggesting that octanoic acid is less potent than decanoic acid in regards to in vitro 
seizure control (Chang et al., 2013). We found that 4-BCCA had a stronger growth 
inhibitory effect than decanoic acid or octanoic acid in Dictyostelium (IC50 1.5 μM), 
this is also consistent with research showing that 4-BCCA has increased potency over 
these medium-chain fatty acids in in vitro seizure control (Chang et al., 2015). 
 Demonstrating that Dictyostelium is sensitive to medium-chain fatty acids in 
cellular proliferation but not in development, suggests that these compounds are not 
having a general toxic effect, where a disruption in both proliferation and 
development would be expected, but are acting through specific molecular 
mechanisms (Perry et al., 2020). In order to elucidate these molecular mechanisms, 
the growth inhibitory effects caused by decanoic acid and 4-BCCA were utilized to 
screen for resistant mutants representing potential molecular targets. Three genes, 
dna-pkcs, tkt and ubxd18 were identified from a mutant library screen in decanoic 
acid. Growth assays with independent knockouts of dna-pkcs (DNA-PKCs-) and 
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ubxd18 (UBXD18-), and an independent knockdown of tkt (TKT-) confirmed that a 
disruption in each of these genes results in partial resistance to decanoic acid. Growth 
assays with an independent gene knockout of fcsA, identified from a mutant library 
screen in 4-BCCA, demonstrated that a disruption in this gene confers partial 
resistance to both decanoic acid and 4-BCCA. These findings from independently 
generated mutants suggest that the observed fatty acid resistant phenotypes have 
arisen as a direct result of the disruptions in the identified genes, rather than any 
potential off target mutations, thus, implicating the corresponding proteins as 
potential molecular targets for decanoic acid or 4-BCCA. 
The fundamental theory behind the Dictyostelium mutant library screen 
discussed in the chapter is that resistance to a compound arises due to a disruption 
in a gene encoding a protein that controls the sensitivity to that compound during 
growth, thus implicating that protein, or wider pathway in the action of the 
compound. However, if certain gene disruptions cause Dictyostelium cells to 
proliferate more rapidly, to expel the compound from the cell, or to prevent uptake 
of the compound, this could confer growth resistance to the cells without providing 
any useful insight into the mechanism of action of that compound. Therefore, 
consideration of potential targets is necessary to avoid false leads.  
DNA-PKcs- has been identified as partially resistant to the inhibitory effect of 
decanoic acid on Dictyostelium growth implicating DNA-PKcs as a potential target 
involved in regulating decanoic acid sensitivity. DNA-PKcs is the catalytic subunit of a 
protein kinase required for non-homologous end joining (NHEJ) in the repair of DNA 
double strand breaks (Ma et al., 2002). DNA-PKcs has been shown to interact with a 
highly conserved AAA (ATPase Associated with diverse cellular activities) ATPase, 
p97, as part of the machinery for NHEJ (Jiang et al., 2013; Livingstone et al., 2005). 
Interestingly p97 is also known to interact with UBX domain containing proteins such 
as UBXD18, also identified as a potential molecular target for decanoic acid 
(Schuberth and Buchberger, 2008). This finding initially suggested a strong indication 
for p97 as a common target for decanoic acid. However, through communication with 
other members of the Dictyostelium community we became aware that the REMI 
mutant with a disruption within DNA-PKcs has been identified from multiple mutant 
library screens for unrelated compounds. It is unlikely that this protein is a target for 
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multiple unrelated compounds, suggesting that this mutant confers general 
resistance. Therefore, investigations into DNA-PKcs as a potential target for decanoic 
acid were halted. Since DNA-PKcs- is defective in repairing DNA double strand breaks 
(Hudson et al., 2005), there is an increased chance of DNA damage resulting in 
additional gene disruptions in this cell line. Off-site mutations generated in this cell 
line may be responsible for the resistance to multiple compounds in growth. 
The Dictyostelium mutant with an insertion within the gene fcsA has 
demonstrated growth resistance to both 4-BCCA and decanoic acid. This gene 
encodes a long-chain fatty acyl co A-synthetase (FcsA), an enzyme which catalyses 
the reaction between long-chain fatty acids and ATP to form fatty acyl-CoA. Fatty 
acyl-coA is the activated form of a fatty acid, available for metabolism (von Lohneysen 
et al., 2003). As well as catabolic metabolism through beta oxidation or anabolism 
into triacylglycerol in fat droplets, acyl-coAs are involved in multiple processes such 
as membrane trafficking, cell signalling, enzyme activation, protein acylation, and the 
control of transcription, making the protein FcsA a potentially interesting molecular 
target for 4-BCCA and decanoic acid (von Lohneysen et al., 2003). However, in 
Dictyostelium the FcsA protein has been demonstrated to localise to the membranes 
of endocytic vesicles and mediate the fatty acid retrieval from endosomes into the 
cytoplasm (von Lohneysen et al., 2003). This has been demonstrated by using a 
fluorescently labelled fatty acid analogue (C1-BODIPY-C12) to show that in FcsA- fatty 
acid uptake and fatty acid retrieval from phagosomes is reduced. Therefore, the fatty 
acyl coA-synthetase has been implicated in the retrieval of fatty acids from the 
phagosome thus making the activated fatty acyl-coA available to the cell. These 
findings are supported by results from mammalian cells that show that 
overexpression of long-chain fatty acyl co A-synthetase enhances fatty acid 
accumulation (Chiu et al., 2001). A defect in fatty acid uptake in Dictyostelium FcsA- 
cells could be responsible for conferring the partial resistance to decanoic acid and 
4-BCCA that we have demonstrated. For this reason, we stopped investigations into 
FcsA as a potential target for medium-chain fatty acids. However, questions remain, 
as it unclear as to whether decanoic acid and 4-BCCA would be taken up into the cell 
through the same mechanisms as long-chain fatty acids. 
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The protein transketolase (TKT) has been implicated in regulating the 
sensitivity of Dictyostelium to decanoic acid, since knocking out the tkt gene confers 
partial growth resistance to this medium-chain fatty acid. Transketolase is a 
ubiquitous enzyme catalysing the reversible transfer of two carbon ketol units 
between ketose and aldose phosphates, connecting the pentose phosphate pathway 
to glycolysis, and thus is required for the production of reducing agent nicotinamide 
adenine dinucleotide phosphate (NADPH) (Boyle et al., 2016). Following 
identification of the tkt REMI mutant, generation of an independent tkt knockdown 
(TKT-) and recapitulation of the decanoic resistant phenotype, communication with 
other members of the Dictyostelium community has established that this mutant has 
also been identified as resistant in multiple mutant library screens.  TKT- has been 
identified as resistant to compounds such as tanshinones, myrigalone A, and a range 
of mammalian teratogens. Furthermore, analysis of mutant pools by REMI-seq has 
identified TKT- as having a growth advantage (Gruenheit et al., 2019). It is unclear 
how a disruption in the gene tkt could result in a general resistance to the growth 
inhibitory effects of multiple compounds or lead to a growth advantage, since a 
disruption in transketolase would reduce NADPH levels resulting in increased 
oxidative stress which would be expected to reduce proliferation rather than activate 
it (Xu et al., 2016). The identification of a tkt REMI mutant from mutant library screens 
with multiple unrelated compounds and the discovery of an inherent growth 
advantage of this mutant suggest that TKT is not a specific molecular target for 
decanoic acid, but that when disrupted, confers general resistance. For this reason, 
investigations into TKT as a potential target for decanoic acid were concluded at this 
point. 
The mutant library screen has implicated the protein UBXD18 as a regulator 
of sensitivity to decanoic acid. This target belongs to the UBX domain containing 
family of proteins, the largest group of cofactors for the ubiquitous p97 protein 
(Schuberth and Buchberger, 2008). p97 is a AAA ATPase known to function in multiple 
cellular processes such as autophagy, endoplasmic reticulum-associated degradation 
(ERAD), NF-κB signaling, and DNA damage response, making the UBXD18 protein an 
exciting potential target for decanoic acid (Yamanaka, Sasagawa and Ogura, 2012). 
This target is investigated in more detail in the following chapters.  
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 Dictyostelium mutant libraries provide an excellent genetic system for 
understanding the molecular mechanisms of compounds and identifying regulators 
of cellular processes. In this chapter we have proposed UBXD18 as a potential target 
for decanoic acid and will address this target in the following chapters. However, the 
mutant library screens described in this chapter have led to the identification of 
potential false targets known to be resistant to other unrelated compounds, thus 
highlighting a limitation of this system. Further limitations of REMI mutant library 
screens exist, for example not all relevant genes can be discovered since some genes 
are vital for growth, precluding their appearance in a mutant library. Furthermore, 
using a traditional mutant library screen only genes conferring increased resistance 
to a compound can be identified, while mutants conferring increased sensitivity to a 
compound of interest are selected against. Recent innovations have been developed 
to overcome these deficits. An important new development is the REMI-seq 
approach which allows the frequency of each mutant to be quantified at the start and 
end of selection (Gruenheit et al., 2019). This technique has employed a novel 
insertion vector containing sequences allowing identification of the insertion point 
via ligation of sequencing adapters. This technique allows illumina sequencing to 
accurately quantify the frequency of the different mutants before and after selection, 
increasing the throughput. Another recent development is an approach using 
chemical mutagenesis combined with whole genome sequencing (Li et al., 2016). This 
technique utilises random mutagenesis via a chemical mutagen, followed by 
screening for a chosen trait. Whole genome sequencing can then be used to identify 
which genes carry frequent base changes, implicating that gene in the response to 
the trait. The benefit of this technique is the generation of partial loss of function or 
gain of function mutations in addition to null mutations primarily generated by REMI 
mutagenesis (Li et al., 2016; Loomis, 2016).  
In this chapter we have demonstrated that the key component of the MCT 
ketogenic diet, decanoic acid, along with the accompanying fatty acid, octanoic acid, 
and related compound, 4-BCCA, inhibit Dictyostelium cell proliferation in a dose 
dependent manner while having no effect on multicellular development. These 
findings indicate the presence of specific molecular targets for medium-chain fatty 
acids in Dictyostelium. In order to identify these targets, we utilised the growth 
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inhibitory effect of decanoic acid and 4-BCCA to screen a mutant library for mutants 
resistant to these effects. Using this process, we identified three genes from a screen 
in decanoic acid, dna-pkcs, tkt and ubxd18 and one gene from a screen using 4-BCCA, 
fcsA. Investigation into these genes has implicated UBXD18 as an exciting potential 
target for decanoic acid, which is investigated in more detail in the following 
chapters. 
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Chapter 4 
 
Investigating the UBX domain-containing protein 18 as 
a potential target for decanoic acid 
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4.1 Introduction 
In order to identify mechanisms of action behind the antiseizure effects of 
decanoic acid we have shown that decanoic acid inhibits Dictyostelium cell 
proliferation, enabling the use of a genetic screen to identify that cells lacking a UBX 
domain containing protein (UBXD18) are partially resistant to these growth inhibitory 
effects. Using an independent UBXD18- mutant we have confirmed this resistant 
phenotype and have established that re-introducing ubxd18 gene expression is 
capable of restoring sensitivity to decanoic acid. These findings implicate the UBX 
domain containing protein 18 as a potential target for decanoic acid. 
 UBXD18 belongs to the UBX domain containing family of proteins, of which 
there are eleven in Dictyostelium, and thirteen in humans (Rijal et al., 2016). This 
family of proteins make up the largest subgroup of cofactors for the evolutionarily 
conserved protein p97 (Kloppsteck et al., 2012; Schuberth and Buchberger, 2008). 
p97 is a AAA ATPase (Halawani and Latterich, 2006), also called VCP in Humans and 
CdcD in Dictyostelium. This ATPase uses the energy from ATP hydrolysis to extract 
substrate proteins from cellular structures such as protein complexes, membranes of 
cellular structures and chromatin (Meyer and Weihl, 2014; Patel and Latterich, 1998; 
Meyer et al., 2000), allowing the released polypeptides to be degraded and protein 
homeostasis to be maintained. This function is required in processes such as 
endoplasmic reticulum-associated degradation (ERAD) (Ye, Meyer and Rapoport, 
2001), autophagy (Ju et al., 2009), golgi reassembly (Meyer, 2005), NFκB signalling (Li 
et al., 2014), chromatin associated degradation (Vaz, Halder and Ramadan, 2013), 
DNA damage response (Indig et al., 2004) as well as ribosomal and mitochondrial 
associated degradation (Fujii et al., 2012; Meyer and Weihl, 2014) (Fig. 4.1). 
Mutations in p97 can lead to amyotrophic lateral sclerosis (ALS) (Tang and Xia, 2016) 
as well as to the rare multisystem degenerative disorder, inclusion body myopathy 
associated with Paget disease of bone and frontotemporal dementia (IBMPFD), that 
affects the central nervous system, muscle, and bone (Watts et al., 2004). The 
importance of p97 in maintaining cellular homeostasis, and the association between 
p97 mutations and neurological disorders, highlights the disease relevance of this 
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protein, and establishes the cofactor UBXD18 as a potentially relevant target of 
decanoic acid.   
 In this chapter we demonstrate that the growth resistance of UBXD18- to 
decanoic acid is not shared with the related ketogenic diet associated fatty acid 
octanoic acid, suggesting a structurally specific response to decanoic acid. We 
establish the phenotypic characteristics of UBXD18-, and through phylogenetic 
analysis identify potential human homologues. We further demonstrate that these 
conserved UBX domain containing proteins share a common UBX domain, containing 
a shared p97 binding site and establish that UBXD18 binds to p97 in Dictyostelium, 
implicating p97 as potential target for decanoic acid. Finally, we demonstrate that 
decanoic acid inhibits p97 activity in a UBXD18 dependent manner confirming an 
involvement of this ATPase as in the cellular response to decanoic acid. 
  
                                                                    Schematic showing the multiple roles of p97 
dependent on the ATPase activity to extract substrate proteins from cellular 
structures.  
 
Figure 4. 1 Cellular functions of p97.  
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4.2 Results 
4.2.1 The effects of octanoic acid and 4-BCCA on UBXD18- proliferation 
To establish whether UBXD18 regulates sensitivity to other medium-chain 
fatty acids in addition to decanoic acid, the effects of octanoic acid, and 4-BCCA on 
UBXD18- growth were investigated (Fig. 4.2A). UBXD18- showed no change in 
sensitivity to octanoic acid compared to wild type (Ax2) (wild type IC50 79 µM, 95 % 
CI: 73 µM to 100 µM and UBXD18- IC50 87 µM, 95 % CI: 82 µM to 113 µM, p = 0.49, n ≥ 
4), suggesting structural specificity in the targeting of UBXD18 by decanoic acid (Fig. 
4.2B and C). The growth effect of the related compound 4-BCCA on UBXD18- was also 
investigated (Fig. 4.2D). UBXD18- showed partial resistance to 4-BCCA when 
compared to wild type (wild type IC50 1.5 µM, 95 % CI: 0.83 µM to 2.46 µM and 
UBXD18- IC50 7.4 µM, 95 % CI: 5.11 µM to 9.37 µM, p = 0.0022, n = 6) (Fig. 4.2E and F). 
Thus, growth sensitivity analysis implicates UBXD18 in the cellular response to 4-
BCCA but not octanoic acid. 
4.2.2 Phenotypic and phylogenetic analysis of UBXD18- 
In order to investigate the cellular function of UBXD18 we initially investigated 
the role of this protein in Dictyostelium growth and development (Fig. 4.3). 
Dictyostelium cell proliferation was quantified after 7 days, with no significant 
difference observed in cell number between wild type and UBXD18-, indicating a 
comparable rate of proliferation between the two cell lines (Fig. 4.3A). To investigate 
whether UBXD18 is required for Dictyostelium development, we assessed the ability 
of UBXD18- to form fruiting bodies by starving cells on nitrocellulose filters for 22 
hours (Fig. 4.3B). UBXD18- formed fruiting bodies in the same time frame and of the 
same morphology as those formed by wild type. These data suggest that knocking 
out ubxd18 has no effect on Dictyostelium growth or development.  
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Figure 4. 2 Effects of octanoic acid and 4-BCCA of on UBXD18- growth. 
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A) An independent knockout of UBXD18- was treated with a range of concentrations 
of octanoic acid (µM) for 168 hours. Percentage growth was plotted normalised to 
the solvent control (0 µM, 0.2 % DMSO) at 168 hours (n = 4). B) Dose response curves 
of normalised growth rate plotted against Log concentration of octanoic acid were 
used to compare the octanoic acid sensitivity of wild type (Ax2) (n = 4) to UBXD18- (n 
= 4). C) IC50 values for wild type (n = 4) and UBXD18- (n = 4) in octanoic acid were 
compared. D) UBXD18- was treated with a range of concentrations of 4-BCCA (µM) 
for 168 hours (n = 6). E) Dose response curves were used to compare the 4-BCCA 
sensitivity of wild type (n = 6) and UBXD18- (n = 6). F) IC50 values for wild type (n = 4) 
and UBXD18- (n = 4) in 4-BCCA were compared. G) Sensitivity of wild type and 
UBXD18- was compared. Data represent the mean ± SEM. Significance is indicated by 
** p ≤ 0.01 (Mann Whitney test). 
A D 
B 
E 
C F 
 Ax2  IC50 (µM) UBXD18- IC50 (µM) Significance 
difference   
Decanoic acid 18 (95% Cl:17 to 20) 37 (95% Cl:31 to 43) p ≤ 0.0001 
Octanoic acid 86 (95% Cl:73 to 100) 96 (95% Cl:82 to 113) p = 0.49 
4-BCCA 1.5 (95% Cl:0.83 to 2.46) 7.4 (95% Cl:5.11 to 9.37 p = 0.0022 
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A 
B 
Top down view Side view 
Wild type 
UBXD18- 
                                   A) Dictyostelium wild type (Ax2) and UBXD18- cells were set up 
at 2 x 104 cells/ml. Cell density was quantified after 7 days (n = 10). Data represent 
the mean ± SEM (unpaired t-test). B) Qualitative evaluation of the developmental 
phenotype of UBXD18- compared to wild type following 22 hours starvation on 
nitrocellulose filters. Top down view (scale bar 1 mm) and side on (scale bar 0.2 mm) 
images represent results from triplicate experiments. 
 
Figure 4. 3 UBXD18- behaves like wild type Dictyostelium in cellular proliferation 
and development.
0
200
400
600
800
1000
1200
Wild type UBXD18-C
e
ll 
d
e
n
si
ty
 (
x1
0
4
ce
lls
/m
l)
 
101 
 
Cladistic analysis of all Dictyostelium and human UBX proteins was carried out 
with the aim of investigating their relatedness (Fig. 4.4A). This analysis suggested that 
the human UBXN1 (uniprot Q04323) and UBXD2 (uniprot Q92575) proteins are the 
most evolutionarily related to the Dictyostelium UBXD18 protein. These three 
proteins share a conserved UBX domain that was further analysed to assess amino 
acid conservation (Fig. 4.4B and C). The Dictyostelium UBX domain shared 28 % 
identical, and 51 % similar amino acids with the UBX domain of UBXN1, and 27 % 
identical and 51 % similar amino acids with the UBX domain of UBXD2 (Fig. 4.4B). The 
AAA ATPase p97 binding loop (s3/s4 loop) was partially conserved between these 
proteins (Fig. 4.4B and C) (Dreveny et al., 2004), suggesting that these proteins are 
potential p97 binding partners.  
4.2.3 Phylogenetic analysis of p97  
Since UBXD18 contains a general p97 interaction motif (Dreveny et al., 2004; 
Schuberth and Buchberger, 2008) (Fig. 4.4B and C) we verified the presence of a 
conserved p97 protein in Dictyostelium. The Dictyostelium p97 protein shows 
conservation of domain organisation (Fig. 4.5A) and a high sequence identity (78 %) 
with the human protein (Fig. 4.5B). Amino acids (Asp35, Ser37, Val38 Phe52, Ile70, 
Leu72, Tyr110, and Tyr143) involved in creating a hydrophobic binding pocket for the 
p97 binding loop of UBX domain containing proteins (Hanzelmann, Buchberger and 
Schindelin, 2011; Dreveny et al., 2004) are conserved between the Dictyostelium and 
human p97 proteins (Fig. 4.5B), indicating a potential cellular interaction between 
UBXD18 and p97 in Dictyostelium. 
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-Thioredoxin domain 
-Ubiquitin-associated 
domain 
-Zinc finger, ZZ-type 
-UBX domain 
D.UBXD18 504  LSSTYPRKIY 
H.UBXN1  259  LLSGFPRRAF 
H.UBXD2  361  LATMFPRREF 
296 AA 
540 AA 
508 AA 
D.UBXD18 
H.UBXN1 
H.UBXD2 
A 
B 
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  C 
                                                                                                              A) Cladistic analysis of 
Dictyostelium and human UBX domain contacting proteins. Protein sequences were 
aligned using Clustal and the phylogenetic tree was generated using the neighbour 
joining method based on the alignment (MEGA7). The tree is drawn to scale, with 
branch lengths in the same units as those of the evolutionary distances used to infer 
the phylogenetic tree. The evolutionary distances were computed using the Poisson 
correction method and are in the units of the number of amino acid substitutions per 
site. B) The two most highly conserved human proteins UBXN1 and UBXD2 (H. UBXD2 
and H. UBXN1) are shown alongside a schematic of the Dictyostelium UBXD18 protein 
(D. UBXD18). These proteins share a common UBX domain (highlighted in yellow) 
with a highly conserved s3/s4 loop involved in binding p97 (highlighted in blue). The 
s3/s4 loop consists of an aromatic amino acid tyrosine or phenylalanine, followed by 
proline and arginine.  C) Full protein sequence alignment of the Dictyostelium 
UBXD18 protein with the two most highly conserved human proteins UBXN1 and 
UBXD2. Identical amino acids are coloured black, and similar amino acids are coloured 
grey. The UBX domains are highlighted in yellow and the s3/s4 loop is highlighted in 
blue. 
 
Figure 4. 4 The Dictyostelium UBXD18 protein, identified from a mutant library 
screen, contains the evolutionarily conserved UBX domain. 
D.UBXD18    1 MSRVKVLVDNQLDSELVTAGKRLVVVDFTATWCGPCKMISPYFEQLSSEYKDVIFLKVDV 
H.UBXD2     1 MLWFQ------------------------------------------------------- 
H.UBXN1     1 MAELT------------------------------------------------------- 
 
D.UBXD18   61 DQCKSTTQSQGVRAMPTFKFFIERKQVHEFSGADKNQLKSSIERLQPQLSFASQGNALGG 
H.UBXD2     6 ------------------------------------------------------------ 
H.UBXN1     6 ------------------------------------------------------------ 
 
D.UBXD18  121 GGGGSGNSRQAYLDNLEKKQQEQQAQYQQQYGNTTTSPTVPTPITSSSSSTATKSRPPAR 
H.UBXD2     6 ------------------------------------------------------------ 
H.UBXN1     6 ------------------------------------------------------------ 
 
D.UBXD18  181 ATQPDPIMMKD-LIDMGFPENRCRKALIMVN--NSSSQSAMDWIFENMDSP--------- 
H.UBXD2     6 -------GAIPAAIATA-KRSGAVFVVFVAGDDEQSTQMAASW----EDDKVTEASSNSF 
H.UBXN1     6 -------ALES-LIEMGFPRGRAEKALALTG--NQGIEAAMDWLMEHEDDP--------- 
 
D.UBXD18  229 -------------------------------TIDDPLEGDTGATTTKSESTTTTTPSTTN 
H.UBXD2    54 VAIKIDTKSEACLQFSQIYPVVCVPSSFFIGDSGIPLEVIAGSVSADE-LV-TRIHKVRQ 
H.UBXN1    47 -------------------------------DVDEPLETPLGHILGRE------------ 
 
D.UBXD18  258 TDGSTTTTTTTTTTTSEQKEYPTTVHNALCDMCQNQIIGYRYKCKVCPNYDLCQTCKDTN 
H.UBXD2   112 MHLLKSETSVANGSQSESSVSTPSASFEPNNTCENSQSRNAELCEIPPTSDT-KSDTATG 
H.UBXN1    64 -----------------------------------------------PTSSE-QGG---- 
 
D.UBXD18  318 KHNPEHEFVAHENDIENYQMTPEEKAEQKKRLEARIQEIRVKKAEEEAKKEIEREINRRQ 
H.UBXD2   171 GESAGHATSSQEPSGCSDQRPAEDLNIRVERLTKKLEERREEKRKEEEQREIKKEIERRK 
H.UBXN1    72 LEGSGSAAGEGKP-----ALSEEERQEQTKRMLELVAQKQREREEREEREALERERQRRR 
 
D.UBXD18  378 GGKSTQQALTKWQEDQLKREQEKDRKEKEADRIAKAKIKAKVEADRLERAAKKNATLNNN 
H.UBXD2   231 TGKEMLDYKRKQEEELTKRMLEERNREKAEDRAARERIKQQIALDRAERAARFAKTKEEV 
H.UBXN1   127 QGQELSAARQRLQEDEMRRAAEERRREKAEELAARQRVREKIERDKAERAKKYGGSVGSQ 
 
D.UBXD18  438 VATTTTTTTTTPTPVP---VYVPKQNYTESLIQIRLTDGTTIKGTFPLSTKLIDVHTFIS 
H.UBXD2   291 EAAKAAALLAKQAEMEVKRESYARERSTVARIQFRLPDGSSFTNQFPSDAPLEEARQFAA 
H.UBXN1   187 PPPVAPE--PGPVPSSPSQEPPTKREYDQCRIQVRLPDGTSLTQTFRAREQLAAVRLYVE 
 
D.UBXD18  495 NNTS-Q----HGKFTLSSTYPRKIYTNDELKSISVQDAGLVPNGTLQVQK---------- 
H.UBXD2   351 QTVGNT----YGNFSLATMFPRREFTKEDYKK-KLLDLELAPSASVVLLPAGRPTASIVH 
H.UBXN1   245 LHRGEELGGGQDPVQLLSGFPRRAFSEADMER-PLQELGLVPSAVLIVAKK-CPS----- 
 
D.UBXD18  540 ------------------------------------------------------------ 
H.UBXD2   406 SSSGDIWTLLGTVLYPFLAIWRLISNFLFSNPPPTQTSVRVTSSEPPNPASSSKSEKREP 
H.UBXN1       ------------------------------------------------------------ 
 
D.UBXD18  540 ------------------------------------------L 
H.UBXD2   466 VRKRVLEKRGDDFKKEGKIYRLRTQDDGEDENNTWNGNSTQQM 
H.UBXN1       ------------------------------------------- 
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Dictyostelium (p97) 
Human (p97) 
-CDC48, N-terminal subdomain 
-CDC48, domain 2 
-AAA+ ATPase domain 
-Vps4 oligomerisation, C-terminal 
793 AA 
806 AA 
A 
B D.P97    1 MATIEDTSKD-NNNPILERKKAPNRLFVEEAINDDNSVVTLNPETMDQLQFFRGDTLLIK 
H.P97    1 MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLK 
 
 
D.P97   60 GKKRRDTVCIVLSDPTIDPSKIRMNKVVRNNLRVRLGDMISVHQCSDVKYGKRIHVLPID 
H.P97   61 GKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPID 
 
 
D.P97  120 DTIEGLSGNLFDLYLKPYFLEAYRPVRKGDLFLVRGGMRAVEFKVVETDPGEYCIVAPET 
H.P97  121 DTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDT 
 
 
D.P97  180 FIHCEGEAVKREDED-RLDEVGYDDIGGVRKQLGQIRELVELPLRHPQLFKNIGVKPPKG 
H.P97  181 VIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRG 
 
 
D.P97  239 ILLYGPPGCGKTMIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPSI 
H.P97  241 ILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAI 
 
 
D.P97  299 IFIDEIDSIAPKREKTQGEVERRIVSQLLTLMDGLKSRAHVIVMGATNRPNSIDPALRRF 
H.P97  301 IFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRF 
 
 
D.P97  359 GRFDREIDITIPDATGRLEIMRIHTKNMKLDETVDLEAVANETHGYVGADLAALCTESAL 
H.P97  361 GRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAAL 
 
 
D.P97  419 QCIREKMDVIDLEDETISAEILESMSVTQDHFRTALTLSNPSALRETVVEVPTTTWEDIG 
H.P97  421 QAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIG 
 
 
D.P97  479 GLEGVKRELRETVQYPVEHPEKFRKFGMQPSKGVLFYGPPGCGKTLLAKAIANECQANFI 
H.P97  481 GLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFI 
 
 
D.P97  539 SIKGPELLTMWFGESEANVRELFDKARQAAPCVLFFDELDSIARSRGSSQGDAGGAGDRV 
H.P97  541 SIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRV 
 
 
D.P97  599 INQILTEMDGMNAKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDLPSRVAILKAC 
H.P97  601 INQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKAN 
 
 
D.P97  659 LNKSPVAKDVDLEFLGQKTQGFSGADLTEICQRACKLAIRESIEKDIESTKARQESGDTK 
H.P97  661 LRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTN-PSA 
 
 
D.P97  719 MEDDSVDPVPEITRDHFQEAMRSARRSVSDNDIRKYESFAQTLVQSRGLGNNFKFPDQES 
H.P97  720 MEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFG-SFRFPSGNQ 
 
 
D.P97  779 SG--------------QFNQDQSDDLFSN 
H.P97  779 GGAGPSQGSGGGTGGSVYTEDNDDDLYG- 
                                                                                                                                    A) Schematic 
of the Dictyostelium and human p97 proteins, showing 78 % sequence identity. B) Full 
protein sequence alignment of the Dictyostelium p97 (D. p97) and human p97 (H. p97) 
proteins. Amino acids creating a hydrophobic binding pocket for the s3/s4 loop of UBX 
domain containing proteins are highlighted (Asp35, Ser37, Val38 Phe52, Ile70, Leu72, 
Tyr110, and Tyr143) (Hanzelmann, Buchberger and Schindelin, 2011; Dreveny et al., 
2004).  
Figure 4. 5 Dictyostelium and human p97 proteins are highly conserved.
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4.2.4 Analysis of an interaction between UBXD18 and p97 
Following the identification of a general p97 interaction motif in UBXD18 
(Dreveny et al., 2004; Schuberth and Buchberger, 2008) (Fig. 4.4), and establishing 
that the Dictyostelium and human p97 proteins share high sequence identity (Fig. 
4.5), we designed an immunoprecipitation experiment to investigate an interaction 
between UBXD18 and p97. For immunoprecipitation, cells co-expressing 
fluorescently tagged UBXD18 and p97 were required. We employed the GFP-UBXD18 
expression vector (Fig. 3.15) and generated an extrachromosomal vector designed to 
express p97 with a carboxy-terminal RFP domain attached (p97-RFP) (Fig. 4.6A). To 
make this vector the open reading frame of p97 was amplified from wild type (Ax2) 
cDNA with the incorporation of restriction enzyme sites to enable cloning into the 
pTX-GFP vector. This expression vector was verified by sequencing before being 
transfected into wild type cells and cell lysates were analysed by western blotting to 
confirm the presence of the correct size (116 kDa) RFP-tagged protein (Fig. 4.6B). This 
p97-RFP vector was then transfected into Dictyostelium cells along with the GFP-
UBXD18 vector to create a cell line co-expressing GFP-UBXD18 and p97-RFP. A cell 
line expressing the GFP vector (pTX-GFP) without the ubxd18 coding sequence was 
also transfected into cells along with the p97-RFP vector as a control. To monitor 
binding of p97-RFP and GFP-UBXD18, cell lysates from both cell lines were mixed with 
agarose beads coated with GFP antibody, and the interacting proteins were isolated 
and analysed using western blot with anti-GFP and anti-RFP antibodies (Fig. 4.6C). 
p97-RFP was found to bind to GFP-UBXD18 but not to free-GFP (Fig. 4.6C), suggesting 
that UBXD18 interacts with p97 in Dictyostelium. 
To confirm an interaction between GFP-UBXD18 and p97-RFP we investigated 
the cellular localisation of these fluorescently tagged proteins.  Using live cell imaging, 
GFP-UBXD18 and p97-RFP were found to co-localise throughout the cytoplasm and 
the nucleus (Fig. 4.6D), consistent with that suggested for the human UBXD2 and 
UBXN1 proteins (Wang et al., 2013; Liang et al., 2006). Colocalization was also 
observed using immunofluorescence with antibodies against GFP and RFP and DAPI 
to confirm nuclear localisation (Fig. 4.6E). 
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                                                                                                  A) Schematic for the generation 
of a p97 expression vector (p97-RFP). B) The presence of p97-RFP within the Ax2 p97-RFP 
cell line was confirmed by western blot analysis using an antibody against RFP (with 
MCCC1 as a loading control). C) Cell lysates of Dictyostelium cells co-expressing GFP-
UBXD18 (87 kDa) (or free-GFP (27 kDa) as a control) and p97-RFP (116 kDa) were 
subjected to pull down with GFP trap beads and the interaction analysed by western blot 
using anti-GFP and anti-RFP antibodies. Co-localisation of GFP-UBXD18 and p97-RFP 
observed by D) visualising fluorescence in live cells co-expressing GFP-UBXD18 and p97-
RFP or by E) immunofluorescence using antibodies against GFP and RFP. Scale bars 
represent 10 µm. 
Figure 4. 6 Dictyostelium UBXD18 interacts with p97. 
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4.2.5 Investigating the effect of decanoic acid on p97 activity  
An interaction between UBXD18 and p97 suggests a role for UBXD18 in 
regulating p97 function, and thus implicates p97 in the cellular changes caused by 
decanoic acid in Dictyostelium. To analyse this, we assessed the effect of decanoic 
acid on p97 activity by treating wild type (Ax2) Dictyostelium p97-RFP expressing cells 
with decanoic acid, octanoic acid or the established selective p97 inhibitor DBeQ 
(N2,N4-dibenzylquinazoline-2,4-diamine) (Parzych et al., 2015; Ching et al., 2013) for 
24 hours before immunoprecipitation of p97-RFP and the direct assessment of 
specific p97 activity  (Rule, Patrick and Sandkvist, 2016) (Fig. 4.7A and D). Treatment 
with decanoic acid (60 µM) caused a 33 % decrease in p97-RFP ATPase activity (95 % 
Cl: 31 % to 36 %, p = 0.038, n = 6). Treatment with octanoic acid (120 µM) had no 
significant effect on p97-RFP ATPase activity (7 % decrease, p > 0.99, n = 6), while the 
p97 inhibitor DBeQ (7.5 µM) significantly reduced p97-RFP ATPase activity (51 % 
decrease, 95 % Cl: 47 %  to 56 %, p = 0.00040, n = 6). Having demonstrated that 
decanoic acid but not octanoic acts to reduce p97-RFP activity, we assessed the effect 
of decanoic acid on p97-RFP activity in cells lacking UBXD18 (UBXD18-) (Fig. 4.7B and 
E). p97-RFP activity in UBXD18- was unresponsive to treatment with decanoic acid (10 
% decrease, p = 0.31, n = 6). UBXD18-/+ showed restored decanoic acid sensitivity 
following 24-hour treatment (49 % decrease in p-4E-BP1 levels, 95 % Cl: 46 % to 57 %, 
p = 0.026, n = 6) (Fig. 4.7C and F). These findings suggest that decanoic acid is acting 
through a mechanism involving UBXD18 to reduce p97 activity in Dictyostelium. 
4.2.6 Predicted binding of decanoic and octanoic acid to UBXD18 
Following the identification that decanoic acid but not octanoic acid inhibits 
p97 activity in a UBXD18 dependent manner, we used computational docking 
software to predict how these fatty acids may interact with the UBXD18 protein, with 
the aim of highlighting differences capable of explaining differential effects on p97 
activity. We first predicted the tertiary structure of UBXD18 using the protein 
prediction software Phyre2 (Kelley et al., 2015), then used the swiss-dock ligand 
interaction programme to predict potential decanoic and octanoic acid docking sites 
(Grosdidier, Zoete and Michielin, 2011a; Grosdidier, Zoete and Michielin, 2011b). 
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                                                                                                                                                 A) 
Analysis of phosphate release from an ATP hydrolysis reaction with p97-RFP isolated 
from wild type Dictyostelium cells treated with decanoic acid (60 µM), octanoic acid 
(120 µM) or DBeQ (7.7 µM) for 24 hours (n = 6). Phosphate release was also analysed 
from ATP hydrolysis reactions with p97-RFP isolated from B) UBXD18- (n = 6) and C) 
UBXD18-/+ (n = 6) treated with decanoic acid (60 µM) for 24 hours. The amount of 
released phosphate (µM) relative to protein concentration (µg) was plotted versus 
time (minutes) and subjected to linear regression analysis. The gradient was plotted, 
representing the rate of ATP hydrolysis (p97 activity µM phosphate/µg protein/min) 
for D) wild type (n = 6, Kruskal-Wallis test with Dunn’s post hoc test), E) UBXD18- (n = 
6, Mann-Whitney test) and F) UBXD18-/+ (n = 6, Mann-Whitney test). G) Schematic of 
UBXD18 (UBX) dependent decanoic acid (DA) induced p97 inhibition.  Significance is 
indicated by ns p > 0.05, * p ≤ 0.05, *** p ≤ 0.001. 
 
Figure 4. 7 Decanoic acid inhibits p97 activity in a UBXD18 dependent manner.
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Protein templates from 14 proteins with structures deposited in the protein 
data bank (PDB) were selected to model UBXD18. This approach provided good 
coverage of the thioredoxin domain and the UBX domain of the UBXD18 protein. 
Docking analysis of both decanoic acid and octanoic acid to the modelled structure 
for UBXD18 suggests that the location of the most energetically favourable location 
for binding is conserved between these fatty acids (Fig. 4.8A). The location of this 
predicted docking site is in the vicinity (within 5 angstroms) of the s3/s4 loop involved 
in binding p97 (Fig. 4.8A). Binding of decanoic acid to this site is predicted to be 
slightly more energetically favourable than the binding of octanoic acid (decanoic 
acid ∆G -9.1 and octanoic acid ∆G -8.7). Docking analysis of all viable interaction sites 
for decanoic and octanoic acid suggests that there are multiple binding sites 
predicted to exclusively bind decanoic acid (Fig. 4.8B), which could explain the 
specificity to this fatty acid. 
While this protein model provides good coverage of the thioredoxin and UBX 
domains, the modelling of the mid-section of this protein is unreliable, due to a lack 
of homologous protein structures. To overcome these problems, and to investigate 
predicted binding to a human protein, we also investigated the predicted docking of 
decanoic acid and octanoic acid to the UBX domain of the human UBXD2 protein. The 
structure of this domain was available (solution NMR) on the protein data bank, 
avoiding complications resulting from ab initio modelling. Docking analysis on this 
domain predicted that the most energetically favourable location for the binding of 
decanoic acid (∆G -7.53) is at a different location to that of octanoic acid (∆G -7.51) 
(Fig. 4.9A). However, when all viable binding sites are considered clusters of octanoic 
acid are observed at the same locations as decanoic acid (Fig. 4.9B). Observing 
predicted docking of these fatty acids in the vicinity (within 5 angstroms) of the p97 
binding site, reveals that both fatty acids bind in the same conformation, with 
decanoic acid binding slightly more favourably than octanoic acid (decanoic acid ∆G 
-6.69, octanoic acid ∆G -6.54) (Fig. 4.9C). While these data, gathered from 
computational docking programmes, highlight some differences in binding site and 
affinity of decanoic acid and octanoic acid, lack of an exact structure limits the 
reliability of these predictions. 
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A 
B 
                                                                                      The tertiary structure of the 
Dictyostelium UBXD18 protein was predicted using phyre2 protein prediction 
software. The thioredoxin domain is labelled in red, the ubiquitin-associated 
domain is labelled in pink, the zinc finger domain is labelled in orange, and the 
UBX domain is labelled in yellow, with the s3/s4 loop (within the UBX domain), 
involved in binding p97, highlighted in blue. Potential decanoic acid and octanoic 
acid sites have been identified using swiss-dock ligand interaction software. A) The 
most energetically favorable locations for decanoic acid (∆G -9.1) and octanoic 
acid (∆G -8.7) are displayed. B) All viable binding sites are displayed, with decanoic 
acid only binding clusters highlighted. 
Figure 4. 8 Predicted docking analysis of decanoic acid (blue) and octanoic acid 
(green) to the Dictyostelium UBXD18 protein.
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4.3 Discussion 
In order to understand the therapeutic mechanisms of decanoic acid provided 
by the ketogenic diet, we have screened a Dictyostelium mutant library to identify 
UBXD18 as a potential target for this fatty acid. We have confirmed that a mutant 
with a disruption in the gene ubxd18 is partially resistant to the effects of decanoic 
acid implicating the protein UBXD18 in regulating the cellular effects of decanoic acid. 
In this chapter we demonstrate that UBXD18- is not resistant to octanoic acid, the 
other fatty acid provided at high concentrations by the MCT diet, suggesting that 
UBXD18 is regulating the response to decanoic acid in a structurally specific manner. 
In order to understand the potential role of the relatively uncharacterised UBXD18 
protein in Dictyostelium we demonstrate that the basic cellular characteristics of 
growth and development are unaffected in the mutant UBXD18-. Furthermore, we 
use phylogenetic analysis to identify the human proteins, UBXN1 and UBXD2 as the 
A B C 
                                                                                    The structure of the UBX domain of 
human UBXD2 has been determined by solution NMR, with the s3/s4 loop, involved 
in binding p97, highlighted in blue. Potential decanoic acid and octanoic acid sites 
have been identified using swiss-dock ligand interaction software. A) The most 
energetically favorable locations for decanoic acid (∆G -7.53) and octanoic acid (∆G 
-7.51) are displayed. B) All viable binding sites are displayed, with decanoic acid 
binding clusters highlighted. C) Predicted docking of decanoic acid and octanoic acid 
in the vicinity (within 5 angstroms) of the p97 binding site is displayed (decanoic acid 
∆G -6.69, octanoic acid ∆G -6.54). 
Figure 4. 9 Predicted docking analysis of decanoic acid (blue) and octanoic acid 
(green) to the UBX domain of human UBXD2.
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closest related human UBX domain containing proteins to Dictyostelium UBXD18. 
Following the identification of a conserved p97 binding site in this protein, we 
demonstrate an interaction between Dictyostelium GFP-UBXD18 and p97-RFP. 
Finally, we show that decanoic acid but not octanoic acid inhibits p97 in a UBXD18 
dependent manner, indicating an involvement of p97 in the cellular changes caused 
by decanoic acid. 
Having implicated UBXD18 as a potential target for decanoic acid, we 
demonstrated that UBXD18- does not confer resistance to the growth inhibitory 
effects of octanoic acid, suggesting that the UBXD18 is not a generic target for all 
medium-chain fatty acids (Fig. 4.2A, B and C). We established that UBXD18- is partially 
resistant to 4-BCCA (Fig. 4.2B, C and D), suggesting that 4-BCCA and decanoic acid 
both act on Dictyostelium in a UBXD18 dependent manner. This is of interest since 
decanoic acid and 4-BCCA have similar effects in reducing epileptiform activity in an 
ex vivo hippocampal slice model (Chang et al., 2015; Chang et al., 2016), suggesting 
a potential conserved mechanism between these related fatty acids. 
Confirming the role of UBXD18 in the cellular response to decanoic acid 
requires an understanding of the cellular function of this protein. While this protein 
is uncharacterised in Dictyostelium, we analysed sequence similarity to identify 
UBXN1 and UBXD2 as the most highly conserved human proteins (Fig. 4.4) and 
investigated the known roles of these proteins to help us to better understand the 
function of UBXD18. Both human proteins are involved in endoplasmic reticulum-
associated protein degradation (ERAD) (Liang et al., 2006; Lim et al., 2009; LaLonde 
and Bretscher, 2011), via binding to p97, with UBXD2 promoting ERAD, and UBXN1 
negatively regulating ERAD. These findings suggest that Dictyostelium UBXD18 might 
also play a role in ERAD, however, while these proteins all share a UBX domain, they 
also possess diverse domains allowing these proteins to have potentially different 
functional properties and bind to select partners (Rezvani, 2016). The presence of a 
zinc finger domain in UBXD18, not present in any human UBX domain containing 
protein indicates that UBXD18 may have a different function to UBXN1 and UBXD2. 
This type of ZZ zinc finger domain is thought to be involved in protein-protein 
interactions, but can also bind DNA, RNA, and lipids (Ponting et al., 1996; Klug, 2010; 
Brown, 2005; Matthews and Sunde, 2002). Thus, due to the disparity between the 
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sequences and domains of UBX domain containing proteins the cellular function of 
UBXD18 is unclear, with potential for a conserved role in maintaining protein 
homeostasis. 
The functional activities of proteins correspond with their subcellular 
expression, and therefore, establishing the localization of a protein can help to 
elucidate its function. With this aim, we ascertained that UBXD18 is localised 
throughout the cytoplasm and nucleus of Dictyostelium (Fig. 4.6D and E), suggesting 
that this protein is more closely related to the human UBXN1 which also localises 
throughout the cytoplasm (Wang et al., 2013), than to UBXD2 which localises to the 
endoplasmic reticulum (ER) and the nuclear envelope (Liang et al., 2006).  This 
conclusion is supported by the lack of transmembrane domains in both the 
Dictyostelium UBXD18 protein and the human UBXN1 protein (TMHMM, TMPRED, 
HMMTOP), and the presence of one transmembrane domain in the human UBXD2 
protein. Our data suggesting that UBXD18 also localises to the nucleus in 
Dictyostelium, could indicate a role for UBXD18 in nuclear protein degradation. Taken 
together these findings implicate UBXN1 as the closest related human protein to 
UBXD18, while differences in subcellular localisation suggest potentially diverse 
functions of these proteins.  
The conserved s3/s4 loop present in the UBX domain of UBX domain 
containing proteins has been demonstrated to be involved in binding to p97, via 
insertion into a hydrophobic pocket (Dreveny et al., 2004) conserved in Dictyostelium 
(Fig. 4.5). Furthermore, deletion of, or point mutations within this loop reduce p97 
binding, suggesting that UBX domains act as general p97 binding modules (Dreveny 
et al., 2004). We have demonstrated that GFP-UBXD18 binds to Dictyostelium p97-
RFP (Fig. 4.6), implicating p97 in the cellular changes caused by decanoic acid. Thus, 
we demonstrated that decanoic acid but not octanoic acid inhibits the ATPase activity 
of p97 in a UBXD18 dependent manner (Fig. 4.7). The identification of decanoic acid 
as an inhibitor of p97 is of interest since p97 inhibitors have been proposed as 
treatments for cancer and epilepsy (Tang and Xia, 2016; Han et al., 2015; Tang et al., 
2019).  
Since we have demonstrated efficacy of decanoic acid but not octanoic acid 
in UBXD18 dependent inhibition of p97 we utilised computational docking software 
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to highlight differences in binding locations and affinities of these fatty acids to a 
model of the UBXD18 protein (Fig 4.8). Due to the lack of defined protein structure 
for UBXD18 we utilised a model generated by Phyre2. Predictions from this model 
suggested that the most energetically favourable binding site is conserved for both 
decanoic acid and octanoic acid (Fig 4.8A). While analysis of all viable interaction 
sites, predicted multiple sites exclusively binding decanoic acid (Fig. 4.8B). 
Investigations into these exclusive sites could explain the difference in activity of 
these fatty acids. However, due to ab initio modelling, only 50 % of the protein was 
modelled at > 90 % confidence, suggesting that ligand docking from this model may 
be unreliable (Kelley et al., 2015). To overcome this, we investigated the predicted 
docking of decanoic acid and octanoic acid to a solution NMR derived structure of the 
UBX domain of the human UBXD2 protein. Predictions from this model suggest that 
octanoic acid binds to the same sites as decanoic acid with comparable affinity (Fig. 
4.9). However, ligand binding is likely to be affected by interactions with other 
domains, thus limiting the reliability of these predictions. Accurate modelling of 
ligand binding can shed light on the biological activity of ligands and can be used to 
aid the development of improved drugs by determining how drug modifications can 
alter binding affinity and activity (Grosdidier, Zoete and Michielin, 2011b; Boehm et 
al., 2000). Therefore, reanalysis of decanoic acid and octanoic acid docking following 
validation of a reliable protein structure could clarify the molecular interactions of 
these fatty acids.  
 Our discovery that decanoic acid acts with structural specificity to inhibit p97 
activity in a UBXD18 dependent manner, suggests that decanoic acid could impact a 
variety of cellular processes regulated by p97 (Fig. 4.1). Autophagy is a key 
homeostatic process regulated by p97 that is essential for cell survival. Loss of p97 
results in an impairment in this pathway and an accumulation of autophagosomes  
(Ju et al., 2009) and inhibitors of p97 have been demonstrated to block 
autophagosome maturation (Chou et al., 2011). Autophagy dysfunction has been 
linked to neurodegenerative disorders including epilepsy (Giorgi et al., 2015; Wong, 
2013), with ketogenic diets credited with activating this pathway via mTORC1 
inhibition (McDaniel et al., 2011). Our findings implicating decanoic acid in p97 
inhibition, suggest a potential effect of decanoic acid on autophagy. Autophagy has 
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been widely studied in Dictyostelium with multiple established methods available 
(Dominguez-Martin et al., 2017; Mesquita et al., 2013), thus, this pathway provides 
a rational avenue of investigation. 
In this chapter we have identified UBXD18 as a p97 binding partner and 
demonstrate that decanoic acid inhibits p97 activity in a UBXD18 dependent manner. 
Inhibiting p97 has been proposed to have therapeutic benefits in cancers and 
epilepsy, suggesting potential efficacy for decanoic acid in these areas. Since p97 has 
a well-established role in autophagy, a process closely associated with cancer and 
epilepsy, we investigate the effect of decanoic acid on autophagy in Dictyostelium in 
the following chapter. 
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Chapter 5   
 
Investigating the effects of medium-chain fatty acids 
on autophagy in Dictyostelium 
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5.1 Introduction 
In previous chapters we have identified that in Dictyostelium, decanoic acid 
acts via a UBXD18 dependent mechanism to inhibit p97 activity, thus implicating this 
protein in the therapeutic effects of this fatty acid. Since p97 is known to play a 
significant role in protein homeostasis, in this chapter we investigate the effects of 
decanoic acid on autophagy, a key homeostatic process associated with 
neurodegenerative disorders, cancer and epilepsy (Wong, 2013; Saha et al., 2018).  
Macroautophagy, the most prevalent form of autophagy, is conserved 
between Dictyostelium and humans. In Dictyostelium, macroautophagy (hereafter 
referred to as autophagy) is required to liberate nutrients during starvation, as well 
as in the degradation of proteins, and in response to pathogen infection (Otto et al., 
2003; Cardenal-Munoz et al., 2017; Mesquita et al., 2016). Dictyostelium has been 
widely used as a model to study autophagy with findings from this organism providing 
important advances in the study of autophagy-related pathologies. Research in 
Dictyostelium has demonstrated a link between the neurodegenerative disease, 
Chorea-acanthocytosis (ChAc), and autophagy (Munoz-Braceras, Calvo and 
Escalante, 2015),  with further research implicating Vmp1, an ER protein involved in 
cancer, in the clearance of ubiquitinated protein aggregates through autophagy 
(Calvo-Garrido and Escalante, 2010). In addition to this, several studies in 
Dictyostelium have suggested a role for protein sequestration in neuronal 
malfunction (Kim et al., 2009; Schmauch et al., 2009). The prevalence of autophagy 
related studies using this model highlights the value of using Dictyostelium to 
research this conserved cellular process.  
Due to the widespread use of Dictyostelium in autophagy research there are 
several well-established methods for assessing autophagy in this model. 
Fluorescence microscopy is widely employed to visualise autophagy structures within 
the cell, with Atg8a (Atg8) (microtubule-associated protein 1A/1B-light chain 3 (LC3) 
in mammals) tagged to GFP (GFP-Atg8) used extensively in Dictyostelium as a 
fluorescent marker (Mesquita et al., 2016). GFP-Atg8 is employed as an autophagy 
marker since this protein is incorporated into the membrane of the phagophore 
following the induction of autophagy, and remains in the membrane until the 
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autophagosome is degraded (King, Veltman and Insall, 2011; Mesquita et al., 2013). 
An increase in the number of GFP-Atg8 positive structures in the cell indicates an 
induction in autophagy, whereas a decrease in the number and an increase in the size 
of GFP-Atg8 labelled structures suggests a blockage of autophagy (Sharma et al., 
2019; Dominguez-Martin et al., 2017). Another method to study autophagy involves 
monitoring the amount of material degraded by this pathway over time, termed 
autophagic flux (Mesquita et al., 2016). Autophagic flux is commonly measured by 
observing the autophagic cleavage of GFP from tagged cytosolic proteins such as GFP-
Atg8 (Calvo-Garrido et al., 2011). This technique utilises the hydrolase resistant 
properties of GFP such that when GFP is fused to a cytosolic protein (GFP-Atg8) and 
delivered to lysosomes by autophagy, free GFP accumulates while the rest of the 
fusion protein (Atg8) is degraded. Alternatively, when flux is blocked the fusion 
protein (GFP-Atg8) accumulates, since degradation is blocked, and thus free GFP 
disappears. Quantification of these proteins by western blot provides an effective 
indication of changes in autophagic flux (Welter, Thumm and Krick, 2010; Cardenal-
Munoz et al., 2017). One further method to study autophagy is quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) which can be used to measure 
expression levels of autophagy genes (Cardenal-Munoz et al., 2017). The availability 
of multiple well studied techniques, along with the conservation of most mammalian 
autophagy genes, makes Dictyostelium an ideal model for the study of autophagy.  
In this chapter we demonstrate, using live cell fluorescent microscopy, that 
both decanoic acid and octanoic acid significantly increase the number of GFP-Atg8 
positive structures in Dictyostelium in wild type and UBXD18- cells, indicating that 
these medium-chain fatty acids regulate autophagy independently of UBXD18. We 
confirm that this coincides with an alteration in autophagic flux in both wild type and 
UBXD18- cells treated with decanoic acid and octanoic acid, and further demonstrate 
that decanoic acid treatment leads to an increase in the expression of two autophagy 
genes in wild type cells, suggesting a role for medium-chain fatty acids in inducing 
autophagy in Dictyostelium. To assess the mechanism behind this change we show 
that both decanoic acid and octanoic acid modulate autophagy independently of the 
autophagy regulating second messenger PIP3. 
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5.2 Results 
5.2.1 Decanoic acid and octanoic acid induce autophagosome formation in 
Dictyostelium 
During autophagy inducing conditions, Atg8 associates with emerging 
autophagosomes, thus employing Dictyostelium cells expressing GFP-Atg8 enables 
the quantification of autophagosome formation (Fig 5.1A). To confirm the effect of 
autophagy induction on autophagosome number we initially quantified the number 
of GFP-Atg8 positive structures in control conditions and under autophagy inducing 
starvation conditions. The number of GFP-Atg8 positive structures increased from an 
average of 2.6 autophagosomes per cell (95 % Cl: 1.7 to 3.4) to an average of 7.4 
autophagosomes per cell following starvation (95 % Cl: 6.2 to 8.5, p = 0.0022, n = 6) 
(Fig. 5.1B and C). This increase in autophagosome number was independent of any 
change in autophagosome size (non-significant increase from 0.46 µm to 0.48 µm, p 
= 0.3939, n = 6) (Fig. 5.1D). This starvation induced increase in GFP-Atg8 structures is 
consistent with an induction of autophagy leading to an increase in autophagosome 
number (Dominguez-Martin et al., 2017). 
To investigate the effects of decanoic acid and octanoic acid on autophagy in 
Dictyostelium, we quantified the average number of GFP-Atg8 structures per cell 
following treatment with these fatty acids. Treatment with decanoic acid (at 60 µM, 
a concentration that resulted in an approximately 95 % inhibition of growth) under 
control (non-starvation) conditions, significantly increased the number of Atg8 
positive structures from an average of 2.5 autophagosomes per cell (95 % Cl: 2.0 to 
3.0) to 7.3 autophagosomes per cell after 4 hours (95 % Cl: 5.3 to 9.2, p = 0.0079, n = 
6) and 8.3 autophagosomes per cell following 24 hours (95 % Cl: 5.1 to 11.49, p = 
0.0023, n = 6) (Fig. 5.2A and B). Treatment with octanoic acid (at 120 µM, a 
concentration that resulted in an approximately 95 % inhibition of growth), increased 
the number of Atg8 positive structures from an average of 2.5 autophagosomes per 
cell to 6.9 autophagosomes per cell after 4 hours (95 % Cl: 4.5 to 9.3, p = 0.0342, n = 
6) and 6.7 autophagosomes per cell following 24 hours (95 % Cl: 5.1 to 8.3, p = 0.0437, 
n = 6) (Fig. 5.2A and B). Treatment with the autophagy inducer (AR-12, 2.5 µM) also 
increased the average number of Atg8 containing structures from 2.5 
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autophagosomes per cell to 7.5 autophagosomes per cell (95 % Cl: 5.7 to 9.3, p = 
0.0022, n = 6) (Fig. 5.2A and B). Protease inhibitors, employed to inhibit lysosomal 
activity and block autophagic flux, had no significant effects on the number of Atg8 
containing structures (non-significant increase from 2.5 to 4.7 autophagosomes per 
cell, p > 0.9999, n = 6) (Fig. 5.2A and B). None of the treatment conditions had a 
significant effect on the size of Atg8 containing structures (p > 0.9999, n = 6) (Fig. 5.2A 
and C). Our data suggest that the increase in GFP-Atg8 structures observed following 
treatment with both decanoic acid and octanoic acid is consistent with an increase in 
autophagy. 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
 
 
 
                                                                                    A) Exogenous GFP-Atg8 is integrated 
into the membranes of the phagophore and autophagosome. B) Representative 
images of Dictyostelium cells expressing GFP-Atg8, untreated (control) or starved for 
1 hour in nutrient free phosphate buffer. Scale bar represents 20 µm. Images were 
analysed for C) autophagosome number (n = 6) and D) autophagosome size (n = 6). 
Data represented are mean ± SEM. Significance is indicated by ** p ≤ 0.01 (Mann-
Whitney test). Each data point is derived from 30 individual cells or autophagosomes, 
box and whisker (10-90th percentile). 
 
Figure 5. 1 GFP-Atg8 as an autophagy marker.
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A 
                           A) Representative images of wild type (Ax2) Dictyostelium cells 
expressing GFP-Atg8 untreated (control) or treated with decanoic acid (60 µM) for 4 
or 24 hours, octanoic acid (120 µM) for 4 or 24 hours, autophagy inducer (AR-12, 2.5 
µM) or protease inhibitor (2.5x). Scale bar represents 20 µm. Images were analysed 
for B) autophagosome number per cell (n = 6) and C) autophagosome size (n = 6). Data 
represented are mean ± SEM. Significance is indicated by ns p > 0.05, * p ≤ 0.05, ** p 
≤ 0.01 (Kruskal-Wallis with Dunn's multiple comparisons test). Each data point is 
derived from 30 individual cells or autophagosomes, box and whisker (10-90th 
percentile). 
 
Figure 5. 4 Decanoic acid induces autophagosome formation in wild type 
Dictyostelium.
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5.2.2 Decanoic acid and octanoic acid induce autophagosome formation 
independently of UBXD18 
Since the cellular function of UBXD18 is poorly characterised, we initially 
assessed the intrinsic levels of autophagy in a cell line lacking a functional copy of this 
protein (UBXD18-). The average number of GFP-Atg8 containing structures per 
UBXD18- cell was 2.4 (95 % Cl: 2.2 to 2.6), compared with 2.5 in wild type cells (95 % 
Cl: 2.0 to 3.0), suggesting that autophagosome formation is unchanged in UBXD18- (p 
= 0.9719, n ≥ 5, Mann-Whitney test) (Fig. 5.2 and 5.3). 
 Since UBXD18 has been implicated in regulating the cellular response to 
decanoic acid in regards to growth and p97 activity, we assessed the effect of 
decanoic acid on autophagosome size and number in UBXD18- cells (Fig. 5.3). 
Decanoic acid treatment (60 µM) resulted in a significant increase in the average 
number of autophagosomes in UBXD18- cells, from 2.4 autophagosomes per cell in 
control conditions to 7.2 autophagosomes per cell following 4 hours (95 % Cl: 5.8 to 
8.5, p = 0.0017, n ≥ 4) and 6.5 autophagosomes per cell following 24 hours (95 % Cl: 
4.5 to 8.5, p = 0.0442, n ≥ 4) (Fig. 5.3 A and B). Treatment with octanoic acid (120 µM) 
also increased the number of Atg8 positive structures in  UBXD18- cells, from an 
average of 2.4 autophagosomes per cell to 6.5 autophagosomes per cell after 4 hours 
(95 % Cl: 4.4 to 8.6, p = 0.0460,  n ≥ 4) and 6.6 autophagosomes per cell following 24 
hours (95 % Cl: 5.0 to 8.2, p = 0.0433, n ≥ 4) (Fig. 5.3 A and B). Treatment with 
autophagy inducer (AR-12, 2.5 µM) also increased the average number of Atg8 
positive structures per cell from 2.4 to 6.7 (95 % Cl: 5.1 to 8.3, p = 0.0279, n ≥ 4), while 
treatments with protease inhibitors had no significant effect (non-significant increase 
from 2.4 to 4.6 autophagosomes per cell, p > 0.9999, n ≥ 4) (Fig. 5.3 A and B). 
Consistent with our data from wild type cells, none of the treatment conditions had 
a significant effect on the size of Atg8 containing structures in UBXD18- cells (p > 
0.9999, n ≥ 4) (Fig. 5.3A and C). Our data suggest that the increase in GFP-Atg8 
structures observed in UBXD18- cells following treatment with both decanoic acid and 
octanoic acid is consistent with an increase in autophagy. 
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A) Representative images of UBXD18- Dictyostelium cells expressing GFP-Atg8 
untreated (control) or treated with 60 µM decanoic acid (DA) for 4 or 24 hours, 
120 µM octanoic acid (OA) for 4 or 24 hours, autophagy inducer (AR-12 2.5 µM) 
or protease inhibitor (2.5x). Scale bar represents 20 µm. Images were analysed 
for B) autophagosome number (n ≥ 4) and C) autophagosome size (n ≥ 4). Data 
represented are mean ± SEM. Significance is indicated by ns > 0.05, * p ≤ 0.05, ** 
p ≤ 0.01. (Kruskal-Wallis with Dunn's multiple comparisons test). Each data point 
is derived from 30 individual cells or autophagosomes, box and whisker (10-90th 
percentile). 
 
Figure 5. 7 Decanoic acid induces autophagosome formation in UBXD18-.
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Our data representing the number of GFP-Atg8 positive structures per cell is 
limited by reflecting the steady-state levels of autophagosomes. Thus, it is difficult to 
differentiate between an increase in the number autophagosomes resulting from an 
increase in autophagosome induction or from a blockage in autophagy degradation. 
One approach to distinguish between an induction or blockage in autophagy is use of 
autophagic flux assays to evaluate autophagic degradation. 
 
5.2.3 Medium-chain fatty acids alter autophagic flux in Dictyostelium 
In order to analyse not only autophagosome formation but also the 
degradation of cytoplasmic constituents, we utilised an autophagic flux assay 
quantifying the autophagy-dependent cleavage of GFP from GFP-Atg8 by western 
blot analysis (Fig. 5.4). In control conditions cytoplasmic proteins along with GFP-Atg8 
are known to be degraded in the autolysosome resulting in the release of free GFP 
(Fig. 5.4A, D and E). Following the induction of autophagy post starvation, the 
formation of autophagosomes is increased (Fig. 5.1) resulting in increased protein 
degradation, and leading to a reduction in GFP-Atg8 (71 % reduction, 95 % Cl: 66 % to 
79 %, p = 0.0079, n = 5) (Fig. 5.4B, D and F) and an increase in the ratio of free GFP to 
GFP-Atg8 (340 % increase, 95 % Cl: 304 % to 392 %, p = 0.0079, n = 5) (Fig. 5.4G). 
Treatment with protease inhibitors has been demonstrated to inhibit lysosomal 
activity and block autophagic flux resulting in a reduction in free GFP and an 
accumulation of GFP-Atg8 (Cardenal-Munoz et al., 2017)(Fig. 5.4C). Using this 
technique, changes in degradative capacity can be evaluated in the presence of 
medium-chain fatty acids.  
To investigate the effects of decanoic acid and octanoic acid on autophagic 
degradation in Dictyostelium we employed an autophagic flux assay following 
treatment with these fatty acids. The levels GFP-Atg8 and free GFP were quantified 
in wild type untreated cells, and in cells treated with decanoic acid (60 µM) or 
octanoic acid (120 µM) for 4 or 24 hours (Fig. 5.5). Cells treated with autophagy 
inducer (AR-12, 2.5 µM), previously established to increase autophagic flux (Cardenal-
Munoz et al., 2017), and protease inhibitors (2.5x), previously established to block 
autophagic  flux (Cardenal-Munoz et al., 2017),  were  also  assessed. Treatment with  
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                                                                                                                                    Cytosolic 
GFP-Atg8 is integrated into the inner and outer membranes of the phagophore and 
autophagosome. A) In control conditions following lysosomal fusion, engulfed 
cytoplasmic material is degraded inside the autolysosome by lysosomal hydrolases 
(blue triangles) along with GFP-Atg8 which is cleaved to form free GFP. The GFP-
Atg8 located at the outer side is released to the cytosol. B) Treatment with 
autophagy inducer results in an increase in the formation of autophagosomes as 
well as an increase in degradation by autophagy, while the rate of GFP-Atg8 
production in the cell remains the same. This results in an increase in 
autophagosomes (as observed by microscopy), while the intensity of the GFP-Atg8 
band observed following western blot is reduced. C) Treatment with protease 
inhibitors impairs lysosomal activity leading to a reduction in free GFP. D) 
Dictyostelium cells expressing GFP-Atg8 untreated (control) or starved for 1 hour in 
nutrient free phosphate buffer (starved) were analysed by western blotting using 
an antibody against GFP, with MCCC1 as a loading control. Means and SEM of E) 
free GFP, F) GFP-Atg8 and G) the ratio of free GFP /GFP-Atg8 are represented (n = 5). 
Significance is indicated by ** p ≤ 0.01 (Mann-Whitney test). 
 
Figure 5. 10 Autophagic flux assay in Dictyostelium expressing GFP-Atg8. 
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decanoic acid for 4 hours resulted in a 71 % decrease in free GFP levels (95 % Cl: 67 % 
to 77 %, p < 0.0001, n ≥  8), with a 43 % decrease following 24 hours treatment (95 % 
Cl: 38 % to 50 %, p = 0.032, n ≥ 8) (Fig. 5.5A and B). Treatment with octanoic acid for 4 
hours also resulted in a 75 % decrease in free GFP levels (95 % Cl: 71 % to 80 %, p < 
0.0001, n ≥ 8), with a 47 % decrease following 24 hours (95 % Cl: 36 % to 62 %, p = 
0.024, n ≥ 8) (Fig. 5.5A and B). Treatment with autophagy inducer (AR- 12) caused a 
40 % decrease in free GFP levels (95 % Cl: 37 % to 45 %, p = 0.024, n ≥  8) (Fig. 5.5A and 
B) consistent with an induction of autophagy (Cardenal-Munoz et al., 2017), while no 
significant difference in free GFP levels were observed following treatment with 
protease inhibitors (39 % decrease, p = 0.0606, n ≥ 8) (Fig. 5.5A and B). These results 
demonstrating that treatment of Dictyostelium with both decanoic acid and octanoic 
acid results in a decrease in free GFP levels, are consistent with a corresponding 
increase in autophagic flux (Cardenal-Munoz et al., 2017).  
Levels of GFP-Atg8 were also monitored following treatments with medium-
chain fatty acids. A 25 % reduction in GFP-Atg8 levels was observed in cells treated 
with decanoic acid for 4 hours (95 % Cl: 24 % to 26 %, p = 0.0077, n ≥ 8) and a 27 % 
decrease following 24 hours (95 % Cl: 24 % to 31 %, p = 0.015, n ≥ 8) (Fig. 5.5A and C). 
A 38 % reduction in GFP-Atg8 levels was observed in cells treated with octanoic acid 
for 4 hours (95 % Cl: 37 % to 41 %, p < 0.0001, n ≥ 8), and a 28 % decrease following 24 
hours (95 % Cl: 20 % to 37 %, p = 0.023, n ≥ 8) (Fig. 5.5A and C). Autophagy inducer also 
led to a 29 % decrease in GFP-Atg8 levels (95 % Cl: 28 % to 30 %, p = 0.0011, n ≥ 8) 
indicating increased autophagic degradation of this protein (Fig. 5.5A and C). Levels 
of GFP-Atg8 were unchanged following treatment with protease inhibitors (0.08 % 
increase, p > 0.9999, n ≥ 8) (Fig. 5.5A and C) consistent with a reduction of 
degradation caused by lysosomal inhibition (Cardenal-Munoz et al., 2017).  
The ratio of free GFP to GFP-Atg8 was monitored as a readout for autophagic 
flux. A significant reduction in this ratio was observed in cells treated with either 
decanoic acid or octanoic acid for 4 hours (decanoic acid caused a 68 % reduction, 95 
% Cl: 63 % to 74 %, p < 0.0001, n ≥  8, and octanoic acid caused a 60 % reduction, 95 % 
Cl: 53 % to 70 %, p < 0.0001, n ≥ 8).  No  significant  change  in  the  ratio of free GFP to  
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                                                                                                                                                    A) 
Dictyostelium cells expressing GFP-Atg8 untreated (control) or treated with 60 µM 
decanoic acid (DA) for 4 or 24 hours (h), 120 µM octanoic acid (OA) for 4 or 24 hours, 
autophagy inducer (AR-12, 2.5 µM) or protease inhibitor (2.5x) were analysed by 
western blotting using an antibody against GFP, with MCCC1 as a loading control. 
Means and SEM of B) free GFP, C) GFP-Atg8 are represented normalised to loading 
control and D) the ratio of free GFP /GFP-Atg8 is displayed (n  ≥  8). Significance is 
indicated by ns > 0.05, * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001 (Kruskal-Wallis with 
Dunn's multiple comparisons test). 
 
Figure 5. 13 Autophagic flux assay in wild type Dictyostelium expressing GFP-Atg8. 
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GFP-Atg8 was observed in cells treated for 24 hours with either decanoic acid (29 % 
reduction, p =  0.4161, n ≥ 8) or octanoic acid (30 % reduction, p = 0.3786, n ≥ 8) (Fig. 
5.5D). As a result of the large decrease in free GFP observed following treatment with 
medium-chain fatty acids and autophagy inducer, the change in the ratio of free GFP 
to GFP-Atg8 is the inverse of that observed following starvation induced autophagy 
induction. This suggests that these fatty acids and AR-12 may promote the 
degradation of free GFP as well as the autophagic degradation of GFP-Atg8. Free GFP 
fragments may be resistant to degradation in starvation conditions, due to an increase 
in lysosomal pH preventing the free GFP fragments from being degraded (Korolchuk 
et al., 2011; Mundy et al., 2012), but susceptible to degradation in the absence of 
starvation and in the presence of autophagy inducing compounds (Fig. 5.5). Finally, a 
non-significant reduction in the ratio of free GFP to GFP-Atg8 was observed following 
treatment with protease inhibitors (27 % decrease, p = 0.23, n ≥ 8) (Fig. 5.5D), a trend 
that is consistent with an accumulation of GFP-Atg8 caused by a block in autophagic 
flux resulting in a reduction in released free GFP. Taken together our data suggests 
that both decanoic acid and octanoic acid are activating autophagic flux in 
Dictyostelium. 
 
5.2.4 Medium-chain fatty acids alter autophagic flux independently of UBXD18 
Since a role for UBXD18 in regulating the cellular response to decanoic acid 
has been suggested, we assessed autophagic flux in UBXD18- cells. As in wild type 
cells, 4 hour treatment with decanoic acid caused a significant, 65 %, reduction in free 
GFP levels in UBXD18- (95 % Cl: 60 % to 72 %, p < 0.0001, n ≥ 9) and 24 hour treatment 
with decanoic acid caused a 39 % decrease (95 % Cl: 35 % to 43 %, p = 0.034, n ≥ 9) (Fig. 
5.6A and B). Octanoic acid treatment for 4 hours also caused a significant, 67 %, 
reduction in free GFP levels in UBXD18- (95 % Cl: 60 % to 76 %, p < 0.0001, n ≥ 9) and 
24 hour treatment caused a 40 % decrease (95 % Cl: 33 % to 49 %, p = 0.022, n ≥ 9) (Fig. 
5.6A and B). The autophagy inducer, AR-12, also caused a 43 %, decrease in free GFP 
levels in UBXD18- cells (95 % Cl: 39 % to 49 %, p = 0.0030, n ≥ 9), while protease 
inhibitors had no significant effects (33 % decrease, p = 0.0739, n ≥ 9). These findings 
are consistent with medium-chain fatty acids causing an increase in autophagic flux 
in UBXD18- cells.   
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                                                                                                                                                   A) 
Dictyostelium UBXD18- cells expressing GFP-Atg8 untreated (control) or treated with 
60 µM decanoic acid (DA) for 4 or 24 hours (h), 120 µM octanoic acid (OA) for 4 or 24 
hours, autophagy inducer (AR-12, 2.5 µM) or protease inhibitor (2.5x) were analysed 
by western blotting using an antibody against GFP, with MCCC1 as a loading control. 
Means and SEM of B) free GFP, C) GFP-Atg8 are represented normalised to loading 
control and D) the ratio of free GFP /GFP-Atg8 is displayed (n ≥ 9). Significance is 
indicated by ns > 0.05, * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001 (Kruskal-Wallis with 
Dunn's multiple comparisons test). 
 
Figure 5. 16 Autophagic flux assay in UBXD18- Dictyostelium expressing GFP-Atg8. 
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Levels of GFP-Atg8 were also monitored in UBXD18- cells following treatments 
with medium-chain fatty acids. Decanoic acid treatment for 4 hours caused a 59 % 
reduction in GFP-Atg8 levels (95 % Cl: 54 % to 65 %, p < 0.0001, n ≥ 9) and 24-hour 
treatment led to a 39 % decrease (95 % Cl: 37 % to 43 %, p = 0.023, n ≥ 9) (Fig. 5.6A and 
C). Octanoic acid treatment for 4 hours caused a 50 % reduction in GFP-Atg8 levels (95 
% Cl: 41 % to 61 %, p = 0.0014, n ≥ 9) and a 41 % decrease following 24 hours (95 % Cl: 
31 % to 55 %, p = 0.042, n ≥ 9) (Fig. 5.6A and C). Treatment with autophagy inducer 
also led to a 48 % reduction in GFP-Atg8 levels (95 % Cl: 43 % to 51 %, p = 0.0026, n ≥ 
9) (Fig. 5.6A and C) consistent with an increase in autophagic flux. Finally, protease 
inhibitors had no significant effect on GFP-Atg8 levels (7.1 % decrease, p > 0.9999, n ≥ 
9) consistent with a reduced autophagic degradation.  
The ratio of free GFP to GFP-Atg8 was also monitored in UBXD18- cells as a 
readout for autophagic flux. A significant reduction in the ratio of free GFP to GFP-
Atg8 was observed in cells treated for 4 hours with either decanoic acid or octanoic 
acid (26 % reduction following decanoic acid treatment, 95 % Cl: 26 % to 28 %, p =  
0.0178, n ≥ 9 and a 26 % reduction following octanoic acid treatment, 95 % Cl: 17 % to 
38 %, p = 0.0340, n ≥ 9). No significant change was observed following 24 hour 
treatment with decanoic acid (0.66 % reduction, p > 0.9999, n ≥ 9), or octanoic acid 
(4.5 % reduction, p > 0.9999, n ≥ 9), or following treatment with protease inhibitors 
(23 % decrease, p = 0.0715, n ≥ 9) (Fig. 5.6D). These findings are consistent with those 
observed in wild type cells, suggesting that knocking out ubxd18 has no significant 
effect on cellular autophagy, or the autophagic response to medium-chain fatty acids. 
These data indicate that that in Dictyostelium decanoic acid and octanoic acid are 
regulating autophagy independently of UBXD18. 
 
5.2.5 Employing protease inhibitors to investigate blockage of autophagic flux 
To further investigate the role of decanoic acid on autophagy in Dictyostelium 
we aimed to utilise protease inhibitors to differentiate between an induction or 
blockage of autophagic flux. Protease inhibitors are established to impair lysosomal 
function (Cardenal-Munoz et al., 2017), and thus are employed to reduce autophagic 
flux. We have shown that treatment with protease inhibitors results in a non-
significant reduction in free GFP levels together with unchanged levels of GFP-Atg8 
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equating to a non-significant trend towards a reduction in the ratio of free GFP to 
GFP-Atg8 (Fig 5.5 and 5.6). This trend is consistent with protease inhibitors causing a 
blockage in the degradation of GFP-Atg8.   
Treating cells in the presence or absence of protease inhibitors, can provide 
an indication of autophagic flux, since in cells with functional autophagy, protease 
inhibitors block autophagic flux, while in cells with dysfunctional autophagic 
degradation is unaffected by further blockages in autophagy caused by protease 
inhibitors (Sharma et al., 2019; Cardenal-Munoz et al., 2017). To investigate this, we 
assessed free GFP and GFP-Atg8 levels in control cells alone and in combination with 
protease inhibitors, as well and in cells treated with decanoic acid (4 hours, 60 µM) 
or autophagy inducer (AR-12) alone or in combination with protease inhibitors (Fig. 
5.7). Our findings revealed that protease inhibitors caused a non-significant reduction 
(40 % decrease, p = 0.9999, n ≥ 7) in the ratio of free GFP to GFP-Atg8 in control cells, 
a trend consistent with a blockage of autophagic flux. The ratio of free-GFP to GFP-
Atg8 was not significantly reduced in cells treated with decanoic acid and protease 
inhibitor compared to cells treated with decanoic acid alone (24 % decrease, p > 
0.9999, n ≥ 7). Similarly, the ratio of free-GFP to GFP-Atg8 was not significantly 
reduced in cells treated with autophagy inducer in combination with protease 
inhibitor compared to cells treated with autophagy inducer alone (38 % decrease, p > 
0.9999, n ≥ 7). The absence of change in the ratio of free GFP to GFP-Atg8 following 
addition of protease inhibitor in these conditions may result from the initially low 
levels of free GFP in these treatment conditions preventing firm conclusions from this 
data, however, these low levels of free GFP are likely to be caused by increased 
autophagic degradation of GFP rather than a blockage of autophagy. Thus, these 
findings suggest that cells treated with decanoic acid respond comparably to cells 
treated with autophagy inducer in response to treatment with protease inhibitors, 
consistent with an induction in autophagy following treatment with decanoic acid. 
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                                      A) Dictyostelium Ax2 cells expressing GFP-Atg8 untreated 
(control) or treated with protease inhibitor (PI, 2.5x) (1 hour) alone or in combination 
with 60 µM decanoic acid (4 hours) or autophagy inducer (AR-12, 2.5 µM) (2 hours) 
were analysed by western blotting using an antibody against GFP with MCCC1 as a 
loading control. Means and SEM of B) free GFP, C) GFP-Atg8 are represented 
normalised to loading control and D) the ratio of free GFP /GFP-Atg8 is displayed (n 
≥ 6). Significance is indicated by ns > 0.05, * p ≤ 0.05, ** p ≤ 0.01 *** p ≤ 0.001 
(Kruskal-Wallis with Dunn's multiple comparisons test). 
 
Figure 5. 19 Autophagic flux assay in the absence and presence of lysosomal 
protease inhibitors. 
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5.2.6 Decanoic acid increases autophagy gene expression 
In order to further assess the effects of decanoic acid and octanoic acid on 
autophagy we investigated changes in expression levels of autophagy genes  
following treatment with these fatty acids. mRNA levels of two autophagy genes, 
atg1 and atg8a, were monitored following treatment with decanoic acid (60 µM) for 
1, 4 or 24 hours (Fig. 5.8A and B). The expression of both atg1 and atg8a, was 
significantly upregulated following 24-hour treatment with decanoic acid (9.2-fold 
increase, 95 % Cl: 4.3 to 14, p = 0.0235 and 6.2-fold increase, 95 % Cl: 3.5 to 8.9, p = 
0.0315, respectively, n=3), consistent with an induction of autophagy. Conversely 
treatment with decanoic acid for 1 hour had no significant effect on the expression 
levels of atg1 and atg8a (1.5-fold increase, p > 0.9999, and 0.46-fold change, p > 
0.9999, respectively, n = 3) (Fig 5.8A and B), despite transcriptional upregulation of 
autophagy genes being possible in this time frame (Kirisako et al., 1999). Treatment 
with decanoic acid for 4 hours caused a noticeable albeit non-significant increase in 
the expression levels of atg1 and atg8a (6.6-fold increase, p = 0.07, and 2.7-fold 
increase, p = 0.3082, n = 3) (Fig 5.8A and B), despite showing comparable changes in 
autophagy (autophagosome number and flux) to 24-hour treatment (Fig. 5.2 and Fig. 
5.5). This suggests that acute (4-hour) regulation of autophagy by decanoic acid may 
be mediated via changes in activation of existing autophagy proteins as well as 
changes in gene expression, or that induction of autophagy gene expression past a 
certain point does not further induce autophagy. By monitoring mRNA levels of atg1 
and atg8a we have demonstrated that 24-hour treatment with decanoic acid 
increases the expression levels of these genes consistent with an induction of 
autophagy. 
Treatment of Dictyostelium with octanoic acid results in a comparable effect 
on autophagosome number (Fig. 5.2) and autophagic flux (Fig. 5.5) as with decanoic 
acid treatment. In order to further investigate the effects of octanoic acid on 
Dictyostelium autophagy we assessed the gene expression levels of the autophagy 
genes, atg1 and atg8a, following treatment with octanoic acid (120 µM) for 1, 4 or 
24 hours (Fig. 5.8C and D). None of these octanoic acid treatment conditions caused 
a change in relative expression levels of either atg1  (1.1-fold increase at 1 hour, p > 
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0.9999, 0.99-fold change at 4 hours, p > 0.9999, 1.9-fold increase at 24 hours p > 
0.9999, n = 3) or atg8a  (1.05-fold increase at 1 hour, p > 0.9999, 0.72-fold-change at 
4 hours, p > 0.9999, 1.39-fold increase at 24 hours, p > 0.9999, n = 3). This finding 
suggests that while octanoic acid appears to modulate autophagy in Dictyostelium, 
this effect may be independent of the gene expression levels of atg1 and atg8a.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.7 Medium-chain fatty acids alter autophagy independently of PIP3 
Following the identification that decanoic acid and octanoic acid activate 
autophagy in Dictyostelium independently of UBXD18, with differing effects on 
autophagy gene expression, we investigated a role for the autophagy regulating 
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                                                  Cells treated with decanoic acid (60 µM) (or control) 
were analysed by qPCR measuring the relative abundance of A) atg1 and B) atg8a 
(n = 3). Cells treated with octanoic acid (120 µM) (or control) were also analysed by 
qPCR measuring the relative abundance of C) atg1 and D) atg8a (n = 3). mRNA was 
normalised to the housekeeping gene gapdh in all conditions with the mRNA levels 
normalised so that untreated cells have a relative expression level of 1. Data 
represented are mean ± SEM. Significance is indicated by * p ≤ 0.05 (Kruskal-Wallis 
with Dunn's multiple comparisons test). 
 
Figure 5. 22 Decanoic acid but not octanoic acid increases autophagy gene 
expression after 24 hours.
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second messenger PIP3, in the cellular response to these fatty acids. PIP3 has been 
identified as regulating autophagy through inhibition of the mTORC1 pathway (Jang 
and Lee, 2016), and since both decanoic acid and octanoic acid have been suggested 
to attenuate phosphoinositide phosphorylation (Chang et al., 2012), we investigated 
the effects of these fatty acids on PIP3 production in Dictyostelium as a potential basis 
for the observed fatty acid induced activation of autophagy.  
To monitor the effects of medium-chain fatty acids on PIP3 production in 
Dictyostelium we observed the translocation of a PIP3-specific PH domain fused to a 
fluorescent protein (PHcrac-GFP) in chemotactically competent cells. In these cells, 
global stimulation with the chemoattractant cAMP activates PI3K through G proteins 
to produce PIP3 on the plasma membrane, leading to the transient localization of 
proteins containing Pleckstin Homolog (PH) domains that bind to PIP3. Neither 
decanoic acid nor octanoic acid treatment significantly affected PHcrac-GFP 
translocation assessed by maximum membrane fluorescence (27 % decrease for 
decanoic acid, p = 0.5743, and 19 % decrease for octanoic acid,  p = 0.617, n = 6) and 
total membrane fluorescence (21 % decrease for decanoic acid, p > 0.9999, and 5 % 
decrease for octanoic acid, p > 0.9999, n = 6) (Fig. 5.9). The PI3K inhibitor (LY294002) 
significantly suppressed PHcrac-GFP translocation (97 % decrease in maximum 
membrane fluorescence, 95 % Cl: 94 % to 103 %, p = 0.0004, and 85 % decrease in 
total membrane fluorescence, 95 % Cl: 76 % to 98 %, p = 0.0028, n = 6) (Fig. 5.9). 
These results demonstrate that decanoic acid and octanoic acid do not alter PIP3 
production following 4 hours of treatment, suggesting that the observed effects of 
these fatty acids on autophagy occur via a PIP3 independent pathway. 
We conclude that in Dictyostelium following treatment with decanoic acid 
autophagosomes accumulate, concomitantly with an increase in autophagic flux and 
an induction of autophagic gene expression. We further demonstrate that the effects 
of decanoic acid on autophagosome accumulation and autophagic flux are 
independent of UBXD18, and PIP3 production. Taken together these findings provide 
strong evidence for decanoic acid induced activation of autophagy in Dictyostelium 
by a UBXD18 and PIP3 independent mechanism. We further suggest that octanoic 
acid also causes an increase in autophagy independent of UBXD18 and PIP3 
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production, however, the effects of octanoic acid on autophagy appear independent 
of changes in the expression levels of atg1 or atg8a.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B C D 
                             A) Cells expressing PHcrac-GFP were treated with decanoic acid (60 
µM, 4 hours), octanoic acid (60 µM, 4 hours), PI3K inhibitor (LY294002, 100 µM, 15 
minutes) or solvent control (DMSO) during induction to form chemotactic 
competence. Cells were stimulated with cAMP (1 µM) and examined by fluorescence 
microscopy over time. Arrows highlight when PHcrac-GFP first becomes visually 
identifiable at the membrane. B) Membrane fluorescence was quantified, normalized 
to whole cell fluorescence, and C) maximum membrane fluorescence was compared 
between treatments. D) Total membrane fluorescence was calculated by analyzing 
the area under the curves of relative membrane fluorescence.  Data represent mean 
and SEM from 6 independent experiments. Each data point is derived from 3 
independent cells, box and whisker (10-90th percentile). Scale bar represents 10 µm. 
Significance is indicated by ns > 0.05, ** p ≤ 0.01, *** p ≤ 0.001 (Kruskal-Wallis with 
Dunn's multiple comparisons test).  
  
Figure 5. 9 Decanoic acid and octanoic acid act independently of PIP3
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5.3 Discussion 
Following the identification of UBXD18 as a target for decanoic acid, and the 
finding that decanoic acid acts via this protein to inhibit p97 activity, we investigated 
the effects of decanoic acid on autophagy, a key homeostatic pathway regulated by 
p97. In this chapter we demonstrate that decanoic acid activates autophagy in 
Dictyostelium, resulting in an increase in the number of autophagosomes per cell, 
coinciding with an increase in autophagic flux and an increase in the expression of 
two autophagy genes. We establish that the effect of decanoic acid on autophagy is 
independent of UBXD18, suggesting that decanoic acid may be acting via a 
mechanism distinct from UBXD18 and p97 to activate autophagy. We further 
demonstrate that octanoic acid also regulates autophagy independently of UBXD18 
in Dictyostelium, as monitored by an increase in autophagosome number and 
autophagic flux. Finally, we show that the effects of decanoic acid and octanoic acid 
on autophagy are independent of the key signalling molecule PIP3. 
Since autophagy is required for the degradation of misfolded proteins and 
damaged organelles, dysfunction in this process can lead to a variety of diseases in 
humans, with mutations in autophagy related genes associated with epilepsy, 
neurodegenerative diseases and cancers (Jiang and Mizushima, 2014; Carvill et al., 
2018; (Costa et al., 2016). A link between epilepsy and autophagy was first 
 Decanoic acid Octanoic acid 
Effect on autophagosome number in Ax2 Increase Increase 
Effect on autophagosome number in UBXD18- Increase Increase 
Effect on autophagosome flux in Ax2 Increase Increase 
Effect on autophagosome flux in UBXD18- Increase Increase 
Effect on atg1 and atg8a gene expression after 24 
hours 
Increase No change 
Effect on PIP3 levels No change No change 
                                    A) Statistically significant increases in autophagosome number, flux (as 
identified by a decrease in GFP-ATG8 at 4 and 24 hours), and atg1, and atg8a gene 
expression, following exposure to decanoic acid or octanoic acid are highlighted in green. 
Neither decanoic acid or octanoic acid altered PIP3 levels in Dictyostelium. 
 
 
Figure 5. 10 Summary of the Dictyostelium autophagic response to decanoic acid 
and octanoic acid
A 
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established following findings implicating rapamycin, an autophagy inducer, in 
supressing seizures in epilepsy models (Giorgi et al., 2015). Subsequently, a blockage 
in autophagy has been identified in patients with genetic epilepsy conditions such as 
tuberous sclerosis complex (TSC) (Wong, 2013; McMahon et al., 2012), and Lafora 
disease (Knecht et al., 2010). Thus, therapies such as electroconvulsive therapy and 
rapamycin demonstrated to activate autophagy are under investigation as epilepsy 
treatments for these patients (Kim et al., 2019; Giorgi et al., 2015). Furthermore, the 
capacity of the classical ketogenic diet and intermittent fasting to increase starvation-
induced autophagy has substantiated these dietary interventions as potential 
treatments for epilepsy (Yuen and Sander, 2014; (Camberos-Luna et al., 2016) (Fig. 
5.11). Dysfunctional autophagy is also associated with the neurodegenerative 
disorders, ALS, Huntington’s, Parkinson’s, and Alzheimer’s disease, and activating 
autophagy has proven successful in models of all four of these disorders (Fowler and 
Moussa, 2018; Ravikumar et al., 2004; Caccamo et al., 2014; Castillo et al., 2013). 
Interestingly, most current cancer drugs increase autophagy in tumour cells 
(Thorburn, Thamm and Gustafson, 2014), with autophagy activation suggested as an 
important therapeutic mechanism, however, autophagy is thought to have 
competing roles in cancer, with autophagy induction leading to chemoresistance, and 
inhibitors of autophagy also appearing promising in clinical trials (Amaravadi et al., 
2011). Reports of detrimental effects of autophagy activation (Cao et al., 2009) 
highlight the complexity of this process and the need to predict individual responses 
to autophagy modulators in order to allow personalised therapies. Our findings 
suggest that further analysis of a role for medium-chain fatty acids in autophagy 
regulation may identify associated therapeutic benefits in epilepsy, 
neurodegenerative disorders and cancers.  
Fatty acids have previously been suggested to modulate autophagy with 
therapeutic implications, however, this process is poorly understood. Our findings 
connecting decanoic acid and octanoic acid to autophagy activation in Dictyostelium 
are consistent with research demonstrating that feeding mice medium-chain fatty 
acids restores supressed autophagy (Wang et al., 2017), however, how medium-chain 
fatty acids regulate this process is unknown. A comprehensive understanding of the 
roles of fatty acids on autophagy is lacking, with most research focusing on the most 
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abundant dietary fatty acids, palmitic acid (long-chain saturated fatty acid, C16:0) and 
oleic acid (long-chain mono-unsaturated fatty acid, C18:1). Both palmitic acid and 
oleic acid have been reported to inhibit autophagy (Mei et al., 2011; Las et al., 2011; 
Sauvat et al., 2018), as well as activate it (Martino et al., 2012; Park et al., 2019; 
Pauloin et al., 2010; Mei et al., 2011) (Fig 5.11). Short chain fatty acids have also been 
suggested to regulate autophagy  (Hu et al., 2010; Elamin et al., 2013) (Fig. 5.11), with 
the length of fatty acid as well as the saturation status thought to alter the effect on 
autophagy (Sauvat et al., 2018). There are many discrepancies regarding the roles of 
fatty acids on autophagy with no current consensus on how medium-chain fatty acids 
regulate this process. Our findings in this chapter have suggested a role for both 
decanoic acid and octanoic acid in regulating autophagy, but further research is 
required to understand the mechanisms and specificity behind these effects. In order 
to compare the effects of different fatty acids on autophagy, it would be preferable 
to assess identical concentrations rather than concentrations resulting in equivalent 
growth inhibition as investigated in this chapter. 
Our previous data indicates that decanoic acid inhibits p97 in a UBXD18 
dependent manner (Fig. 4.7), a cellular effect anticipated to cause UBXD18 
dependent autophagy inhibition (Chou et al., 2011; Ju et al., 2009). In this chapter we 
suggest that both decanoic acid and octanoic acid activate autophagy in 
Dictyostelium and establish that this effect is independent of UBXD18 and p97. 
Consequentially the mechanism behind the effects of these fatty acids on 
Dictyostelium autophagy remains undefined. Understanding how medium-chain 
fatty acids regulate autophagy would provide valuable insight into potential 
therapeutic benefits provided by these fatty acids. 
 Autophagy is regulated by cellular nutrient status through multiple signalling 
pathways, such as adenosine monophosphate-activated protein kinase (AMPK), 
phosphatidylinositol 3‑kinase (PI3K)/protein kinase B (AKT) and cAMP-dependent 
protein kinase (PKA), which regulate autophagy via the mechanistic target of 
rapamycin complex 1 (mTORC1) (Mavrakis et al., 2006; He and Klionsky, 2009), as 
well as through activation of Beclin 1 (Meléndez and Neufeld, 2008) (Fig. 5.11). The 
classical ketogenic diet has been suggested to modulate autophagy in a similar 
manner to starvation (McDaniel et al., 2011; Thio et al., 2006; Miyamoto et al., 2019; 
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Wang et al., 2018) (Fig. 5.11). Autophagy is also known to be regulated in response 
to cell stress through pathways such as the RNA-dependent protein kinase-like ER 
kinase (PERK) pathway (Kouroku et al., 2007), the inositol-requiring kinase 1 (IRE1) 
pathway (Bernales, McDonald and Walter, 2006), as well as through calcium release 
(Hoyer-Hansen et al., 2007). Determining the effects of medium-chain fatty acids on 
these signalling pathways would provide valuable insight into the mechanisms 
underlying fatty acid induced autophagy activation.  
Phosphoinositides have been well established to play a role in regulating 
autophagy, with PIP3 playing an important role in inhibiting autophagy through the 
activation of AKT and mTORC1 (Jang and Lee, 2016) (Fig 5.11). While both decanoic 
acid and octanoic acid have been suggested to reduce production of PIP and PIP2 in 
Dictyostelium (Chang et al., 2012), effects of medium-chain fatty acids on PIP3 have 
not previously been investigated. Here we demonstrate that neither decanoic acid or 
octanoic acid alter PIP3 production in Dictyostelium, and thus suggest that these fatty 
acids act independently of this phosphoinositide. While PIP3 is an important signaling 
molecule in the activation of mTORC1 and inhibition of autophagy, mTORC1 is 
regulated by multiple upstream pathways and understanding the effects of medium-
chain fatty acids on mTORC1 signaling could help to explain the mechanism behind 
the autophagy inducing effects of these fatty acids.  
The mTOR pathway is the major regulator of autophagy, maintaining the 
essential balance between the synthesis and degradation of cellular components. 
mTOR is a evolutionarily conserved serine/threonine kinase comprising two 
structurally and functionally different complexes, mTOR complex 1 (mTORC1) and 
mTOR complex 2 (mTORC2). mTORC1 senses nutrient and energy status within the 
cell, and when activated by high levels of energy and nutrients promotes anabolic 
processes such as protein and lipid synthesis and inhibits cellular catabolism through 
repression of autophagy by direct phosphorylation of the Atg1/ULK1 complex (Ganley 
et al., 2009) (Fig. 5.11). Conversely, following conditions of nutrient starvation 
mTORC1 inhibition stimulates the formation of the Atg1/ULK1-containing pro-
autophagic complex inducing the formation of autophagosomes and promoting 
autophagy (Sarkar, 2013). Inhibition of mTORC1 additionally regulates the 
subsequent steps of autophagy through altering the phosphorylation state, and thus 
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activity of autophagy machinery and regulators, as well as modulating the 
phosphorylation of transcription factors (such as transcription factor EB (TFEB)), 
altering their localisation and upregulating the expression of autophagy genes 
(Dossou and Basu, 2019) (Fig. 5.11). This activation of autophagy following starvation 
allows cells to break down cellular components and maintain cellular energy levels 
(Jung et al., 2010).  Hyperactivation of mTOR is associated with reduced autophagy 
activity, and has been linked to the epilepsy condition TSC, as well as other disorders 
termed ‘mTORopathies’ (Taneike et al., 2016; Franz and Capal, 2017). Furthermore, 
clinical trials with mTORC1 inhibitors have proven effective at reducing seizures in 
TSC patients highlighting the importance of this pathway in certain epilepsy 
conditions (Citraro et al., 2016; French et al., 2016). Investigating the effects of 
decanoic acid and octanoic acid on mTORC1 signalling could help to explain the 
autophagy inducing activity that we have identified and could prove valuable in 
elucidating the therapeutic mechanisms of these fatty acids.  
In this chapter we have identified that the medium-chain fatty acids, decanoic 
acid and octanoic acid activate autophagy independently of UBXD18. Since activation 
of autophagy has been suggested as a potential treatment for epilepsy and 
neurodegenerative disorders, we aim to further investigate the mechanism behind 
fatty acid induced autophagy activation. In the following chapter we examine the 
effects of medium-chain fatty acids, on the major regulator of autophagy, mTORC1.   
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                                                                                                                                Autophagy 
activating pathways are displayed in green and inhibitory pathways are shown in 
red. Autophagy is activated in response to starvation and the ketogenic diet through 
inhibition of mTORC1 (via inhibition of the PI3K/AKT pathway, or activation of 
AMPK), inhibition of protein kinase A (PKA) and induction of Beclin 1 dependent 
autophagy. The mTORC1 pathway plays a central role in nutrient-dependent 
autophagy response, through phosphorylation and activation of the Atg1/ULK1 
complex, as well as through phosphorylation of the transcription factor TFEB 
leading to upregulation of autophagy gene expression. The effects of fatty acids on 
autophagy are unclear with short chain fatty acids thought to activate autophagy 
through AMPK (Hu et al., 2010; Elamin et al., 2013) while palmitic acid is suggested 
to both inhibit and activate autophagy through differential activity on AMPK 
(Fediuc, Gaidhu and Ceddia, 2006; Sun et al., 2008). Palmitic acid has also been 
suggested to activate autophagy though the c-Jun N-terminal kinase (JNK) pathway 
(Komiya et al., 2010) while oleic acid has been shown to prevent this (Sauvat et al., 
2018). How the medium-chain fatty acids decanoic and octanoic acid activate 
autophagy is currently unknown.  
Figure 5. 11 Overview of nutrient-dependent autophagy regulation.
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Chapter 6  
 
Investigating the effect of medium-chain fatty acids on 
mTORC1 
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6.1 Introduction 
 In the previous chapter we identified that octanoic acid and decanoic acid 
regulate autophagy in Dictyostelium and suggested that dietary activation of this 
pathway could provide a useful approach to restore autophagic balance in patients 
with epilepsy, neurodegenerative disorders and cancers. In this chapter we 
investigate the effects of medium-chain fatty acids on mTORC1 the major regulator 
of autophagy. 
The mTORC1 pathway is a highly conserved regulator of cellular nutrient and 
energy status which acts to maintain homeostasis by regulating cellular metabolism 
(Tatebe et al., 2017). Following starvation, when nutrient levels are low, mTORC1 
signalling is inhibited, leading to the initiation of autophagy, allowing cells to reutilise 
their constituents for energy (Ganley et al., 2009). In addition to regulating 
autophagy, mTORC1 signalling also functions to activate anabolic processes such as 
the transcription and translation of proteins, and the synthesis of lipids. Aberrant 
mTORC1 signalling has been associated with a number of human diseases, from 
epilepsy (McMahon et al., 2012), to neurodegenerative disorders (Fujikake, Shin and 
Shimizu, 2018), and cancers (Xie, Wang and Proud, 2016), with inhibition of this 
pathway providing a potential strategy for treating these conditions (Taneike et al., 
2016; Franz and Capal, 2017; Citraro et al., 2016; Xie, Wang and Proud, 2016). 
Rapamycin is a well-known inhibitor of mTORC1 which, along with its 
analogues (rapalogues) is under investigation for treating a range of conditions. 
Inhibition of mTORC1 via these compounds is thought to lead to a range of benefits, 
such as increased autophagy and the clearance of misfolded proteins in 
neurodegenerative disorders (Fujikake et al, 2018), as well as autophagy independent 
benefits such as the decrease of cell proliferation in cancers (Xie et al, 2016) and 
reduced stress response and improved mitochondrial function credited with 
increasing longevity (Johnson et al, 2013). Hyper-activation of mTORC1 has been 
observed in patients with Tuberous sclerosis complex (TSC), a neurodevelopmental 
disorder recently treated using the rapalogue ‘Everolimus’ (Svarrer et al., 2019; Franz 
et al., 2018). In patients with this condition, mutations in the genes for hamartin 
(TSC1) or tuberin (TSC2) result in overactivated mTORC1, leading to upregulated cell 
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growth and proliferation and the development of tumours. Tumours developing in 
the brains of these patients manifest in epilepsy and cognitive disability (Crino et al, 
2006). The use of mTORC1 inhibitors to treat these patients reduces uncontrolled 
growth of brain cells and decreases excitability, preventing seizures (Franz & Capal, 
2017; Franz et al, 2006; Li et al, 2019). While the inhibition of mTORC1 with rapamycin 
and rapalogues appears promising in the treatment of multiple conditions associated 
with hyperactivated mTORC1 signalling, off target effects of these compounds on 
mTORC2 cause side effects such as glucose intolerance, diabetes, and 
immunosuppression (Arriola Apelo and Lamming, 2016). Therefore, the Identification 
of alternative mTORC1 inhibitors lacking the toxicity of rapamycin would be 
beneficial.  
 The classical ketogenic diet has been suggested as an alternative means to 
reduce mTORC1 signalling. This effect is thought to be caused by a reduction in 
glucose and insulin levels in patients on the diet (McDaniel et al, 2011; Newman et 
al, 2017; Ostendorf & Wong, 2015; Roberts et al, 2017; Sweeney et al, 2017; Thio et 
al, 2006). While this dietary intervention is well established to reduce mTORC1 
signalling without the toxicity associated with rapamycin, compliance of patients is 
low due to the restrictive nature of this diet (Ye et al., 2015a). The ability of the less 
restrictive MCT diet to regulate this pathway has not yet been investigated. 
Employing Dictyostelium to identify the effects of medium-chain fatty acids on 
mTORC1 activity will help to establish whether the MCT diet could have potential in 
the dietary management of conditions associated with hyperactivated mTORC1 
signalling.  
In this chapter we use Dictyostelium to investigate the effects of medium-
chain fatty acids on mTORC1 function. We initially demonstrate a structurally specific 
effect of decanoic acid in reducing mTORC1 activity. Since this effect occurs in the 
absence of insulin and in the presence of glucose this suggests a novel molecular 
mechanism for decanoic acid in mTORC1 inhibition. We demonstrate that cells 
lacking the UBX domain containing protein (UBXD18) are partially resistant to the 
effects of decanoic acid on mTORC1 signalling as well as on growth, implicating 
UBXD18 and its ubiquitous binding partner p97 in the mechanism of decanoic acid on 
mTORC1, and suggesting that the effects of decanoic acid on autophagy and mTORC1 
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are distinct. We further demonstrate that inhibition of p97 corresponds to a 
reduction in mTORC1 signalling in Dictyostelium, suggesting that this effect of 
decanoic acid on p97 activity could explain the observed mTORC1 inhibition. We then 
translate our findings to a rat hippocampal slice model, where acute decanoic acid 
treatment reduces mTORC1 signalling in the absence of insulin or reduced glucose. 
Finally, we employ astrocytes derived from patients with the neurodevelopmental 
disorder tuberous sclerosis complex (TSC), associated with deregulated mTORC1 
activity, to demonstrate that decanoic acid reduces mTORC1 signalling in healthy 
patients and patients with TSC1 mutations.  
 
6.2 Results 
6.2.1 Decanoic acid inhibits mTORC1 activity in Dictyostelium 
In order to establish if the observed effects of decanoic acid and octanoic acid 
on autophagy are regulated via mTORC1, we investigated the effects of both fatty 
acids on mTORC1 signalling. In these experiments, we quantified levels of 
phosphorylated 4E-BP1 (p-4E-BP1), a translation repressor directly phosphorylated 
by mTORC1, as a read out for mTORC1 activity (Rosel et al., 2012) (Fig. 6.1A). Here, 
Dictyostelium cells were treated with the fatty acids, decanoic acid (60 M) or 
octanoic acid (120 M), for 1 or 24 hours before p-4E-BP1 levels were quantified by 
western blot (Fig. 6.1B and C). Decanoic acid decreased p-4E-BP1 levels by 24 % (95 % 
Cl: 20 % to 30 %, p = 0.0009, n = 10) at 1 hour (Fig. 6.1B), and by 34 % (95 % Cl: 32 % to 
37 %, p ≤ 0.0001, n = 10) at 24 hours (Fig. 6.1B). Treatment with octanoic acid had no 
significant effect on the levels of p-4E-BP1 at either treatment duration (Fig. 6.1C) (12 
% decrease, p = 0.3830 at 1 hour and a 15 % decrease, p = 0.2453 at 24 hours, n = 10). 
These findings suggest that decanoic acid inhibits mTORC1 signalling in Dictyostelium 
in a structurally specific manner, and that the effects of octanoic acid on autophagy 
are independent of mTORC1. 
 Structural specificity of seizure control has previously been demonstrated in 
a rat hippocampal slice model, with several fatty acids and fatty acid derivatives 
showing potent anti-epileptiform activity (Chang et al., 2015). Since we have 
demonstrated  structural  specificity  of  mTORC1    inhibition,    with   decanoic   acid   
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displaying  both  strong  anti-epileptiform activity (Chang et al., 201) and mTORC1 
inhibition (Fig. 6.1B), and octanoic acid lacking both epileptiform control (Chang et 
al., 2013) and mTORC1 inhibition (Fig. 6.1C), we investigated whether potency in 
reducing epileptiform activity in a rat hippocampal slice model is related to mTORC1 
inhibition in Dictyostelium. Thus, we assessed compounds demonstrating potent 
anti-epileptiform activity for their effects on Dictyostelium cell proliferation and p-
4E-BP1 levels. Compounds were chosen based on data from PTZ rat hippocampal slice 
models, where a decrease in the frequency of epileptiform discharge was used as a 
readout for anti-epileptiform activity (Chang et al., 2013; Chang et al., 2015) (Fig. 
6.2A). 4-BCCA caused the most potent reduction in growth (100 % reduction, 95% Cl: 
96% to 105 % p ≤ 0.0001, n = 7), followed by decanoic acid (84 % reduction, 95 % Cl: 65 
% to 112 %, p = 0.0004, n = 7), 4-EOA (54 % reduction, p > 0.05, n = 7), 5-MOA (53 % 
A) Inhibition of mTORC1 prevents the phosphorylation of 4E-BP1, this 
phosphorylation (p-4E-BP1) is used as a read out for mTORC1 activity. p-4E-BP1 (11 
kDa) levels were analysed in wild type cells treated for 1 hour or 24 hours (h) with B) 
decanoic acid (n = 10) or C) octanoic acid (n = 10). MCCC1 (80 kDa) was used as a 
loading control. Data represent the mean ± SEM. Significance is indicated by *** p ≤ 
0.001, **** p ≤ 0.0001. 1-way ANOVA with Dunnett’s post hoc test. 
  
 
Figure 6. 1 Decanoic acid causes a reduction in p-4E-BP1 levels in Dictyostelium. 
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reduction, p > 0.05, n = 7) and octanoic acid (20 % reduction, p > 0.05, n = 7) (Fig. 6.2B). 
This potency correlated with the previously determined anti-epileptiform activity 
(Fig. 6.2) (Chang et al., 2013; Chang et al., 2015). We further assessed these 
compounds for their effects on mTORC1 activity and identified that decanoic acid was 
the only compound to reduce p-4E-BP1 levels at 60 µM (25 % reduction, 95 % Cl: 18 
% to 31 %, p = 0.0476, n = 7) (Fig 6.2C), demonstrating that the potency of these 
compounds in reducing epileptiform activity is not related to their mTORC1 inhibitory 
effect in Dictyostelium.  
To confirm that assessing p-4E-BP1 levels is an appropriate method of 
monitoring mTORC1 activity we quantified Dictyostelium samples following 
starvation, a physiological process well established to reduce mTORC1 activity (Ye et 
al., 2015b; Tan, Sim and Long, 2017). Starvation for 10 minutes in nutrient free 
phosphate buffer (KK2) caused a significant decrease (35 % decrease, 95 % Cl: 33 % to 
41 %, p = 0.0022, n = 6) in p-4E-BP1 levels in Dictyostelium (Fig 6.3A). This suggests that 
monitoring p-4E-BP1 levels provides a suitable readout for mTORC1 activity. 
Furthermore, we established that the mTOR inhibitor Torin2 (10 µM) caused a 
significant decrease in p-4E-BP1 levels (29 % decrease, 95 % Cl: 26 % to 32 %, p = 
0.0049, n = 6)  (Fig 6.3B). Treatment with rapamycin did not significantly alter p-4E-
BP1 levels in this model (7.3 % decrease following 1 hour, p = 0.8763, and a 8.9 % 
decrease following 24 hours, p = 0.6025, n = 7) (Fig. 6.3C), consistent with earlier 
studies (Dominguez-Martin et al., 2017; Williams and Kay, 2018). In order to quantify 
p-4E-BP1 levels between samples, values were normalised to the established loading 
control, mitochondrial 3-methylcrotonyl-CoA carboxylase α (MCCC1) (Davidson, King 
and Insall, 2013). We confirmed that MCCC1 is a suitable loading control by 
comparing the ratio of MCCC1 levels to the levels of a second internal control 
(calnexin) and demonstrating that MCCC1 levels are not altered following treatment 
with decanoic acid (Fig. 6.3C). These controls confirm the validity of our 
interpretation that decanoic acid, but not octanoic acid (or the derivatives 4-BCCA, 4-
EOA or 5-MOA), causes a reduction of mTORC1 signalling in Dictyostelium. 
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Structure 
A
                                                A) Chemical structures of the fatty acid derivatives, 4-butl 
cyclohexane carboxylic acid (4-BCCA), 4-ethyl octanoic acid (4-EOA), 5-methyl 
octanoic acid (5-MOA), alongside the fatty acids octanoic acid (OA) and decanoic acid 
(DA). Inhibition of seizure like activity by these compounds is displayed as a 
percentage of the baseline (Chang et al., 2013; Chang et al., 2015). The effects of 
specific modified fatty acid derivatives on B) growth (n = 7, Kruskal-Wallis test with 
Dunn’s post hoc test) and C) phosphorylated-4E-BP1 (p-4E-BP1) levels (n = 7, Kruskal-
Wallis test with Dunn’s post hoc test) in wild type cells were investigated alongside 
octanoic acid and decanoic acid (60 µM, 24 hours). MCCC1 was used as a loading 
control. Data represent the mean ± SEM. Significance is indicated by ns p > 0.05, * p ≤ 
0.05, *** p ≤ 0.001 and **** p ≤ 0.0001. 
 
Figure 6. 2 Anti-epileptiform activity of fatty acid derivatives shows no correlation 
with mTORC1 inhibition.
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A) Analysis of phosphorylated-4E-BP1 (p-4E-BP1) levels in wild type cells untreated 
or starved for 10 minutes in nutrient free phosphate buffer. MCCC1 was used as a 
loading control (n = 6, Mann-Whitney test). B) Analysis of p-4E-BP1 levels in wild 
type cells treated with 1 or 10 µM  mTOR inhibitor Torin2 for 24 hours, normalised 
to total protein (due to effects of Torin2 on mitochondria) (n = 6, Kruskal-Wallis test 
with Dunn’s post hoc test). C) Analysis of p-4E-BP1 levels in wild type cells untreated 
or treated with 500 nM rapamycin for 1 hour (h) or 24 hours  (n = 7), with MCCC1 
as a loading control (Kruskal-Wallis test with Dunn’s post hoc test). D) MCCC1 and 
Calnexin levels were analysed in wild type cells treated for 1 hour or 24 hours with 
decanoic acid (n = 7, Kruskal-Wallis test with Dunn’s post hoc test). Data represent 
the mean ± SEM. Significance is indicated by ** p ≤ 0.01. 
 
Figure 6. 3 Measuring p-4E-BP1 levels as a read out for mTORC1 in Dictyostelium. 
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6.2.2 Decanoic acid acts independently of AMPK or PI3K/AKT signalling in Dictyostelium 
Since mTORC1 is activated by PI3K/AKT signalling and inhibited by AMPK signalling 
(Fig. 6.4A), we also investigated the effect of decanoic acid on these signalling 
pathways. We monitored the effects of decanoic acid on PI3K/AKT signalling using an  
antibody against phosphorylated AKT substrate (p-AKT-S) which detects multiple 
substrates phosphorylated by AKT (Williams et al., 2019). No significant difference 
was observed in p-AKT substrate levels after treatment with decanoic acid (60 µM) 
for 1 hour or 24 hours (10 % decrease after 1 hour, p = 0.6444 and a 15% increase after 
24 hours, p = 0.1219, n = 8) (Fig. 6.4B). This indicates that decanoic acid targets 
mTORC1 independently of PI3K/AKT signalling, consistent with our data 
demonstrating that decanoic acid does not alter production of PIP3. This finding 
further suggests that decanoic acid inhibits mTORC1 without altering mTORC2 
activation, since AKT is directly phosphorylated by mTORC2.  We also evaluated the 
effect of decanoic acid on AMPK signalling using a phospho-AMPK-α (p-AMPK) 
antibody (Jaiswal and Kimmel, 2019). No significant difference was observed in p-
AMPK levels following decanoic acid treatment (60 µM) for 1 hour or 24 hours (0.032 
% increase following 1 hour, p > 0.9999, and a 5.9 % increase following 24 hours, p = 
0.9227, n = 10) (Fig. 6.4C). Thus, our findings suggest that decanoic acid targets 
mTORC1 independently of both PI3K/AKT and AMPK signalling. 
To verify that the use of the phosphorylated AKT substrate antibody provides an 
accurate readout for PI3K/AKT signalling we investigated p-AKT substrate levels 
following the use of a PI3K inhibitor (LY294002). We demonstrated a significant 
reduction in p-AKT substrate levels following 24-hour treatment with 60 µM PI3K 
inhibitor (15 % reduction, 95 % Cl: 13 % to 16 %, p = 0.026, n = 6) (Fig. 6.5A). 
Furthermore, we showed that AKT substrate phosphorylation was negligible in a 
pkbA-/pkgB- double knockout (Fig. 6.5B). These findings suggest that the p-AKT 
substrate antibody provides a suitable readout for PI3K/AKT signalling. In addition, 
we confirmed that western blotting using the antibody against phospho-AMPK-α 
provides an appropriate method for evaluating AMPK signalling. We quantified p-
AMPK levels following starvation (Fig. 6.5C), a process known to lead to 
phosphorylation and activation of AMPK and demonstrated that starvation for 2 
hours in nutrient free phosphate buffer (development buffer) resulted in a significant 
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increase in p-AMPK levels (1400 % increase, 95 % Cl: 710 % to 7000 %, p = 0.0022, n = 
9), suggesting that this antibody provides a reliable method for the quantification of 
AMPK activity. Validating the suitability of these antibodies to monitor PI3K/AKT and 
AMPK signalling provides us with greater confidence in our results demonstrating the 
decanoic acid is regulating mTORC1 independently of either of these pathways. 
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                            A) Simplified schematic diagram of mTORC1 pathway signalling 
regulated by AMPK and PI3K/AKT. B) AKT activity was evaluated in wild type cells 
treated for 1 hour or 24 hours with decanoic acid using an antibody against phospho-
AKT substrate antibody (p-AKT-S). MCCC1 was used as a loading control (n = 8, 1-way 
ANOVA with Dunnett’s post hoc test). C) AMPK activation was analysed using an 
antibody against phospho-AMPK (p-AMPK) MCCC1 was used as a loading control (n 
= 10, 1-way ANOVA with Dunnett’s post hoc test). Data represent the mean ± SEM.  
Figure 6. 4 Decanoic acid acts independently of AMPK or PI3K/AKT signalling in 
Dictyostelium. 
Control 1 h 24 h
0.0
0.2
0.4
0.6
Decanoic acid (60 M)
p
-A
M
P
K
(R
el
at
iv
e 
b
an
d
 w
ei
gh
t)
Control 1 h 24 h
0.0
0.2
0.4
0.6
Decanoic acid (60 M)
p
-A
K
T
-S
(R
el
at
iv
e 
b
an
d
 w
ei
gh
t)
(R
el
at
iv
e 
b
an
d
 d
en
si
ty
) 
(R
el
at
iv
e 
b
an
d
 d
en
si
ty
) 
A 
 
153 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
6.2.3 UBXD18 regulates the sensitivity of Dictyostelium to decanoic acid 
 
 
We have previously demonstrated that the growth response, but not the 
autophagic response of Dictyostelium to decanoic acid is partially dependent on the 
UBX domain containing protein UBXD18. In order to investigate a role of UBXD18 
both in regulating mTORC1 activity and in the decanoic acid-dependent change in 
mTORC1 function, western blot analysis of 4E-BP1 phosphorylation was carried out 
with UBXD18- and UBXD18-/+ in the absence and presence of decanoic acid. Loss of 
                                                                                                                                                   
A) AKT-substrate phosphorylation (p-AKT-S) was evaluated in wild type cells treated 
with 60 µM PI3K inhibitor for 24 hours (LY294002), with MCCC1 as a loading control 
(n = 6, Mann-Whitney test). B) A pkbA-/pkgB- (PKB-/-) double knockout shows 
negligible AKT-substrate phosphorylation, with MCCC1 as a loading control. C) 
Phosphorylated-AMPK (p-AMPK) levels were analysed in wild type cells, untreated or 
starved for 2 hours in nutrient free phosphate buffer. MCCC1 was used as a loading 
control (n = 6, unpaired t-test). Data represent the mean ± SEM. Significance is 
indicated by * p ≤ 0.05, ** p ≤ 0.01. 
 
Figure 6. 5 Analysis of AKT-substrate and AMPK phosphorylation in Dictyostelium. 
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UBXD18 caused a 37 % decrease in p-4E-BP1 levels (95 % Cl: 29 % to 47 %, p = 0.0305, 
n = 8) compared to wild type (Fig. 6.6A). p-4E-BP1 levels were restored in the rescue 
cell line (UBXD18-/+) (116 % increase compared to UBXD18-, 95 % Cl: 115 % to 118 %, p 
≤ 0.0001, n = 8) (Fig. 6.6A). Analysing p-4E-BP1 levels following decanoic acid 
treatment (60 µM for 1 or 24 hours), showed that UBXD18- was unresponsive to 
treatment with this fatty acid (4.6 % decrease in p-4E-BP1 following 1 hour decanoic 
acid treatment, p > 0.9999, n = 9, and an 8 % increase following 24 hours, p = 0.1926, n 
= 9) (Fig 6.6B). UBXD18-/+ showed restored decanoic acid sensitivity following 24-hour 
treatment (25 % decrease in p-4E-BP1 levels, 95 % Cl: 23 % to 29 %, p = 0.0010, n = 9) 
(Fig. 6.6C). These findings suggest that UBXD18 is involved in regulating the sensitivity 
of Dictyostelium to decanoic acid, and thus imply that decanoic acid is acting through 
distinct mechanisms to regulate autophagy and mTORC1 signalling. 
6.2.4 Decanoic acid induced mTORC1 inhibition in Dictyostelium could result from 
inhibition of p97 activity  
Our data demonstrate that in Dictyostelium the inhibitory effect of decanoic acid on 
mTORC1 is dependent on the protein UBXD18. We proceeded to establish whether 
this effect is linked to our earlier finding suggesting that decanoic acid inhibits p97 
activity in a UBXD18 dependent manner. To investigate this, we assessed the effect 
of p97 inhibition on mTORC1 activity by using the p97 inhibitor DBeQ (N2,N4-
dibenzylquinazoline-2,4-diamine) (Parzych et al., 2015; Ching et al., 2013). p-4E-BP1 
levels were monitored following DBeQ treatment (7.5 µM and 15 µM for 24 hours) 
(Fig. 6.7A). Treatment with DBeQ caused a significant reduction in p-4E-BP1 levels at 
7.5 µM (54 % reduction, 95 % CI: 49 % to 62 % decrease, p = 0.0138, n = 9) and at 15 µM 
(70 % reduction, 95 % CI: 66 % to 77 % decrease, p = 0.0001, n = 9) (Fig. 6.7A). This was 
consistent with a comparable inhibition of growth caused by these concentrations of 
DBeQ (7.5 µM DbeQ caused a 34 % inhibition of growth, 95 % Cl: 32 % to 36 %, p = 
0.0263, n = 9, and 15 µM DbeQ caused a 56 % inhibition in growth, 95 % Cl: 53 % to 60 
%, p ≤ 0.0001, n = 9) (Fig. 6.7B). These findings indicate that the inhibitory effect of 
decanoic acid on p97 activity may explain the observed mTORC1 and growth 
inhibitory effects of decanoic acid in Dictyostelium. This is consistent with UBXD18- 
mutants displaying resistance to decanoic acid in p97 inhibition, growth inhibition 
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and mTORC1 inhibition. These findings suggest a potential mechanism for decanoic 
acid in inhibiting Dictyostelium growth and mTORC1 signalling via a UBXD18 
dependent inhibition of p97 activation. 
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Analysis of phosphorylated-4E-BP1 (p-4E-BP1) levels in wild type, UBXD18
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≤ 0.0001. 
 Figure 6. 6 UBXD18 regulates the sensitivity of Dictyostelium to decanoic acid.
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6.2.5 Decanoic acid causes a reduction in mTORC1 activation in rat hippocampal 
brain slices 
Having identified a novel effect of decanoic acid in reducing mTORC1 activity 
independent of altered glucose levels and insulin signaling in Dictyostelium, we 
sought to translate these findings to a mammalian system. Here, we employed rat 
hippocampal slice preparations maintained in artificial cerebrospinal fluid (aCSF), 
ensuring constant glucose levels in the absence of insulin, treated with decanoic acid 
(100 and 300 M for 1 hour) (as prepared by Dr Eleonora Lugarà, UCL) prior to 
assessing mTORC1 activity by western blot analysis of p-4E-BP1 and total-4E-BP1 
levels (Fig. 6.8). Decanoic acid at 100 μM had no significant effect on p-4E-BP1 levels 
(6 % reduction, p > 0.9999, n = 6) (Fig. 6.8A and B) but, decreased p-4E-BP1 levels by 
27 % at 300 M (95 % Cl: 22 %  to 34 %, p = 0.021, n = 6) (Fig. 6.7A and B). Decanoic acid 
                 A) Analysis of phosphorylated-4E-BP1 (p-4E-BP1) levels in wild type cells 
treated for 24 hours with p97 inhibitor (DBeQ). MCCC1 is used as a loading control 
(n = 9, Kruskal-Wallis test with Dunn’s post hoc test). B) Dictyostelium cells (30 x 104 
cells/ml) were grown for 24 hours in 0 µM, 7.5 µM, and 15 µM DbeQ, before cell 
growth was quantified (n = 9, Kruskal-Wallis test with Dunn’s post hoc test). Data 
represent the mean ± SEM. Significance is indicated by   * p ≤ 0.05, *** p ≤ 0.001, 
**** p ≤ 0.0001. 
 
Figure 6. 7 p97 inhibitor (DBeQ) inhibits mTORC1 activity and Dictyostelium cell 
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at 100 μM or 300 μM had no significant effect on total-4E-BP1 levels (Fig. 6.8A and 
C), but decreased p-4E-BP1/ total-4E-BP1 levels by 28 % at 300 M (95 % Cl: 20 % to 
38 %, p = 0.0165, n = 6) (Fig. 6.8A and D). These findings suggest that decanoic acid 
(300 M) causes a significant decrease in mTORC1 signalling in rat hippocampal slice 
models.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To confirm the effect of decanoic acid on mTORC1 activity in the rat 
hippocampal slice model, we also analysed p70 ribosomal protein S6 Kinase (S6K) 
phosphorylation levels. In this role, increased phosphorylation at threonine 389 (p-
S6K) indicates increased mTORC1 activation (Datan et al., 2014). Decanoic acid at 100 
μM had no significant effect on p-S6K levels (20 % reduction, p = 0.1986, n = 6) (Fig. 
                        A) Rat hippocampal brain slices treated for 1 hour with artificial cerebral 
spinal fluid (control), DMSO solvent control (-), 100 µM decanoic acid (DA) or 300 µM 
decanoic acid (DA) were analysed for phosphorylated-4E-BP1 (p-4E-BP1) and total-4E-
BP1. β-Actin was used as a loading control. Relative band densities were plotted for 
B) p-4E-BP1 (n = 6) and C) total-4E-BP1 (n = 6). D) The ratio of p-4E-BP1/ total-4E-BP1 
was used as a readout for mTORC1 (n = 6). Data represent the mean ± SEM. 
Significance is indicated by * p ≤ 0.05, ** p ≤ 0.01 (Kruskal-Wallis test with Dunn’s post 
hoc test). 
Figure 6. 8 Decanoic acid causes a reduction in p-4E-BP1 levels in rat hippocampal 
brain slices.   
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6.9A and B) but significantly decreased p-S6K levels by 32 % at 300 M (95 % Cl: 21 %  
to 50 %, p = 0.0165, n = 6) (Fig. 6.9A and B). No significant difference was observed in 
the ratio of p-S6K over total-S6K for either 100 μM or 300 μM decanoic acid (Fig. 6.9A 
and C), however, a non-significant reduction was observed at 300 μM decanoic acid 
(18 % reduction, p = 0.8110, n = 6)  consistent with a trend for a reduction in mTORC1 
activity. Taken together these data suggest that decanoic acid (300 M) causes a 
decrease in mTORC1 signalling in rat hippocampal slice models under conditions of 
constant glucose and in the absence of insulin, consistent with that observed in 
Dictyostelium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          A) Rat hippocampal brain slices treated for 1 hour 
with artificial cerebral spinal fluid (control), DMSO solvent control (-), 100 µM 
decanoic acid (DA) or 300 µM decanoic acid (DA) were analysed for phosphorylated-
S6K (p-S6K) and total-S6K. β-Actin was used as a loading control. B) Relative band 
densities were plotted for B) p-S6K (n = 6) and C) total-S6K (n = 6). D) The ratio of p-
S6K/ total-S6K was used as a readout for mTORC1 (n = 6). Data represent the mean ± 
SEM. Significance is indicated by * p ≤ 0.05 (Kruskal-Wallis test with Dunn’s post hoc 
test). 
Figure 6. 9 Decanoic acid causes a reduction in p-S6K but not p-S6K/ Total-S6K levels 
in rat hippocampal brain slices.
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6.2.6 Decanoic acid acts independently of PI3K/AKT signalling in rat hippocampal 
slices 
Our results implicate decanoic acid in inhibiting mTORC1 activity in rat 
hippocampal slices. In order to investigate how decanoic acid targets this pathway 
we assessed the effects of decanoic acid on PI3K/AKT signalling, a pathway known to 
activate mTORC1. We monitored the effects of decanoic acid on PI3K/AKT signalling 
using antibodies against phosphorylated-AKT at Thr308, p-AKT(Thr308), 
phosphorylation of which is controlled by the PI3K pathway, and at Ser473, p-
AKT(Ser473),  phosphorylation of which is required for full activation, as well as 
monitoring total-AKT levels (Kamimura, Tang and Devreotes, 2009; Tariqul Islam et 
al., 2019; Alam et al., 2019). No significant difference was observed in p-AKT(Thr308), 
p-AKT(Ser473), total-AKT or in the ratios of p-AKT(Thr308)/total-AKT or p-
AKT(Ser473)/total-AKT levels after treatment with decanoic acid at 100 µM or 300 
µM (p > 0.05, n = 6) (Fig. 6.10). This indicates that decanoic acid targets mTORC1 
independently of PI3K/AKT signalling, and furthermore, suggests that decanoic acid 
inhibits mTORC1 without altering mTORC2 activation. 
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             A) Rat hippocampal brain slices treated for 1 hour with artificial cerebral spinal 
fluid (control), DMSO solvent control (-), 100 µM decanoic acid (DA) or 300 µM 
decanoic acid (DA) were analysed for phosphorylation at Thr308 (controlled by the 
PI3K pathway) and Ser473 (required for full activation) and for total-AKT levels, with 
β-Actin as a loading control. Relative band densities were plotted for B) total-AKT (n = 
6) (Kruskal-Wallis test with Dunn’s post hoc test) C) phospho-AKT at Thr308 (n = 6) 
(Kruskal-Wallis test with Dunn’s post hoc test) D) phospho-AKT at Ser473 (n = 6) 
(Kruskal-Wallis test with Dunn’s post hoc test). The ratio of E) p-AKT(Thr308)/total-
AKT (n = 6) (Kruskal-Wallis test with Dunn’s post hoc test) and F) p-AKT(Ser473) (n = 6) 
(Kruskal-Wallis test with Dunn’s post hoc test) was plotted. Error bars represent the 
mean ± SEM. Significance is indicated by ns p > 0.05. 
 
  
Figure 6. 10 Decanoic acid does not alter p-AKT in levels in rat hippocampal brain 
slices. 
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6.2.7 Decanoic acid causes a reduction in mTORC1 activation in patient derived 
astrocytes 
To investigate the potential ability of decanoic acid to reduce mTORC1 activity 
in a clinically relevant setting, we monitored mTORC1 activity in astrocytes derived 
from patients with tuberous sclerosis complex (TSC) (as prepared by Dr Stephanie 
Dooves, Vrije Universiteit Amsterdam). mTORC1 signalling is reportedly activated in 
astrocytes during epileptogenesis (Sha et al., 2012), with this cell type believed to 
play a significant role in the causation of seizures  (Wong, 2019; Coulter and 
Steinhäuser, 2015; de Lanerolle, Lee and Spencer, 2010). In these experiments, 
patients with mutations in either TSC1 (TSC1-) or TSC2 (TSC2-) and healthy controls 
provided samples to produce induced pluripotent stem cells (iPSCs) that were 
differentiated into astrocytes (Nadadhur et al., 2018; Nadadhur et al., 2019) and 
treated with decanoic acid (300 M for 24 hours) prior to western blot analysis of p-
4E-BP1 and total-4E-BP1 levels (Fig. 6.11). Decanoic acid caused a 41% reduction in 
the ratio of p-4E-BP1/ total-4E-BP1 in astrocytes derived from healthy (control) 
patients (95 % Cl: 39 % to 42 %, p ≤ 0.0001, n = 30) (Fig. 6.11B) confirming a role for 
decanoic acid in regulating mTORC1 activity in human cells in the absence of altered 
glucose or insulin signalling. Decanoic acid also caused a 46 % reduction in the ratio 
of p-4E-BP1/ total-4E-BP1 in astrocytes derived from patients with mutations in TSC1 
(95 % Cl: 45 % to 48 %, p = 0.0002, n = 20) (Fig. 6.11B). However, decanoic acid had no 
significant effect on the ratio of p-4E-BP1/ total-4E-BP1 in astrocytes derived from 
patients with mutations in TSC2 (4 % reduction, p = 0.8172, n = 20) (Fig. 6.11B). Levels 
of p-4E-BP1 were not significantly altered following treatment with decanoic acid 
(control showing 1 % increase, p = 0.9096, n = 30; TSC1-, 6 % decrease, p = 0.7561, n = 
20; TSC2- 15 % increase, p = 0.4775, n = 20) (Fig. 6.11C). The reduction in the ratio of p-
4E-BP1/ total-4E-BP1 following treatment with decanoic acid was caused by a 
significant increase in post treatment levels of total-4E-BP1 (Fig. 6.11D). Decanoic 
acid caused a 64 % increase in total-4E-BP1 levels in control patients (95 % Cl: 58 % to 
73 %, p = 0.0222, n = 30), and a 74 % increase in astrocytes derived from patients with 
mutations in TSC1 (95 % Cl: 69 % to 81 %, p = 0.000139, n = 20) (Fig. 6.11D). A non-
significant increase (50 %) was observed in total-4E-BP1 levels in astrocytes derived 
from patients with TSC2 mutations (p = 0.4240, n = 20) (Fig. 6.11D). Variation between  
 
162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
                             A) Astrocytes 
derived from iPSCs from three 
healthy patients (control), two 
patients with mutations in 
TSC1 (TSC1-) or two patients 
with mutations in TSC2 (TSC2-) 
were treated with DMSO 
solvent control (-), or 300 µM 
decanoic acid (DA) for 24 hours 
before analysis of 
phosphorylated-4E-BP1 (p-4E-
BP1) and total-4E-BP1 levels by 
western blot. β-Actin was used 
as a loading control.  B) The 
ratio of p-4E-BP1/ total-4E-BP1 
was used as a readout for 
mTORC1 (n = 10). Relative band 
densities were plotted for C) p-
4E-BP1 (n = 10) and D) total-4E-
BP1 (n = 10). Data from 
individual patients are 
differentiated by colour. Data 
represent the mean ± SEM. 
Significance is indicated by ns p 
> 0.05, * p ≤ 0.05, *** p ≤ 0.001, 
**** p ≤ 0.0001 (nested t-test). 
Figure 6. 11 Decanoic acid 
causes a decrease in the ratio 
of p-4E-BP1/ total-4E-BP1 in 
astrocytes derived from 
patient iPSCs.
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individual patients was observed in astrocytes derived from TSC2- patients, with one 
patient showing no significant change in total-4E-BP1 levels following decanoic acid 
treatment, while one patient showed a significant increase (79 %) in total-4E-BP1 
levels following decanoic acid treatment (95 % Cl: 59 % to 69 %, p = 0.0246, n = 10) (Fig. 
6.11D). These data suggest that decanoic acid reduces mTORC1 signalling in 
astrocytes derived from healthy patients as well as from patients with TSC1 
mutations, with more data required to evaluate the effect in patients with TSC2 
mutations. To confirm the effect of decanoic acid on mTORC1 activity in patient-
derived astrocytes, we also analysed p70 ribosomal protein S6 Kinase (S6K) 
phosphorylation levels (Fig. 6.12). Decanoic acid caused a 54% reduction in the ratio 
of p-S6K/ total-S6K in astrocytes derived from control patients (95 % Cl: 54 % to 55 %, 
p = 0.0458, n = 30) and a 69 % reduction in astrocytes derived from patients with 
mutations in TSC1 (95 % Cl: 34 % to 66 %, p ≤ 0.0001, n = 20) (Fig. 6.12B). However, 
decanoic acid had no significant effect on the ratio of p-S6K/ total-S6K in astrocytes 
derived from patients with mutations in TSC2 (3 % decrease, p = 0.9261, n = 20) (Fig. 
6.12B). The reduction in the ratio of p-S6K/ total-S6K following treatment with 
decanoic acid was caused by a significant reduction in post treatment levels of p-S6K 
(Fig. 6.12C). Decanoic acid caused a 53 % decrease in p-S6K levels in astrocytes 
derived from control patients (95 % Cl: 51 % to 55 %, p = 0.0468, n = 30), and a 50 % 
decrease in p-S6K levels in astrocytes derived from patients with mutations in TSC1 
(95 % Cl: 44 % to 59 %, p  ≤  0.0001, n = 20) (Fig. 6.12C). A non-significant decrease (38 
%) in p-S6K levels following decanoic acid treatment was also observed in astrocytes 
derived from patients with mutations in TSC2 (p = 0.2275, n = 20) (Fig. 6.11C). Variation 
between individual patients was observed in astrocytes derived from patients with 
TSC2 mutations, with one patient showing no significant change in p-S6K levels 
following decanoic acid treatment, while one patient showed a significant decrease 
(51 %) in p-S6K levels following decanoic acid treatment (95 % Cl: 30 % to 61 %, p = 
0.0071, n = 10) (Fig. 6.12C). No significant differences were observed in total-S6K 
levels (Fig. 6.12D). These results suggest that decanoic acid causes a reduction in 
mTORC1 activity in healthy patients and in patients with TSC1 mutations. However, 
due to the rarity of this condition, samples were derived from only a small number of 
patients (n = 3 control, n = 2 TSC1-, n = 2 TSC2-), highlighting the requirement for more 
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samples to confirm the effect of decanoic acid, especially in patients with TSC2 
mutations. 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                
   A) Astrocytes 
derived from iPSCs from three 
healthy patients (control), two 
patients with mutations in 
TSC1 (TSC1-) or two patients 
with mutations in TSC2    
(TSC2-) were treated with 
DMSO solvent control (-), or 
300 µM decanoic acid (DA) for 
24 hours before analysis of 
phosphorylated-S6K (p-S6K) 
and total-S6K levels by 
western blot. β-Actin was 
used as a loading control. B) 
The ratio of p-S6K/ total-S6K 
was used as a readout for 
mTORC1 (n = 10). Relative 
band densities were plotted 
for C) p-S6K (n = 10) and D) 
total-S6K (n = 10). Data from 
individual patients are 
differentiated by colour. Data 
represent the mean ± SEM. 
Significance is indicated by ns 
> 0.05, * p ≤ 0.05, **** p ≤ 
0.0001 (nested t-test).  
Figure 6. 12 Decanoic acid 
causes a decrease in the ratio 
of p-S6K/ total-S6K in 
astrocytes derived from 
patient iPSCs. 
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6.3 Discussion 
Following the identification of a stimulatory effect of both decanoic acid and 
octanoic acid on Dictyostelium autophagy we investigated the major regulator of this 
process, mTORC1 signalling, in order to better understand the therapeutic 
mechanisms of these fatty acids. In this chapter, we have employed Dictyostelium to 
establish that decanoic acid displays structurally specific mTORC1 inhibition. While 
inhibition of mTORC1 signalling is consistent with the observed activation of 
autophagy, we have demonstrated that the effect of decanoic acid on mTORC1 is 
dependent on UBXD18, whereas we previously identified that the autophagic effects 
of decanoic acid are independent of this protein. We therefore conclude that the 
effects of decanoic acid on autophagy in Dictyostelium are independent from the 
effects on mTORC1 signalling. To describe the effects on mTORC1, we suggest that 
decanoic acid functions in a UBXD18 dependent manner to inhibit p97 activity and 
reduce mTORC1 activity. We then confirm the mTORC1 inhibitory effect of decanoic 
acid using a rat hippocampal slice model widely used in epilepsy research (Chang et 
al., 2015; Chang et al., 2013). We further confirm this effect in astrocytes derived 
from healthy patients and patients with tuberous sclerosis complex 1 (TSC1) 
mutations. Our data therefore identifies a new and evolutionarily conserved effect of 
decanoic acid in down regulating mTORC1 signalling, with potential relevance to a 
wide range of medical treatments.   
Due to the importance of mTORC1 signalling in a diverse range of cellular 
processes, and the association of this pathway with a range of diseases, mTOR 
signalling has been well studied in eukaryotic organisms including in Dictyostelium. In 
both Dictyostelium and other eukaryotes, starvation inhibits mTORC1 signalling 
(Rosel et al., 2012; Tan, Sim and Long, 2017; Varghese et al., 2019), and our findings 
support this role (Fig. 6.3A). Components of the mTORC1 complex, including, TOR, 
Raptor and Lst8 are conserved throughout eukaryotes, as is the eukaryotic initiation 
factor 4E-binding protein (4E-BP1) (Morio et al., 2001; Liao et al., 2008). In eukaryotes 
including Dictyostelium, phosphorylation of 4E-BP1 by mTORC1 induces its 
dissociation from the eukaryotic translation initiation factor 4E (eIF4E), promoting 
initiation of protein translation (Haghighat et al., 1995) and this phosphorylation is 
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used in this study as a read out for mTORC1 activation (Fig. 6.1A). Dictyostelium has 
also been used in a range of mTORC1-related studies regarding its role in autophagy 
(Mesquita et al., 2016), cell migration (Liu et al., 2010), and phagocytosis (Rosel et al., 
2012). Thus, Dictyostelium is a suitable model for mTORC1 research, supporting our 
findings of a novel mechanism of decanoic in inhibiting mTORC1 activity. 
Having revealed a novel effect of decanoic acid in reducing mTORC1 activity 
independently of PI3K/AKT and AMPK signaling, we sought to describe a mechanism 
for this effect. In this chapter we have demonstrated that UBXD18 is required in 
Dictyostelium to confer sensitivity to decanoic acid in regards to mTORC1 regulation 
(Fig. 6.6) as well as previously described in growth (Fig. 3.16) and in the inhibition of 
the ubiquitous binding partner of UBXD18, p97 (Fig. 4.7). By employing a specific 
inhibitor (DBeQ) for p97, we confirmed that pharmacological inhibition of this protein 
decreased mTORC1 activity as well as cell proliferation (Ching et al., 2013) (Fig. 6.7). 
This finding suggests that UBXD18 dependent decanoic acid induced p97 inhibition 
(Fig. 4.7) could explain the inhibitory effects of decanoic acid on both mTORC1 activity 
and cell growth in Dictyostelium (Fig. 6.13). We have previously demonstrated that 
UBXD18- displays partial resistance to the growth inhibition caused by 4-BCCA as well 
as decanoic acid (Fig. 4.2), suggesting that 4-BCCA may also act on Dictyostelium in a 
UBXD18 dependent manner. Here we establish that 4-BCCA has no effect on p-4E-
BP1 levels in Dictyostelium (Fig. 6.2), indicating that these compounds target UBXD18 
through independent mechanisms, with further investigation required to elucidate 
the mechanism and effects of 4-BCCA. 
Inhibition of p97 has previously been established to reduce mTORC1 (Parzych 
et al., 2015; Ching et al., 2013), and p97 inhibitors have been proposed as a treatment 
for cancer and epilepsy (Tang and Xia, 2016; Han et al., 2015). In cancers, expression 
of p97 is increased to manage excessive proteotoxic stress (Vekaria et al., 2016), and 
p97 inhibitors are in clinical trials for the treatment of solid tumours (ClinicalTrials.gov 
Identifier: NCT02243917 and NCT04372641) (Stach and Freemont, 2017; Lan et al., 
2017). p97 also plays a role in a common form of epilepsy (autosomal dominant 
juvenile myoclonic epilepsy), where a mutation in a GABAA receptor (A322D mutation 
in the α1 subunit) results in misfolding and rapid ERAD of GABAA,  resulting in epilepsy 
(Cossette et al., 2002; Han et al., 2015). By inhibiting p97, α1(A322D) subunits have  
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 Dictyostelium Rat 
Hippocampus 
Healthy Patient 
derived 
astrocytes 
Tuberous sclerosis 
patient derived 
astrocytes 
Effect of decanoic acid 
on 4E-BP1 activation  
Decrease Decrease Decrease Decrease 
Effect of decanoic acid 
on AKT activation 
No change No change   
Effect of decanoic acid 
on AMPK signaling 
No change    
 
 
 
 
 
 
 
 
 
 
more time to fold in the ER, allowing functional GABAA receptors to form and act as 
inhibitory ion channels  (Han et al., 2015).  Our findings suggest that further analysis 
of a role for decanoic acid in inhibiting p97 and mTORC1 may identify associated 
therapeutic benefits. 
Our data suggest a novel mechanism for decanoic acid in regulating mTORC1. 
The classical ketogenic diet is well established to reduce mTORC1 activation, with a 
A B C 
A) In wild type Dictyostelium cells decanoic acid but not octanoic acid leads to a 
reduction in both p97 activity and mTORC1 signalling consistent with a reduction in 
growth.  B) In UBXD18- Dictyostelium cells decanoic acid (DA) has no effect on p97 
activity or mTORC1 signalling consistent with a resistance to decanoic acid induced 
growth inhibition. C) In UBXD18-/+ Dictyostelium cells decanoic acid leads to a 
reduction in both p97 activity and mTORC1 signalling consistent with a reduction in 
growth. Thus, we propose that decanoic acid (and not octanoic acid) acts to inhibit 
mTORC1 signalling though a UBXD18 (UBX) dependent inhibition of p97. D). Table 
summarising the effects of decanoic acid on mTORC1 signalling in Dictyostelium, a rat 
hippocampal model and in patient derived astrocytes.  
Figure 6. 13 Summary of the effects of decanoic acid on mTORC1 signalling. 
D 
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proposed mechanism through a reduction in glucose and insulin levels (Fig. 6.14) 
(McDaniel et al., 2011; Ostendorf and Wong, 2015; Sweeney et al., 2017; Thio et al., 
2006; Newman et al., 2017; Roberts et al., 2017). This reduction in mTORC1 signalling 
has been associated with the therapeutic effects of the classical ketogenic diet in 
treating epilepsy (McDaniel et al., 2011). While several studies have suggested that 
decanoic  acid  in the MCT  diet provides  the therapeutic  benefits  in seizure control 
(Chang et al., 2015; Wlaz et al., 2015; Augustin et al., 2018b; Chang et al., 2016), the 
role of decanoic acid on mTORC1 signaling as a therapeutic mechanism for seizure 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
control has not previously been reported. A small number of studies have 
independently investigated the effects of decanoic acid on mTORC1 activity, with 
inconsistent results. One study looking at the hepatic effects of medium-chain fatty 
acids in regards to non-alcoholic liver disease concluded that decanoic acid promoted 
activation of mTORC1 (Rial et al., 2018), while another study investigating the effects 
                                  The classical ketogenic diet inhibits mTORC1 signalling through 
reduced glucose and insulin (black). We propose a novel role of decanoic acid through 
a UBXD18 (UBX) and p97 mediated pathway (blue). Inhibition of dysregulated 
mTORC1 signalling may provide a useful approach to treat a range of conditions (red). 
Figure 6. 14 Simplified schematic portraying the canonical effect of the classical 
ketogenic diet on mTORC1 and our proposed mechanism of decanoic acid through 
UBXD18 and p97.
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of decanoic acid on trophoblast development found that decanoic acid caused a 
significant reduction in mTORC1 signalling (Yang et al., 2018). Each of these studies 
presented data from a single (dissimilar) cell line, with differing preparations of fatty 
acid (conjugated to BSA or free), and with differing treatment conditions, potentially 
explaining the disparity between the results. Here we demonstrate that in 
Dictyostelium, decanoic acid inhibits mTORC1 activity under conditions of constant 
glucose and in the absence of insulin (Fig 6.1B). Since we have translated this effect 
to both a rat hippocampal slice model  (Fig. 6.9 and 6.10) and patient derived 
astrocytes (Fig. 6.11 and 6.12), again under conditions of constant glucose and in the 
absence of insulin signalling, our data proposes an evolutionarily conserved effect of 
decanoic acid, provided in the MCT diet, distinct to that proposed for the classical 
ketogenic diet.  
The mTORC1 pathway acts as a regulator for cell growth through the 
phosphorylation of targets activating anabolic processes and inhibiting catabolic 
processes. In this role, mTORC1 inhibition has been credited with providing 
therapeutic effects in many areas of health, including treating epilepsy and 
neurodegenerative disorders, preventing the proliferation of cancer cells, improving 
cognitive function after traumatic brain injury, and in increasing longevity (McDaniel 
et al., 2011; Fujikake, Shin and Shimizu, 2018; Xie, Wang and Proud, 2016; Johnson, 
Rabinovitch and Kaeberlein, 2013). mTORC1 inhibition is also being investigated as a 
therapeutic target for the neurodevelopmental disorder TSC (Tee et al., 2002; Li et 
al., 2019; Franz and Capal, 2017; Franz et al., 2006; French et al., 2016). Mutations in 
these patients result in aberrant mTORC1 signalling, leading to excessive cell 
proliferation and the formation of tumours, which when arising in the brain can cause 
epilepsy (Crino, Nathanson and Henske, 2006). mTORC1 dysregulation has been 
identified in astrocytes in these patients (Sosunov et al., 2012), however, in cell 
culture, feedback loops on the TSC complex have been suggested to maintain 
balanced mTOR signalling (Blair, Hockemeyer and Bateup, 2018), potentially 
explaining why mTORC1 activation (p-4E-BP1/ total-4E-BP1 (Fig. 6.11), and p-S6K/ 
total-S6K (Fig. 6.12)) in astrocytes derived from patients with TSC mutations is 
unchanged from mTORC1 activation in astrocytes derived from healthy control 
individuals. Importantly, we demonstrate that decanoic acid reduces mTORC1 
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signalling in astrocytes derived from both healthy control individuals and in multiple 
patients with TSC mutations, suggesting that decanoic acid functions independently 
of disease state, but shows efficacy in cells derived from patients with disease-
associated mutations (Fig. 6.11 and 6.12). Our data suggests that heterogeneity 
between patients with mutations in TSC2 (Fig. 6.11 and 6.12), could represent 
differential efficacy of decanoic acid between individuals, however, additional 
patient derived samples would be required to confirm this. The decrease in the ratio 
of p-4E-BP1/ total-4E-BP1 observed following decanoic acid treatment was caused by 
an increase in total-4EBP1 levels rather than a decrease in p-4E-BP1 (Fig. 6.11). This 
increase in total-4E-BP1 levels is likely to alter functional activity of the protein (Elia 
et al., 2017), since hypo-phosphorylated 4E-BP1 interacts strongly with eIF4E, 
preventing initiation of translation (Haghighat et al., 1995). These findings suggest 
that decanoic acid downregulates mTORC1 signalling in healthy and disease 
associated human cells. 
Inhibition of mTORC1 provides a promising strategy for the treatment of a 
wide range of diseases (Li, Kim and Blenis, 2014; Harrison et al., 2009; Lamming and 
Sabatini, 2011; Franz et al., 2006). The recent development of new pharmacological 
inhibitors for mTORC1 inhibition, based around rapamycin, have focused on 
identifying ‘rapalogs’ without the toxicity associated with rapamycin (French et al., 
2016). Limitations of these currently available rapalogs have led to new approaches 
for reducing mTORC1 such as through dietary treatment, i.e. the classical ketogenic 
diet (McDaniel et al., 2011), however, this diet is highly restrictive for patients 
resulting in low compliance (Ye et al., 2015a). Our data suggests that this effect may 
also arise through decanoic acid, provided in the MCT ketogenic diet, that is more 
palatable, less restrictive and aversive than the classical ketogenic diet. Thus, further 
investigation into dietary decanoic acid may provide a useful approach to treat a 
range of diseases associated with dysregulation of mTORC1.  
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Chapter 7  
 
Discussion 
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7.1 Advances in understanding the mechanisms of action of medium-chain fatty 
acids 
The medium-chain triglyceride (MCT) diet provides effective seizure control 
for patients with drug resistant epilepsy, and has recently been suggested as a 
potential treatment for conditions such as neurodegenerative disorders  (Ota et al., 
2019; Taylor et al., 2018), mitochondrial disorders (Kanabus et al., 2016) and cancers 
(Jóźwiak et al., 2020; Narayanan et al., 2015), however, the therapeutic mechanisms 
underlying these effects are poorly understood. In this thesis we advance our 
understanding of the mechanisms of action underlying the MCT diet, providing 
insight into extending the application of this diet for use in a range of medical 
conditions. 
In this project we have employed the tractable model Dictyostelium 
discoideum to identify mechanisms of action of fatty acids provided by the MCT diet. 
We have demonstrated that in Dictyostelium, the sensitivity to decanoic acid is 
regulated in part by a ubiquitin regulatory X (UBX) domain-containing protein 
(UBXD18). To investigate this mechanism, we demonstrated that UBXD18-GFP binds 
to the ubiquitous protein p97(-RFP) and established that decanoic inhibits p97(-RFP) 
activity in a UBXD18 dependent manner. Since autophagy is an important pathway 
regulated by p97, this process was investigated as a target for decanoic acid, and both 
decanoic acid and octanoic acid were shown to regulate this process independent of 
UBXD18 (Fig. 7.1A). Another downstream target of p97, mTORC1 was also 
investigated. We have demonstrated that treatment with decanoic acid but not 
octanoic acid leads to a decrease in mTORC1 activity, and to describe this mechanism, 
we suggest that decanoic acid functions through UBXD18 to inhibit p97 activity and 
reduce mTORC1 activity, thus, indicating that the cellular effects of decanoic acid on 
autophagy and mTORC1 are distinct (Fig. 7.1A). Due to the importance of mTORC1 
inhibition in treating a range of conditions (Svarrer et al., 2019; Citraro et al., 2016; 
Xie, Wang and Proud, 2016), we translated this effect of decanoic acid-induced 
mTORC1 inhibition using a rat hippocampal slice model and patient-derived 
astrocytes with tuberous sclerosis complex mutations (Fig. 7.1 B and C). Our results 
showed that decanoic acid also decreases mTORC1 activity in these models in the 
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absence of insulin and under high glucose conditions. Our data therefore identifies a 
new and evolutionarily conserved effect of decanoic acid in down regulating mTORC1 
signalling, with potential relevance to a wide range of medical treatments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The classical ketogenic diet is thought to reduce mTORC1 signalling through 
reduced levels of glucose and insulin and this effect is believed to provide 
antiepileptogenic effects (McDaniel et al., 2011). Our data suggests that decanoic 
acid provided by the MCT ketogenic diet may provide direct mTORC1 inhibition 
independent of glucose and insulin levels, providing an alternative means of 
achieving the same effect. Data indicating that the classical ketogenic diet reduces 
mTORC1 signalling comes from findings that phosphorylation levels of ribosomal 
protein S6 (p-S6) are reduced in the livers and hippocampi of rats following 2 week 
administration of long-chain fatty acids (KD; Bioserv F3666) (McDaniel et al., 2011). 
A B C
                                                   A) Using Dictyostelium discoideum as a cell model we 
have identified that both decanoic acid and octanoic acid activate autophagy, 
independently of UBXD18. In this same model we demonstrate that decanoic acid but 
not octanoic acid inhibits mTORC1 and propose that this effect is resulting from a 
UBXD18 dependent decanoic acid induced inhibition of p97. B) We confirm that 
decanoic acid reduces mTORC1 signaling in a rat hippocampal slice model. C) Using 
patient-derived astrocytes, we demonstrate that decanoic acid reduces mTORC1 
signaling in healthy patients, as well as in patients with tuberous sclerosis complex. 
Figure 7. 1 Advances in understanding the molecular mechanism of decanoic acid 
in multiple model systems.
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These findings, along with a corresponding reduction in p-AKT and increase in p-
AMPK (McDaniel et al., 2011) were correlated with a previously established reduction 
in glucose and insulin (Thio et al., 2006) to explain the reduction in mTORC1 signalling. 
This proposed mechanism is supported by evidence that long-chain fatty acids and 
ketone bodies provided in the diet do not contribute to a reduction in mTORC1 
signalling (Yasuda et al., 2014; Vandoorne et al., 2017). Taken together this data 
suggests that the inhibitory effect of decanoic acid on mTORC1 could provide an 
alternative means of achieving the beneficial effects of the classical ketogenic diet, 
without the requirement for reduced glucose and insulin.    
 In this thesis we have utilised Dictyostelium as a model to propose a 
mechanism for decanoic acid in regulating mTORC1 signalling though a UBXD18 
dependent inhibition of p97, providing novel insight into the role of decanoic acid. 
While we have demonstrated that the inhibitory effect of decanoic acid on mTORC1 
signalling is conserved in a rat model and in human derived astrocytes, we were 
limited to describing this mechanism in the simple model Dictyostelium. The p97 
protein is highly conserved (78 % identical) between Dictyostelium and human, 
indicating that inhibitory regulation of this protein could be conserved between these 
species. Furthermore, interactions between fatty acids and UBX domain containing 
proteins have previously been implicated in blocking p97 activity in mammalian cells 
(Lee et al., 2008). This suggests that regulation of p97 via an interaction of decanoic 
acid with a UBX domain containing protein represents a viable mechanism in humans, 
with p97 inhibition established to inhibit mTORC1 signalling (Parzych et al., 2015). 
However, despite the high conservation between p97 proteins, the UBX domain 
containing protein, UBXD18, identified in Dictyostelium and postulated to mediate 
the decanoic acid induced inhibition of p97 shows a lesser degree of homology with 
two distinct human homologues (UBXN1 and UBXD2). Elucidating the mechanism of 
action of decanoic acid on mTORC1 inhibition in humans could lead to improved 
implementation of decanoic acid-based diets, and confirming a p97 inhibitory effect 
of this fatty acid could provide a rationale for use in the treatment of cancers (Vekaria 
et al., 2016; Anderson et al., 2015) and certain epilepsy conditions (Han et al., 2015).   
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7.2 Insights into decanoic acid-based therpaies 
In this thesis we provide evidence that decanoic acid inhibits mTORC1 
signalling in multiple models, and thus suggest that decanoic acid-based therapies 
could provide benefits in conditions with hyperactivated mTOR signalling. 
mTORopathies represent a group of genetic disorders resulting from hyperactivated 
mTORC1 signalling associated with malformations of cortical development (Crino, 
2015) and are characterised by refractory epilepsy, neurological alterations, 
overgrowth and central nervous system (CNS) manifestations (Crino, 2015). In 
mTORopathies, hyperactivity of mTORC1 signalling is thought to lead to alterations 
in cell size as well as structural alterations leading to epileptogenesis, and therapies 
to inhibit the activity of mTORC1 have been demonstrated to inhibit seizures and 
improve behavioural changes and learning deficits in patients with these conditions 
(Hillmann and Fabbro, 2019). 
 Tuberous sclerosis complex (TSC) is a mTORopathy resulting from loss of 
function mutations in either TSC1 or TSC2 (Fig. 7.2). Disruption of these genes leads 
to constitutive activation of mTORC1, manifesting in the development of tumours, 
with cortical tubers leading to seizures and behavioural changes. Therapy options for 
patients with TSC are limited and while the use of rapalogs, such as Everolimus, to 
reduce mTORC1 signalling have beneficial effects on seizures, these compounds are 
limited by immunosuppressive side effects (Franz et al., 2018). Novel mTOR kinase 
domain inhibitors (TORKinibs) have been considered to overcome these issues, 
however, they lack the penetration of the blood brain barrier (Borsari et al., 2019). 
Alternately, inhibition of this pathway is possible through dietary treatment with the 
classical ketogenic diet (McDaniel et al., 2011), however, this diet is highly restrictive 
for patients resulting in low compliance (Ye et al., 2015a). Our data demonstrates 
that decanoic acid reduces mTORC1 signalling in astrocytes derived from patients 
with TSC1 mutations, suggesting that the MCT diet could provide a less restrictive and 
safer alternative therapy for these patients. Heterogeneity in treatment response for 
patients with TSC2 mutations highlights the need for further research into factors 
influencing responsiveness to decanoic acid.   
Other mTORopathies have been identified with mutations in various genes in  
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the mTORC1 signalling cascade (Fig. 7.2), these include focal cortical dysplasia (FCD), 
familial focal epilepsy with variable foci (FFEVF), hemimegalencephaly and 
polyhydramnios megalencephaly symptomatic epilepsy syndrome (PMSE). Currently 
treatment options for these patients is limited to conventional and often ineffective 
AEDs, highlighting the requirement for new therapies. Everolimus is in a clinical trial 
for use in FCD (ClinicalTrials.gov: NCT03198949) but is associated with serious 
negative side effects. Limited evidence suggests that the classical ketogenic diet is 
effective in a range of mTORopathies such as TSC (Kossoff et al., 2005), focal cortical 
dysplasia  (Pasca et al., 2018) and Hemimegalencephaly (Mirzaa et al., 2018). These 
beneficial effects are thought to arise though restoration of controlled mTORC1 
signalling and our findings suggest that decanoic acid as provided in the MCT 
ketogenic diet could provide a safer alternative therapy for treating these 
mTORopathies. 
 
 
 
 
  
                               mTORC1 integrates cellular energy levels via upstream kinases 
and modulates downstream functions such as cell growth and proliferation. 
Mutations in specific genes in this pathway have been implicated in several 
mTORopathies. Each mTORopathy is labeled in grey at the point of mutation 
(indicated as gain of function (gof) or loss of function (lof). Decanoic acid could 
provide a therapy for the management of multiple mTORopathies (Blue).  
Figure 7. 2 Mutations activating mTORC1 are associated with multiple 
mTORopathies.  
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Our data demonstrating that decanoic acid but not octanoic acid inhibits 
mTORC1 signalling, supports previous studies describing the efficacy of this specific 
fatty acid (Chang et al., 2013; Chang et al., 2016; Hughes et al., 2014). Evidence 
substantiating the role of decanoic acid in seizure control, has led to the development 
of Betashot, a high decanoic acid supplement for children and adults with epilepsy 
(ClinicalTrials.gov: NCT02825745). This product is advantageous over the traditional 
MCT diet, allowing patients to maintain a relatively normal diet while supplementing 
MCTs (Betashot). Formulated to contain elevated levels of decanoic acid, this product 
has demonstrated effectiveness in a clinical trial for seizure control, palatability, 
tolerability and compliance (ClinicalTrials.gov: NCT02825745). Our findings that 
decanoic acid but not octanoic acid provides mTORC1 inhibition suggest that a 
supplement high in decanoic acid, such as Betashot, could provide an enhanced 
therapeutic effect over traditional MCT diets in the treatment of mTORopathies.   
In addition to treating mTORopathies, mTOR inhibitors are being investigated 
for use in other conditions such as mitochondrial disorders, Alzheimer’s disease, and 
certain cancers. Mitochondrial disorders arise from dysfunctions in the respiratory 
chain, with tissues and organs highly dependent of aerobic metabolism affected in 
patients. The mTORC1 pathway has recently been implicated in these disorders 
(Wang et al., 2016; Sage-Schwaede et al., 2019) and has been identified as a key 
upstream regulator of stress responses (Khan et al., 2017). The mTORC1 inhibitor 
rapamycin has been demonstrated to attenuate disease progression in a mouse 
model of the mitochondrial disorder Leigh syndrome (Johnson et al., 2013), and has 
had beneficial effects in a child with this syndrome (Sage-Schwaede et al., 2019). 
Although the mechanisms behind these therapeutic effects are unclear, these studies 
propose that mTOR inhibitors provide a potential therapeutic strategy for patients 
with mitochondrial disorders. The MCT ketogenic diet has previously been suggested 
for use in mitochondrial disorders, following the identification that decanoic acid 
increases mitochondrial biogenesis (Hughes et al., 2014), and our findings provide 
further support for use of the MCT diet in mitochondrial disorders, through decanoic 
acid induced inhibition of mTORC1. Thus, since decanoic acid has the potential to 
provide multiple therapeutic benefits in patients with mitochondrial disorders, more 
research should be carried out into the use of MCT diets in these patients.  
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Aberrant mTORC1 signalling has commonly been associated with failed 
clearance of toxic protein aggregates, such as tau and amyloid β in Alzheimer’s 
disease (Chang et al., 2002; An et al., 2003; Crino, 2016). In Alzheimer’s patients 
activation of mTORC1 is associated with the upregulation of tau translation and 
phosphorylation contributing to disease pathology (Tang et al., 2013; Morita and 
Sobue, 2009). Furthermore, inhibition of mTORC1 using rapamycin has been shown 
to suppress the translation of tau (Morita and Sobue, 2009) and protect against 
neuronal death in mice (Siman, Cocca and Dong, 2015). These findings suggest that 
mTORC1 inhibitors could rescue cellular neurodegeneration and indicate that 
decanoic acid supplementation could be beneficial in patients with this 
neurodegenerative disease. In addition to mTORC1 signalling, autophagy has also 
been suggested to play a key role in Alzheimer’s, in the metabolism of Aβ and tau 
(Uddin et al., 2018), and our data suggesting that medium-chain fatty acids activate 
degradation through this pathway, enhances the therapeutic relevance of the MCT 
diet for patients with Alzheimer’s disease. 
Octanoic acid has previously been investigated for use in patients with 
Alzheimer’s disease, due to its ability to induce ketosis to bypass dysfunctional 
glucose metabolism in the brain (Henderson et al., 2009). This fatty acid proved 
ineffectual at improving cognition in patients carrying the APOE4 allele (an allele of 
Apolipoprotein (APOE) representing a genetic determinant of Alzheimer disease), 
however, octanoic acid provided cognitive benefits in patients not carrying this allele 
(Henderson et al., 2009). Since astrocytes expressing APOE4 have been demonstrated 
to exhibit lower autophagic flux under autophagy-inducing conditions than those 
expressing other APOE isoforms (Simonovitch et al., 2016), our data demonstrating 
medium-chain fatty acid induced autophagy activation suggests that octanoic acid 
induced autophagy in patients lacking APOE4, but not those with APOE4, could explain 
the observed heterogeneity in response to octanoic acid. In addition, the efficacy of 
decanoic acid in humans with Alzheimer’s disease has not yet been investigated and 
our findings suggest that a decanoic acid supplement could provide additional 
benefits to Alzheimer’s patients through mTORC1 inhibition and autophagy 
activation as well as through bypassing glucose metabolism.  
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Due to the fundamental role of mTOR signalling in regulating cellular 
proliferation, growth, and survival, hyperactivation of this pathway is observed in 
various types of cancers (Tian, Li and Zhang, 2019). Activating mutations in MTOR 
that result in an increase in kinase activity are observed in a range of cancers such as 
breast, lung, ovarian and skin cancer (Grabiner et al., 2014). Mutations in upstream 
genes such as PI3K, AKT and RHEB leading to hyperactivation of mTORC1 are also 
frequently detected in human cancers (Ghosh et al., 2015; Hua et al., 2019) (Fig. 7.3). 
Furthermore, loss of function mutations are also known to contribute to mTORC1 
activation in cancer with PTEN inactivating mutations occurring in 40 % of 
glioblastomas (Pachow et al., 2015; Akhavan, Cloughesy and Mischel, 2010; Crino, 
2015), and patients with germline PTEN mutations at risk of thyroid and breast cancer 
(Sansal and Sellers, 2004) (Fig. 7.3). Due to the critical role of mTOR signalling in 
tumour progression, mTOR inhibitors are promising for use as cancer therapies. 
Several mTORC1 inhibitors have been examined in cancer models in combination 
with conventional therapies, and evidence for anti-tumour effects have been 
identified in animal and human studies (Klement, 2017). Although mTOR inhibitors 
show efficacy in preclinical studies, many inhibitors are associated with serious 
adverse effects in patients, thus safer alternatives are required. Our data suggests 
that dietary decanoic acid may provide a safer alternative for reducing mTORC1 
signalling in a range of different cancers.  
Ketogenic diets have been shown previously to enhance the effectiveness of 
chemotherapy and radiotherapy in various cancer types (Weber et al., 2020). This 
efficacy is thought to arise from a reduction in glucose levels leading to the starvation 
of cancer cells, as well as though reduced insulin and downstream signalling of 
mTORC1. Medium-chain triglycerides have been demonstrated to provide more 
effective anti-tumour effects than long-chain triglycerides on neuroblastoma 
xenografts (Aminzadeh-Gohari et al., 2017) and this observation is supported by our 
research suggesting that decanoic acid could provide direct inhibition of mTORC1. In 
addition to restoring balanced mTORC1 signalling in cancers, pharmacological 
inhibition of mTORC1 has been suggested to provide therapeutic effects though the 
corresponding induction in autophagy (Evans et al., 2005; Paquette, El-Houjeiri and 
Pause, 2018; Tian, Li and Zhang, 2019). Our data implicating medium-chain fatty acids 
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in autophagy activation, suggest that this effect could provide an additional 
advantage of medium-chain triglycerides over long-chain triglycerides as a cancer 
treatment.   
  
Specific genes in the mTORC1 pathway have been implicated in several cancers. The 
frequency of mutation in cancer patients is labeled in grey at the point of mutation 
(indicated as gain of function (gof) or loss of function (lof) (André F, 2017). Decanoic 
acid could provide a therapy for the management of multiple cancers (Blue).  
Figure 7. 3 Mutations activating mTORC1 have been implicated in several cancers. 
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7.3 Conclusion 
Inhibition of mTORC1 has been suggested to provide wide-ranging clinical 
benefits, including as a treatment for mTORopathies, mitochondrial disorders, 
neurodegenerative disorders and cancer (Hillmann and Fabbro, 2019; Sage-
Schwaede et al., 2019; Crino, 2016; Klement, 2017). Pharmacological inhibitors based 
around rapamycin are under development for use in these conditions, alternatively 
the classical ketogenic diet is well established to inhibit mTORC1 signalling through a 
reduction in glucose and insulin (McDaniel et al., 2011). Side effects associated with 
pharmacological inhibitors (French et al., 2016) and the restrictive nature of the 
classical ketogenic diet highlight the need for safer and more tolerable methods of 
mTORC1 inhibition. Our data suggest that decanoic acid provided by the MCT diet 
could provide a safe alternative for mTORC1 inhibition, with the added benefit of 
autophagy activation. Thus, further investigation into dietary decanoic acid may 
provide a useful approach to treat a range of diseases associated with hyperactivated 
mTORC1 signalling.   
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Since the original report of seizure control through starvation in the 1920s, the ketogenic
diet has been considered an energy-related therapy. The diet was assumed to be
functioning through the effect of reduced carbohydrate intake regulating cellular energy
state, thus giving rise to seizure control. From this assumption, the generation of
ketones during starvation provided an attractive mechanism for this altered energy state;
however, many years of research has sought and largely failed to correlate seizure control
and ketone levels. Due to this focus on ketones, few studies have examined a role for free
fatty acids, as metabolic intermediates between the triglycerides provided in the diet and
ketones, in seizure control. Recent discoveries have now suggested that the medium-
chain fats, delivered through the medium-chain triglyceride (MCT) ketogenic diet, may
provide a key therapeutic mechanism of the diet in seizure control. Here we describe
an unusual pathway leading to this discovery, beginning with the use of a tractable
non-animal model—Dictyostelium, through to the demonstration that medium-chain fats
play a direct role in seizure control, and finally the identification of a mechanism of action
of these fats and related congeners leading to reduced neural excitability and seizure
control.
Keywords: decanoic acid, Dictyostelium, epilepsy, ketogenic diet, ketones, non-animal models
INTRODUCTION
Identifying the key therapeutic target of drugs is of great importance for biomedical science, since
this enables rapid screening to develop improved compounds (Chang et al., 2012), and strengthens
our understanding of the basic physiology underlying disease phenotypes. To confirm a mechanism
of a compound it is essential to remove or silence the target gene, in order to demonstrate a
subsequent loss of response to the compound. However, ablation of potential protein targets in
mammalian models is problematic, due to the diploid nature of cells (making gene ablation difficult)
and the complex array of related proteins often with overlapping catalytic function (e.g., in various
isoforms or protein families). To address these issues, simple tractable models can be used, where
gene ablation is rapid and efficient and a low complexity genome provides less redundancy in
cellular function (Williams et al., 2002), to provide innovative proposals relating to drug targets
that can then be validated in mammalian models. Using this approach, cells lacking the proposed
target, having lost response to the compound, would confirm a direct activity for the compound
against the target.
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AN INNOVATIVE TRACTABLE MODEL
SYSTEM PROVIDES THE GREAT LEAP
FORWARD
The social amoeba, Dictyostelium discoideum, provides an
unconventional system for molecular neuroscience research.
This organism grows naturally in the leaf litter of temperate
forests, existing in both single and multicellular stages (Figure 1;
Williams et al., 2006). Dictyostelium belongs to the Phylum
Amoebozoa, where phylogenetic analysis suggests that it
diverged from the animal linage after plants, but before yeast
and fungi. Despite the earlier divergence, many Dictyostelium
proteins maintain more homology with human proteins than
those of unicellular fungi (Eichinger et al., 2005). The haploid
nature of Dictyostelium enables rapid gene ablation by insertional
mutagenesis (Faix et al., 2013), and the production of mutant
libraries (Kuspa, 2006). The model can then be used to
investigate acute cellular effects, chronic growth effects and
developmental effects of compounds to demonstrate cellular
function (Robery et al., 2013; Waheed et al., 2014; Cocorocchio
et al., 2016, 2018). It is important to verify that targets identified
from mutant library screens are specific to the compound of
interest and are not conferring broad resistance to a range of
compounds. Furthermore, while Dictyostelium contains many
proteins highly conserved with humans, some proteins are absent
or have non-conserved functions. It is therefore not possible
to make translatable findings about non-conserved proteins
in Dictyostelium, and due to potential differences in cellular
function of Dictyostelium and human proteins, it is imperative
to validate findings in mammalian models.
FIGURE 1 | The tractable model organism, Dictyostelium discoideum has been used to investigate cellular mechanisms of epilepsy treatments and medium-chain
triglyceride (MCT) ketogenic diet associated fatty acids. The organism can exist in (A) a single cell stage, with cells around 10 µm in diameter. Due to their haploid
nature, genes can be easily ablated and isogenic mutants analyzed in drug target studies. Under starvation conditions Dictyostelium cells form (B) multicellular
fruiting bodies, of around 1–2 mm in height, comprising a spore head held above the substratum by dead vacuolated stalk cells, where the process of aggregation
and development has been widely studied. (C) The life cycle of Dictyostelium begins with unicellular growth, where cells consume bacteria and divide by binary
fission. Following the onset of starvation, cells enter a development cycle where cells aggregate and enter a multicellular stage through streaming to form a mound
and then finger structure. Motile slugs are able to migrate towards favorable locations and develop, or development may progress straight into a tipped mound, early
culminant and then mature fruiting body. Spores within the head of the fruiting body, which are able to survive unfavorable conditions, can then be released, and
germinate to re-enable unicellular growth.
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Dictyostelium has been used in a range of projects to
investigate the cellular and molecular mechanisms of the widely
used epilepsy treatment valproic acid (VPA). It has been used
to demonstrate a common mechanism of action of bipolar
disorder treatments through inositol depletion (Williams et al.,
2002; Eickholt et al., 2005), and in a conserved mechanism
to regulate the MAP Kinase pathway in neuroprotection
(Boeckeler et al., 2006). Dictyostelium has been valuable in
identifying an uptake mechanism for VPA via an orthologe
of the mammalian solute carrier family 4 (SLC4) bicarbonate
transporter (Terbach et al., 2011). Importantly, it was also the
first system to suggest a mechanism of VPA in regulating
phosphoinositide turnover in relation to seizure control (Xu
et al., 2007; Chang et al., 2012), which was subsequently
validated using in vivo mammalian models (Chang et al.,
2014). Dictyostelium was also employed in the identification
of a range of compounds related to VPA that showed efficacy
in neuroprotection and seizure control in mammalian models
(Chang et al., 2013, 2015, 2016). One of the compounds
identified through this pathway, decanoic acid, provides a
major constituent administered in the medium-chain triglyceride
(MCT) ketogenic diet.
METABOLISM OF THE KETOGENIC DIET
Ketogenic diets have been used to treat seizures since the 1920s
(Wheless, 2008). A modified form of the diet, the MCT ketogenic
diet introduced in 1971 (Neal, 2017), provides a restricted
carbohydrate diet, with around 45% of dietary energy delivered
as fatty acids, an improvement on the classic ketogenic diet
which makes up 60%–80% of dietary energy. This advancement
of the diet allows more carbohydrate and protein to be consumed
which improves tolerability and reduces gastrointestinal side
effects. While the classic ketogenic diet relies on long-chain
fatty acids, the MCT ketogenic diet provides energy in the form
of medium-chain fatty acids within triglycerides, consisting of
the eight-carbon octanoic acid and the ten-carbon decanoic
acid in a 40–60 ratio (Sills et al., 1986; Liu, 2008). Cleavage of
triglycerides in the gut leads to the release of free fatty acids,
which are absorbed through the gut wall and are metabolized
in the liver, where β-oxidation leads to the production of
ketone bodies (β-hydroxybutyrate, acetoacetate and acetone)
which are only seen in patients on a carbohydrate restricted
(or starvation) diet (Haidukewych et al., 1982; Augustin et al.,
2018). Although most fatty acids are degraded at this stage
(Sills et al., 1986), some medium-chain fatty acids along
with ketone bodies are distributed via the vascular system
throughout the body and to the brain (Wlaź et al., 2012,
2015).
SEIZURE CONTROL ACTIVITIES OF
KETONES AND FREE FATTY ACIDS
As the most investigated mechanism for ketogenic-diet
dependent seizure control, many studies have focused on a
role of ketones, with variable outcomes. In the absence of
dietary carbohydrates, ketones are generated and distributed
at concentrations of around 5 mM (Veech, 2004), where
they are thought to provide an alternate energy source to
glucose. In clinical studies, ketone levels poorly correlate with
anticonvulsant efficacy, and this ketone-based mechanism has
not been widely supported in animal model studies (Likhodii
et al., 2000; Thavendiranathan et al., 2000). Ketones have
been demonstrated to regulate GABA and glutamate levels
(Lutas and Yellen, 2013), but do not directly act at GABA or
glutamate receptors at physiological concentrations (Donevan
et al., 2003), nor do they directly alter hippocampal synaptic
transmission (Thio et al., 2000). Ketones do not directly
block seizure activity in hippocampal slice models, induced
to generate seizure-like activity with either pentelentetrazol
(PTZ) or low magnesium conditions (Chang et al., 2016;
Figure 2) or in 4-aminopyridine induced ex vivo seizure
models (Thio et al., 2000). Although the role of ketones in
the ketogenic diet is controversial there is evidence in support
of their efficacy. Ketones have been demonstrated to regulate
mitochondrial function (Kim et al., 2015b) implicating cellular
energy regulation. The ketogenic diet has also been suggested
to function in seizure control through increasing activation
of adenosine A1 receptors in a mouse model, however it
remains to be determined if this effect is through ketone-
dependent or fat-dependent mechanisms (Masino et al., 2011).
Ketones have also been demonstrated to regulate synaptic
KATP channels, providing a further potential mechanism in
seizure control (Kim et al., 2015a; Li et al., 2017). Finally,
ketones may function through epigenetic effects, regulating
gene expression in relation to seizure susceptibility (Kobow
et al., 2013; Lusardi et al., 2015). A comprehensive evaluation
of the current experimental understanding of the efficacy
of ketone bodies is reviewed elsewhere (Simeone et al.,
2018).
The first investigation of medium-chain fatty acids relating to
seizure control arose through several papers identifying elevated
levels of both octanoic acid and decanoic acid in the plasma
of patients on the MCT ketogenic diet (Haidukewych et al.,
1982; Sills et al., 1986; Dean et al., 1989). Here, decanoic acid
was shown at an average level of 157 µM (87–552 µM) and
octanoic acid at 310 µM (104–859 µM). The relatively low
number of patients assessed in these studies (up to 12 individuals)
prevented a correlation between fatty acid levels and seizure
control. Subsequently, an in vivo study of straight-chain fatty
acids identified strong effects of long-chain fatty acids (e.g.,
palmitic acid containing 16 carbons) in a picrotoxin-induced
seizure model in mice, with small but significant effects of
decanoic acid in delaying the onset of clonic convulsions without
an effect on survival time. The opposite effect was found
for decanoic acid with subcutaneous PTZ induced seizures,
where survival time was increased but clonic convulsions were
not delayed (Nakamura et al., 1990). The small magnitude
of the effect and the large variability of response did not
provide clear support for a mechanism of decanoic acid in
seizure control. More compelling evidence was provided by later
studies.
It has been identified in Dictyostelium that medium-
chain fatty acids regulate phosphoinositide signaling, in a
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FIGURE 2 | Seizure-like activity in an in vivo model is acutely blocked by decanoic acid (DA) and related compounds but not by ketones. The MCT ketogenic diet
involves the oral intake of (A) medium-chain triglycerides, which are converted into the fatty acids decanoic acid and octanoic acid in the intestine. These
medium-chain fatty acids are then transferred to the liver, where they are further metabolized to form ketone bodies. Fatty acids and ketones are transported in the
blood to the brain where they are able to cross the blood brain barrier. Following the identification of decanoic acid as a potential therapeutic effector of the MCT
ketogenic diet in Dictyostelium, its seizure control activity was compared to that of the ketones acetone and β-hydroxybutyrate (BHB), with seizure-like activity
induced in a rat hippocampal slice model following (B) pentelentetrazol (PTZ) or (C) low magnesium treatment. In both models, epileptiform activity was not blocked
by either ketones (BHB or acetone) at high concentrations (10 mM). In contrast, the medium-chain fatty acid, DA rapidly blocked activity at 1 mM. Data is derived
from Chang et al. (2016). (D,E) A range of novel compounds and related structures implicated through the use of Dictyostelium have also been demonstrated to
show seizure control activity, where seizure-like activity is induced in a rat hippocampal slice model following PTZ treatment. Data derived from Chang et al. (2014).
similar but more potent mechanism to valproic acid (Chang
et al., 2012). This study further demonstrated that some of
these fatty acids blocked PTZ-induced epileptiform activity
in an in vitro rat hippocampal model (Figure 2), again
with a more potent effect than VPA. This anti-seizure effect
occurred within 10 min of treatment, continually perfused
with artificial CSF with high glucose content suggesting
that the mechanism of seizure control was not dependent
upon the build-up of ketones through the metabolism of
fatty acids. Further studies identified that decanoic acid, and
derivatives of octanoic acid show strong seizure control in
a PTZ induced rat hippocampal model for seizure activity,
again under perfusing CSF conditions unlikely to allow ketone
generation (Chang et al., 2013). Medium-chain fatty acids
were effective in a (perforant path stimulation-induced) status
epilepticus in vivo model within 20 min of administration.
A further study confirmed that branched-chain octanoic acid
compounds showed strong structure-specific seizure control
activity in a PTZ-induced hippocampal seizure model (Chang
et al., 2015), in addition to blocking excitotoxic cell death
induced by low magnesium levels in primary hippocampal
neurons. Some related structures in this study showed potent
control of epileptiform activity (Figure 2), without the negative
side effect of VPA on histone deacetylase activity, widely
associated with teratogenicity (Phiel et al., 2001; Gurvich et al.,
2004).
Medium-chain fatty acids have also been demonstrated to
function in seizure control in in vivo models. In one study in
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mice, seizure thresholds were increased in the in vivo 6 Hz
model using a single bolus oral gavage dose of decanoic acid
at 10 mmol/kg and 30 mmol/kg, and a similar increase was
observed in the MES threshold model at 50 mmol/kg p.o.,
although no effect was observed at decanoic acid doses up
to 50 mmol/kg p.o following seizure induction with i.v. PTZ
(Wlaź et al., 2015). This group also showed that octanoic acid
provided as a single bolus oral gavage dose at 20 mmol/kg and
30 mmol/kg significantly increased the dose of i.v. PTZ required
to induce myoclonic twitch, and at 30 mmol/kg increased the
dose of i.v. PTZ required to induce clonus, and that octanoic
acid increased the seizure threshold above 10 mmol/kg in the
6-Hz model (Wlaź et al., 2012). The comparative importance of
octanoic acid and decanoic acid was also examined in a mouse
study. In this study, dietary treatment of mice with medium-
chain triglycerides comprising either only octanoic acid or only
decanoic acid was followed by induction of seizure like activity
using both the 6 Hz model and the latency to first generalized
seizure in the flurothyl model (Tan et al., 2016). This study
showed that decanoic acid (only) triglycerides increased seizure
thresholds whereas octanoic acid (only) triglycerides did not,
supporting a role for decanoic acid in seizure control. It is also
worthwhile to note that, since this study showed both decanoic
acid and octanoic acid triglycerides provided a common level
of ketosis, but only the decanoic acid triglyceride diet provided
seizure control, this decanoic acid-dependent seizure control
activity is likely to be unrelated to the generation of ketones.
These studies therefore support a mechanism of seizure control
through decanoic acid.
In many of these in vivo studies, a therapeutic role of
fatty acids has been overlooked due to the perceived role
of ketones as the mechanism of the diet. Therefore, it
remains to be determined if free fatty acids may provide the
therapeutic effects underlying the diet. For example, in one
study (Mantis et al., 2014), augmentation of the ketogenic
diet with glucose increased seizure susceptibility in a genetic
mouse model, however, this study did not describe ketone
levels or free fatty acid levels following glucose administration,
thus it remains unclear if the role of glucose in these
experiments was due to effects on ketosis or free fatty acid
levels.
The MCT ketogenic diet leads to elevated levels of both
octanoic acid and decanoic acid in the plasma of patients
(Haidukewych et al., 1982), however, most studies suggest
that decanoic acid and not octanoic acid is responsible for
the therapeutic benefits of the diet (Chang et al., 2013,
2016; Hughes et al., 2014; Tan et al., 2016). So is there a
benefit of including octanoic acid in the diet? Interestingly,
recent studies have shown that octanoic acid, rather than
decanoic acid, is preferentially metabolized in neurones by
β-oxidation (Khabbush et al., 2017). This finding suggests
that the presence of octanoic acid in the MCT ketogenic
diet may allow decanoic acid to escape catabolism, thus
accumulating, to enhance a therapeutic mechanism in preventing
seizures. This finding supports an earlier in vivo study in mice
using the 6 Hz seizure test that demonstrates an increased
anticonvulsant activity of combined octanoic acid and decanoic
acid in comparison to decanoic acid alone (Wlaź et al.,
2015).
CELLULAR TARGETS FOR FREE FATTY
ACIDS IN RELATION TO NEURONAL
EXCITABILITY AND SEIZURE CONTROL
Two molecular mechanisms for decanoic acid have recently
been proposed. As an acute mechanism for seizure control,
decanoic acid has been shown to reduce excitatory postsynaptic
currents (EPSCs) using whole cell patch clamp recordings from
CA1 pyramidal neurons, likely through inhibition of excitatory
AMPA receptors (Chang et al., 2016). By expressing distinct
AMPA receptor subunits (GluA1, GluA2 and GluA3) in a
Xenopus oocyte model, a direct inhibitory effect of decanoic
acid against AMPA receptors was then confirmed, enabling
detailed electrophysiological characterization (Chang et al.,
2016). These studies showed that decanoic acid directly inhibits
the two most abundant AMPA receptors subunit combinations
found in the brain, with greatest potency against GluA2/3
(IC50 = 0.52 mM) and GluA1/2 (IC50 = 1.16 mM). This
inhibitory effect was voltage-dependent, where potency against
GluA2/3 receptors at −80 mV (IC50 of 1.11 mM) was elevated
following depolarization to −40 mV (to IC50 of 0.43 mM),
suggesting stronger inhibitory activity during prolonged seizure
activity.
As a chronic mechanism of action, decanoic acid has also
recently been demonstrated to activate the nuclear receptor,
PPARγ, leading to increased mitochondrial proliferation
(Hughes et al., 2014). Using cultured neuronal cells, decanoic
acid but not octanoic acid was shown to trigger mitochondrial
biogenesis and elevate the activity of the mitochondrial
complex I. Since seizure activity is commonly found arising
from a wide array of mitochondrial mutations (Zsurka and
Kunz, 2015), this mechanism of decanoic acid is thought
to increase ATP availability and improve brain energy
metabolism, leading to an increase in seizure threshold
and to a reduction in seizure activity following long term
treatment.
CONCLUSION
Understanding the mechanism of action of the MCT ketogenic
diet in regulating neuronal excitability is critical for improving
the treatment of patients with drug resistant epilepsy. Although
the diet has clearly shown therapeutic relevance (Liu, 2008;
Neal et al., 2008), evidence for a ketone-dependent mechanism
in this function remains limited. The recent proposal for the
efficacy of the diet is that fats provided through triglycerides
in MCT supplements, in particular decanoic acid (Chang
et al., 2013, 2015, 2016), may provide a direct function in
blocking seizure activity independent of ketosis. Furthermore,
novel compounds related to these medium-chain fatty acids
may offer new approaches for seizure control without dietary
restrictions (Chang et al., 2013). The studies outlined here
provide a range of corollaries that should be considered in
future experimentation. These include closely monitoring both
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fatty acid and ketone levels at a cellular and in vivo level,
in both research and clinical settings to clarify the distinct
contributions of fatty acids and ketones in epilepsy treatment.
Furthermore, further studies may investigate improvements in
the diet by modifying the fatty acid content of the diet, in
addition to exploring other secondary targets of these fatty
acids, and in the development of related chemicals that may
function through the same therapeutic mechanism but lack
the rapid metabolic degradation shown for medium-chain
fatty acids.
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Gamma secretase orthologs are required for lysosomal activity and autophagic
degradation in Dictyostelium discoideum, independent of PSEN (presenilin)
proteolytic function
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ABSTRACT
Mutations in the γ-secretase complex are strongly associated with familial Alzheimer disease. Both
proteolytic and non-proteolytic functions for the γ-secretase complex have been previously described
in mammalian model organisms, but their relative contributions to disease pathology remain unclear.
Here, we dissect the roles of orthologs of the γ-secretase components in the model system Dictyostelium,
focusing on endocytosis, lysosomal activity and autophagy. In this model, we show that the orthologs of
PSEN (psenA and psenB), Ncstn (nicastrin) and Aph-1 (gamma-secretase subunit Aph-1), are necessary
for optimal fluid-phase uptake by macropinocytosis and in multicellular development under basic pH
conditions. Disruption of either psenA/B or Aph-1 proteins also leads to disrupted phagosomal proteo-
lysis as well as decreased autophagosomal acidification and autophagic flux. This indicates a general
defect in lysosomal trafficking and degradation, which we show leads to the accumulation of ubiqui-
tinated protein aggregates in cells lacking psenA/B and Aph-1 proteins. Importantly, we find that all the
endocytic defects observed in Dictyostelium PSEN ortholog mutants can be fully rescued by proteoly-
tically inactive Dictyostelium psenB and human PSEN1 proteins. Our data therefore demonstrates an
evolutionarily conserved non-proteolytic role for presenilin, and γ-secretase component orthologs, in
maintaining Dictyostelium lysosomal trafficking and autophagy.
Abbreviations: Atg8: autophagy protein 8a; Aph-1: gamma-secretase subunit Aph-1; crtA: calreticulin; ER:
endoplasmic reticulum; GFP: green fluorescent protein; GSK3B: glycogen synthase kinase 3 beta; Ncstn:
nicastrin; PSEN1: presenilin 1; psenA and psenB: Dictyostelium presenilin A and B; TRITC; tetramethylrhodamine
isothiocyanate.
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Introduction
Many studies have sought to explore a role for the γ-secretase
complex (and PSEN [presenilin] proteins) in the pathology of
Alzheimer disease [1–4]. One function of the mammalian com-
plex (consisting of PSEN1 [presenilin 1], APH1 [aph-1 homolog,
gamma-secretase subunit], NCSTN [nicastrin] and PSENEN/
PEN2 [presenilin enhancer, gamma-secretase subunit]) or
PSEN1 proteins alone is to regulate endocytosis, lysosomal acid-
ification, and autophagy [5–7]. This role has been implicated in
disease pathology, since mutations in PSEN1 proteins associated
with familial Alzheimer disease result in elevated lysosomal pH,
and aberrant autophagy in mouse models [7–9]. Dysfunctional
endosomal-lysosomal and autophagic pathways have also been
implicated in the pathogenesis of several other neurodegenera-
tive disorders, including amyotrophic lateral sclerosis (ALS) and
Parkinson disease [10–13]. These studies have given rise to
a theory of neurodegenerative disease pathology relating to
reduced protein clearance [13–15].
The role of the γ-secretase complex is primarily thought to be
through its proteolytic activity and cleavage of target proteins
[2–4,16]. Here, PSEN proteins contain two key aspartic acid
residues necessary for the proteolytic activity of the complex in
cleaving a range of substrates including the amyloid-β and
NOTCH proteins [17]. However, the γ-secretase complex has
also been proposed to act through non-proteolytic scaffolding
functions in a variety of model organisms [18–24]. In mamma-
lian models, these functions include stabilizing the binding of
CTNNB1 and GSK3β, where Alzheimer disease causing muta-
tions result in reduced stability of CTNNB1 [18,19,25,26], and in
endoplasmic reticulum (ER) calcium regulation [27,28]. In
D. melanogaster, presenilin proteins have been found to mod-
ulate the levels of CREBBP (cyclic-AMP Response Element
Binding protein) independently of proteolytic activity [29].
A similar non-proteolytic function for presenilin proteins or
the γ-secretase complex has also been proposed in both
C. elegans [30] and the moss P. patens [20]. However, although
protease-independent functions of the γ-secretase complex have
been observed in evolutionarily diverse species, our understand-
ing of the mechanistic significance of these functions and rele-
vance to Alzheimer pathology remains limited.
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To better understand the role of the γ-secretase complex,
several studies have employed the social amoeba Dictyostelium
discoideum [22,31]. Dictyostelium contains orthologs of the core
components of the complex including two PSEN (presenilin)
proteins (psenA and B), Aph-1 and Ncstn [22,23,31]. In
Dictyostelium, the complex components play roles in multicel-
lular development, in cyclic AMP signalling and in intracellular
calcium release [22] as well as in phagocytosis [31]. Although
proteolytic targets(s) for the complex in Dictyostelium have not
been defined, Dictyostelium psenA and psenB proteins show
proteolytic activity in a Notch reporter assay [22]. In multi-
cellular development, psenB plays a non-proteolytic (scaffold)
function, since removal of the two key catalytic aspartic acids
(348 and 394) does not block the formation of mature fruiting
bodies. Furthermore, the roles of psenA and psenB proteins in
Dictyostelium development are also complemented using the
proteolytically inactive human PSEN1 protein, lacking the key
catalytic aspartic acids 257 and 385 [22]. These studies have
demonstrated the relevance of using Dictyostelium to examine
the cellular and developmental roles of presenilin proteins and
orthologs of other γ-secretase components.
Dictyostelium has been widely used as a model organism in
a range of cell and molecular studies, often enabling translation
to mammalian models [32,33]. It has been used in the study of
endosomal- and autophagy-lysosomal systems and related path-
ways where WASH is required for lysosomal recycling and both
autophagic and phagocytic digestion [34]; mucolipin is required
for lysosomal exocytosis [35]; myosin I is involved in membrane
recycling from early endosomes [36] as well as many other
discoveries [37–41]. Here we advance our understanding of the
role of the Dictyostelium orthologs of γ-secretase complex com-
ponents in endocytosis and autophagy by demonstrating that
these components are required for the efficient activity of these
processes. We further show that regulation of endocytosis and
autophagy activities occurs through a proteolysis-independent
mechanism, where these activities are conserved in the human
PSEN1 protein. We also show that loss of these proteolysis-
independent functions leads to an increase in large poly-
ubiquitinated autophagosome-like vesicles, demonstrating an
ancient and conserved non-proteolytic role of presenilin and
orthologs of other components of the γ-secretase complex in
proteostasis.
Results
Dictyostelium mutants lacking γ-secretase component
orthologs are unable to endocytose efficiently
Since the γ-secretase complex has been implicated in endocy-
tosis in mammalian model organisms [5,6,42], we initially set
out to investigate if orthologous components of this complex
also play roles in Dictyostelium macropinocytosis – the domi-
nant form of endocytosis and fluid-phase uptake in this
organism. In wild-type cells, uptake of TRITC-Dextran was
linear for 60 minutes and was therefore used to determine the
rate of macropinocytosis (Figure 1(a,b), Figure S1).
Macropinocytosis in the absence of the γ-secretase complex
orthologs was analysed through the use of stable isogenic cells
lacking Ncstn [22], Aph-1 or both presenilin proteins (psenA/
B [22]). We observed that loss of all three γ-secretase compo-
nent orthologs caused a 40–50% decrease in fluid-phase
uptake (Figure 1(c)), and this effect was not due to altered
exocytosis (Figure S2). These data suggest a role for the three
γ-secretase component orthologs in regulating endocytosis in
Dictyostelium.
A previous study has suggested that the Dictyostelium γ-
secretase complex shows both proteolytic and non-proteolytic
functions of psenB [22], thus we sought to distinguish these
roles in macropinocytosis. In these experiments, the
Dictyostelium psenB-GFP protein was expressed in PsenA−/
B− cells, in addition to a mutated version of the protein lacking
the two key aspartic acid residues necessary for proteolytic
activity (psenBDD-GFP) [22]. In both cases, wild type macro-
pinocytosis levels were restored (Figure 1(b,c)), suggesting that
this role of psenB is through a non-proteolytic function.
Furthermore, expression of the wild type (PSEN1-GFP) and
proteolytically inactive (PSEN1DD-GFP) human PSEN1 pro-
tein also rescued the macropinocytosis defect in PsenA−/B−
cells (Figure 1(b,c), Figure S1) demonstrating the evolutionary
conservation of this function, although expression of proteoly-
tically active PSEN1-GFP did not restore the macropinocytosis
defect in cells lacking Ncstn (Figure S3). These data suggest
that, in Dictyostelium, macropinocytosis was dependent upon
Aph-1, Ncstn and a non-proteolytic function of psenB.
Dictyostelium mutants lacking γ-secretase component
orthologs show pH-dependent development
Since nutrients ingested in macropinosomes are degraded by
fusion with lysosomes [43], and deficiencies in acidification
decrease endocytic rate [44] we next investigated a role for
orthologs of γ-secretase complex components in lysosomal acid-
ification. For these experiments, we initially employed
a qualitative development assay, where Dictyostelium mutants
with severe acidification defects are unable to form mature
fruiting bodies in neutral pH conditions [45]. We therefore
tested the ability of mutants lacking orthologs of γ-secretase
complex components to develop over 24 hours under neutral
(pH 7) and basic conditions (pH 9). In both conditions, wild type
cells were able to develop into mature fruiting bodies consisting
of a basal disk, a stalk, and a spore head. However, while Ncstn−
and Aph-1− cells were able to form fruiting bodies under neutral
conditions, both failed to develop at pH 9 (Figure 2(b), Figure
S4), consistent with defective lysosomal acidification. As
reported previously [22], PsenA−/B− cells were unable to develop
under neutral conditions showing more severe developmental
defects than Ncstn− or Aph-1− cells, halting at the mound stage,
but development was reduced further under basic conditions at
pH 9 (Figure 2(a)).
We then speculated that if the block in development of
PsenA−/B− cells at neutral pH was related to defects in lyso-
somal acidification, development may be restored by simply
reducing the extracellular pH. We therefore examined devel-
opment of PsenA−/B− cells at pH 5 [22,45]. While acidic
conditions had no observable effects on the development of
wild type cells the development of PsenA−/B− cells was par-
tially rescued, forming morphologically normal but smaller
sized fruiting bodies (Figure 2(c)). This rescue suggested that
1408 D. SHARMA ET AL.
the developmental defects observed are at least partly due to
defects in pH homeostasis, consistent with a role for the
Dictyostelium orthologs of γ-secretase complex components
in lysosomal acidification. However, the differences in the
developmental phenotype between PsenA−/B− cells and
Ncstn− or Aph-1− mutants indicate that psenA and psenB
proteins may also function through other independent roles
in Dictyostelium development.
Importantly, the development of PsenA−/B− cells was fully
rescued by expression of either proteolytically active or inactive
Dictyostelium psenB or human PSEN1 proteins (Figure S5)
[22] indicating a non-proteolytic role for these proteins in pH
regulation.
Dictyostelium mutants lacking orthologs of γ-secretase
components show defective lysosomal degradation
In order to directly test whether disruption of orthologs of the γ-
secretase complex components leads to defects in lysosomal activ-
ity, we measured the ability of mutant cells lacking these compo-
nents to degrade phagosomes. As a professional phagocyte,
Dictyostelium cells readily engulf extracellular particles into endo-
cytic vesicles which immediately fuse with lysosomes to be
degraded. We therefore utilised a simple assay measuring the
phagosomal proteolysis of beads coated with the self-quenching
dye DQ-BSA, which becomes fluorescent upon proteolysis
(Figure 3(a)) [46]. In this assay, we observed a significant decrease
in proteolysis upon loss of multiple Dictyostelium orthologs of γ-
secretase complex components. Ablation of Aph-1 or PsenA/B
caused a reduction in proteolysis activity to 41.4%±4.1% (p = 0.05)
and 42.1%+12.8% (p = 0.03) respectively relative to wild type cells
(Figure 3(b)). Upon expression of proteolytically active, or inac-
tive Dictyostelium psenB, relative proteolysis was restored to
78.9%±9.9% (p = 0.10) and 128.5%±25.1% (p = 0.36) and expres-
sion of active or inactive human PSEN1 resulted in a degradation
rate of 98.8%±12.6% (p = 1.00) and 120.8%±7.9% (p = 0.35). The
reduction in phagosomal proteolysis following loss of Aph-1 was
not restored by expression of human PSEN1 (Figure S6).
Although this assay does not distinguish between defective pha-
gosome-lysosome fusion and decreased lysosomal activity, these
data demonstrate that full degradative activity is dependent upon
the presence of Aph-1, and psenB functioning through a non-
proteolytic mechanism, and this activity is conserved in the
human PSEN1 protein.
Loss of γ-secretase components orthologs causes
defective autophagy
The degradation of intracellular components by autophagy is also
dependent on lysosomal activity. As autophagy is required for
normal development of Dictyostelium [37] and has been heavily
implicated in supressing the accumulation of mis-folded proteins
characteristic of Alzheimer and several other neurodegenerative
diseases [11,13,15,47,48], we next investigated the effects of loss of
orthologs of γ-secretase components on autophagy.
We first measured autophagosome acidification and degrada-
tion in mutant lacking Aph-1 and psenA/B activity. In these
experiments, we employed a fluorescent marker, GFP-Atg8,
which becomes lipidated and incorporated into the membrane
of nascent autophagosomes as they expand. Following comple-
tion, autophagosomes rapidly fuse with lysosomes and acidify –
quenching the luminal GFP fluorescence, while the exterior GFP-
Atg8 is removed [38,41]. In Dictyostelium cells this can be clearly
observed by microscopy and by quantifying the time required for
GFP quenching after autophagosome formation, where a rate of
Figure 1. Dictyostelium mutants lacking γ-secretase component orthologs are
unable to endocytose at wild type levels. Dictyostelium cells were shaken in
media containing fluorescent TRITC-Dextran, and fluorescence uptake was used
to monitor macropinocytosis over time, in wild-type cells, PsenA−/B−, Aph-1−
and Ncstn− cells, and PsenA−/B− following rescue by the proteolytic and non-
proteolytic human PSEN1 proteins (PsenA−/B−::PSEN1-GFP and PsenA−/B−::
PSEN1DD). (a) Representative images showing uptake of TRITC-Dextran by wild-
type cells over a 60-min period. Scale bar: 10μ m. (b) Quantification of macro-
pinocytosis over 60 min (±SEM). (c) Rate of macropinocytosis over 60 min (±SD).
Data are provided from at least three independent experiments with technical
duplicates. ++p > 0.01 to wild type, **p > 0.01 to PsenA−/B−.
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acidification can be defined for individual vesicles (Figure 3(c);
MovieS1) [38,41]. In wild type cells, GFP-Atg8 quenched in
35.3 ± 6.8 seconds (Figure 3(d)). In contrast, Aph-1− cells showed
significantly increased acidification time to 49.8 ± 6.8 seconds
(p < 0.001), and PsenA−/B− cells also significantly increased
quenching time to 46.4 ± 9.7 seconds (p < 0.001). The acidification
defect in PsenA−/B− cells was rescued upon expression of proteo-
lytically active versions ofDictyostelium psenB (32.2 ± 4.7 seconds)
as well as a proteolytically inactive version of the protein
(31.5 ± 6.5 seconds) suggesting this effect was mediated by non-
proteolytic functions of these proteins. The acidification defect in
PsenA−/B− cells was also rescued by both proteolytically active
and inactive versions of human PSEN1 protein (32.8 ± 6.4 and
28.8 ± 5.6 seconds respectively). Therefore, the defects in lysoso-
mal activity we observed upon disruption of Aph-1 and psenA/B
proteins also impact on autophagosome maturation, suggesting
an explanation for both the observed defects in Dictyostelium
development as well as cell pathology in the absence of these
proteins.
Alterations in the process of vesicle acidification have been
shown to regulate autophagy [15], in which cells recycle material
for energy. In Dictyostelium, interruption in the autophagic path-
way results in a decrease in the number and an increase in the size
of GFP-Atg8 labelled structures [34,38,49]. As a result, we mon-
itored their size and frequency in Aph-1− and PsenA−/B− cells for
signs of autophagic dysfunction. Wild type cells expressing GFP-
Atg8 show a majority of small (below 0.4μm) diameter structures
(79%), with very few structures above 0.8 μm (1.4%) representing
normal functioning autophagosomes (Figure 4(a,b). In Aph-1−
cells, a significant reduction was seen in the occurrence of small
structures to 26% (p < 0.01) and a significant increase in the
formation of large GFP-Atg8-positive structures, to 17%
(p < 0.05) typical of cells with reduced autophagy [37,39].
Similarly, PsenA−/B− cells also showed single large GFP-Atg8
structures. These data suggest that loss of Aph-1 and psenA/B
proteins caused autophagic dysfunction.
To test for the relevance of proteolytic activity in regulating
autophagic function, we again expressed both active and inactive
forms of both Dictyostelium psenB and human PSEN1 in
PsenA−/B− cells expressing GFP-Atg8. In these live-cell experi-
ments, fluorescence was primarily derived from GFP-Atg8
(Figure S7), rather than fluorescently labelled psenB, Aph-1
and Ncstn proteins that localize to the ER (Figure S8).
Expression of each form of presenilin rescued the ability of
cells to form numerous small GFP-Atg8 structures, confirming
this effect was related to loss of presenilin, again independent of
proteolytic activity, and with conserved function shown in the
human protein (Figure 4(a,b)).
Finally, we investigated a role for the Dictyostelium γ-secretase
component orthologs in autophagic degradation, by employing
a western blot approach to examine autophagic flux as indicated
by the cleavage of free GFP from GFP-Atg8 [50]. Comparing
wild-type cells with PsenA−/B− and Aph-1− cells expressing GFP-
Atg8, we measured the ratio of free GFP to total GFP-Atg8 in the
absence and presence of lysosomal protease inhibitors as
a measure of autophagic degradation. We showed that treatment
of wild-type cells with protease inhibitor significantly inhibited the
release of free GFP from GFP-Atg8 (p < 0.05) consistent with
reduced autophagic degradation (Figure 5(a,b)). Ablation of
psenA/B or Aph-1 resulted in a 39% and 49% decrease in the
ratio of free GFP:GFP-Atg8, which was not significantly changed
upon protease inhibitor treatment, suggesting a severe reduction
in autophagic flux in PsenA−/B− and Aph-1− cells. Expression of
the human PSEN1 in the PsenA−/B− cells restored wild-type
autophagic levels. These experiments confirm a role for psenA/B
and Aph-1 proteins in autophagic regulation and demonstrate
that this cellular function is conserved with the human PSEN1
protein.
Loss of γ-secretase components orthologs results in large
ubiquitin-positive structures
In Dictyostelium, large GFP-Atg8-positive structures typically
consist of high molecular weight ubiquitinated protein that
cannot be cleared when autophagy is impaired [39]. We there-
fore examined the colocalization of GFP-Atg8 with ubiquitin-
positive structures in the mutants lacking psenA/B and Aph-1
proteins. In wild type cells, the multiple small GFP-Atg8 puncta
Figure 2. Dictyostelium mutants lacking γ-secretase component orthologs are unable to development under varying pH conditions. The development of
Dictyostelium, through starvation over a 24-h period on nitrocellulose filters, leads to the formation of fruiting bodies consisting of round spore heads held aloft
by a stalk, and provides a qualitative approach to monitor development in mutants. (a) At pH 7 and pH 9, wild type cells are capable of normal multi-cellular
development forming fruiting bodies. In contrast, PsenA−/B− cells are unable to develop at pH 7, forming short variable structures, and development is further
inhibited at pH 9 where cells are unable to aggregate. (b) Aph-1− and Ncstn− cells form wild-type fruiting bodies at pH 7 but development is blocked at pH 9 (see
also Figure S4). (c) Under acidic conditions, pH 5, wild-type cells form morphologically normal fruiting bodies, and PsenA−/B− development is partially rescued,
showing the formation of small fruiting bodies with round spore heads and stalks, similar to that shown for wild-type cells. Images are representative of triplicate
experiments. Scale bar: 1 mm.
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that were observed did not contain ubiquitinated proteins
(Figure 6(a)). In contrast, the large GFP-Atg8-positive structures
observed following loss of the γ-secretase complex, in both Aph-
1− and PsenA−/B− cells, colocalized with ubiquitinated protein.
Figure 3. Dictyostelium mutants lacking γ-secretase component orthologs show
abnormal lysosomal activity. Phagosome degradation is quantified by monitoring
the increase in fluorescence of DQ-BSA-coated beads, taken up by phagocytosis,
which becomes unquenched upon hydrolysis. This approach was used to assess
in wild type cells, PsenA−/B−, and Aph-1− cells, and PsenA−/B− cells following
rescue by the proteolytic and non-proteolytic Dictyostelium psenB or the equiva-
lent human PSEN1 proteins (PsenB-GFP and PsenBDD-GFP or PSEN1-GFP and or
PSEN1DD-GFP) respectively. (a) Quantification of proteolysis shows loss of
a functional γ-secretase complex reduces phagolysosomal degradation, and this
is restored by proteolytically active or inactive human PSEN1, from quadruplicate
independent experiments (±SEM), which is reflected in (b) the rate of lysosomal
acidification in (±SD). +P < 0.05. (c) Dictyostelium cells exhibit puncta of GFP-Atg
8 that may be tracked (arrow) over time to determine the quenching time of GFP
due to acidification. (d) Quantification of GFP-Atg8 quenching time shows an
increase in the absence of a functional γ-secretase complex, and this is restored
by both Dictyostelium and human presenilin proteins (both proteolytically active
and inactive) (n = 25). +++p > 0.001 to wild type, ***p > 0.001 to PsenA−/B.
Figure 4. Dictyostelium mutants lacking γ-secretase component orthologs show
aberrant size and localisation of GFP-Atg8. Visualization of GFP-Atg8 localisation
in wild type cells, PsenA−/B− and Aph-1− and PsenA−/B− cells following rescue
by the proteolytic and non-proteolytic Dictyostelium psenB or the equivalent
human PSEN1 proteins (PsenB-GFP and PsenBDD-GFP or PSEN1-GFP and or
PSEN1DD-GFP) respectively. (a) Wild-type cells show multiple small and distrib-
uted GFP-Atg8-containing autophagosomes, whereas a single large punctum is
seen in a proportion of PsenA−/B− and Aph-1− cells, that is no longer observed
when cells are rescued following expression of Dictyostelium psenB orhuman
PSEN1 (proteolytically active or inactive). Scale bar: 10μ m. (b) Quantification of
the size of GFP-Atg8 -containing autophagosomes shows an increase in the
absence of a functional γ-secretase complex, and this is restored by both
Dictyostelium and human presenilin proteins (both proteolytically active and
inactive). Data are derived from triplicate experiments measuring approximately
50 cells per experiment. ‘+’ compares to Aph-1−, ‘*’compares to PsenA−/B−,
where * or + is P < 0.05, ** or ++ is P < 0.01, *** or +++ is P < 0.05.
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Rescue of this phenotype in the PsenA−/B− cells with both the
proteolytically active and inactive version of the Dictyostelium
PsenB and human PSEN1 proteins led to clearance of these
ubiquitinated structures.
We then confirmed the effect of the loss of psenA/B and
Aph-1 proteins on the accumulation of high molecular weight
ubiquitinated proteins by western blotting (Figure 6(b,c)).
Consistent with our results above, both the Aph-1− and
PsenA−/B− cells showed a significant increase in high mole-
cular weight ubiquitinated proteins (by 55% and 46% respec-
tively; p = 0.0002 and p = 0.0001 respectively) again
suggesting impaired protein degradation in these mutants.
Accumulation of high molecular weight ubiquitinated protein
Figure 5. Dictyostelium mutants lacking γ-secretase component orthologs show
decreased autophagic flux. Representative western blot analysis using an anti-
GFP antibody enables comparison of levels of free GFP to GFP-Atg8 in the
presence or absence of protease inhibitor (PI) treatment, allowing the compar-
ison of wild type, Aph-1−, and PsenA−/B− cell autophagic flux, and following
rescue by the proteolytically active human PSEN1 protein (PSEN1-GFP). (a) Levels
of free GFP are reduced in wild-type cells following PI treatment. In both Aph-1−
and PsenA−/B− cells, free GFP levels are reduced in the absence of PI, and
remain low following PI treatment. Expression of PSEN1-GFP in the PsenA−/B−
cells restores free GFP levels in untreated cells, and PI sensitivity. Endogenously
biotinylated mitochondrial protein MCCC1 was used as a loading control. (b)
Quantitation of free GFP to GFP-Atg8 ratios shows the absence of a functional γ-
secretase complex reduces autophagic flux, and this is restored by the human
PSEN1 protein. Data are derived from triplicate independent experiments
(±SEM). ‘*’ compares to wild type, ‘+’ compares to PsenA−/B−, where * or + is
P < 0.05, ** or ++ is P < 0.01; NS, not significant.
Figure 6. Dictyostelium mutants lacking γ-secretase component orthologs show
ubiquitination defects. Analysis of ubiquitination levels in wild-type cells, PsenA−/B−
and Aph-1− and PsenA−/B− cells following rescue by the proteolytic and non-
proteolytic Dictyostelium PsenB or the equivalent human PSEN1 proteins (PsenB-
GFP and PsenBDD-GFP or PSEN1-GFP and PSEN1DD-GFP) respectively. (a) In cells
expressing GFP-Atg8, immunofluorescence analysis shows co-localization of GFP and
ubiquitin in single large puncta in Aph-1− and PsenA−/B− cells that are absent in wild-
type cells, and are absent following rescue with the presenilin proteins. Scale bar:
10μ m. (b) Representative western blot analysis using anti-ubiquitin in the wild type,
mutants and following rescue as indicated. Anti-PDI was used as a loading control for
normalisation. (c) Quantification of anti-ubiquitin western blot shows a ~ 50%
increase in largemolecular weight ubiquitinated protein in cells lacking a functional γ-
secretase complex when compared to normalized wild type levels. This increase is
restored to wild type levels in PsenA−/B− cells expressing Dictyostelium PsenB or
human PSEN1 proteins regardless of proteolytic activity. Data are derived from 5
independent experiments.
1412 D. SHARMA ET AL.
was reversed by restoration of presenilin activity for both the
Dictyostelium psenB (wild type and proteolytically inactive)
and human PSEN1 (wild type and proteolytically inactive)
rescue strains (Figure 6(b)). Importantly, accumulation of
high molecular weight ubiquitinated protein indicated that
these presenilin proteins and Aph-1 are physiologically
important in maintaining basal autophagy levels and clearing
misfolded proteins in Dictyostelium. Furthermore the function
of these presenilin proteins are non-proteolytic and are con-
served between Dictyostelium and humans.
Discussion
In this study, we have shown that in Dictyostelium, orthologous
components of the γ-secretase complex have roles in macropi-
nocytosis, phagocytosis and autophagy, most likely through
mediating lysosomal acidification. Recent studies in mammalian
models of Alzheimer disease have investigated the role of these
components in vesicular trafficking [7,11,13,15,48,51–53], and
suggest that dysfunction of these processes may contribute to the
progression and pathology of Alzheimer disease. These studies
typically describe aberrant intracellular degradation as a result of
dysfunction of presenilin proteins, rather than the entirety of the
complex [5,42,51,52]. Here, we usedDictyostelium discoideum as
a model to investigate orthologous components of the γ-
secretase complex, taking advantage of the ability to delete
individual genes in stable isogenic cultures to monitor changes
in cell and developmental function, and to restore protein activ-
ity using wild type and proteolytically inactive presenilin pro-
teins to rescue mutant phenotypes [22,31]. Using these
approaches we show that in Dictyostelium, ablation of Ncstn,
Aph-1 or both psenA/B genes results in deficient endocytosis
and pH-dependent development, and loss of Aph-1 and psenA/
B proteins gives rise to defects in lysosomal acidification and
autophagy. We further show that these functions are dependent
on the non-proteolytic activity of the psenA/B proteins that are
conserved in the human PSEN1 protein.
We show that loss of Ncstn, Aph-1 or both psenA/B proteins
inhibits macropinocytosis, a process by which cells take up large
quantities of extracellular fluid. However, the exact mechanism
that drives and controls the process is not yet fully understood
[54]. Dictyostelium has proven to be an important model organ-
ism in macropinocytosis research and has led to a number of
related discoveries, including the role of RasS in maintaining
normal actin function in this process [55], the roles of phospha-
tidylinositol 3-kinases in macropinocytosis control [56], and the
role of WASH in macropinosome recycling [49,54]. Further,
both axeB/neurofibromin [57] and ndkC/nucleoside dipho-
sphate kinase C [58] function to negatively regulate macropino-
cytosis. In mammalian cells, a number of these key regulatory
pathways are conserved across evolution, including the function
of RAS proteins, phosphatidylinositol 3-kinases, F-actin and
WASH [49,59–61]. Our data now adds to this list, suggesting
that orthologous components of the γ-secretase complex are
necessary for optimal fluid uptake in Dictyostelium [55,57,62],
involving a non-proteolytic activity of psenB protein, and these
defects can be rescued by expression of a human PSEN1 protein.
These results are consistent with but extend those shown in
mammalian Alzheimer disease models, where loss of γ-
secretase function results in aberrant macropinocytosis [5,6],
and dysfunctional protein aggregate clearance for affected neu-
ronal cells [5,6,42,52].
After extracellular material has been internalized, vesicles
move through the intracellular endocytic pathway before
finally fusing with lysosomes for degradation of vesicular
material [63–65]. We show here, that Dictyostelium cells lack-
ing Ncstn, Aph-1 or both psenA/B proteins fail to develop
under basic pH conditions, consistent with that seen in other
mutants that are unable to appropriately acidify their vesicles
[45]. We then confirmed this role directly, by measuring
autophagosome acidification, phagosome proteolysis [34,41]
and autophagic flux in cells lacking Aph-1 or both psenA/B
proteins. In mammalian models, dysfunctional lysosomal pH
regulation has been linked to Alzheimer disease [66], in addi-
tion to other disease such as Pompe [67] and Niemann-Pick
disease [68], as well as cholesterol uptake, and atherosclero-
sis – all resulting in inefficient degradation of intra-endosome
material. In regard to Alzheimer disease, presenilin proteins
have been implicated in a non-proteolytic, complex-
independent role in maintaining lysosomal pH [15,51,52].
These studies suggest that presenilin regulates lysosomal pH
through vacuolar-ATPase-mediated lysosomal acidification,
resulting in altered calcium levels [51]. In Dictyostelium, we
have shown that Ncstn, Aph-1 and psenA/B proteins are
localized in the endoplasmic reticulum and this localization
is unaltered in the absence of other complex components
(Figure S8), consistent with that shown for Vmp1 involved
with lysosomal function and autophagy [39] and a role of the
complex in interacting with v-ATPase proteins for vesicle
acidification and lysosomal activity. It is important to note
here that our data do not explicitly link macropinocytosis and
acidification defects, and further studies will need to investi-
gate this in detail.
Previous research in Dictyostelium suggested that the γ-
secretase complex is important for phagocytosis, and that this
process is dependent upon proteolytic activity [31]. Our study
confirms the role of Aph-1 and psenA/B proteins in phago-
cytosis, but demonstrates that it is not reliant upon proteolytic
activity [22]. These data quantify the loss of (phago-)lysoso-
mal proteolysis in cells lacking the orthologs of multiple γ-
secretase complex components, and together with data on
macropinocytosis, suggest that material ingested through
both processes are unlikely to be efficiently degraded, and
these effects are commonly observed in cellular models for
Alzheimer disease [5,6,66].
Another cellular process dependent upon lysosomal degra-
dation is autophagy [69]. Dictyostelium has been widely used to
investigate autophagy and the importance of autophagy, and its
role in multicellular development [40]. Here we show that cells
lacking psenA/B or Aph-1 proteins share a number of pheno-
types with autophagy dysfunctional mutants, including defec-
tive GFP-Atg8 localization [37,39], co-localisation between
GFP-Atg8 and ubiquitin aggregates [39], and an abundance of
high molecular weight ubiquitinated protein [39,70], reduced
AUTOPHAGY 1413
autophagic flux, and aberrant development. These data demon-
strate that orthologs of multiple γ-secretase complex compo-
nents play a key role in the autophagic process in Dictyostelium.
Consistent with this, neurons of patients diagnosed with
Alzheimer disease also accumulate neurotoxic peptides due to
inefficient lysosomal acidification and a resultant build-up of
autophagosomes rich in amyloid precursor protein [7,8,52]. We
further show that, in Dictyostelium, this deficiency in autophagy
and accumulation of ubiquitinated proteins is not caused by loss
of psenB proteolytic activity, and this activity can be fulfilled by
the human PSEN1 protein [7,51].
In this study, we demonstrate that the Dictyostelium ortho-
logs of γ-secretase complex components play a key role in
regulating macropinocytosis, phagocytosis, acidification of
lysosomal vesicles, and autophagy. The reduction of these
activities following the loss of two (psenA/B and Aph-1) or
three (psenA/B, Aph-1 and Ncstn) orthologs of γ-secretase
complex components suggest that these phenotypes may be
regulated by a Dictyostelium γ-secretase complex, but we
cannot explicitly demonstrate that these roles are not inde-
pendent. Similarly, the interrelatedness of these cellular func-
tion is also consistent with a common role for a Dictyostelium
γ-secretase complex in this process, and that this function is
not dependent on the proteolytic activity of the putative γ-
secretase complex. Finally, we demonstrate that these roles of
the psenA/B proteins can be rescued in Dictyostelium through
expression of human PSEN1. Thus we propose that, in
Dictyostelium, an orthologous γ-secretase complex plays
a key role in maintaining endocytosis, lysosomal trafficking
and autophagy through a non-proteolytic function, conserved
between Dictyostelium and humans across the vast evolution-
ary gap that separates these two organisms.
Materials and methods
Cell culture and maintenance
Dictyostelium wild type strain Ax2 were grown in HL5 med-
ium (Formedium, HLB0103) supplemented with 10% glucose
(Sigma-Aldrich, G8270). PsenA−/B− cells and rescue strains,
and Ncstn− cells have been previously described [22], and are
maintained in HL5 medium supplemented with/without 10
μg/ml hygromycin (Formedium, HYG1000).
Plasmid construction and transformation
Aph-1− mutant cells were generated by homologous integra-
tion using the Cre-Lox system [71].
Briefly, a knockout vector was designed consisting of a 5ʹ
and 3ʹ arm of homology (primers:
GTG GAT CCT ATA AGT ATT TTA AAG ATT/AAC
TGC AGA GAT ATT TAA AAA TGT TTC TTA CC and
TTA TTC CAT GGA GTT TAT AAC GTT TT/AAT GGT
ACC TTG ATA ATG TTA AAA TGA) in order to ablate
a central 762 base pair region of the gene. The linearized
vector was electroporated into wild-type Dictyostelium cells,
and transformants were screened by PCR in order to identify
homologous recombinants [72].
Macropinocytosis and exocytosis assay
Rate of TRITC-Dextran uptake was measured as described
previously [62]. Briefly, 2.5 × 107 cells were resuspended in
5 ml of HL5 medium supplemented with 100 μl or 100 mg/ml
TRITC-Dextran (Sigma-Aldirch, T1162). At time points 0, 15,
30, 45, 60, 90, and 120 min, 500 μl of this suspension was
removed, washed in phosphate buffer and measured on
a Perkin Elmer LS50B spectrophotometer. Relative change in
fluorescence was calculated and normalised against total pro-
tein content of each respective cell line. The rate of uptake was
measured using the linear function in GraphPad Prism.
To determine whether efflux was also affected by γ-
secretase ablation a simple assay was utilised [73]. Briefly,
2.5 × 107 cells were incubated in HL-5 with 100 mg/ml
TRITC-Dextran for a period of 3 h. Following incubation,
cells were washed and resuspended in 5 ml of phosphate
buffer before shaking incubation. At time points 0, 15, 30,
45, 60, 90 and 120 min 500 μl of the suspension was removed
and the fluorescence measured. Change in fluorescence was
calculated relative to the measurement at time point 0 min of
each respective cell line. The rate of efflux was calculated
using GraphPad Prism.
Dictyostelium development at varying pH
In these assays, 1 × 107 cells were plated and allowed to develop
on 47mm nitrocellulose filters (Millipore, HAWP04700) over
24 h [74]. Each filter was placed on an absorbent 3M paper pad
(Millipore, AP1004700) soaked in phosphate buffer of varying
pH. Phosphate buffer was prepared using varying amounts of
KH2PO4 and K2HPO4 to modulate pH without altering ionic
strength. Subsequent developmental phenotypes were imaged
using a dissection microscope (Leica) and a QICAM FAST 1394
camera (QImaging).
Fluorescence microscopy and quantification
Cells were imaged on an Olympus IX71 wide-field fluores-
cence microscope. Images were captured using a QICAM
FAST 1394 camera. For measurement of Atg8-positive struc-
ture size cells were analysed using ImageJ [75] and cell size
was measured across the largest diameter. More than 100
GFP-Atg8 positive structures were measured, using around
50 cells per experiment including at least three independent
experimental repeats. For live-cell imaging, cells were imaged
under a layer of ~1.5-mm thick 1% phosphate buffered agar-
ose [49].
Analysis of autophagosome maturation
The autophagy reporter GFP-Atg8 was expressed in cells
using the extrachromosomal expression plasmid pDM430
[38]. To both reduce the movement of vesicles in the
Z-plane and stimulate autophagosome formation cells were
compressed under a thin layer of 1% agarose in HL-5 medium
as previously described [38]. Cells were seeded in glass-
bottomed microscopy dishes before removal of most of the
medium, application of a ~ 2-mm thick agarose slab and
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compression by blotting with paper and capillary action. After
10 min, images were captured using a Perkin-Elmer Ultraview
VoX inverted spinning disc microscope, using a 100 × 1.4NA
objective and Hammamatsu C9100-50 EM-CCD camera. 4
Z planes at 1μM spacing were captured every 2 s. The point
of autophagosome completion was determined by the char-
acteristic enlargement and diming of GFP fluorescence [41].
The time until GFP-fluorescence was undetectable was subse-
quently measured from randomised, blinded movies captured
from at least three independent experiments.
Phagosomal proteolysis assays
Phagosomal proteolytic activity was measured by feeding cells
DQgreen/Alexa Fluor 594 (DQ-BSA; Invitrogen, D12050) co-
labelled 3-μm silica beads (Kisker Biotech, PSI-3.0COOH) as
previously described [76]. Briefly 3 × 105 cells/well were
seeded in a 96-well plate before addition of beads, and fluor-
escence measured on a plate reader each minute in triplicate.
Proteolysis was normalised to Alexa Fluor 594 fluorescence,
over time to account for potential differences in bead uptake
and rates normalized to wild-type cells to calculate relative
activity.
Western blotting and immunofluorescence
Analysis of high molecular weight ubiquitinated protein was
carried out by western blot as previously described [70].
Briefly, the proteins of 2 × 105 cells were separated by SDS
gel electrophoresis and the membrane was probed with α-PDI
[77] (an ER marker protein, disulfide isomerase a kind gift
from Annette Muller-Taübenberger) as a loading control and
α-ubiquitin (Cell Signalling Technology, P4D1) at 1:50, and
1:1000 dilutions, respectively. Relative amounts of high mole-
cular weight ubiquitinated protein were calculated using
Image Studio Lite (LI-COR Biosciences) and these were nor-
malized against wild-type levels of ubiquitinated protein.
For colocalization of ubiquitin and GFP-Atg8, cells were
fixed in −80°C methanol as previously described [78]. After
fixation cells were probed with α-GFP (Chromotek, 3H9) and
anti-ubiquitin (New England Biolabs, 3936S) antibodies at
1:500 and 1:200 dilution concentrations, secondary antibodies
used were anti-rat Alexa Fluor 488 and anti-mouse Alexa
Fluor 350 (Life Technologies, A-21,210 and A-31,552 respec-
tively) at 1:1000 concentration dilutions. Cells were then
imaged to visualise colocalization between ubiquitin and GFP-
Atg8-positive structures.
To analyze autophagic flux a western blot based approach
was utilised [50]. Briefly, 1.3 × 106 cells were seeded in a 6
well plate before treatment with protease inhibitors (Roche
Life Science, 05892791001) for 1 h, when cells were harvested
and proteins extracted. Western blots were probed with an
anti-GFP antibody (1:1000 dilution) and levels of the endo-
genously biotinyated mitochondrial protein MCCC1 detected
with a streptavidin-conjugated antibody used as a loading
control [79] (Thermo Fisher Scientific, S21378). The
fluorescent ratio of free GFP to GFP-Atg8 was calculated to
determine a measure of autophagic flux.
To visualize Dictyostelium γ-secretase components locali-
zation, cells were fixed using 80°C methanol [78] and probed
with antibodies. Briefly, cells overexpressing GFP-tagged com-
ponents were seeded onto coverslips and fixed by submerging
in −80°C methanol for 30 min. Following fixation, cells were
washed in room temperature phosphate-buffered saline,
stained with anti-GFP and anti-crtA (calreticulin) antibodies
(a kind gift from Annette Muller-Taübenberger), subse-
quently stained with appropriate secondary antibodies to
allow for ER visualization, and nuclei were stained with DAPI.
Statistical analysis
Statistical analysis depended upon the data analyzed. For
normally distributed data a two-way ANOVA was utilised
when comparing multiple data groups to each other. For
data that is not normally distributed the Mann-Whitney test
was used, and for data that was compared to a single normal-
ised mean value a one sample T-test was used. Statistical
analysis was carried out using GraphPad Prism Software.
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Background and Purpose: Epidiolex™, a form of highly purified cannabidiol (CBD)
derived from Cannabis plants, has demonstrated seizure control activity in patients
with Dravet syndrome, without a fully elucidated mechanism of action. We have
employed an unbiased approach to investigate this mechanism at a cellular level.
Experimental Approach: We use a tractable biomedical model organism,
Dictyostelium, to identify a protein controlling the effect of CBD and characterize this
mechanism. We then translate these results to a Dravet syndrome mouse model and
an acute in vitro seizure model.
Key Results: CBD activity is partially dependent upon the mitochondrial glycine
cleavage system component, GcvH1 in Dictyostelium, orthologous to the human
glycine cleavage system component H protein, which is functionally linked to folate
one-carbon metabolism (FOCM). Analysis of FOCM components identified a
mechanism for CBD in directly inhibiting methionine synthesis. Analysis of brain
tissue from a Dravet syndrome mouse model also showed drastically altered levels of
one-carbon components including methionine, and an in vitro rat seizure model
showed an elevated level of methionine that is attenuated following CBD treatment.
Conclusions and Implications: Our results suggest a novel mechanism for CBD in the
regulating methionine levels and identify altered one-carbon metabolism in Dravet
syndrome and seizure activity.
Abbreviations: 5mTHF, 50methyl THF; bsR, blasticidin S deaminase; CBD, cannabidiol;
FOCM, folate one-carbon metabolism; GCS, glycine cleavage system; GCSH, human glycine
cleavage system component H; GCVH1, Dictyostelium glycine cleavage system component
H1; THF, tetrahydrofolate.
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1 | INTRODUCTION
The use of Cannabis extracts as a medicinal treatment has been
recorded for nearly 2,000 years (BRAND & ZHAO, 2017), covering a
range of disorders including pain management, multiple sclerosis, and
epilepsy (Devinsky et al., 2014). Of the ~100 cannabinoids found
within, or derived from, Cannabis species, cannabidiol (CBD) is among
the most abundant of the non-psychoactive cannabinoids and has
received considerable interest as a therapeutic treatment (Jones et al.,
2010; Jones et al., 2012). CBD has been shown to provide
antiepileptiform and anti-seizure properties within numerous in vitro
and in vivo mammalian epilepsy models (Jones et al., 2012; Klein et
al., 2017). CBD is also used as a lead cannabinoid-based treatment for
severe epilepsies such as Dravet syndrome (Devinsky et al., 2017) and
Lennox–Gastaut syndrome (Devinsky et al., 2018; Thiele et al., 2018).
A range of targets for CBD in seizure control have also been identi-
fied, including glycine receptors (Xiong et al., 2012), GPR55 (Kaplan,
Stella, Catterall, & Westenbroek, 2017), NMDA receptors (Rodriguez-
munoz, Onetti, Cortes-Montero, Garzon, & Sanchez-Blazquez, 2018),
transient receptor potential of vanilloid type-1 channels (Vilela et al.,
2017) and voltage-dependent anion selective channels (Rimmerman
et al., 2013).
The cell and molecular basis of epilepsy and seizures is
well-accepted to be related to electrical signalling and ion channel
activity; however, a range of models have suggested that deregula-
tion of several key amino acids is also involved in, or associated
with, seizures and epilepsy (Bejarano & Rodriguez-navarro, 2015;
Gupta et al., 2004). For example, numerous studies have proposed
altered mitochondrial function in epilepsy pathology (Doccini et al.,
2015; Kumar et al., 2016; Panneman, Smeitink, & Rodenburg, 2018;
Pearson-smith, Liang, Rowley, Day, & Patel, 2017). Mitochondria
contain the glycine cleavage system (GCS) that is responsible for
regulation of glycine levels (Kikuchi & Hiraga, 1982) subsequently
controlling numerous functions including protein synthesis and
neurotransmission (Kolker, 2018). The GCS also plays a role in
providing glycine-derived one-carbon units into the folate one-
carbon metabolism (FOCM), leading through folate-containing inter-
mediates, to production of methionine from homocysteine (Ducker
& Rabinowitz, 2017). Isotope labelling has directly demonstrated 1C
donation from glycine to FOCM in humans and mice in vivo
(Lamers et al., 2009; Leung et al., 2017). Methionine fulfils a funda-
mentally important role in protein synthesis and as a precursor to S-
adenosyl methionine (SAM) that is responsible for the transfer of a
methyl group to a number of acceptor molecules including
neurotransmitters and DNA methyltransferases (Moore, Le, & Fan,
2013). SAM is further hydrolysed to form adenosine and
homocysteine which can again be converted into methionine or
instead into cysteine. These various metabolites and amino acids
have been described as “primordial” metabolites (Boison, 2016),
suggested to provide the original components for the beginning of
life, and are thus highly conserved across many species. In addition,
many of these components are regulated by mitochondrial function
and relate to energy production, where both have been proposed as
mechanistic targets for cannabinoids (Bénard et al., 2012).
Understanding the molecular mechanisms of newly developed
medicines provides an important aspect of validation, where simple
biomedical model systems such as the social amoeba Dictyostelium
discoideum have proved effective (Cunliffe et al., 2015; Warren,
What is already known
• CBD, a key constituent of Epidiolex™, is effective in the
treatment of specific drug-resistant epilepsies.
• A full understanding of mechanisms for CBD-dependent
s eizure control remains to be established.
What does this study add
• We identified a molecular mechanisms of CBD in regulat-
ing the one-carbon cycle components including
methionine.
• We show one-carbon cycle components are deregulated
in a Dravet model and during seizure-like activity.
What is the clinical significance
• Our data will increase clinical focus on one-carbon
metabolism in epilepsy and other CBD-treatable
disorders.
• Clinical studies relating to Dravet syndrome, in particular,
will benefit from monitoring one-carbon signalling.
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Walker, & Williams, 2018). D. discoideum is a eukaryote more
evolutionarily related to animals than to plants and bacteria
that possesses a range of highly conserved signalling pathways
and proteins that have been linked to human diseases
(Müller-taubenberger, Kortholt, & Eichinger, 2013). It exists in both
a single cell stage, where cells divide by binary division, and a
multicellular stage induced by starvation leading to the formation of
small (~1 mm tall) fruiting bodies. Using D. discoideum, insertional
mutant libraries have been employed to identify genes controlling
the effect of a natural product or medicinal treatment (Cocorocchio
et al., 2018; Waheed et al., 2014), including treatments for epilepsy
(Chang et al., 2012; Warren et al., 2018) and bipolar disorder
(Kelly, Sharma, Wilkinson, & Williams, 2018; Williams, Cheng,
Mudge, & Harwood, 2002). In many of these studies, discoveries
based in D. discoideum have been subsequently validated in
mammalian models (Chang et al., 2013; Chang et al., 2015; Chang,
Walker, & Williams, 2014; Waheed et al., 2014). Thus, employing
D. discoideum to investigate the cellular mechanisms of CBD may
provide a suitable, innovative approach to identify therapeutic
mechanisms of this important cannabinoid.
In the initial phase of this study, we used D. discoideum to better
understand the molecular mechanism of CBD. We show that CBD
affects D. discoideum cell proliferation and by performing an unbiased
genome wide screen, we identify a role for the mitochondrial GCS
component, GCVH1, homologous to the human protein GSCH in this
effect. Analysis of glycine, one-carbon cycle intermediates
(methionine and cysteine), and folates confirmed a role for GCVH1 in
regulating these components through attenuating activity of the GCS
and suggested a novel molecular mechanism of CBD through
inhibition of methionine synthase activity. We then examined the
regulation of one-carbon-related amino acids in the brain of a mouse
model of Dravet syndrome (Scn1A+/−), a CBD responsive condition in
humans (Thiele et al., 2018), and identified altered levels of glycine,
methionine, and cysteine, implicating dysregulation of one-carbon
metabolism in this disease. Moreover, methionine levels were altered
in this model following chronic CBD treatment. We finally
investigated this effect using an in vitro mammalian model of seizure
activity, where methionine levels were shown to rapidly increase
during seizure activity and this increase was corrected by CBD
treatment.
2 | METHODS
2.1 | D. discoideum growth assay
D. discoideum cell lines grown in HL5 medium on a 10-cm dish
were plated onto a 24-well plate at 5 × 103 cells per well in
495 μl of media (HL5, Formedia, UK). For each well, 5 μl of CBD
from 100-mM stock in DMSO was added to achieve final
concentrations ranging from 0- to 20-μM CBD (DMSO made up
1% of final volume). Cells were maintained at 22C, counted after
72 hr (lag phase), and then every 24 hr. These data are presented
as normalized (fold change from control [untreated, Day 7]) to
correct for variation between independent experiments. Each
concentration was analysed using at least six independent
experiments, where rate of exponential cell growth (Days 4 to 6) at
each concentration was used to create secondary plots
(concentration–response curves), providing IC50 values for each cell
type (wild type, mutants, and rescue lines), determined using
non-linear regression analysis.
2.2 | D. discoideum development assay
Wild-type D. discoideum cells in the exponential phase of growth were
washed in KK2 buffer (16.2-mM KH2PO4, 4-mM K2HPO4) and
1 × 107 cells placed onto a nitrocellulose filter (Millipore, Cork).
Absorbent pads (Millipore, Cork) were placed in 2-ml culture dishes
and soaked with 0.5-ml KK2 buffer containing CBD from 100-mM
stock in DMSO to achieve a final concentration of 20 μM (DMSO
made up 1% of final volume). Nitrocellulose filters and cells were
placed upon absorbent pads and maintained in a humid environment
at 22C for 24 hr. Fruiting body morphology was recorded using a
dissection microscope and camera.
2.3 | Restriction enzyme-mediated integration
screen
A mutant library containing approximately 5,000 insertional
mutants was created by restriction enzyme-mediated integration.
Library cells taken from the exponential growth phase were
screened for resistance to 9.47-μM CBD (80% inhibitory concen-
tration) taken from 100-mM stock in DMSO. Cells were maintained
at 22C and screened over a 3-week period, with the media rep-
laced every 2 days. Resistant mutants were isolated, and isogenic
strains created. Location of the blasticidin S deaminase (bsR) inser-
tion was identified using whole-genome next-generation sequenc-
ing (NGS).
2.4 | NGS analysis
Five hundred-nanogram DNA was fragmented on the Covaris S2 to
a target size of 300 bp (intensity: 4, duty cycle: 10%, cycles-per-
burst: 200, time: 80 s). A library was then prepared using the NEB
DNA Ultra II kit (New England Biolabs, E7645), with bead selection
for 300- to 400-bp fragments and five cycles of PCR. Sequencing
was performed by UCL Genomics on an Illumina NextSeq 500,
using a 150-bp paired-end protocol. NGS assemblies were per-
formed using Sequencher software (RRID:SCR_001528), using Vel-
vet (Zerbino & Birney, 2008) for de novo assembly, or GSNAP
(RRID:SCR_005483) for bsR-cassette-guided assembly, to reveal the
sites of bsR-cassette insertions in the D. discoideum genome using
BLAST searches (RRID:SCR_001653).
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2.5 | Creation of gcvH1− cell line and
overexpression cell lines
In order to recapitulate the resistance seen in the insertional gcvH1−
mutant, a gcvH1− cell line was created via homologous recombination.
Primers to both the 50 and 30 region of gcvH1 were used to amplify
PCR products for both regions (Figure S1). A 281-bp fragment was
amplified from the 50 region, while a 343-bp fragment was amplified
of the 30 region (Figure S1). Both fragments were ligated into the
pLPBLP plasmid flanking the bsR gene with their reading frames in
opposite orientation to bsR. A knockout cassette consisting of bsR
and the flanking gcvH1 fragments was created by a SpeI/KpnI
restriction digest. Wild-type cells were transformed with the digested
plasmid by electroporation. Transformants were selected by growing
in liquid medium containing 10 μgml−1 blasticidin and screened for
homologous recombinants. Primers were designed that would
produce diagnostic knockout fragments unique to the homologously
integrated transformants, as well as the necessary controls (Figure S1).
To create a gcvH1 overexpression plasmid (Figure S1), the gcvH1
cDNA was cloned into an extra-chromosomal vector (Fischer et al.,
2004), enabling expression of the 42-kDa fluorescently labelled
protein (Figure S2). The PCR product was digested with EcoRI and
BamHI and then ligated into the extra-chromosomal plasmid pDXA-
389-2 and sequenced to confirm that no mutations were introduced.
The resulting plasmid was transformed into gcvH1− cells and selected
using geneticin (10 mgml−1) to create an overexpression cell line. A
cDNA encoding the Homo sapiens orthologue human glycine cleavage
system component H (GCSH) was codon optimized for D. discoideum
and amplified using primers 11 + 12. This was also inserted into
pDXA-389-2 and a further overexpression cell line was created that
overexpresses the human GCSH cDNA. In both cases, the
recombinant proteins were tagged with RFP at the C-terminus.
2.6 | Analysis of D. discoideum gcvH1 and
H. sapiens GCSH expression by RT-PCR
Total RNA was extracted from cell lines using an RNeasy mini-kit
(Qiagen). cDNA was synthesized from total RNA treated with DNase
(Life Technologies) using a first-strand cDNA synthesis kit (Thermo
Scientific). Gene expression was confirmed via RT-PCR using the
primers 13 + 14 for the D. discoideum gene and primers 15 + 16 for
the H. sapiens gene. A control was used based upon the constitutive
expression of the Ig7 housekeeping gene using primers 17 + 18.
2.7 | Western blot analysis to confirm the
presence of RFP fusion proteins in the overexpression
cell lines
Cell lysates from cell lines were separated by gel electrophoresis,
transferred to nitrocellulose membranes (Merck Millipore,
IPFL00010), and analysed by Western blotting. A mouse anti-RFP
primary antibody (Chromotek, 6G6 anti-RFP, 1:1,000) and a goat
anti-mouse secondary antibody (Li-Cor goat anti-mouse IRDye®,
1:1,000) were used to confirm the presence of RFP. A conjugated
anti-streptavidin antibody (Invitrogen, Streptavidin Alexa Fluor 680
conjugate) was used as a loading control. Blots were analysed using
Odyssey software.
2.8 | Fluorescence and live-cell microscopy
The immuno-related procedures used comply with the recommenda-
tions made by the British Journal of Pharmacology (Alexander et al.,
2018). For immunolabelling, gcvH1− cells, expressing either D. dis-
coideum gcvH1-RFP or H. sapiens GCSH-RFP, were plated on round
12-mm glass coverslips and after 20 min were fixed with 15% picric
acid/2% paraformaldehyde in 10-mM PIPES, pH 6.0, for 20 min and
postfixed with 70% ethanol for 10 min. Cells were then washed three
times in PBS, once with 10-mM PIPES and twice with PBS/1%
glycine, and incubated in blocking buffer (PBS plus 2% BSA) for 1 hr
at room temperature (RT). After blocking, the cells were washed three
times with PBS and incubated with primary antibodies for 2 hr at RT,
followed by the incubation with secondary antibodies and DAPI, to
stain DNA, for 1 hr at RT. After immunostaining, samples were
washed three times in PBS and embedded using Dako mounting
medium (Agilent Technologies). For visualization of filamentous actin,
cells were stained with Atto 488-phalloidin (Sigma Aldrich). In order to
visualize mitochondrial porin, cells were stained with mouse
monoclonal anti-porin antibodies (70-100-1; Troll et al., 1993), and
Alexa 488-conjugated goat anti-mouse IgG. DNA was visualized by
staining with DAPI. For live-cell microscopy, cells were seeded in
μ-dishes (Ibidi, Germany) or open chambers as described previously
(Fischer, Haase, Simmeth, Gerisch, & Muller-Taubenberger, 2004).
Confocal microscopy was performed at the Bioimaging core
facility of the Biomedical Center (LMU Munich) using an inverted
Leica TCS SP8 equipped with lasers for 405-, 488-, 552-, and 638-nm
excitation. Images were acquired with an HC PL APO 63×/1.40 oil
PH3 objective. Recording was sequentially to avoid bleed through.
Atto-488 and Alexa-488 and RFP were recorded with the hybrid
photo detectors and DAPI with the conventional photomultiplier
tube.
2.9 | Amino acid analysis by GC–MS
GC–MS analysis of amino acid levels within either cell lysate or brain
tissue was adapted from an earlier study (Svagera, Hanzlikova, Simek,
& Husek, 2012), where 40 μl of sample (cell lysate or plasma) was
spiked with 10 μl of DL-4-chlorophenylalanine (internal standard)
followed by 10 μl of the reducing agent Tris(3-hydroxypropyl)phos-
phine (0.5% w/v in water). Samples were gently mixed and left to
stand for 1 min before adding 40-μl trichloroacetic acid (0.6 M in
water), vortexed twice, and samples centrifuged at 3,000 g for 10 min.
Using 80 μl of supernatant, in a clean glass culture tube, 40 μl of a 3:1
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1-propanol:pyridine mixture was added, followed by 130 μl of a
reactive mixture containing a 10:3:1 mix of 2,2,4-trimethylpentane,
butyl acetate, and propyl chloroformate. Samples were vortexed for
30 s and centrifuged at 3,000 g for 10 s, and the upper organic phase
removed and used in GC–MS analysis. GC–MS was carried out on an
HP5890 Series II chromatograph interfaced to an HP5972 MSD mass
spectrometer; 2-μl samples were injected in splitless mode (injector
temp 240C, purge delay 1.0 min) on a J&W DB5 column or Abel AB-
5MS (30 m × 0.25 mm dia × 0.25 μ film) using helium as the carrier
gas at constant flow of 30 cms−1. The column oven was programmed
from 90C (2 min) to 300C at 7.5Cmin−1, the GC–MS interface
temperature was 300C. Retention times and mass spectra of deriva-
tives of amino acids were determined in TIC mode and confirmed to
be in agreement with library and literature data. Quantitative analysis
was carried out in SIM mode using 4-chlorophenylalanine as internal
standard. Chromatograms were integrated using MZmine (RRID:SCR_
012040) or manually using Agilent MSD Chemstation to yield peak
areas of amino acid derivatives relative to that from the internal stan-
dard, and peak areas were processed using Prism software (RRID:
SCR_005375). To ensure unbiased analysis, samples were blinded and
randomized prior to quantification. Samples size was estimated using
data from a similar technique, where calculations with an observed
effect of ≥20% suggested group size should be up to nine to observe
an effect.
2.10 | Treatment of D. discoideum with CBD for
folate and amino acid (GC–MS and NMR) analysis
Cells (5 × 106 cells) in the exponential phase of growth were plated
onto a 10-cm tissue culture dish in 10 ml of HL5 medium. Cells were
allowed to adhere for 30 min, and then the medium was replaced con-
taining 1.89-μM CBD from 100-mM stock in DMSO. Plates were
maintained at 22C for 12 hr. Following the 12-hr incubation, cells
were washed three times with KK2 buffer (16.2-mM KH2PO4, 4-mM
K2HPO4), pelleted, and stored at −80C. Prior to GC–MS analysis,
200 μl of sterile KK2 buffer with protease inhibitors was added to
samples, which were briefly vortexed and subjected to five freeze
thaw cycles from −80C to 30C. Samples were centrifuged at
5,000 g for 5 min and the cell lysate collected. The cell lysate was
further centrifuged at 21,000 g for 10 min and the lysate collected for
GC–MS analysis. To ensure unbiased analysis, samples were blinded
and randomized prior to quantification.
2.11 | Quantification of folate-mediated one-
carbon metabolism intermediates by MS
Analysis of multiple folates was performed by UPLC–MS/MS as
described previously (Leung et al., 2017; Pai et al., 2015). Buffer con-
taining 20-mM ammonia acetate, 0.1% ascorbic acid, 0.1% citric acid,
and 100-mM DTT at pH 7 was added to cell pellets. Cell suspensions
were sonicated for 10 s using a hand-held sonicator at 40% amplitude
on ice. Protein was removed by precipitation with addition of two
volumes of acetonitrile, mixing for 2 min and centrifugation for
15 min at 12,000 g and 4C. Supernatants were transferred to fresh
tubes, lyophilized, and stored at −80C prior to analysis.
Lyophilized blinded samples were resuspended in 30-μl water
(Milli-Q) and centrifuged for 5 min at 12,000 g at 4C.
Supernatants were transferred to glass sample vials for UPLC–
MS/MS analysis. Metabolites were resolved by reversed-phase
chromatography using Acquity UPLC BEH C18 column
(50 mm × 2.1 mm; 1.7-μm bead size, Waters Corporation, UK).
Solvents for UPLC were buffer A, 5% methanol, 95% Milli-Q water,
and 5-mM dimethylhexylamine at pH 8.0; buffer B, 100% methanol.
The column was equilibrated with 95% buffer A: 5% buffer B. The
sample injection volume was 25 μl. The UPLC protocol consisted of
95% buffer A: 5% buffer B for 1 min, followed by a gradient of
5–60% buffer B over 9 min and then 100% buffer B for 6 min
before re-equilibration for 4 min. The metabolites were eluted at a
flow rate of 500 nlmin−1. The UPLC was coupled to a XEVO-TQS
mass spectrometer (Waters Corporation, UK) operating in
negative-ion mode using the following settings: capillary 2.5 kV,
source temperature 150C, desolvation temperature 600C, cone
gas flow rate 150 Lhr−1, and desolvation gas flow rate
1,200 Lhr−1. Folates were measured by multiple reaction
monitoring with optimized cone voltage and collision energy for
precursor and product ions (as described in Leung et al., 2013).
2.12 | LC–MS-IT-TOF analysis of cellular CBD
levels in D. discoideum
Cell pellets, blinded and randomized prior to quantification, were
homogenized in acetone and sonicated in an ultrasonic bath for 8 min.
An internal standard for CBD quantification by isotope dilution
(d4-CBD 10 pmol) was added to the homogenate and extracted four
times with acetone. The lipid-containing solution was dried down,
weighed, and pre-purified by open bed chromatography on silica gel.
Fractions were obtained by eluting the column with 99:1, 90:10, and
50:50 (v/v) chloroform/methanol. The 99:1 fraction was used for
CBD quantification by LC–MS-IT-TOF analysis as described
previously (Piscitelli, Pagano, Lauritano, Izzo, & Di Marzo, 2017).
2.13 | Amino acid analysis by NMR
Intracellular metabolites were extracted as previously described
(Viant, 2007). Briefly, a two-phase extract was generated using a
mixture of methanol, chloroform, and water in the volume ratio of
4:4:2.85. The aqueous phase containing water-soluble low molecular
weight endogenous metabolites was transferred to microtubes, and
solvents were removed using a vacuum concentrator Eppendorf AG
(Eppendorf, Hamburg, Germany), 8 hr at 60C. Samples were then
reconstituted in 70 μl of NMR phosphate buffer (pH 7.4) 0.2 M (80%
of D2O, 20% of H2O, 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid;
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Sigma-Aldrich) 1 mM, serving as NMR reference, vortexed for 10 s,
and centrifuged at 12 000 g at 4C for 10 min; 60 μl of resulting
supernatant was pipetted into a 1.7-mm capillary tube (Bruker, UK)
for NMR analysis.
NMR analysis was carried out using a Bruker AV700 NMR
instrument equipped with a 5-mm inverse cryoprobe. A standard
one-dimensional nuclear Overhauser effect spectroscopy experiment
was performed on each sample, using a standard preset pulse
sequence (noesypr1d, 90 pulse length at 9.25 μs, total acquisition
time of 2 s, and water pre-saturation during relaxation delay of 5 s).
All samples were analysed at 297 K and free induction decay was
acquired on 19,607 data points (spectral width 9,803.9 Hz) using 512
scans (eight dummy scans). Free induction decay was then zero filled
to 64 k points, and line broadening of 0.6 Hz was applied prior to fast
Fourier transform. Phase and baseline corrections were performed
manually using MestreNova software (version 10.0 m MestreLab
Research). NMR spectra were referenced to 3-(trimethylsilyl)
propionic-2,2,3,3-d4 acid peak at 0 ppm. All samples were blinded
prior to analysis.
2.14 | Amino acid analysis of brain samples of a
heterozygous Scn1a mouse model treated with CBD
129S-Scn1atm1Kea/Mmjax heterozygote (+/−) male mice (Jackson
Laboratory, USA), maintained in the Bioresource Unit, University of
Reading, were crossed with female C57BL/6 mice (Charles River, UK)
to obtain hybrid Scn1a heterozygote (+/−) and wild-type animals used
in this study. This strain of Scn1a+/− mice show the characteristics of
Dravet syndrome, a severe form of childhood epilepsy (Miller,
Hawkins, McCollom, & Kearney, 2014). Scn1a+/− (epileptic) animals
were randomly assigned to either vehicle (ethanol: kolliphor®: 0.9%
saline = 2:1:17; n = 10) or CBD (100 mgkg−1 twice daily subcutane-
ous injection, n = 10; GW Pharmaceuticals batch number 070214) for
6 weeks from postnatal Day 8 onwards. Likewise, a wild-type group
was taken as healthy control (n = 9) and treated with vehicle for
6 weeks. All the animals were group housed and maintained in a
12 hr:12 hr dark:light cycle at an RT of 21C and humidity of
50 ± 10%, with ad libitum access to food and water. This experiment
was conducted in the dark cycle (dim red light 8:00–20:00), and
injections were made at circa 8 a.m. and circa 8 p.m. by both male and
female experimenters. The dose of CBD used here was selected to
compare with the effective clinical dose used in humans to treat
Dravet syndrome and epilepsy in other rodent models (Patra et al.,
2019) estimated using a method as described earlier (Nair & Jacob,
2016). At the end of the treatment period, all animals were humanely
killed by cervical dislocation for collection of blood (heparinized tube;
Fisher Scientific, UK) and brain (flash frozen in liquid nitrogen). Tissue
was stored at −80C until used in amino acid analyses. The experi-
ments were conducted following UK Home Office regulations
(Animals [Scientific Procedures] Act, 1986) under licence 70/8397
“Mouse Model of Dravet Syndrome” and was approved by the Animal
Welfare and Ethics Review Board at the University of Reading. We
used previous data from a similar technique and standard sample size
calculations to estimate group size to observe an effect ≥20%,
suggesting a group size should be up to nine animals to observe an
effect. To ensure unbiased analysis, samples were blinded and ran-
domized prior to quantification. Unfortunately, we could not
determine the effect of CBD on one-carbon cycle amino acids in
healthy animals as our previous preliminary data did not warrant
inclusion of this group in a chronic dosing study as CBD is well
tolerated in healthy rodents. Animal studies are reported in
compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill,
Emerson, & Altman, 2010) and with the recommendations made by
the British Journal of Pharmacology.
2.15 | Acute seizure model of rat primary
hippocampal neurons treated with pentylenetetrazol
and CBD
Pregnant female Sprague-Drawley rats (4–5 months old) at 18 days of
gestation were culled by concussion. The embryos were removed and
5 × 105 cells were extracted from the embryo hippocampi, seeded
onto a six-well plate and matured for 21 days in modified neurobasal
medium (Thermo Fisher Scientific, UK) with B27 supplement
(1 ml/50 ml). Intervention groups were treated with CBD from
100-mM stock in DMSO to a final concentration of 1.89 μM and incu-
bated at 37C and 5% CO2 with sample provided for analysis random-
ized and blinded. After 1 hr of incubation, both intervention and
untreated cells were treated with pentylenetetrazol (PTZ) from 1-M
stock to a final concentration of 5 mM and placed at 37C and 5%
CO2 for 20-min cells. Media was aspirated and the cells were washed
three times with ice cold PBS. Cells were lysed for 10 min using
200-μl RIPA buffer containing protease inhibitors and then collected
using a cell scraper. Samples were immediately frozen at −80C and
used in subsequent GC–MS and protein analyses.
2.16 | Data and analysis
The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and
analysis in pharmacology (Curtis et al., 2018). The distribution of all
experimental data was tested for using the Anderson–Darling test for
normality. All data that showed a Gaussian distribution were analysed
using parametric tests. No outliers were excluded from analysis.
Normally distributed data from two groups were statistically analysed
using a Student's t-test. The one-way ANOVA statistical test was used
to test for significance between the means of three or more
independent groups of normally distributed data. In conjunction with
the one-way ANOVA, Tukey multiple comparison tests were
performed to test for significance between all possible pairs of means.
All experimental data involving two independent variables were
analysed using a two-way ANOVA. The two-way ANOVA was used
to test for an interaction between these independent variables and
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the dependent variable. In conjunction with the two-way ANOVA, a
Bonferroni multiple comparison test was performed to test for
significance between all possible pairs of means. Post hoc analysis in
ANOVA tests was only performed if the F-test value of the ANOVA
reached significance (P < .05). N values are defined as a sample
derived from an individual animal or experiment, that is, technical
replicates were not considered as an n value. Only data with n ≥ 5
were statistically analysed. Data were considered statistically
significant if P < .05. Data provided in the results are not paired, and
thus the number in each group does not need to be identical
(providing each set of data was sufficiently powered). We have thus
always performed a minimum of six experiments and that each group
was statistically powered to see the effect size observed.
2.17 | Materials
CBD was provided by GW Research Ltd.
2.18 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018), and are permanently
archived in the Concise Guide to PHARMACOLOGY 2017/18
(Alexander et al., 2017).
3 | RESULTS
3.1 | Investigating cellular mechanisms of CBD in
the model system D. discoideum
To investigate a molecular mechanism of CBD, independent of
previously described targets and effects, we initially employed the
tractable model D. discoideum. Treatment with CBD at concentrations
from 0 to 20 μM caused a concentration-dependent inhibition of
unicellular growth, providing a readout for mechanistic studies
(Figure 1a). Growth inhibition had an IC50 of 1.9 μM (95% CI
[1.6–2.2 μM]; Figure 1b), where growth was significantly reduced at
0.5 μM (P < .05) and blocked at 20 μM CBD. This concentration is
close to steady-state plasma levels shown in clinical studies (Devinsky
et al., 2017; Devinsky et al., 2018), rather than high concentrations
reported in some investigations (Bih et al., 2015). These data suggest
the presence of CBD-sensitive processes in D. discoideum, with
regulation of a potential target at similar concentrations shown to
block seizure activity in mammalian models (Jones et al., 2012; Kaplan
et al., 2017; Klein et al., 2017).
We continued by analysing the effect of CBD on D. discoideum
development, a process where starvation initiates aggregation and the
formation of multicellular fruiting bodies over a 24-hr period (Kelly et
al., 2018). In this model, development and cellular growth can be
mutually exclusive cell functions, controlled by groups of both
independent and common proteins, providing the opportunity to
assess the effect of CBD on both functions. Cell aggregation and
development led to the formation of mature fruiting bodies in the
absence and presence of CBD (20 μM; Figure 1c), demonstrating that
CBD had no effect on development. Hence, the CBD target is
necessary for cellular growth but is not involved in multicellular
development, suggesting a specific molecular effect in this model
rather than a general toxic effect.
3.2 | Identification of D. discoideum GCVH1 and
H. sapiens GCSH as regulators of CBD cellular function
In order to understand the effect of CBD on D. discoideum growth, we
sought to identify molecular requirements for CBD action by isolating
mutants with reduced CBD sensitivity in a genetic screen of an
insertional mutant library (Figure 2a). A library of mutants was treated
with CBD at a concentration that inhibits cell growth by 80%
(9.5 μM). After 2-week incubation, four CBD-resistant mutants were
isolated and the insertionally inactivated gene potentially controlling
CBD sensitivity was identified using inverse PCR (Keim, Williams, &
Harwood, 2004) or whole-genome sequencing (Figure S1). This
approach identified a CBD-resistant gcvH1− mutant, with an insertion
in exon 1 of gcvH1 (DDB_G0287773) encoding the glycine cleavage
system H protein (GCVH1; Figure 2b). The gcvH1− mutant was
recapitulated in wild-type cells by removal of a central part of the
encoding gene by homologous recombination and the mutant was
confirmed to have lost gcvH1 expression (Figures S2 and S3).
We further assessed if D. discoideum GCVH1 is a likely
homologue of GCSH (UniProt P23434). GCSH and GCVH1 are of
similar size and domain structure and contain a mitochondrial-
targeting peptide sequence at the N-terminus (Figure 2b). Similarly,
both proteins possess a lipoyl-binding domain containing a highly
conserved motif (Figure 2c), including a key lysine residue that binds
the lipoic acid co-factor to facilitate shuttling of the glycine intermedi-
ates within the GCS. This motif is highly conserved throughout the
kingdom of life (Figure 2d; Kikuchi & Hiraga, 1982). This analysis
suggests that the D. discoideum GCVH1 protein is likely to represent a
homologue of the mammalian GSCH, with similar catalytic activity
and function. Since changes in glycine (Boison, 2016; Lynch, 2004;
Xiong et al., 2012) and components of glycine in the one-carbon cycle
such as adenosine have been associated with epilepsy (Boison, 2016;
Kobow et al., 2013), we continued our analysis of this mutant rather
than the other identified mutants (Figure S1).
We then investigated whether the D. discoideum GCVH1
protein localizes to mitochondria, consistent with the localization of
GCSH in mammalian systems using fluorescently tagged gcvH1
(GCVH-RFP) expressed in gcvH1− cells (Figures 3 and S3).
Visualization of the resulting GCVH1-RFP expressing cells showed
localization in small intracellular dots corresponding to mitochondria
seen by phase-contrast microscopy (Figures 3a, S4, S5, and S6). A
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F IGURE 1 Cannabidiol (CBD) is likely to have molecular targets in D. discoideum cell affecting proliferation but not development. (a) The
effect of CBD on D. discoideum cell growth was treated over a 7-day period under a range of indicated concentrations (μM), with CBD blocking
growth at 4 μM (data derived from 6 to 9 independent experiments) and presented as normalized to fold change from control values (untreated,
Day 7). (b) A concentration–response curve of normalized cell density against the Log (concentration) of CBD was used to calculate the IC50 value
with a 95% confidence interval. (c) The effect of CBD on D. discoideum development was analysed using cells plated upon nitrocellulose filters
under starvation conditions where fruiting bodies were formed, shown for a field of fruiting bodies (aerial view) and for a single fruiting body.
Treatment of cells with either 20 μM CBD or vehicle alone did not block development (n = 9)
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similar localization was seen on overexpression of H. sapiens
GCSH-RFP (Figures 3b and S4). To validate this localization, cells
were fixed and probed with antibodies to both RFP and porin, a
mitochondrial protein (Troll et al., 1992). Porin labelling encapsulated
both GCVH1-RFP and GCSH-RFP proteins (Figure 3a,b), consistent
with a mitochondrial matrix localization of both GCS proteins and
the mitochondrial membrane localization of porin. These data,
together with three-dimensional reconstruction of labelling
(Figures 3c, S4, S5, and S6), confirm a localization of the GCVH1
and the H. sapiens orthologue GCSH in mitochondria in
D. discoideum, consistent with a role for these proteins in the GCS.
To confirm a role for gcvH1 in the regulation of CBD
sensitivity, growth resistance to CBD was assessed in the gcvH1−
mutant and following rescue with GCVH1-RFP and GCSH-RFP
proteins. The gcvH1− cell line showed partial resistance to CBD
(Figures 4a and S7) with a growth inhibitory constant (IC50) of
F IGURE 2 Identifying a role for the glycine cleavage system component, GCVH1, in regulating the cellular effect of CBD in D. discoideum. (a)
A genetic screen of an insertional mutant library was carried out to identify mutants unaffected by the inhibitory effects of CBD on growth. (b)
This screen identified GCVH1 as a potential molecular target for CBD, with an insertion in the first of three exons (red triangle), interrupting the
coding region. Both the D. discoideum and the H. sapiens GCVH1 proteins are of similar size and contain highly conserved functional domains,
include a mitochondrial localization sequence/transit peptide and a lipoyl binding domain, containing the ESVKAAS motif for lipoic acid binding.
(c) The lipoic acid binding motif is highly conserved across a broad range of species but absent in the related dihydrolipoyllysine-residue
succinyltransferase (DLST/DLAT) proteins. (d) Such conservation highlights the evolutionary similarity of D. discoideum GCVH1 to orthologues
found in higher organisms
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4.2 μM (95% CI [3.2–5.3 μM]). Expressing either D. discoideum
GCVH1-RFP or H. sapiens GCSH-RFP protein in gcvH1− restored
sensitivity to growth inhibition, with IC50 of 2.2 μM (95% CI
[1.6–2.9 μM]) and 0.82 μM (95% CI [0.67–1.0 μM]) respectively
(Figures 4a, S3, and S7). These data support a role for both
GCVH1 and GCSH in regulating CBD sensitivity, in addition to
confirming a common function of the D. discoideum and the H. sapi-
ens proteins.
To ensure the resistance observed in the gcvH1− mutant was not
from increased xenobiotic degradation or a decreased uptake and
increased removal of CBD, we quantified cellular CBD levels in
mutant and wild-type cells. Here, cells were treated with CBD
(1.89 μM) for 12 hr, and cellular CBD levels were quantified by LC–
MS. No significant difference in CBD levels was found between
wild-type and the gcvH1− cell lines (Figure 4b). This supports the
hypothesis that the effect of CBD is dependent upon a pathway
controlled by the mitochondrial GCS (GCVH1 or GCSH) but not by
CBD metabolic degradation or transport.
3.3 | Monitoring one-carbon cycle amino acids and
folates in D. discoideum following CBD treatment
We then sought to examine the molecular mechanism underlying the
role of GCVH1 in CBD sensitivity, focusing on the function of the
GCS and the interacting FOCM components (Figure 5a). In these
experiments, we first examined the role of GCVH1 in regulating
glycine, methionine, and cysteine levels using GC–MS. We found that
glycine levels were significantly increased in gcvH1− cells compared to
wild-type cells (P < .05), with a moderate decrease in methionine
levels (P < .05) and no change in cysteine levels, supporting a role for
the encoded protein in the GCS (Figure 5b). We then examined the
effect of CBD treatment in both wild-type gcvH1− cells (using
1.89 μM for 12 hr), where CBD gave no change in glycine levels. In
contrast, methionine levels were significantly reduced in wild-type
cells following CBD treatment (P < .05), and this effect was lost in
gcvH1− cells, consistent with a CBD-dependent inhibitory effect on
methionine synthesis that is suppressed in gcvH1− cells (Figure 5b).
F IGURE 4 The CBD-resistant phenotype through loss of GCVH1 is rescued by both D. discoideum GCVH1 and H. sapiens GCSH proteins and
is not caused by reduced CBD uptake or increased removal/degradation. (a) Concentration–response assays of wild-type, gcvH1−, and rescue cell
lines with either the D. discoideum or H. sapiens genes replaced was carried out. Data are mean +/− SEM (*, P < .05 one-way ANOVA, Tukey post
hoc test). (b) Cellular CBD levels were quantified within wild-type D. discoideum and gcvH1− cell lines using LC–MS-IT-TOF following a prolonged
CBD treatment regime (n = 4 or 6 as indicated). Data are mean +/− SEM (P > .05, Student's t-test)
F IGURE 3 The D. discoideum GCVH1 and H. sapiens GCSH proteins localize to mitochondria in D. discoideum. (a) Confocal imaging of
D. discoideum gcvH1− cells expressing D. discoideum GCVH1-RFP, imaged using phase contrast, with RFP fluorescence (red), a porin antibody
(green), and DAPI to visualize DNA (blue), and with a merged fluorescence image on the right. (b) Shows D. discoideum gcvH1− cells expressing
H. sapiens GCSH-RFP, imaged using phase contrast, with RFP fluorescence (red), a porin antibody (green), and DAPI to visualize DNA (blue), and
with a merged fluorescence image on the right. (c) Three-dimensional reconstruction of D. discoideum gcvH1− cells expressing D. discoideum
GCVH1-RFP, using RFP fluorescence (red), filamentous actin imaged using Atto488-phalloidin (green), and DAPI to visualize DNA (blue). Scale
bars correspond to 5 μm
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F IGURE 5 CBD treatment regulates the one-carbon cycle and folate signalling dependent upon the glycine cleavage system in D. discoideum.
(a) A schematic diagram showing how the glycine cleavage system (GCS—green) found within the mitochondria (orange) is linked to the one-
carbon cycle (blue), involving key amino acids—glycine, methionine, and cysteine, with methionine synthase providing the key point of interaction
between the two systems. (b) To analyse changes in these systems, both wild-type and gcvH1− cell lines were treated with CBD (1.89 μM, 24 hr)
or vehicle alone, and their amino acid composition was analysed by GC–MS (n = 6–9). Analysis shows that gcvH1 ablation and CBD treatment
alters the levels of methionine and glycine. (c) Amino acid level changes were supported using NMR analysis (n = 6–9). All data are mean +/− SEM
(*, P < .05, two-way ANOVA, Bonferroni post hoc test). (d) Folate-containing compounds tetrahydrofolate (THF) and 5-methyltetrahydrofolate
(5mTHF) were also assessed following equivalent treatment conditions (n = 3–7) consistent with a reduction in the glycine cleavage system by
loss of GCVH1, and a CBD dependent increase in 50mTHF consistent with a mechanism of CBD through inhibition of methionine production. All
data are mean +/− SEM (*, P < .05, two-way ANOVA, Bonferroni post hoc test)
922 PERRY ET AL.
Similar notable trend towards reduced cysteine levels (P = .0502) were
observed in wild-type cells following CBD treatment that was again
absent in the gcvH1− mutant (Figure 5b). These data support a role for
CBD in reducing methionine synthase activity, dependent upon GCS
activity. We independently confirmed these changes using an NMR-
based approach with an identical treatment regimen used in the GC–
MS analysis. Again, glycine levels were elevated in the gcvH1− mutant
compared to wild-type cells (P < .05; Figure 5c) but did not change fol-
lowing CBD treatment. Here, CBD treatment again caused a signifi-
cant reduction in wild-type methionine levels (P < .05) with this effect
lost in the gcvH1− mutant (Figure 5c), again consistent with GC–MS
results. Thus, these two distinct approaches highlight a common
effect of CBD in reducing methionine levels and show that the effects
of CBD on these components are reliant upon activity of the GCS.
We continued by analysing the potential effect of CBD treatment
on the relative abundance of folate mediators of one-carbon metabo-
lism, with exploratory analysis of wild-type and gcvH1− cells, using
LC–MS/MS. Comparison of folate profile in wild-type and untreated
gcvH1− cells identified a significant (P < .05) increase in
tetrahydrofolate (THF) levels in mutant, consistent with impaired
activity of the GCS (Leung et al., 2017; Figure 5d). Following CBD
treatment, wild-type cells showed a significant 23% reduction in THF
levels (P < .05), with a concomitant 8% increase in 5-methylTHF
(5mTHF; P < .05; Figure 5d). As with lower methionine abundance,
this effect is consistent with a CBD-dependent block in methionine
synthase activity. In comparison, gcvH1− cells showed a reduced sen-
sitivity to the effect of CBD, with only a 7% increase in THF and a 3%
decrease in 5mTHF following treatment (both P < .05). Hence, differ-
ence in THF levels between gcvH1− cells and wild-type cells (P < .05)
was of greater magnitude following CBD treatment (Figure 5d). These
data implicate a role for CBD in reducing methionine synthase activity
in this model as a potential mechanism underlying diminished THF
production, with ablation of gcvH1− attenuating this effect.
3.4 | Monitoring amino acid regulation in a Dravet
syndrome epilepsy model following CBD treatment
We then investigated potential changes in amino acid signalling in
epilepsy models. First, we employed a heterozygous Scn1a+/−
mouse model lacking one copy of the NaV1.1 protein (Thiele et al.,
2018) that is used as a model for a variety of seizure types from
simple febrile seizures to severe genetic disorders such as Dravet
(Nakayama et al., 2018) and Lennox–Gastaut syndromes (Zhou et
al., 2018). We initially analysed brain amino acid levels in healthy
(wild-type) and Scn1a+/− mice, where a significant increase in
glycine (P < .05) and methionine (P < .05) levels and a decrease in
cysteine (P < .05) levels were found in these epileptic model mice
compared to wild-type controls (Figure 6a). We also examined
potential changes in these amino acids following 6-week CBD
treatment (twice daily subcutaneous injection at 100 mgkg−1). In
CBD-treated Scn1a+/− animals, glycine, methionine, and cysteine
remained deregulated compared to untreated animals (Figure 6a),
consistent with a role of these elevated amino acid levels providing
a trait marker for Dravet syndrome, although methionine levels
significantly increased (P < .05) following CBD treatment above that
of untreated animals. This CBD-dependent increase was
unexpected, as brain levels of methionine are normally tightly
regulated in healthy animals (Gupta et al., 2004; Selmer, Lund,
Brandal, Undlien, & Brodtkorb, 2009). These insights suggest that
F IGURE 6 A Dravet syndrome model and an in vitro seizure model implicate the one-carbon (amino acid) cycle as a potential mechanistic
target of cannabidiol (CBD) treatment in epilepsy. (a) Analysis of one-carbon cycle amino acids (glycine, methionine, and cysteine) in a mouse
Scn1a+/− Dravet model suggests significant dysregulation of these amino acids in brain tissue, with chronic CBD-treatment further modifying
methionine levels. (b) Analysis of rat primary hippocampal neurons, pretreated with CBD (60 min 1.89 μM), or following induction of seizure-like
activity induced with PTZ (with or without CBD treatment), shows no alteration in glycine or cysteine levels but demonstrates elevates
methionine levels upon seizure induction, with this increase attenuated by CBD treatment. Data are shown as mean ± SEM (*, P < .05, one-way
ANOVA, Tukey post hoc test, n ≥ 7)
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in the Dravet model, extended treatment with CBD modulates
levels of methionine, a key component of one-carbon metabolism.
3.5 | Monitoring one-carbon metabolism amino
acids in an in vitro seizure model following CBD
treatment
Since the Dravet model mice showed altered levels of methionine fol-
lowing long-term CBD treatment, we also employed an in vitro seizure
model to investigate potential changes in this amino acid (and glycine
and cysteine) at a cellular level following acute CBD treatment. Here,
primary hippocampal neurons from wild-type rats were matured for
21 days to develop synaptic connections and pretreated with CBD
(1.89 μM for 60 min) followed by the induction of seizure-like activity
by treatment with 5-mM PTZ for 20 min (Chang et al., 2014). PTZ is
known to be a GABAA receptor antagonist and has been used exten-
sively in epilepsy research to induce seizure activity by preventing the
inhibitory response of GABA (Armand, Louvel, Pumain, & Heinemann,
1998). In this acute model, neurons showed a significant increase in
methionine levels following seizure induction (P < .05), consistent with
that observed in the Dravet model brain, while this increase was sig-
nificantly reduced by pretreatment with CBD (P < .05; Figure 6b). No
significant changes in cysteine or glycine levels were found following
seizure-like activity or with CBD treatment in this model (Figure 6b).
These data suggest that induction of seizure-like activity elevates neu-
ronal methionine levels, and acute CBD treatment attenuates this
effect. Thus, both chronic and acute CBD treatment regulate methio-
nine levels, suggesting a novel effect not previously reported and
potentially related to the therapeutic mechanism of CBD.
4 | DISCUSSION
Understanding the therapeutic mechanism(s) of Cannabis-derived
compounds has been a recent priority in research, particularly in the
treatment of epilepsy. Here, we investigated potential mechanisms
underlying the molecular function of CBD using D. discoideum as a
tractable 3Rs (replacement, refinement, or reduction) model organism
that has been used in a range of other pharmacogenetic studies
including those focused on epilepsy (Chang et al., 2012; Kelly et al.,
2018; Warren et al., 2018). Using this model enabled the
identification of a mechanism for CBD dependent upon the
mitochondrial GCS protein, GCVH1, a component of FOCM, where
this role that is conserved with the human orthologue (GCSH). We
demonstrated that GCVH1 localized to mitochondria, consistent with
studies of GCSH in other models (Lamers et al., 2009; Leung et al., 2017).
Loss of GCVH1 significantly elevated glycine levels, increased THF levels,
and reduced 5mTHF levels, all confirming impaired activity of the GCS in
this mutant (Figure 5). Loss of GCVH1 also led to lower methionine levels
(using GC/MS analysis), consistent with impaired GCS activity leading to
decreased conversion of homocysteine to methionine via methionine
synthase (MTR). Thus, loss of GCVH1 gives rise to metabolic outcomes
that resembles those in mouse and human studies (Lamers et al., 2009;
Leung et al., 2017) and highlights an evolutionarily conserved function of
this important metabolic pathway.
We then demonstrated that CBD functions to modulate
methionine levels and folate intermediates in the one-carbon cycle,
dependent upon GCVH1 activity, revealing a novel role for CBD in
inhibition of methionine production. The increased resistance of
gcvH1− mutants to CBD is modest, with a twofold decrease in
sensitivity, suggesting that this mechanism may represent one of
multiple cellular mechanisms commonly found in therapeutic natural
products and drugs (Kobayashi, Endoh, Ohmori, & Akiyama, 2019;
Zhang, Huai, Miao, Qian, & Wang, 2019) but still demonstrates a role
for the GCS in regulating CBD cellular effects. However, in our
studies, CBD treatment did not increase glycine levels, arguing against
a direct inhibitory effect of CBD on the GCS. Excitingly, treatment of
wild-type cells with CBD lowered methionine levels, and this effect
was lost in the gcvH1− mutant, suggesting a mechanism of CBD action
through inhibition of methionine production. Although we were
unable to detect homocysteine in cells, cysteine levels showed a trend
for a CBD-dependent reduction in wild-type cells that was absent in
the gcvH1− mutant, also consistent with a role for CBD in regulating
GCS-dependent one-carbon metabolism. CBD treatment also caused
a decrease in relative abundance of THF and an increase in 5mTHF,
supporting the hypothesis of a role for CBD in suppressing
methionine synthase activity, with this affect attenuated by loss of
GCVH1. These data therefore provide evidence for CBD-dependent
regulation of one-carbon metabolism in D. discoideum, in which
methionine levels are lowered in a GCS-dependent manner, revealing
a new molecular pathway modulated by CBD.
We then sought to translate this research to a relevant epilepsy
model. Employing a mouse Scn1a+/− mutant to investigate a potential
mechanism of CBD provided a logical approach, as this model
reproduces seizure types found in patients with Dravet syndrome
(Marini et al., 2011) and Lennox–Gastaut syndrome (Selmer et al.,
2009). Surprisingly, we demonstrated that brain levels of glycine,
methionine, and cysteine were all significantly altered in the model,
suggesting that neuronal levels of these amino acids may provide trait
markers for epilepsy. Interestingly, epilepsy is a key feature of
non-ketotic hyperglycinemia (also known as glycine encephalopathy),
an autosomal recessive neurometabolic disorder characterized by
elevated levels of glycine in blood and CSF (Swanson et al., 2015)
caused by mutation of components of the GCS (Kure et al., 2006).
These observations provide a potential link between Dravet
syndrome, mitochondrial function and glycine levels, and non-ketotic
hyperglycinemia. Since mitochondrial dysfunction in Dravet syndrome
has been suggested from studies of patient skin fibroblasts (Doccini et
al., 2015), in patients (Panneman et al., 2018), in a zebrafish model
(Kumar et al., 2016), and in epilepsy-related oxidative stress
(Pearson-Smith et al., 2017), our data support and extend these
findings. Thus, this mechanism may now be added to those already
proposed for CBD in epilepsy treatment (Xiong et al., 2012; Kaplan et
al., 2017, Rodriguez-Munoz et al., 2018, Vilela et al., 2017,
Rimmerman et al., 2013).
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In vivo studies can be complicated by chronic treatment causing
long-term cellular and physiological changes in the brain and the
presence of a variety of cell types. To overcome these considerations,
we analysed a role for CBD in regulating glycine, methionine, and
cysteine levels using an acute neuronal seizure model (Chang et al.,
2014). This approach defines acute changes found during seizures,
and in response to drug treatment, where changes in level of these
components would identify a role in seizures. We showed that
seizure-like activity did not alter glycine or cysteine levels in neurons
themselves, however methionine levels were significantly increased,
and this increase was attenuated by CBD treatment. These data are
consistent with an acute role for CBD in reducing methionine
production in seizure activity but do not prove this—since CBD may
simply block seizure activity, and hence a seizure-dependent increase
in methionine. This could be examined in further experiments, with
other anticonvulsants used to block seizure activity and methionine
levels examined, and this represents a limitation in the present study.
However, our results clearly indicate that seizure activity elevates
methionine levels, revealing a new and unexpected effect of seizure
activity. Differing effects of CBD treatment in the Dravet in vivo
model and in primary neurons in vitro may be due to a range of
factors including long-term cellular and physiological changes in brain
following treatment. Whole-brain material also comprises a variety of
cell types, where the GCS is mainly in glia cells not neurons, and these
aspects will need further investigation.
One-carbon metabolism includes a wide range of components
implicated in neuronal excitability, seizure activity, and epilepsy.
Glycine acts as a co-agonist at excitatory NMDA receptors to provide
a key neuronal glutamatergic (excitability) mechanism and through
specific excitatory and inhibitory receptors (Lynch, 2004). The
production of SAM provides a central function in the cycle, acting as
the primary donor of methyl groups within cells for both DNA and
neurotransmitter methylation (Moore et al., 2013). Adenosine has also
been shown to regulate seizure activity (Boison, 2016) and is involved
in DNA methylation to regulate epileptogenesis (Kobow et al., 2013),
although CBD treatment attenuates the reduction in DNA
methylation induced by cell differentiation (Pucci et al., 2013). Finally,
homocysteine is a pro-convulsant and is elevated in patients with
recurrent seizure activity during treatment with antiepileptic drugs
(Baldelli et al., 2010). Thus, one-carbon metabolism provides a wide
variety of potential impacts on seizure activity and epilepsy control,
further emphasized by the current study.
In summary, our data provide new insights to altered
metabolism in epilepsy as a disease state, and potential therapeuti-
cally relevant mechanisms of CBD action. Future research should
thus investigate changes in one-carbon metabolism in epilepsy,
including Dravet syndrome, and other CBD-treatable disorders,
particularly where potential mitochondrial dysfunction may underlie
some pathological symptoms. We further suggest that
pharmacological regulation of methionine levels during seizure
activity may provide a novel therapeutic approach for seizure
control and one-carbon cycle components may provide diagnostic
markers within a clinical setting.
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A B S T R A C T
Visualizing mitochondria in living Dictyostelium discoideum cells using fluorescent dyes is often problematic due
to variability in staining, metabolism of the dyes, and unknown potential effects of the dyes on mitochondrial
function. We show that fluorescent labelling of mitochondria, using an N-terminal mitochondrial localization
sequence derived from the D. discoideum protein GcvH1 (glycine cleavage system H1) attached to a red fluor-
escent protein enables clear mitochondrial imaging. We also show that this labelling has no effect upon mi-
tochondria load or respiratory function.
1. Introduction
Mitochondria play important roles, most notably cellular energy
production by oxidative phosphorylation [1], hence the aptly coined
phrase “the powerhouse of the cell” [2]. Mitochondria are also involved
in Ca2+ management [3], production of ROS [4], redox signalling [5,6]
and apoptosis [7]. Many studies investigating mitochondrial function
observe mitochondrial morphology and their dynamics within the cell
[8]. Such observations can be achieved by the use of various fluorescent
dyes such as Rhodamine 123 (R123) [9], tetramethylrhodamine-me-
thyl-ester (TMRM) [10] and JC-1 (tetraethylbenzimi-dazolylcarbocya-
nine iodide) [11]. However, these dyes rely upon a mitochondrial
membrane potential and can be washed out if the mitochondria ex-
perience depolarisation [12]. Furthermore, these dyes are unsuitable
for use with aldehyde fixation due to resulting changes in mitochon-
drial metabolic state [12]. Other fluorescent dyes developed for vi-
sualizing mitochondria include the Mitotracker Red and Green dyes.
Mitotracker Red binding depends on both the presence of a mi-
tochondrial membrane potential while Mitotracker Green binding does
not. These dyes can be used in combination with a number of cell
fixation methods, however, they may cause cytotoxic effects following
prolonged use. Other methods of real time mitochondrial imaging
include the use of fluorescently tagged mitochondrial localised pro-
teins, where the tagged protein is recognised by the mitochondrial
‘Translocase of the outer/inner membrane’ (TOM/TIM) protein com-
plexes and transported into the mitochondria [13]. The transport of
mitochondrial proteins into the mitochondrial matrix is facilitated by
an N-terminal pre-sequence [14]. This pre-sequence can consist of
10–80 amino acid residues and is usually cleaved off by the matrix
processing peptidase following localization [15]. However, these
fluorescent proteins can interfere with the function of the native protein
and impede mitochondrial function. As such, non-cytotoxic mitochon-
drial markers are required.
Dictyostelium discoideum is a tractable model system widely used for
research in a range of fields including cell and developmental biology,
evolutionary biology, as well as in immunology and molecular phar-
macology studies. In cell and developmental biology, D. discoideum is
often used to improve our understanding of cell motility [16,17]. In
molecular pharmacology research, D. discoideum has been used to in-
vestigate mechanisms of action of pharmaceutical drugs including
treatments for epilepsy [18–20] and neurodegenerative disorders
[21,22]. Other studies investigate mechanisms of action of bioactive
natural products such as curcumin, naringenin and a range of bitter
tastants [23–25]. One recent study, identifying a mitochondrial protein,
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GcvH1, involved in the cellular function of cannabinoids on the glycine
cleavage system [26], highlights the presence of an N-terminal mi-
tochondrial localization sequence and thus raises the possibility of
using this sequence for mitochondrial tagging in D. discoideum. To
further these studies, a non-cytotoxic mitochondrial marker is required
that can be used in D. discoideum without affecting cellular respiratory
function.
In this study we created a novel expression plasmid (REMIT; red
mitochondria) for real time visualization of mitochondria in D. dis-
coideum. The REMIT plasmid allows the expression of an enhanced RFP
protein (mRFPmars) [27] with a mitochondrial localization sequence
situated at its N-terminus. We show that transfection of REMIT into D.
discoideum cells facilitates the localization of mRFPmars to the mi-
tochondrial matrix. We also show that the presence of mRFPmars
within the mitochondria has no effect on mitophagy or cellular re-
spiratory function. We therefore present a method that allows the real
time visualization of mitochondria within D. discoideum cells with no
deleterious effects.
2. Methods
2.1. Creation of the REMIT plasmid and over-expression D. discoideum cell
lines
Primers (fwd: ATAGAATTCATGTTAAAAACCTTAAGATTTG and
rev: TATGGATCCCCATTCATGATCG) complementary to the 5’ region of
gcvH1 were used to amplify the 99-bp mitochondrial localization se-
quence (Fig. 1). The PCR product was digested with EcoRI and BamHI
and cloned into the extra chromosomal plasmid pDXA-389-2 [27,28].
The PCR product was inserted into the multiple cloning site located
immediately 5’ of the mRFPmars gene, and sequenced to confirm that
no mutations were introduced. Insertion of the PCR product at this
location enabled expression of a 27 kDa mRFPmars with a 33 amino
acid residue localization sequence linked to its N-terminus via a 6
amino acid residue linker region (Fig. 1). The resulting plasmid was
transfected into wildtype (AX3) cells and selected using geneticin
(10 μg/ml) to create a REMIT over-expression cell line [29]. The
GREMIT plasmid was based upon the same targeting region inserted
into the GFP vector pDM1209 [30].
2.2. Fluorescence and live-cell microscopy
For immunolabeling, cells expressing REMIT were plated on round
12-mm glass coverslips, and after 20 min were fixed with 15% picric
acid/2% paraformaldehyde in 10 mM PIPES, pH 6.0, for 20 min and
post-fixed with 70% ethanol for 10 min [31]. Cells were then washed
three times in PBS, once with 10 mM PIPES, and twice with PBS/1%
glycine, and incubated in blocking buffer (PBS plus 2% bovine serum
albumin) for 1 h at room temperature (RT). After blocking, the cells
were washed three times with PBS and incubated with primary anti-
bodies (2 μg/ml mouse monoclonal anti-porin antibody (Develop-
mental studies hybridoma bank (DSHB); 70-100-1) [32], and 1:1000 rat
anti-RFP (6G6 anti-red rat mAb, Chromatek) for 2 h, followed by the
incubation with secondary antibodies (1:1000 Alexa 488-conjugated
goat anti-mouse IgG (Invitrogen; A28175) and 1:1000 rabbit anti-rat
(Alexa fluor® 488 rabbit anti-rat IgG, Life technologies), for 1 h. After
immunostaining, samples were washed three times in PBS and em-
bedded using Fluoromount-GTM, with DAPI (1:1000 of 1 mg/ml DAPI
dissolved in methanol; Invitrogen, 00-4959) to stain DNA. For live-cell
microscopy, cells were seeded in μ-dishes (Ibidi, 80606), or open
chambers as described previously [28].
Confocal microscopy was performed at the Bioimaging core facility
of the Biomedical Center (LMU Munich) using an inverted Leica TCS
SP8 equipped with lasers for 405, 488, 552, and 638 nm excitation.
Fig. 1. REMIT plasmid construction. The mitochondrial localization sequence
was ligated into the pDXA-389-2 plasmid 5’ of the mRFPmars gene using EcoRI
and BamHI restriction sites. Actin 6 promoter, A6P; actin promoter 15, AP15;
Ampicillin resistance cassette, APr; monomeric red fluorescence protein,
mRFPmars; actin terminator 8, A8T; Geneticin resistance cassette, G418r. (For
interpretation of the references to colour in this figure legend, the reader is
referred to the Web version of this article.)
Fig. 2. Fixed-cell imaging of REMIT localizing to the mitochondria. (A) D.
discoideum cells expressing REMIT-mRFPmars (red), were fixed and im-
munolabelled using an anti-porin antibody (green), and stained with DAPI to
visualize DNA (blue). Confocal single plane imaging showed red fluorescent
protein localizing to mitochondria in D. discoideum. Scale bar correspond to
5 μm. (For interpretation of the references to colour in this figure legend, the
reader is referred to the Web version of this article.)
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Images were acquired with a HC PL APO 63x/1.40 oil PH3 objective.
Recording was sequential to avoid bleed-through. Alexa-488, and RFP
were recorded with the hybrid photo detectors, DAPI with the con-
ventional photomultiplier tube.
High resolution live-cell imaging was performed using an inverted
Zeiss LSM 900 Airyscan 2 microscope [33]. Images were acquired with
a Plan-Apochromat 63x/1.40 oil DIC objective with a GaASP-PMT de-
tector (450–700 nm) in the MPCX SR-4y modus at an excitation of
558 nm. Z-stacks (25 corresponding to 4.32 μm) were recorded over
time (2.55 s per z-stack). 3D reconstructions of single z-stacks were
performed using the Imaris software package (Bitplane, Zurich, Swit-
zerland).
2.3. Western blot analysis to monitor mitochondrial loading
Cell lysates (30 μg) were separated by gel electrophoresis, trans-
ferred to nitrocellulose membranes (Merck Millipore, IPFL00010), and
analysed by Western blotting. A mouse anti-porin primary antibody
(0.2 μg/ml, DSHB, 70-100-1) and a goat anti-mouse secondary antibody
(1:10000, Li-Cor, 926–32210) were used to confirm the presence of
porin. A streptavidin conjugate (1:5000, Invitrogen, S21378) which
binds to the mitochondrial protein MCCC1 (mitochondrial 3-methyl-
crotonyl-CoA carboxylase α [34]) was used to measure the levels of this
mitochondrial protein. Blots were analysed using Odyssey software.
Total protein loaded was stained with Revert 700 Total Protein Stain
(Li-Cor, 926–11010) and imaged and quantified on the Odyssey CLx.
2.4. Mitochondrial respirometry function
The effects that REMIT expression may have on mitochondrial stress
were investigated in real time [35]. In these experiments, a Seahorse
XFe24 Extracellular Flux Analyzer was used to measure mitochondrial
respirometry within REMIT expressing cells, wildtype cells and cells
expressing mRFPmars lacking the mitochondrial localization sequence.
Mitochondrial respirometry was measured in terms of the basal O2
consumption rate, the O2 consumption rate devoted to the synthesis of
ATP, the maximum O2 consumption rate, the contribution of Complex I
to the maximum O2 consumption rate, the contribution of Complex II to
the maximum O2 consumption rate, and the O2 consumption rate de-
voted to mitochondrial function other than ATP synthesis, i.e. “proton
leak”.
2.5. Statistical analysis
The distribution of all experimental data was tested using the
Anderson-Darling test for normality. All data that showed a Gaussian
distribution were analysed using parametric tests. Data from two
groups not showing a Gaussian distribution were analysed using a
Mann-Whitney T-test. The one-way analysis of variance (ANOVA) sta-
tistical test was used to test for significance between the means of three
or more independent groups of normally distributed data.
3. Results and discussion
The D. discoideum mitochondrial localization sequence (MLS)
(Fig. 1) was derived from the GcvH1 protein, a member of the mi-
tochondrial glycine cleavage system enzyme complex [26]. The glycine
cleavage system is located within the mitochondrial matrix and has a
loose affiliation with the inner mitochondrial membrane. We cloned the
GcvH1 MLS onto the N-terminus of mRFPmars [27] to form the REMIT
vector that was then transfected into wildtype D. discoideum cells. To
validate the mitochondrial localization of mRFPmars in these cells,
mRFPmars fluorescence was examined in fixed cells [36] (Fig. 2),
showing highly localised distribution in mitochondrial-like structures.
Since porin is localised in the outer mitochondrial membrane, we ex-
amined this localization, indicating REMIT mRFPmars in the mi-
tochondrial matrix with porin surrounding this labelling (Fig. 2). We
then assessed the use of REMIT mRFPmars for labelling mitochondria in
live cell imaging experiments. By using live-cell confocal microscopy,
REMIT-expressing cells revealed a highly discrete labelling of mi-
tochondria in real time (Fig. 3, and Supplementary movies 1,2), also
visible using under-agar inverted fluorescence microscopy (Supple-
mentary movie 3). A similar localization was found using a GFP-en-
coding vector, GREMIT (Supplementary Fig. 1). We also employed high
resolution live-cell imaging to monitor mitochondrial dynamics (Sup-
plementary movie 4), and this enabled 3-dimensional reconstruction of
mitochondrial distribution in live cells (Supplementary movie 5).
Supplementary video related to this article can be found at https://
doi.org/10.1016/j.bbrep.2020.100751
In order to maintain a healthy population of mitochondria within
the cells, all mitochondria experiencing damage or dysfunction will
undergo mitophagy. This process results in defective mitochondria
being targeted to the lysosome for autophagic degradation, thereby
maintaining cell health [37]. Because transfection with REMIT leads to
the localization of mRFPmars to the mitochondria we investigated
whether this resulted in mitochondrial damage or dysfunction,
Fig. 3. Live-cell imaging of REMIT localizing to the mitochondria. (A) Time lapse single plane imaging on a confocal microscope showing D. discoideum cells
transfected with REMIT-mRFPmars. The upper panel shows phase contrast images, the lower panels the intensity of the mRFPmars signal according to grey levels
depicted in colour-mode fire [38], scale bar 5 μm. Images correspond to Supplementary movie 1. Similar live cell imaging using red fluorescence are provided in
Supplementary movie 2, using under agar inverted fluorescence in Supplementary movie 3, Z stack imaging in Supplementary movie 4, and 3D reconstruction of live-
cell imaging in Supplementary movie 5. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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resulting in mitophagy, or alternatively increased mitochondrial load
(the mitochondrial protein content). To assess mitochondrial loading,
we compared levels of a mitochondrial protein, mitochondrial 3-me-
thylcrotonyl-CoA carboxylase α [34], in wildtype cells and cells trans-
fected with REMIT using Western blot analysis (Fig. 4A). From this
analysis, no change in mitochondrial load was identified following
REMIT transfection.
The requirement of mitochondria to carry out normal respiratory
function is fundamental to maintaining a healthy cell. Any deleterious
effect on respiratory function as a result of REMIT transfection would
result in downstream processes being disrupted. Thus, it is necessary to
confirm that mitochondrial respiratory function is not disrupted.
Mitochondrial respirometry function was therefore measured in terms
of the basal O2 consumption rate, the O2 consumption rate devoted to
the synthesis of ATP, the maximum O2 consumption rate, the con-
tribution of complex I to the maximum O2 consumption rate, the con-
tribution of complex II to the maximum O2 consumption rate, and the
O2 consumption rate devoted to mitochondrial function other than ATP
synthesis, i.e. “proton leak” (Fig. 4B). These data were obtained from
cells transfected with REMIT, cells transfected with REMIT lacking the
MLS, and untransfected wildtype cells. For all six conditions no sig-
nificant difference (P > 0.05) was found between the three cell lines.
This shows that mitochondrial function is not affected despite the
presence of mRFPmars localised within the mitochondrial matrix.
These experiments thus show that transfection of D. discoideum cells
with REMIT provides a quick, cheap and convenient method to visua-
lize mitochondria in real time. The use of REMIT would be advanta-
geous in studies involving the need for both visualization and normal
respiratory function. These studies can include investigation into mi-
tochondrial fission and fusion events, mitochondrial dynamics and
mitochondrial morphology.
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Low-glucose and -insulin conditions, associated with ketogenic di-
ets, can reduce the activity of the mechanistic target of rapamycin
complex 1 (mTORC1) signaling pathway, potentially leading to a
range of positive medical and health-related effects. Here, we de-
termined whether mTORC1 signaling is also a target for decanoic
acid, a key component of the medium-chain triglyceride (MCT) ke-
togenic diet. Using a tractable model system, Dictyostelium, we
show that decanoic acid can decrease mTORC1 activity, under con-
ditions of constant glucose and in the absence of insulin, measured
by phosphorylation of eukaryotic translation initiation factor 4E-
binding protein 1 (4E-BP1). We determine that this effect of decanoic
acid is dependent on a ubiquitin regulatory X domain-containing pro-
tein, mediating inhibition of a conserved Dictyostelium AAA ATPase,
p97, a homolog of the human transitional endoplasmic reticulum
ATPase (VCP/p97) protein. We then demonstrate that decanoic acid
decreases mTORC1 activity in the absence of insulin and under high-
glucose conditions in ex vivo rat hippocampus and in tuberous scle-
rosis complex (TSC) patient-derived astrocytes. Our data therefore
indicate that dietary decanoic acid may provide a new therapeutic
approach to down-regulate mTORC1 signaling.
Dictyostelium discoideum | epilepsy | mTOR | decanoic acid | tuberous
sclerosis complex
Inhibition of mechanistic target of rapamycin complex 1(mTORC1) has been suggested as a common mechanism
contributing to the therapeutic benefits of ketogenic diets
through a reduction in glucose and insulin (1–4). This inhibitory
activity may provide a component of the therapeutic efficacy of
these diets in the treatment of patients with drug-resistant epi-
lepsies (5), cancers (6), and neurodegenerative disorders (7), and
in providing lifespan extension (4). Inhibition of mTORC1 has
been proposed to lead to increased autophagy and the clearance
of misfolded proteins in neurodegenerative disorders (8), the
decrease of cell proliferation in cancers (9), and reduced stress
response and improved mitochondrial function credited with
increasing longevity (10). Hyperactivation of mTORC1 activity is
also found in the neurodevelopmental disorder tuberous scle-
rosis complex (TSC) (11), resulting from mutations in either the
gene for hamartin (TSC1) or tuberin (TSC2), causing the de-
velopment of tumors and manifesting in epilepsy, cognitive dis-
ability, and neurobehavioral abnormalities (12). The use of
mTORC1 inhibitors to treat patients with TSC appears clinically
promising (13, 14). mTORC1 signaling is also disrupted by mu-
tations in p97 (also called VCP or cdcD, referred to as human
p97; hp97), an evolutionarily conserved AAA ATPase (15),
contributing to the pathogenesis of degenerative diseases (16).
This critical ATPase functions in processes such as endoplasmic
reticulum-associated degradation (ERAD) (17), autophagy (18),
and DNA damage repair (19), with UBX domain-containing
proteins making up the largest group of cofactors required for
p97 function (20).
Ketogenic diets were initially developed to mimic starvation,
with the low-carbohydrate and high-fat intake leading to the
generation of ketone bodies (21). The initial form of the diet,
termed the “classical” ketogenic diet, requires 90% of dietary
energy to be delivered through fats and, despite its efficacy, is
difficult to maintain due to stringent dietary restrictions (22). To
reduce these restrictions, a modified form of the diet, called the
medium-chain triglyceride (MCT) ketogenic diet, was intro-
duced in 1971 (23), requiring around 30% less dietary energy
delivered as fats, with improved tolerability (24, 25). Metabolic
breakdown of these dietary triglycerides in the intestine leads to
the release of the fatty acids octanoic acid (C8) and decanoic
acid (C10), which are absorbed and transported in the blood to
the brain, where they cross the blood–brain barrier (26). Re-
cently, it has been suggested that ketosis may not be necessary
for an antiseizure effect of the MCT diet and that decanoic acid
alone can mediate an antiseizure effect (21). Several mechanisms
of action have been suggested for decanoic acid, including the
direct inhibition of excitatory α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors (5, 27), the activation
of the nuclear peroxisome proliferator-activated receptor gamma
receptor leading to increased mitochondrial proliferation (28), as
well as the inhibition of phosphoinositide turnover and the inhibi-
tion of diacylglycerol kinase (29, 30). However, a potential disad-
vantage of nonketogenic MCT diets is a lack of effect on glucose
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and insulin and therefore mTORC1 signaling, but this has not been
previously investigated. We therefore wished to test this hypothesis
that decanoic acid has no effect on mTORC1 activity.
The eukaryotic social amoeba Dictyostelium discoideum is a
simple model organism which provides a valuable system for
biomedical research. Dictyostelium has a well-described life cycle
where it exists in both single and multicellular stages (31). Many
Dictyostelium proteins are more homologous to human proteins
than to those of unicellular fungi, making it a valuable organism
for studying processes relevant to humans (32). The generation
of libraries of Dictyostelium mutants has enabled pharmacoge-
netic studies leading to the identification of targets for com-
pounds (33, 34). This approach allows rapid identification of
proteins that control sensitivity to a compound, thus implicat-
ing the proteins or the wider pathways in the action of the
compound. In epilepsy research, Dictyostelium has been
employed to identify a mechanism of the commonly used an-
tiepileptic drug valproate to reduce phosphoinositide signaling
(30), with more potent compounds showing improved efficacy
in seizure models (30, 35, 36). Through this research originating
in Dictyostelium, decanoic acid has been identified as an ef-
fective seizure control agent (30, 37), contributing to the de-
velopment and progression to clinical trials of an MCT diet
with an altered decanoic acid content (NCT02825745; https://
clinicaltrials.gov/ct2/show/NCT02825745).
In this study, we investigate a role for decanoic acid in mTORC1
function. We initially show that decanoic acid causes a reduction of
mTORC1 activity in a structurally specific manner in Dictyostelium,
in the absence of insulin and in the presence of glucose, suggesting
a specific molecular mechanism for decanoic acid in regulating this
pathway. To identify this mechanism, we screened a mutant library
to identify a decanoic acid-resistant mutant lacking a UBX
domain-containing protein (UBXD18) that is partially resistant to
the effects of decanoic acid on growth and mTORC1 signaling. We
establish that UBXD18 binds the Dictyostelium p97 protein, dec-
anoic acid reduces the activity of Dictyostelium p97 in a UBXD18-
dependent manner, and p97 inhibition is sufficient to cause a re-
duction in mTORC1 signaling in this model. We then translate our
findings to a rat hippocampal slice model and astrocytes derived
from patients with the neurodevelopmental disorder TSC, to
demonstrate that decanoic acid also reduces normal and dysregu-
lated mTORC1 signaling in mammalian systems.
Results
Decanoic Acid Reduces mTORC1 Signaling in Dictyostelium. As wide-
ranging therapeutic benefits of the classical ketogenic diet have
been associated with inhibition of mTORC1 signaling (1, 4, 8, 9)
(Fig. 1A), we employed Dictyostelium to investigate the effects of
the MCT diet constituents decanoic acid and octanoic acid on this
activity. We initially assessed the effects of these medium-chain
fatty acids on Dictyostelium unicellular growth and multicellular
development to establish relevant concentrations of decanoic acid
and octanoic acid to investigate in this model. Dictyostelium cell
growth was quantified in the presence of a range of concentrations
of both fatty acids, with cell counts being recorded once every 24 h
from 3 to 7 d posttreatment (Fig. 1 B and C). Treatment with both
fatty acids caused a dose-dependent inhibition of growth. The rate
of the exponential growth phase was then used to plot nonlinear
regression curves, and half-maximal inhibitory concentrations (IC50
values) were calculated. Decanoic acid provided an IC50 of 18 μM
(Fig. 1 B and D), while octanoic acid was less potent with an IC50 of
86 μM (Fig. 1C andD). SinceDictyostelium also show amulticellular
development cycle, we also investigated these fatty acids in regulat-
ing this process, where starving cells form fruiting bodies comprising
dead vacuolated stalks holding spore heads aloft under control
condition cells (SI Appendix, Fig. S1). This developmental process
was unaffected by decanoic acid and octanoic acid at concentrations
of fatty acids (200 μM) far greater than that shown to inhibit cell
growth, suggesting that these compounds regulate molecular targets
required for cell proliferation but not development (Fig. 1 B–D and
SI Appendix, Fig. S1). These data also suggest that the medium-chain
fatty acids have a specific molecular effect on Dictyostelium rather
than a general toxic effect.
In order to monitor the effects of decanoic acid and octanoic
acid on mTORC1 signaling in Dictyostelium, we quantified levels
of phosphorylated 4E-BP1 (p-4E-BP1), a translation repressor
directly phosphorylated by mTORC1 (Fig. 1A) (38, 39). Con-
centrations of decanoic acid and octanoic acid corresponding to
an ∼95% reduction in growth rate (60 and 120 μM, respectively)
(Fig. 1D) were employed, providing concentrations relevant to
those observed in plasma of patients on the MCT diet (decanoic
acid, 157 μM; octanoic acid, 310 μM) (24, 40). Dictyostelium cells
were treated with fatty acids for 1 or 24 h before p-4E-BP1 levels
were quantified by Western blot (Fig. 1 E and F). Decanoic acid
decreased p-4E-BP1 levels at 1 and 24 h (Fig. 1E), while treatment
with octanoic acid had no significant effect on the levels of p-4E-
BP1 at either treatment duration (Fig. 1F). Starvation, a physio-
logical process well-established to reduce mTORC1 activity (41,
42), also caused a significant decrease in p-4E-BP1 levels in Dic-
tyostelium (SI Appendix, Fig. S2A), as did two established mTOR
inhibitors (38, 43) (SI Appendix, Fig. S2 B and C). Rapamycin did
not significantly alter p-4E-BP1 levels under our conditions (SI
Appendix, Fig. S2D), consistent with findings showing a lack of
autophagic response to rapamycin in Dictyostelium (44).
Since mTORC1 is activated by phosphatidylinositol 3-kinase
(PI3K)/AKT signaling and inhibited by AMP-activated protein
kinase (AMPK) signaling (Fig. 1A), we also investigated a role
for decanoic acid in these signaling pathways. We monitored the
effects of decanoic acid on PI3K/AKT signaling by measuring
levels of a phosphorylated AKT substrate (p-AKT-S) (45, 46) (SI
Appendix, Fig. S2 E and F). No significant difference was ob-
served in p-AKT-S levels after treatment with decanoic acid (60
μM) for 1 or 24 h (Fig. 1G). This indicated that decanoic acid
targets mTORC1 independent of PI3K/AKT signaling under
these conditions, and further suggests that decanoic acid inhibits
mTORC1 without altering mTORC2 activation. In these grow-
ing cells, it was not possible to assay PI3K signaling through
monitoring phosphorylation of the activation loops of the AKT
homologs PKBR1 (T309) and PKBA (T278), since this signaling
is undetectable during growth (45, 47) (SI Appendix, Fig. S2G).
We also evaluated the effect of decanoic acid on AMPK sig-
naling by assessing phospho-AMPKα (p-AMPK) levels (39, 48)
(SI Appendix, Fig. S2 H–K), where no significant difference was
observed (Fig. 1H).
Identification of UBXD18 as a Potential Molecular Target for Decanoic
Acid. We sought to identify potential molecular targets for dec-
anoic acid by isolating decanoic acid-resistant mutants using an
unbiased genetic screen of a library of Dictyostelium insertional
mutants (Fig. 2A and SI Appendix, Fig. S3A). The library of
mutants was screened with a concentration of decanoic acid that
inhibits wild-type cell growth (120 μM; 7 d). Using this approach,
mutants resistant to decanoic acid were isolated, and the location
of the insertion site within the genome of these mutants was
determined to identify genes controlling decanoic acid sensitiv-
ity. From this, a decanoic acid-resistant mutant, UBXD18−, was
identified (Fig. 2B), with the mutagenic insertion in the region
coding for the ubiquitin-associated domain of the ubxd18 gene
(DDB_G0276057).
Proteomic analysis enabled the initial characterization of the
Dictyostelium UBXD18 protein. The UBXD18 protein sequence
shared homology with two human UBX domain-containing pro-
teins (UBXN1, UniProt Q04323; UBXD2, UniProt Q92575)
(Fig. 2B), with highly conserved UBX domains (SI Appendix, Fig.
S3B). The Dictyostelium UBX domain shared 28% identical and
51% similar amino acids with the UBX domain of UBXN1, and
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27% identical and 51% similar amino acids with the UBX domain
of UBXD2 (SI Appendix, Fig. S3B). A binding loop (s3/s4) known
to interact with the AAA ATPase p97 was partially conserved
between these proteins (SI Appendix, Fig. S3B) (49), suggesting
that these proteins are p97-binding partners. Cladistic analysis of
all Dictyostelium and human UBX proteins (SI Appendix, Fig.
S3C) confirmed that the UBXN1 and UBXD2 proteins are the
most likely homologs of the Dictyostelium UBXD18 protein.
The Effects of Decanoic Acid on Dictyostelium Growth and mTORC1
Signaling Are Dependent on UBXD18. We next generated an inde-
pendent UBXD18− mutant to confirm that the UBXD18 protein
regulates sensitivity to decanoic acid (Fig. 3A and SI Appendix, Fig.
S4A). This recapitulated mutant was produced by insertion of a
1,592-bp blasticidin resistance sequence into the central region of
the ubxd18 gene, and was confirmed by loss of gene expression (SI
Appendix, Fig. S4 A and C). UBXD18 activity was also reintro-
duced to UBXD18− by expression of ubxd18 complementary DNA
(cDNA) in the mutant (SI Appendix, Fig. S4B), where the pres-
ence of green fluorescent protein (GFP)-UBXD18 was confirmed
by Western blot analysis (SI Appendix, Fig. S4D). Wild-type,
knockout (UBXD18−), and rescue (UBXD18−/+) cells were then
assessed for the effect of decanoic acid on growth to quantify
resistance (Fig. 3B), with IC50 values indicating comparative sen-
sitivity (Fig. 3C). This analysis demonstrated that UBXD18− was
partially resistant to the effect of decanoic acid, with an IC50 value
twofold higher than that of the parental cell line (UBXD18− IC50
37 μM, compared with wild-type IC50 18 μM) (Fig. 3C). Reintro-
ducing ubxd18 gene expression restored a decanoic acid-sensitive
phenotype (UBXD18−/+, IC50 13 μM) (Fig. 3C). To establish if
UBXD18 confers partial resistance to the other medium-chain fatty
acids provided in the MCT diet, UBXD18− was also assessed for the
effect of octanoic acid on growth (SI Appendix, Fig. S5), where no
significant change in sensitivity was observed (wild-type, IC50
79 μM; UBXD18−, IC50 87 μM), suggesting structural specificity in
the targeting of UBXD18 by decanoic acid.
The role of UBXD18 in both regulating mTORC1 activity and
controlling the effect of decanoic acid in reducing mTORC1 activity
was investigated by Western blot analysis. Here, 4E-BP1 phosphor-
ylation was monitored in wild-type, UBXD18−, and UBXD18−/+ in
Fig. 1. Decanoic acid causes a reduction in p-4E-BP1 levels in Dictyostelium. (A) Simplified schematic diagram of mTORC1 pathway signaling. Glucose ac-
tivates mTORC1 through inhibition of AMPK. Conversely, the ketogenic diet inhibits mTORC1 through inhibition of PI3K/AKT signaling. Phosphorylation of
4E-BP1 by mTORC1 induces 4E-BP1 to dissociate from eukaryotic translation initiation factor 4E (eIF4E), promoting the initiation of translation, and this
phosphorylation is used in this study as a readout for mTORC1 activation. (B and C) Dictyostelium cells were treated with (B) decanoic acid (n = 12) or (C)
octanoic acid (n = 6) for 7 d at a range of concentrations (μM). Percentage growth was plotted normalized to the solvent control (0 μM, 0.2% DMSO) at 7 d. (D)
Dose–response curves of normalized growth rate plotted against log concentration of compound were used to calculate IC50 values. (E and F) p-4E-BP1 levels
were analyzed in wild-type cells treated for 1 or 24 h with (E) decanoic acid (n = 10) (one-way ANOVA with Dunnett’s post hoc test) or (F) octanoic acid (n =
10) (one-way ANOVA with Dunnett’s post hoc test) at concentrations corresponding to an ∼95% reduction in growth rate. Methylcrotonyl-CoA carboxylase
(MCCC1) served as a loading control. (G) AKT activity was evaluated in wild-type cells treated for 1 or 24 h with decanoic acid using an anti–phospho-AKT
substrate antibody, with MCCC1 as a loading control (n = 10) (one-way ANOVA with Dunnett’s post hoc test). (H) AMPK activation was analyzed using an
antibody against phospho-AMPK, with MCCC1 as a loading control (n = 10) (one-way ANOVA with Dunnett’s post hoc test). Data represent the mean ± SEM.
Significance is indicated by ***P ≤ 0.001, ****P ≤ 0.0001.
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the presence of decanoic acid. Loss of UBXD18 caused a decrease
in p-4E-BP1 levels compared with wild type, and p-4E-BP1 levels
were restored by reintroduction of the protein (UBXD18−/+)
(Fig. 3D). Analyzing p-4E-BP1 levels following decanoic acid treat-
ment (60 μM for 1 or 24 h) showed that UBXD18− was unresponsive
to treatment (Fig. 3E), and UBXD18−/+ showed restored decanoic
acid sensitivity following 24-h treatment (Fig. 3F).
Characterization of UBXD18 as a Binding Partner for Ddp97. Our
results demonstrate that UBXD18 controls sensitivity to decanoic
acid in both growth and mTORC1 regulation in Dictyostelium.
Since UBXD18 contains a p97 interaction motif (20, 49) (Fig. 2B)
and the Dictyostelium p97 (Ddp97) and human p97 (hp97) pro-
teins show conserved domain structure and a high sequence
identity (78%) (Fig. 4A), we used immunoprecipitation analysis to
investigate an interaction between UBXD18 and Ddp97. In these
experiments, cell lines were generated coexpressing Dictyostelium
GFP-UBXD18 (or free GFP as a control) and Ddp97-RFP (red
fluorescent protein) (SI Appendix, Fig. S4). To monitor binding,
cell lysates were mixed with agarose beads coated with anti-GFP
antibody, and the interacting proteins were isolated and analyzed
using Western blot with anti-GFP and anti-RFP antibodies.
Ddp97-RFP was found to bind to GFP-UBXD18 but not to free
GFP (Fig. 4B), suggesting that UBXD18 interacts with Ddp97. In
support of this, GFP-UBXD18 and Ddp97-RFP were found to
colocalize throughout the cytoplasm and nucleus (Fig. 4C), con-
sistent with that suggested for the mammalian homologs (50, 51).
Investigating the Effect of Decanoic Acid on Ddp97 Activity. An in-
teraction between UBXD18 and Ddp97 suggests a role for
UBXD18 in regulating Ddp97 function, and thus implicates Ddp97
in the cellular changes caused by decanoic acid in Dictyostelium. To
analyze this, we assessed the effect of decanoic acid on Ddp97
activity by treating wild-type cells expressing Ddp97-RFP with
decanoic acid, octanoic acid, or the established selective p97 in-
hibitor DBeQ (N2,N4-dibenzylquinazoline-2,4-diamine) (16, 52)
for 24 h before immunoprecipitation of Ddp97-RFP and direct
assessment of ATPase activity (53) (Fig. 5). Treatment with dec-
anoic acid (60 μM) decreased Ddp97-RFP ATPase activity
(Fig. 5 A and D), while octanoic acid (120 μM) had no significant
effect, and the p97 inhibitor DBeQ (7.5 μM) also significantly re-
duced activity. Having demonstrated that decanoic acid but not
octanoic acid acts to reduce Ddp97-RFP activity, we assessed the
effect of decanoic acid on this activity in cells lacking UBXD18
(UBXD18−) (Fig. 5 B and E), where decanoic acid did not affect
Fig. 2. Dictyostelium UBXD18 protein, identified from a mutant library
screen to regulate decanoic acid sensitivity, contains the evolutionarily
conserved UBX domain. (A) A genetic screen of an insertional mutant library
was carried out to identify mutants partially resistant to the growth-
inhibitory effects of medium-chain fatty acids. (B) The genetic screen iden-
tified a gene encoding UBX domain-containing protein 18 (DDB_G0276057)
as being a potential target for decanoic acid. The two most highly conserved
human proteins, UBXN1 and UBXD2, are shown alongside a schematic of the
Dictyostelium UBXD18 protein. These proteins share a common UBX domain
with a highly conserved s3/s4 loop involved in binding p97 (highlighted).
Fig. 3. UBXD18 regulates the sensitivity of Dictyostelium to decanoic acid. (A) A UBXD18 knockout (UBXD18−) was generated by inserting a blasticidin
resistance sequence (BsR) into the ubxd18 gene, and a rescue (UBXD18−/+) was generated by expressing the ubxd18 gene attached to GFP. (B) Growth analysis
of wild-type (n = 12), UBXD18− (n = 12), and UBXD18−/+ (n = 9) Dictyostelium cells in decanoic acid, displayed as dose–response curves of normalized cell
density plotted against log concentration. (C) IC50 values were compared between wild type (n = 12), UBXD18
− (n = 12), and UBXD18−/+ (n = 9) (one-way
ANOVA with Dunnett’s post hoc test). (D) Analysis of p-4E-BP1 levels in wild type, UBXD18−, and UBXD18−/+, with MCCC1 as a loading control (n = 8) (one-way
ANOVA with Dunnett’s post hoc test). (E and F) Analysis of p-4E-BP1 levels in (E) UBXD18− (n = 9) (Kruskal–Wallis test with Dunn’s post hoc test) or (F)
UBXD18−/+ (n = 9) (one-way ANOVA with Dunnett’s post hoc test) treated with decanoic acid (60 μM) for 1 or 24 h, with MCCC1 as a loading control. Data
represent the mean ± SEM. Significance is indicated by *P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 0.0001.
23620 | www.pnas.org/cgi/doi/10.1073/pnas.2008980117 Warren et al.
D
ow
nl
oa
de
d 
by
 g
ue
st
 o
n 
N
ov
em
be
r 
7,
 2
02
0 
Ddp97-RFP activity. Reintroduction of UBXD18 into UBXD18−/+
also restored the decanoic acid-dependent reduction of Ddp97-
RFP activity (Fig. 5 C and F). These findings suggest that dec-
anoic acid functions through a mechanism involving UBXD18 to
reduce Ddp97 activity in Dictyostelium.
Having established an effect of decanoic acid in inhibiting
Dictyostelium p97 activity, we assessed the effect of inhibiting p97
on mTORC1 activity by using DBeQ. In these experiments, cells
were treated with DBeQ (7.5 and 15 μM for 24 h), and cell lysates
were analyzed for 4E-BP1 phosphorylation by Western blot
(Fig. 5G). Treatment with DBeQ caused a significant reduction in
p-4E-BP levels at both 7.5 and 15 μM (Fig. 5G). This was con-
sistent with a comparable inhibition of growth caused by these
concentrations of DBeQ (SI Appendix, Fig. S6). These findings
suggest that the inhibitory effect of decanoic acid on Dictyostelium
p97 activity may be sufficient to explain the observed mTORC1
and growth inhibition effects (Fig. 5H).
Decanoic Acid Reduces mTORC1 Activity in Rat Hippocampal Slices.
Having identified an effect of decanoic acid in reducing mTORC1
activity independent of altered glucose levels and insulin signaling in
Dictyostelium, we sought to translate these findings to a mammalian
system. Here, we employed rat hippocampal slice preparations
maintained in artificial cerebrospinal fluid, ensuring constant glu-
cose levels in the absence of insulin, treated with decanoic acid (100
and 300 μM for 1 h) prior to assessing mTORC1 activity by Western
blot analysis of p-4E-BP1 and total-4E-BP1 levels (Fig. 6). Decanoic
acid at 100 μM had no significant effect on p-4E-BP1 levels
(Fig. 6 A and B) but significantly decreased p-4E-BP1 levels at
300 μM (Fig. 6 A and B) and neither concentration altered total-4E-
BP1 levels (Fig. 6A and SI Appendix, Fig. S7). These combined data
showed a decrease in p-4E-BP1/total-4E-BP1 levels following
treatment with 300 μM decanoic acid (Fig. 6C). Consistent with that
observed in Dictyostelium, no change in p-AKT(Thr308)/total-AKT
or p-AKT(Ser473)/total-AKT was observed in rat hippocampal sli-
ces following decanoic acid treatment (SI Appendix, Fig. S8).
Decanoic Acid Reduces mTORC1 Activity in Patient-Derived Astrocytes.
To investigate a potential role for decanoic acid in reducing
mTORC1 activity in a clinically relevant setting, we monitored this
activity in astrocytes derived from patients with tuberous sclerosis
complex. mTORC1 signaling is reportedly activated in astrocytes
during epileptogenesis (54), with this cell type believed to play a
significant role in seizure induction (55–57). In these experiments,
induced pluripotent stem cells (iPSCs) derived from patients with
mutations in genes encoding either TSC1 or TSC2, or healthy
controls, were differentiated into astrocytes (58) and treated with
decanoic acid (300 μM for 24 h) prior to Western blot analysis of
p-4E-BP1 and total-4E-BP1 levels. Decanoic acid treatment
caused a reduction in the ratio of p-4E-BP1/total-4E-BP1 in as-
trocytes derived from healthy (control) patients (Fig. 7 A–C),
confirming a role for decanoic acid in regulating mTORC1 activity
in human cells in the absence of altered glucose or insulin sig-
naling. Decanoic acid also caused a reduction in the ratio of p-4E-
BP1/total-4E-BP1 in astrocytes derived from patients with muta-
tions in TSC1 (Fig. 7 A–C). However, decanoic acid had no sig-
nificant effect on this ratio in astrocytes derived from patients with
mutations in TSC2 (Fig. 7 A–C). In these assays, levels of p-4E-
BP1 were not significantly altered following treatment (SI Ap-
pendix, Fig. S9 A and B), but the reduction in the ratio of p-4E-
BP1/total-4E-BP1 was caused by a significant increase in levels of
total-4E-BP1 (SI Appendix, Fig. S9 C and D). Interestingly, vari-
ability was observed between cells from different TSC2 patients,
with cells from one patient showing no significant change in total-
4E-BP1 levels following decanoic acid treatment, while cells from
another patient showed a significant increase (SI Appendix, Fig.
S10 A and B).
To confirm the effect of decanoic acid in reducing mTORC1
activity in patient-derived astrocytes, we also analyzed p70 S6
kinase (S6K) phosphorylation levels. For this activity, decreased
phosphorylation at threonine 389 (p-S6K) indicated decreased
mTORC1 activation (59) (Fig. 7D). Analysis of the same protein
extracts showed that decanoic acid treatment also caused a re-
duction in the ratio of p-S6K/total-S6K in astrocytes derived
from control patients and patients with mutations in TSC1
(Fig. 7 D–F) but showed no effect in astrocytes derived from patients
with mutations in TSC2 (Fig. 7 D–F). The reduction in this
ratio was caused by a significant reduction in levels of p-S6K
(SI Appendix, Fig. S9 E and F) without changes in total-S6K
levels (SI Appendix, Fig. S9 G and H). Variability was also observed
between cells from individual TSC2 patients, with cells from one
patient showing no significant change in p-S6K levels following
decanoic acid treatment, while cells from the other showed a sig-
nificant decrease (SI Appendix, Fig. S10 C and D).
Discussion
Ketogenic diets are well-established treatments for epilepsies
(21) and cancers (6) with exciting potential for use in other areas
of health such as treating neurodegenerative disorders (7);
however, the therapeutic mechanisms underlying these effects
are poorly understood. In this study, we have used Dictyostelium
as a tractable model to establish that decanoic acid, one of the
major constituents of the MCT ketogenic diet, inhibits mTORC1
signaling. In order to identify the mechanism behind this effect,
we showed that the effects of decanoic acid on mTORC1 are
dependent on a UBX domain-containing protein (UBXD18).
We demonstrated that decanoic acid inhibits the activity of the
Fig. 4. Dictyostelium UBXD18 interacts with Ddp97. (A) Schematic of the
Dictyostelium (Ddp97) and human (hp97) p97 proteins, showing 78% se-
quence identity. (B) Cell lysates of Dictyostelium cells coexpressing GFP-
UBXD18 (or free-GFP as a control) and Ddp97-RFP were subjected to im-
munoprecipitation with GFP trap beads and the interaction was analyzed by
Western blot using anti-GFP and anti-RFP antibodies (representative of three
independent experiments). Ddp97-RFP was pulled down by GFP-UBXD18
and not by the GFP-only control. (C) Colocalization of GFP-UBXD18 and
Ddp97-RFP by visualizing fluorescence in live cells (representative of three
independent experiments). (Scale bar, 10 μm.)
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ubiquitous binding partner of UBXD18, p97, in a UBXD18-
dependent manner, and further showed that direct p97 inhibi-
tion is sufficient to reduce mTORC1 signaling in Dictyostelium.
We translated this effect of decanoic acid into a rat hippocampal
slice model, demonstrating decanoic acid-dependent inhibition
of mTORC1 signaling in the absence of glucose deprivation or
insulin signaling. Finally, we employed astrocytes derived from
patients with mutations in TSC1 or TSC2 associated with dysre-
gulated mTORC1 activity (11, 58) to demonstrate that treatment
with decanoic acid results in decreased mTORC1 activation in
healthy patients and patients with TSC1 mutations.
We provide mechanistic insight for the role of decanoic acid in
regulating mTORC1 activity in Dictyostelium, through a UBX
domain-containing protein and Dictyostelium p97. UBX proteins
have previously been shown to directly regulate the activity of
p97 in human cells (20). By employing a specific inhibitor for p97
(DBeQ), we also confirmed that pharmacological inhibition of
Dictyostelium p97 decreased mTORC1 activity and cell prolifera-
tion (16) (Fig. 5G and SI Appendix, Fig. S6), suggesting that
decanoic acid-induced p97 inhibition could explain the inhibitory
effects on mTORC1 activity and growth in the model system
(Fig. 5H). Although the role of human p97 in regulating mTORC1
has yet to be established, there is evidence that inhibition of p97
results in the disruption of amino acid homeostasis, potentially
leading to the observed reduction in mTORC1 (16, 52). Our data
provide an indication that decanoic acid may prevent the inter-
action of Dictyostelium p97 with its regulatory cofactor UBXD18,
thus reducing Dictyostelium p97 activity and leading to a reduction
Fig. 5. Decanoic acid inhibits Ddp97 activity in a UBXD18-dependent manner. (A) Analysis of phosphate (Pi) release from an ATP hydrolysis reaction with
Ddp97-RFP isolated from wild-type Dictyostelium cells treated with decanoic acid (60 μM), octanoic acid (120 μM), or DBeQ (7.7 μM) for 24 h (n = 6). (B and C)
Phosphate release was analyzed from ATP hydrolysis reactions with Ddp97-RFP isolated from (B) UBXD18− and (C) UBXD18−/+ treated with decanoic acid (60
μM) for 24 h (n = 6). (D–F) Specific enzyme activity (phosphate [μM] released relative to protein concentration [μg]) was plotted versus time (min) and
subjected to linear regression analysis. The gradient was plotted, representing the rate of ATP hydrolysis (Ddp97 activity μM phosphate·μg protein−1·min−1)
for (D) wild type (Kruskal–Wallis test with Dunn’s post hoc test), (E) UBXD18− (Mann–Whitney t test), and (F) UBXD18−/+ (Mann–Whitney t test) (n = 6). (G)
Analysis of p-4E-BP1 levels in wild-type cells treated for 24 h with DMSO control (0 μM) or p97 inhibitor (DBeQ) at 7.5 or 15 μM (n = 9) (Kruskal–Wallis test with
Dunn’s post hoc test). MCCC1 served as a loading control. (H) Simplified schematic portraying the canonical effect of the classical ketogenic diet on mTORC1
through reduced glucose and insulin (black), downstream diseases displaying elevated mTORC1 (red), and a role of decanoic acid through a UBXD18- and p97-
mediated pathway (blue). Data represent the mean ± SEM. Significance is indicated by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; ns, not significant, P > 0.05.
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in mTORC1. Interactions between long-chain fatty acids and
UBX domain-containing proteins have previously been implicated
in blocking p97 activity in mammalian cells (60), suggesting that
regulation of p97 via an interaction of decanoic acid with a UBX
domain-containing protein represents a viable potential mecha-
nism in humans.
Inhibition of p97 has been proposed as a treatment for cancer
and epilepsy (61, 62). In cancers, expression of p97 is increased to
manage excessive proteotoxic stress (63), and thus p97 inhibitors are
in clinical trials as cancer treatments (64, 65). p97 also plays a role in
a common form of epilepsy (autosomal dominant juvenile myo-
clonic epilepsy), where a mutation in a GABAA receptor subunit
(A322D mutation in the α1-subunit) results in misfolding and rapid
ERAD of the α1-subunit, resulting in epilepsy (62, 66). By inhibiting
p97, α1(A322D) subunits have more time to fold in the endoplas-
mic reticulum, allowing functional GABAA receptors to form and
act as inhibitory ion channels (62). Our findings suggest that further
analysis of a role for decanoic acid in inhibiting p97 and mTORC1
may identify associated therapeutic benefits.
Our data suggest a mechanism for decanoic acid in regulating
mTORC1 independent of glucose and insulin. The classical ke-
togenic diet is known to reduce mTORC1 activation, with a
proposed mechanism through lowering glucose and insulin levels
(1–4) associated with the therapeutic effects of the classical ke-
togenic diet in treating epilepsy. However, the role of the MCT
ketogenic diet fatty acids in this function has not previously been
reported. Several studies have suggested that decanoic acid in
the MCT diet provides therapeutic benefits in seizure control (5, 26,
27, 67), and here we have identified that in Dictyostelium, decanoic
acid inhibits mTORC1 activity under conditions of constant glucose
and in the absence of insulin (Fig. 1E). Since we have translated this
effect to both a rat hippocampal slice model (Fig. 6) and patient-
derived astrocytes (Fig. 7), again under conditions of constant glucose
and in the absence of insulin signaling, our data support an evolu-
tionarily conserved effect of decanoic acid, provided in the MCT diet,
distinct from that proposed for the classical ketogenic diet.
The mTORC1 pathway acts as a regulator for cell growth
through the phosphorylation of targets activating anabolic pro-
cesses and inhibiting catabolic processes. In this role, mTORC1
inhibition has been credited with providing therapeutic effects in
many areas of health, including treating epilepsy and neurode-
generative disorders, preventing the proliferation of cancer cells,
improving cognitive function after traumatic brain injury, and
increasing longevity (8–10). mTORC1 inhibition has also been
investigated as a therapeutic target for the neurodevelopmental
disorder TSC associated with deregulated mTORC1 activity (11,
13, 14, 68). The cause of epilepsy in TSC patients is often related
to the formation of cortical tubers, characterized by cortical dys-
lamination, dysplastic neurons, and astrogliosis (69). Although
astrogliosis may be secondary to neuronal pathology, studies in
animals and humans suggest that TSC involves a primary defect in
astrocytes (55), supported by mTOR dysregulation (70). In cell
culture, however, patient-derived cells have been suggested to
employ a feedback loop to regulate the TSC and maintain bal-
anced mTOR signaling (71). Importantly, we show that decanoic
acid reduces mTORC1 signaling in cells derived from both healthy
individuals and patients with TSC mutations, suggesting that
decanoic acid functions independent of disease state and shows
efficacy in cells derived from patients with disease-associated
mutations (Fig. 7). However, heterogeneity between astrocytes
derived from patients with mutations in TSC2 were observed (SI
Appendix, Fig. S10), which suggests that decanoic acid might
provide differential efficacy between individuals.
Inhibition of mTORC1 has been suggested to provide wide-
ranging clinical benefits, including as a treatment for cancer, epi-
lepsy, neurodegenerative diseases, and aging (14, 72–76). The
recent development of new pharmacological inhibitors for
mTORC1 inhibition, based around rapamycin, have focused on
identifying “rapalogues” without the toxicity associated with rapa-
mycin (68). Alternately, inhibition of this pathway is possible
through dietary treatment, namely the classical ketogenic diet
(1–4); however, this diet is highly restrictive for patients, resulting
in low compliance. Our data suggest that a nonketogenic decanoic
acid-rich diet that is less restrictive and avoids the potential adverse
effects of ketosis could also provide therapeutic effects through
inhibiting this pathway. Thus, further investigation into dietary
decanoic acid may provide a useful approach to treat mTORo-
pathies in addition to providing a range of associated health effects.
Materials and Methods
Detailed methods are available in SI Appendix.
Dictyostelium Growth Assay. Dictyostelium cells in the presence of compound
or a dimethyl sulfoxide (DMSO) control were grown at 22 °C in HL5, and the
cell number was quantified.
Cell Development Assays. Exponentially growing cells were developed on
nitrocellulose filters on absorbent pads soaked in phosphate buffer con-
taining compound or DMSO control. Developmental phenotypes were im-
aged after 24 h.
Dictyostelium Mutant Library Screen. A Dictyostelium mutant library was
grown alongside wild-type cells in decanoic acid or DMSO control and
screened for the appearance of resistant colonies. Resistant mutants were
isolated and selected isogenically and mutation sites were identified using
inverse PCR.
Fig. 6. Decanoic acid causes a reduction in p-4E-BP1 levels in rat hippo-
campal brain slices. (A) Rat hippocampal brain slices in artificial cerebrospinal
fluid (control), treated for 1 h with DMSO solvent control (-), 100 μM dec-
anoic acid, or 300 μM decanoic acid were analyzed for p-4E-BP1 and total-4E-
BP1 (T-4E-BP1), with beta-actin as a loading control. Multiple bands corre-
spond to the three isoforms of 4E-BP1. (B) Relative band weights were
plotted for p-4E-BP1 (n = 6) (Kruskal–Wallis test with Dunn’s post hoc test).
(C) The ratio of p-4E-BP1/T-4E-BP1 was used as a readout for mTORC1 (n = 6)
(Kruskal–Wallis test with Dunn’s post hoc test). Data represent the mean ±
SEM. Significance is indicated by *P ≤ 0.05, **P ≤ 0.01.
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Knockout Generation. UBXD18− cells were generated by homologous inte-
gration. A knockout cassette was generated by PCR amplification over the
REMI insertion site using genomic DNA extracted from the mutant. The PCR
product was electroporated into Dictyostelium wild-type cells.
Creation of GFP-UBXD18 and Ddp97-RFP Constructs. ubxd18 or Dictyostelium
p97 cDNA was cloned into extrachromosomal vectors before electroporation
into Dictyostelium cells.
Western Blotting. Samples were prepared in Laemmli buffer, separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred to
membranes, and probed with antibodies as described. Blots were visualized
using the Odyssey CLx Imager (LI-COR), quantified using LI-COR Image Studio,
and normalized to the loading control or total (unphosphorylated) protein
(as specified).
Immunoprecipitation. GFP-TrapA beads were used for immunoprecipitation
of GFP-fusion proteins before analysis by Western blot.
ATPase Assay. Dictyostelium cells, expressing Ddp97-RFP, were treated for
24 h with compound. RFP-TrapA beads were used for the immunoprecipi-
tation of RFP-tagged proteins and ATPase activity was monitored as
described (53).
Rat Hippocampal Slice Preparation for Western Blot. Adult Sprague–Dawley
rats were used to prepare hippocampal slices as detailed (30). Animal
experiments were conducted in accordance with Animals (Scientific Proce-
dures) Act 1986 and approved by the local University College London ethics
committee.
Patient-Derived Astrocyte Differentiation and Preparation for Western Blot.
iPSCs from three individual control patients, two patients with TSC1 muta-
tions, and two patients with TSC2 mutations were differentiated into as-
trocytes as described (58). The following cell lines were obtained from the
National Institute of General Medical Sciences Human Genetic Cell Reposi-
tory at the Coriell Institute for Medical Research: GM23964, GM23973,
GM06149, GM02332, GM03958, and GM06102. An additional control line
was kindly provided by Eleonora Aronica, Amsterdam Universitair Medi-
sched Centra. All experiments were exempt from approval of the Medical
Ethical Toetsingscommissie, the institutional review board of the Vrije Uni-
versiteit Medical Center.
Data Availability. All data are available in the text and SI Appendix.
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